Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Overview for Request: cder_mpl1r_wp259

Request ID: cder_mpl1r_wp259

Request Description: In this request, we estimated the incidence rates of ocular adverse events (cataract, glaucoma, ocular hypertension and diminished visual acuity) and nasal septal perforation among individuals with new use of a 1350 mcg mometasone furoate nasal stent implant (brand name: Sinuva®) and among individuals with new use of a 370 mcg mometasone furoate nasal stent implant (brand name: Propel®) in the Sentinel Distributed Database (SDD). We also estimated the background rates of glaucoma and cataract among individuals with evidence of repeat use of the 1350 mcg mometasone furoate nasal stent implant (brand name: Sinuva®).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 13.1.2

Data Source: We distributed this query to 14 Sentinel Data Partners on July 22, 2024, including Medicare and Medicaid. Data from Medicare patients have both fee-for-service medical coverage and Part D drug coverage included. The study period included data from December 1, 2017 through January 31, 2024. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified patients aged 18 years and older with evidence of new use of 1350 mcg mometasone furoate nasal stent implant (brand name - Sinuva®) and 370 mcg mometasone furoate nasal stent implant (brand name - Propel®). We evaluated the occurrence of ocular adverse events which included cataract, glaucoma, ocular hypertension and diminished visual acuity, and nasal septal perforation over a follow-up period of one year (primary and sensitivity analysis) as well as two years (secondary analysis). We also identified patients aged 18 years and older with evidence of repeat use of the 1350 mcg mometasone furoate nasal stent implant (brand name - Sinuva®) and evaluated occurrence of glaucoma and cataract over a follow-up period of one year (primary analysis) as well as two years (secondary analysis). This is a Type 2 analysis in the Query Request Package (QRP) documentation.

Exposures of Interest: We defined mometasone furoate nasal stent implant 1350 mcg (brand name - Sinuva®) and mometasone furoate nasal stent implant 370 mcg (brand name - Propel®) using National Drug Codes (NDCs) and Healthcare Common Procedure Coding System (HCPCS) procedure codes.

New or incident use:

- We defined incident or new use as no prior dispensing or administration in the 183 days prior to the first qualifying index exposure (index date).
- If there was evidence of a second exposure code occurring within 30 days of the first code, both of them were considered as referring to the same implant as it is highly unlikely that a second implant would be inserted within such a short time. In such cases, the index date was set to the earliest of the two codes (if both codes were either NDCs or HCPCS codes) or the date of the HCPCS procedure code (if one code was NDC and the other HCPCS code).
- Only the first qualifying exposure episode was included per patient, i.e., no cohort re-entry was allowed.

Repeat use:

- We used two ways of defining repeat exposure of the mometasone furoate nasal stent implant 1350 mcg (brand name - Sinuva®) based on the time periods of assessment: within one year and within two years. Additionally, similar to the new use definition, codes within 30 days of each other were considered the same implant.
- Hence to accommodate the above specifications, repeat use within 365 days was defined as presence of the initial exposure code (NDC or HCPCS) between 31 and 365 days prior to the subsequent exposure code. Repeat use within 730 days was defined as presence of the initial exposure code (NDC or HCPCS) between 31 and 730 days prior to the subsequent exposure code. The date of the subsequent or second exposure was considered the index date. Only the first qualifying repeat exposure combination was included per patient, i.e., no cohort re-entry was allowed.
- We did not assess repeat use of the mometasone furoate nasal stent implant 370 mcg (brand name - Propel®).

Please see Appendix B for a list of generic and brand names of medical products and Appendix C for the list of HCPCS procedure codes used to define exposures in this request.

Overview for Request: cder_mpl1r_wp259
Outcome of Interest: We defined five outcomes of interest in the new exposure cohorts i.e., cataract, glaucoma, ocular hypertension, diminished visual acuity and nasal septal perforation; and two outcomes in the repeat exposure cohorts i.e., cataract and glaucoma. We identified the specified outcomes by presence of a diagnosis or procedure code in any care setting over the specified follow-up time and used International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes, HCPCS codes, and Current Procedural Terminology, Fourth Edition (CPT-4) codes to define them. Please see Appendix D for a list of codes used to define outcomes in this request. **Cohort Eligibility Criteria:** We required members to be enrolled in health plans with medical and drug coverage in the 183 days prior to their index date in order to be included in the cohort; a gap in coverage of up to 45 days was allowed and treated as continuous enrollment. The following age groups were included in the cohort: 18-24, 25-40, 41-64, 65+ years. We also required that the patients in all cohorts (both new use or repeat use) should have no evidence of any of the following in the 183 days before index date: cataract, cataract surgery, glaucoma, ocular hypertension, diminished visual acuity, eye laser surgery, trabeculoplasty or nasal septal perforation. Incident use cohorts (total 60 cohorts): For each exposure stent - outcome combination (ten such combinations), we created a total of six cohorts - one primary, four secondary and one sensitivity. The cohorts differed based on the following: 1) lag period for assessment of the outcome (yes/no), 2) length of follow-up, and 3) censoring criteria. 1) We specified lag periods for each of the outcomes to identify events that fall under a relevant time window, based on clinical feedback. The lag periods are as listed: 273 days for cataract, 28 days for glaucoma, 14 days for ocular hypertension, 28 days for diminished visual acuity and one day for nasal septal perforation. 2) We specified a maximum follow-up time of one year for the primary and sensitivity cohorts and a maximum follow-up time of two years for the secondary cohorts. 3) The two distinct censoring criteria are detailed in the next section (under section on Follow-up Time) Repeat use cohorts (total 12 cohorts): For each repeat exposure definition (repeat use within 365 days or 730 days) - outcome combination (four such combinations), we created a total of three cohorts - one primary and two secondary. The cohorts differed based on the following: 1) length of follow-up, and 2) censoring criteria. All cohorts for repeat use of the mometasone furoate nasal stent implant 1350 mcg (brand name - Sinuva®) had a lag period for outcome assessment (273 days for cataract and 28 days for glaucoma). 1) We specified a maximum follow-up time of one year for the primary and a maximum follow-up time of two years for the secondary cohorts. 2) The two distinct censoring criteria are detailed in the next section (under section on Follow-up Time) See Appendix E for a list of CPT-4, HCPCS, ICD-9-CM, ICD-10-CM, and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes and Appendix F for a list of generic and brand names of medical products used to define inclusion criteria in this request.

Overview for Request: cder_mpl1r_wp259

Follow-up Time: We specified two distinct censoring criteria for the new use as well as the repeat use cohorts.
The first criteria was aligned with that of a fixed follow-up study. Patients were followed up starting the day of the index stent (or after the end of the lag period, where applicable) and continued until the first occurrence of any of the following: 1) occurrence of the outcome, 2) disenrollment, 3) death, 4) 365 days (or 730 days for secondary cohorts) since start of follow-up, 5) the end of the data provided by each Data Partner or 6) the end of the query period.

The second criteria allowed censoring if patients had evidence of the other exposure stent over follow-up. Patients were followed up starting the day of the index stent (or after the end of the lag period, where applicable) and continued until the first occurrence of any of the following: 1) occurrence of the outcome, 2) evidence of the other exposure stent, 3) disenrollment, 4) death, 5) 365 days (or 730 days for secondary cohorts) since start of follow-up, 6) the end of the data provided by each Data Partner or 7) the end of the query period.

Please note that we assessed the distribution of time (in days) from the start of follow-up to end of time at-risk for both the sinus implants. This was done in the overall population as well as stratified by reasons for censoring.

See Appendix G for a list of generic and brand names of medical products and Appendix H for a list of CPT-4, HCPCS, ICD-9-CM, and ICD-10-CM codes used to define exposure censoring criteria in this request.
Baseline Characteristics: We assessed the following characteristics: on index date - age, sex, year, race/ethnicity; in the 183 days prior to and including the index date - evidence of indications, namely diagnosis of nasal polyp, endoscopic sinus surgery; in the 183 days prior to index date - combined comorbidity score[1]; health service and drug utilization; cardiovascular risk factors (e.g., hypertension), cardiac and vascular diseases, cerebrovascular diseases, other cardiovascular diseases (e.g., arrhythmias), type 2 diabetes, chronic kidney diseases, diabetic retinopathy, ocular conditions such as blepharitis, corneal abrasion, corneal graft, keratitis, episcleritis, macular degeneration, uveitis iritis, Fuchs dystrophy, heterochromic cyclitis, retinitis pigmentosa, subconjunctival hemorrhage, vasculitis, and other steroidal formulations such as intranasal, inhalational and oral steroids.

We identified the specified conditions by presence of a diagnosis or procedure code in any care setting and used ICD-9-CM, ICD-10-CM, ICD-10-PCS, HCPCS, and CPT-4 codes to define these conditions. Please see Appendix I for a list of ICD-9-CM, ICD-10-CM, HCPCS, and CPT-4 codes, Appendix J for a list of generic and brand names used to define baseline characteristics in this request.

Please refer to Appendices K to N for the specifications of parameters used in this request and design diagrams

Limitations: As with all observational studies, this evaluation was limited in its ability to control for all sources of potential bias. Algorithms used to define exposures, outcomes, inclusion and exclusion criteria, and characteristics are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's Type 2 Cohort Identification and Descriptive Analysis (CIDA) module, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).

[1] The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

Sentinel

Table of Contents

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.
Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.
Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

- **Ambulatory Visit (AV) -** includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- **Emergency Department (ED) -** includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- **Inpatient Hospital Stay (IP) -** includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- **Non-Acute Institutional Stay (IS) -** includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- **Other Ambulatory Visit (OA) -** includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).
Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.
Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.
Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.
Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.
Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.
Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.
Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.
Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.
Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).
Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."
Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).
Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.
Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.
Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.
Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.
Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.
Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.
Query Period - period in which the modular program looks for exposures and outcomes of interest.
Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).
Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.
Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.
Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.
Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Summary of Characteristics of Sinuva Stent Users* in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Single Sinuva Stent Use	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Unique patients	3,393	N/A
Demographic Characteristics		
Age (years)	54.0	12.6
Age		
18-24 years	168	5.0%
25-40 years	714	21.0%
41-64 years	1,374	40.5%
≥ 65 years	1,137	33.5%
Sex		
Female	1,574	46.4%
Male	1,819	53.6%
Race[2]		
American Indian or Alaska Native	*****	*****
Asian	62	1.8%
Black or African American	146	4.3%
Multi-racial	33	1.0%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,303	38.4%
White	1,838	54.2%
Hispanic origin		
Yes	101	3.0%
No	1,729	51.0%
Unknown	1,563	46.1%
Year		
2017	0	0.0%
2018	*****	*****
2019	423	12.5%
2020	1,258	37.1%
2021	1,026	30.2%
2022	356	10.5%
2023	190	5.6%
2024	*****	*****
Health Characteristics		
Indications [-183, 0]		
Endoscopic Sinus Surgery	2,827	83.3%
Nasal Polyps	2,289	67.5%
Comorbidities [-183, -1]		
Combined comorbidity score[3]	0.9	1.5

Table 1a. Summary of Characteristics of Sinuva Stent Users* in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Single Sinuva Stent Use	
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Cardiovascular Risk Factor	1,311	38.6%
Cardiac and Vascular Disease	558	16.4%
Cerebrovascular Disease	102	3.0%
Other Cardiovascular Disease	320	9.4%
Chronic Kidney Disease	171	5.0%
Diabetes	465	13.7%
Diabetic retinopathy	23	0.7%
Blepharitis	23	0.7%
Corneal abrasion	*****	*****
Corneal graft	*****	*****
Episcleritis	*****	*****
Fuchs dystrophy	*****	*****
Heterochromic cyclitis	0	0.0%
Keratitis	11	0.3%
Macular Degeneration	39	1.1%
Retinitis Pigmentosa	*****	*****
Subconjunctival hemorrhage	*****	*****
Uveitis Iritis	*****	*****
Vasculitis	0	0.0%
Other steroidal formulations [-183, -1]		
Inhaled steroids	1,225	36.1%
Intranasal steroids	916	27.0%
Oral Steroids	2,314	68.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.6	10.3
Mean number of emergency room encounters	0.2	0.8
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.8	7.6
Mean number of filled prescriptions	18.3	14.8
Mean number of generics dispensed	8.9	5.3
Mean number of unique drug classes dispensed	8.2	4.7

Table 1a. Summary of Characteristics of Sinuva Stent Users* in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Single Sinuva Stent Use

*The cohort of Sinuva users described was the same as all analytic cohorts - with or without lag periods, fixed follow-up or not, and all of the 5 outcomes: glaucoma, cataract, ocular hypertension, nasal septal perforation and diminished visual acuity

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

****N/A = Not Applicable

Table 1b. Summary of Characteristics of Propel Stent Users* in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Single Propel Stent Use	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Unique patients	3,924	N/A
Demographic Characteristics		
Age (years)	46.3	12.9
Age		
18-24 years	306	7.8%
25-40 years	1,260	32.1%
41-64 years	1,839	46.9%
≥ 65 years	519	13.2%
Sex		
Female	1,809	46.1%
Male	2,115	53.9%
Race[2]		
American Indian or Alaska Native	14	0.4%
Asian	80	2.0%
Black or African American	111	2.8%
Multi-racial	65	1.7%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	2,363	60.2%
White	1,291	32.9%
Hispanic origin		
Yes	109	2.8%
No	1,103	28.1%
Unknown	2,712	69.1%
Year		
2017	52	1.3%
2018	619	15.8%
2019	498	12.7%
2020	*****	*****
2021	820	20.9%
2022	997	25.4%
2023	879	22.4%
2024	*****	*****
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Indications [-183, 0]		
Endoscopic Sinus Surgery	3,854	98.2%
Nasal Polyps	1,487	37.9%
Comorbidities [-183, -1]		

Table 1b. Summary of Characteristics of Propel Stent Users* in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Single Propel Stent Use	
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Combined comorbidity score[3]	0.5	1.2
Cardiovascular Risk Factor	963	24.5%
Cardiac and Vascular Disease	308	7.8%
Cerebrovascular Disease	50	1.3%
Other Cardiovascular Disease	228	5.8%
Chronic Kidney Disease	97	2.5%
Diabetes	300	7.6%
Diabetic retinopathy	14	0.4%
Blepharitis	19	0.5%
Corneal abrasion	*****	*****
Corneal graft	0	0.0%
Episcleritis	0	0.0%
Fuchs dystrophy	*****	*****
Heterochromic cyclitis	0	0.0%
Keratitis	*****	*****
Macular Degeneration	15	0.4%
Retinitis Pigmentosa	0	0.0%
Subconjunctival hemorrhage	*****	*****
Uveitis Iritis	*****	*****
Vasculitis	*****	*****
Other steroidal formulations [-183, -1]		
Inhaled steroids	947	24.1%
Intranasal steroids	879	22.4%
Oral Steroids	2,857	72.8%
Health Service Utilization Intensity Metrics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Mean number of ambulatory encounters	11.2	9.9
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.2	4.7
Mean number of filled prescriptions	15.4	13.9
Mean number of generics dispensed	8.2	5.1
Mean number of unique drug classes dispensed	7.5	4.5

Table 1b. Summary of Characteristics of Propel Stent Users* in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Single Propel Stent Use

*The cohort of Propel users described was the same as all analytic cohorts - with or without lag periods, fixed follow-up or not, and all of the 5 outcomes: glaucoma, cataract, ocular hypertension, nasal septal perforation and diminished visual acuity

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

****N/A = Not applicable

Table 1c. Summary of Characteristics of Sinuva Repeat Stent Users* in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Sinuva Repeat Stent use within 365 days		Sinuva Repeat Stent within 730 days	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**	**Number/Mean**	**Standard Deviation[1]**
Unique patients	231	N/A	258	N/A
Demographics Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**	**Number/Mean**	**Standard Deviation[1]**
Age (years)	53.0	11.8	53.7	11.7
Age				
18-24 years	11	4.8%	12	4.7%
25-40 years	48	20.8%	51	19.8%
41-64 years	101	43.7%	110	42.6%
≥ 65 years	71	30.7%	85	32.9%
Sex				
Female	106	45.9%	116	45.0%
Male	125	54.1%	142	55.0%
Race[2]				
American Indian or Alaska Native	0	0.0%	0	0.0%
Asian	*****	*****	*****	*****
Black or African American	*****	*****	11	4.3%
Multi-racial	*****	*****	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%	0	0.0%
Unknown	96	41.6%	102	39.5%
White	122	52.8%	141	54.7%
Hispanic origin				
Yes	*****	*****	*****	*****
No	*****	*****	*****	*****
Unknown	117	50.6%	126	48.8%
Year				
2017	0	0.0%	0	0.0%
2018	*****	*****	*****	*****
2019	27	11.7%	27	10.5%
2020	65	28.1%	69	26.7%
2021	88	38.1%	102	39.5%
2022	31	13.4%	38	14.7%
2023	*****	*****	*****	*****
2024	0	0.0%	0	0.0%

Table 1c. Summary of Characteristics of Sinuva Repeat Stent Users* in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Sinuva Repeat Stent use within 365 days		Sinuva Repeat Stent within 730 days	
Health Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**	**Number/Mean**	**Percent/ Standard Deviation[1]**
Indications [-183, 0]				
Endoscopic Sinus Surgery	173	74.9%	187	72.5%
Nasal Polyps	212	91.8%	237	91.9%
Comorbidities [-183, -1]				
Combined comorbidity score[3]	1.0	1.4	1.0	1.5
Cardiovascular Risk Factor	72	31.2%	87	33.7%
Cardiac and Vascular Disease	35	15.2%	40	15.5%
Cerebrovascular Disease	*****	*****	*****	*****
Other Cardiovascular Disease	23	10.0%	26	10.1%
Chronic Kidney Disease	18	7.8%	19	7.4%
Diabetes	42	18.2%	45	17.4%
Diabetic retinopathy	0	0.0%	0	0.0%
Blepharitis	*****	*****	*****	*****
Corneal abrasion	*****	*****	*****	*****
Corneal graft	0	0.0%	0	0.0%
Episcleritis	0	0.0%	0	0.0%
Fuchs dystrophy	0	0.0%	0	0.0%
Heterochromic cyclitis	0	0.0%	0	0.0%
Keratitis	0	0.0%	*****	*****
Macular Degeneration	*****	*****	*****	*****
Retinitis Pigmentosa	0	0.0%	0	0.0%
Subconjunctival hemorrhage	0	0.0%	0	0.0%
Uveitis Iritis	0	0.0%	0	0.0%
Vasculitis	0	0.0%	0	0.0%
Other steroidal formulations [-183, -1]				
Inhaled steroids	127	55.0%	140	54.3%
Intranasal steroids	53	22.9%	59	22.9%
Oral Steroids	168	72.7%	187	72.5%
Health Service Utilization Intensity Metrics	**Number/Mean**	**Percent/ Standard Deviation[1]**	**Number/Mean**	**Percent/ Standard Deviation[1]**
Mean number of ambulatory encounters	15.2	10.2	15.2	10.6
Mean number of emergency room encounters	0.2	0.6	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.2	0.0	0.2
encounters	0.0	0.1	0.0	0.1
Mean number of other ambulatory encounters	2.5	4.7	3.0	9.6

Table 1c. Summary of Characteristics of Sinuva Repeat Stent Users* in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Sinuva Repeat Stent use within 365 days		Sinuva Repeat Stent within 730 days	
Health Service Utilization Intensity Metrics	**Number/Mean**	**Percent/ Standard Deviation[1]**	**Number/Mean**	**Percent/ Standard Deviation[1]**
Mean number of filled prescriptions	20.1	14.5	19.4	14.1
Mean number of generics dispensed	9.4	5.2	9.2	5.1
Mean number of unique drug classes dispensed	8.9	4.7	8.7	4.6

*The cohort of Sinuva users described was the same as all analytic cohorts - fixed follow-up or not, and both the outcomes: glaucoma and cataract

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[3]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

****N/A= Not applicable

Table 2. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Single stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	3,924	61
Single Sinuva Stent Use	3,393	3,393	132
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	3,924	63
Single Sinuva Stent Use	3,393	3,393	110
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (273 day lag period)	3,924	3,924	72
Single Propel Stent Use (fixed follow-up, 273 day lag period)	3,924	3,924	77
Single Propel Stent Use	3,924	3,924	106
Single Propel Stent Use (fixed follow-up)	3,924	3,924	110
Single Sinuva Stent Use (273 day lag period)	3,393	3,393	175
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	3,393	3,393	180
Single Sinuva Stent Use	3,393	3,393	194
Single Sinuva Stent Use (fixed follow-up)	3,393	3,393	198
Single stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	3,924	14
Single Sinuva Stent Use	3,393	3,393	28
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	3,924	14
Single Sinuva Stent Use	3,393	3,393	28
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (28 day lag period)	3,924	3,924	20
Single Propel Stent Use (fixed follow-up, 28 day lag period)	3,924	3,924	21
Single Propel Stent Use	3,924	3,924	19
Single Propel Stent Use (fixed follow-up)	3,924	3,924	20
Single Sinuva Stent Use (28 day lag period)	3,393	3,393	41
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	3,393	42
Single Sinuva Stent Use	3,393	3,393	42
Single Sinuva Stent Use (fixed follow-up)	3,393	3,393	43
Single stent cohorts - Outcome: Ocular Hypertension			
Primary analysis cohorts (14-day lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	3,924	70
Single Sinuva Stent Use	3,393	3,393	110
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	3,924	70
Single Sinuva Stent Use	3,393	3,393	110
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (14 day lag period)	3,924	3,924	83
Single Propel Stent Use (fixed follow-up, 14 day lag period)	3,924	3,924	88
Single Propel Stent Use	3,924	3,924	85
Single Propel Stent Use (fixed follow-up)	3,924	3,924	89
Single Sinuva Stent Use (14 day lag period)	3,393	3,393	148

Table 2. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	3,393	3,393	151
Single Sinuva Stent Use	3,393	3,393	149
Single Sinuva Stent Use (fixed follow-up)	3,393	3,393	152
Single stent cohorts - Outcome: Diminished visual acuity			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	3,924	67
Single Sinuva Stent Use	3,393	3,393	73
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	3,924	72
Single Sinuva Stent Use	3,393	3,393	76
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (28 day lag period)	3,924	3,924	95
Single Propel Stent Use (fixed follow-up, 28 day lag period)	3,924	3,924	100
Single Propel Stent Use	3,924	3,924	101
Single Propel Stent Use (fixed follow-up)	3,924	3,924	104
Single Sinuva Stent Use (28 day lag period)	3,393	3,393	130
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	3,393	134
Single Sinuva Stent Use	3,393	3,393	133
Single Sinuva Stent Use (fixed follow-up)	3,393	3,393	136
Single stent cohorts - Outcome: Nasal Septal Perforation			
Primary analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	3,924	11
Single Sinuva Stent Use	3,393	3,393	*****
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	3,924	*****
Single Sinuva Stent Use	3,393	3,393	*****
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use	3,924	3,924	12
Single Propel Stent Use (fixed follow-up)	3,924	3,924	12
Single Propel Stent Use (1 day lag period)	3,924	3,924	*****
Single Propel Stent Use (fixed follow-up, 1 day lag period)	3,924	3,924	*****
Single Sinuva Stent Use	3,393	3,393	*****
Single Sinuva Stent Use (fixed follow-up)	3,393	3,393	*****
Single Sinuva Stent Use (1 day lag period)	3,393	3,393	*****
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	3,393	3,393	*****
Repeat stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days	231	231	*****
Sinuva Repeat Stent within 730 days	258	258	*****
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days	231	231	12
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	231	12
Sinuva Repeat Stent within 730 days	258	258	12
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	258	12

Table 2. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Repeat stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days	231	231	*****
Sinuva Repeat Stent within 730 days	258	258	*****
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days	231	231	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	231	*****
Sinuva Repeat Stent within 730 days	258	258	*****
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	258	*****

Table 2. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Single stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Single Propel Stent Use	1,703.1	35.82	35.82 (27.87, 46.03)
Single Sinuva Stent Use	2,095.6	62.99	62.99 (53.11, 74.71)
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	2,784.2	22.63	22.63 (17.68, 28.97)
Single Sinuva Stent Use	2,792.7	39.39	39.39 (32.67, 47.48)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (273 day lag period)	2,400.7	29.99	29.99 (23.81, 37.78)
Single Propel Stent Use (fixed follow-up, 273 day lag period)	2,542.9	30.28	30.28 (24.22, 37.86)
Single Propel Stent Use	4,023.3	26.35	26.35 (21.78, 31.87)
Single Propel Stent Use (fixed follow-up)	4,211.9	26.12	26.12 (21.66, 31.48)
Single Sinuva Stent Use (273 day lag period)	3,179.2	55.05	55.05 (47.46, 63.84)
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	3,305.6	54.45	54.45 (47.05, 63.02)
Single Sinuva Stent Use	4,448.0	43.62	43.62 (37.89, 50.21)
Single Sinuva Stent Use (fixed follow-up)	4,608.1	42.97	42.97 (37.38, 49.39)
Single stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use	2,659.8	5.26	5.26 (3.12, 8.89)
Single Sinuva Stent Use	2,757.6	10.15	10.15 (7.01, 14.71)
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	2,804.5	4.99	4.99 (2.96, 8.43)
Single Sinuva Stent Use	2,835.9	9.87	9.87 (6.82, 14.30)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (28 day lag period)	3,862.2	5.18	5.18 (3.34, 8.03)
Single Propel Stent Use (fixed follow-up, 28 day lag period)	4,052.5	5.18	5.18 (3.38, 7.95)
Single Propel Stent Use	4,077.6	4.66	4.66 (2.97, 7.31)
Single Propel Stent Use (fixed follow-up)	4,270.5	4.68	4.68 (3.02, 7.26)
Single Sinuva Stent Use (28 day lag period)	4,455.4	9.20	9.20 (6.78, 12.50)
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	4,616.6	9.10	9.10 (6.72, 12.31)
Single Sinuva Stent Use	4,593.9	9.14	9.14 (6.76, 12.37)
Single Sinuva Stent Use (fixed follow-up)	4,757.9	9.04	9.04 (6.70, 12.19)
Single stent cohorts - Outcome: Ocular Hypertension			
Primary analysis cohorts (14-day lag period with fixed one year follow-up):			
Single Propel Stent Use	2,707.8	25.85	25.85 (20.45, 32.68)
Single Sinuva Stent Use	2,754.5	39.93	39.93 (33.13, 48.14)
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	2,781.4	25.17	25.17 (19.91, 31.81)
Single Sinuva Stent Use	2,793.3	39.38	39.38 (32.67, 47.47)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			

Table 2. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Single Propel Stent Use (14 day lag period)	3,925.0	21.15	21.15 (17.05, 26.22)
Single Propel Stent Use (fixed follow-up, 14 day lag period)	4,109.9	21.41	21.41 (17.37, 26.39)
Single Propel Stent Use	4,033.1	21.08	21.08 (17.04, 26.07)
Single Propel Stent Use (fixed follow-up)	4,219.1	21.09	21.09 (17.14, 25.97)
Single Sinuva Stent Use (14 day lag period)	4,420.2	33.48	33.48 (28.50, 39.34)
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	4,579.0	32.98	32.98 (28.11, 38.68)
Single Sinuva Stent Use	4,488.3	33.20	33.20 (28.27, 38.98)
Single Sinuva Stent Use (fixed follow-up)	4,648.5	32.70	32.70 (27.89, 38.33)
Single stent cohorts - Outcome: Diminished visual acuity			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use	2,640.0	25.38	25.38 (19.97, 32.25)
Single Sinuva Stent Use	2,736.0	26.68	26.68 (21.21, 33.56)
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	2,780.4	25.90	25.90 (20.55, 32.62)
Single Sinuva Stent Use	2,811.7	27.03	27.03 (21.59, 33.84)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (28 day lag period)	3,810.5	24.93	24.93 (20.39, 30.48)
Single Propel Stent Use (fixed follow-up, 28 day lag period)	3,997.4	25.02	25.02 (20.56, 30.43)
Single Propel Stent Use	4,018.1	25.14	25.14 (20.68, 30.55)
Single Propel Stent Use (fixed follow-up)	4,207.7	24.72	24.72 (20.39, 29.95)
Single Sinuva Stent Use (28 day lag period)	4,385.7	29.64	29.64 (24.96, 35.20)
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	4,543.4	29.49	29.49 (24.90, 34.93)
Single Sinuva Stent Use	4,521.4	29.42	29.42 (24.82, 34.86)
Single Sinuva Stent Use (fixed follow-up)	4,682.2	29.05	29.05 (24.55, 34.36)
Single stent cohorts - Outcome: Nasal Septal Perforation			
Primary analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	2,806.2	3.92	3.92 (2.17, 7.08)
Single Sinuva Stent Use	*****	3.17	3.17 (1.65, 6.08)
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):			
Single Propel Stent Use	*****	0.36	0.36 (0.05, 2.53)
Single Sinuva Stent Use	*****	0.70	0.70 (0.18, 2.81)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use	4,085.7	2.94	2.94 (1.67, 5.17)
Single Propel Stent Use (fixed follow-up)	4,278.6	2.80	2.80 (1.59, 4.94)
Single Propel Stent Use (1 day lag period)	*****	0.49	0.49 (0.12, 1.96)
Single Propel Stent Use (fixed follow-up, 1 day lag period)	*****	0.47	0.47 (0.12, 1.87)
Single Sinuva Stent Use	*****	1.95	1.95 (1.01, 3.74)
Single Sinuva Stent Use (fixed follow-up)	*****	1.88	1.88 (0.98, 3.61)
Single Sinuva Stent Use (1 day lag period)	*****	0.43	0.43 (0.11, 1.73)

Table 2. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	*****	0.42	0.42 (0.10, 1.67)
Repeat stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days	*****	64.72	64.72 (33.68, 124.39)
Sinuva Repeat Stent within 730 days	*****	59.72	59.72 (31.08, 114.79)
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days	206.7	58.07	58.07 (32.98, 102.25)
Sinuva Repeat Stent within 365 days (fixed follow-up)	217.3	55.21	55.21 (31.36, 97.22)
Sinuva Repeat Stent within 730 days	222.3	53.99	53.99 (30.66, 95.07)
Sinuva Repeat Stent within 730 days (fixed follow-up)	233.0	51.51	51.51 (29.25, 90.69)
Repeat stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days	*****	10.63	10.63 (2.66, 42.52)
Sinuva Repeat Stent within 730 days	*****	9.59	9.59 (2.40, 38.36)
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days	*****	6.70	6.70 (1.68, 26.80)
Sinuva Repeat Stent within 365 days (fixed follow-up)	*****	6.45	6.45 (1.61, 25.81)
Sinuva Repeat Stent within 730 days	*****	6.12	6.12 (1.53, 24.48)
Sinuva Repeat Stent within 730 days (fixed follow-up)	*****	5.90	5.90 (1.48, 23.59)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Single stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,809	1,809	29
Male	2,115	2,115	32
Single Sinuva Stent Use			
Female	1,574	1,574	73
Male	1,819	1,819	59
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,809	1,809	31
Male	2,115	2,115	32
Single Sinuva Stent Use			
Female	1,574	1,574	61
Male	1,819	1,819	49
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (273 day lag period)			
Female	1,809	1,809	34
Male	2,115	2,115	38
Single Propel Stent Use (fixed follow-up, 273 day lag period)			
Female	1,809	1,809	36
Male	2,115	2,115	41
Single Propel Stent Use			
Female	1,809	1,809	51
Male	2,115	2,115	55
Single Propel Stent Use (fixed follow-up)			
Female	1,809	1,809	52
Male	2,115	2,115	58
Single Sinuva Stent Use (273 day lag period)			
Female	1,574	1,574	93
Male	1,819	1,819	82
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)			
Female	1,574	1,574	94
Male	1,819	1,819	86
Single Sinuva Stent Use			
Female	1,574	1,574	105
Male	1,819	1,819	89
Single Sinuva Stent Use (fixed follow-up)			
Female	1,574	1,574	105
Male	1,819	1,819	93
Single stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,809	1,809	*****
Male	2,115	2,115	*****
Single Sinuva Stent Use			

Table 3. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Female	1,574	1,574	16
Male	1,819	1,819	12
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,809	1,809	*****
Male	2,115	2,115	*****
Single Sinuva Stent Use			
Female	1,574	1,574	16
Male	1,819	1,819	12
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use Cohort (28 day lag period)			
Female	1,809	1,809	*****
Male	2,115	2,115	*****
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)			
Female	1,809	1,809	*****
Male	2,115	2,115	*****
Single Propel Stent Use			
Female	1,809	1,809	*****
Male	2,115	2,115	*****
Single Propel Stent Use Cohort (fixed follow-up)			
Female	1,809	1,809	*****
Male	2,115	2,115	*****
Single Sinuva Stent Use (28 day lag period)			
Female	1,574	1,574	22
Male	1,819	1,819	19
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)			
Male	1,819	1,819	20
Single Sinuva Stent Use			
Female	1,574	1,574	23
Male	1,819	1,819	19
Single Sinuva Stent Use (fixed follow-up)			
Female	1,574	1,574	23
Male	1,819	1,819	20
Single stent cohorts - Outcome: Ocular Hypertension			
Primary analysis cohorts (14-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,809	1,809	40
Male	2,115	2,115	30
Single Sinuva Stent Use			
Female	1,574	1,574	66
Male	1,819	1,819	44
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,809	1,809	41
Male	2,115	2,115	29
Single Sinuva Stent Use			

Table 3. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Female	1,574	1,574	66
Male	1,819	1,819	44
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (14 day lag period)			
Female	1,809	1,809	50
Male	2,115	2,115	33
Single Propel Stent Use (fixed follow-up, 14 day lag period)			
Female	1,809	1,809	51
Male	2,115	2,115	37
Single Propel Stent Use			
Female	1,809	1,809	51
Male	2,115	2,115	34
Single Propel Stent Use (fixed follow-up)			
Female	1,809	1,809	52
Male	2,115	2,115	37
Single Sinuva Stent Use (14 day lag period)			
Female	1,574	1,574	95
Male	1,819	1,819	53
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)			
Female	1,574	1,574	95
Male	1,819	1,819	56
Single Sinuva Stent Use			
Female	1,574	1,574	96
Male	1,819	1,819	53
Single Sinuva Stent Use (fixed follow-up)			
Female	1,574	1,574	96
Male	1,819	1,819	56
Single stent cohorts - Outcome: Diminished Visual Acuity			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,809	1,809	35
Male	2,115	2,115	32
Single Sinuva Stent Use			
Female	1,574	1,574	39
Male	1,819	1,819	34
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,809	1,809	40
Male	2,115	2,115	32
Single Sinuva Stent Use			
Female	1,574	1,574	39
Male	1,819	1,819	37
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (28 day lag period)			
Female	1,809	1,809	52
Male	2,115	2,115	43

Table 3. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Single Propel Stent Use (fixed follow-up, 28 day lag period)			
Female	1,809	1,809	53
Male	2,115	2,115	47
Single Propel Stent Use			
Female	1,809	1,809	55
Male	2,115	2,115	46
Single Propel Stent Use (fixed follow-up)			
Female	1,809	1,809	56
Male	2,115	2,115	48
Single Sinuva Stent Use (28 day lag period)			
Female	1,574	1,574	73
Male	1,819	1,819	57
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)			
Female	1,574	1,574	74
Male	1,819	1,819	60
Single Sinuva Stent Use			
Female	1,574	1,574	73
Male	1,819	1,819	60
Single Sinuva Stent Use (fixed follow-up)			
Female	1,574	1,574	74
Male	1,819	1,819	62
Single stent cohorts - Outcome: Nasal Septal Perforation			
Primary analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,809	1,809	*****
Male	2,115	2,115	*****
Single Sinuva Stent Use			
Female	1,574	1,574	*****
Male	1,819	1,819	*****
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,809	1,809	*****
Male	2,115	2,115	*****
Single Sinuva Stent Use			
Female	1,574	1,574	*****
Male	1,819	1,819	*****
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use			
Female	1,809	1,809	*****
Male	2,115	2,115	*****
Single Propel Stent Use (fixed follow-up)			
Female	1,809	1,809	*****
Male	2,115	2,115	*****
Single Propel Stent Use (1 day lag period)			
Female	1,809	1,809	*****
Male	2,115	2,115	*****

Table 3. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Single Propel Stent Use (fixed follow-up, 1 day lag period)			
Female	1,809	1,809	*****
Male	2,115	2,115	*****
Single Sinuva Stent Use			
Female	1,574	1,574	*****
Male	1,819	1,819	*****
Single Sinuva Stent Use (fixed follow-up)			
Female	1,574	1,574	*****
Male	1,819	1,819	*****
Single Sinuva Stent Use (1 day lag period)			
Female	1,574	1,574	*****
Male	1,819	1,819	*****
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)			
Female	1,574	1,574	*****
Male	1,819	1,819	*****
Repeat stent cohorts - Outcome: Cataract Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days			
Female	106	106	*****
Male	125	125	*****
Sinuva Repeat Stent within 730 days			
Female	116	116	*****
Male	142	142	*****
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days			
Female	106	106	*****
Male	125	125	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)			
Female	106	106	*****
Male	125	125	*****
Sinuva Repeat Stent within 730 days			
Female	116	116	*****
Male	142	142	*****
Sinuva Repeat Stent within 730 days (fixed follow-up)			
Female	116	116	*****
Male	142	142	*****
Repeat stent cohorts - Outcome: Glaucoma Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days			
Female	106	106	*****
Male	125	125	*****
Sinuva Repeat Stent within 730 days			
Female	116	116	*****
Male	142	142	*****
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days			

Table 3. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Sex

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Female	106	106	*****
Male	125	125	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)			
Female	106	106	*****
Male	125	125	*****
Sinuva Repeat Stent within 730 days			
Female	116	116	*****
Male	142	142	*****
Sinuva Repeat Stent within 730 days (fixed follow-up)			
Female	116	116	*****
Male	142	142	*****

Table 3. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Sex

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Single stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	776.6	37.34	37.34 (25.95, 53.73)
Male	926.5	34.54	34.54 (24.42, 48.84)
Single Sinuva Stent Use			
Female	970.9	75.19	75.19 (59.77, 94.57)
Male	1,124.6	52.46	52.46 (40.65, 67.71)
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,269.8	24.41	24.41 (17.17, 34.72)
Male	1,514.5	21.13	21.13 (14.94, 29.88)
Single Sinuva Stent Use			
Female	1,293.8	47.15	47.15 (36.68, 60.60)
Male	1,498.9	32.69	32.69 (24.71, 43.25)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (273 day lag period)			
Female	1,111.1	30.60	30.60 (21.86, 42.83)
Male	1,289.6	29.47	29.47 (21.44, 40.50)
Single Propel Stent Use (fixed follow-up, 273 day lag period)			
Female	1,171.6	30.73	30.73 (22.16, 42.60)
Male	1,371.2	29.90	29.90 (22.02, 40.61)
Single Propel Stent Use			
Female	1,844.4	27.65	27.65 (21.01, 36.38)
Male	2,179.0	25.24	25.24 (19.38, 32.88)
Single Propel Stent Use (fixed follow-up)			
Female	1,923.2	27.04	27.04 (20.60, 35.48)
Male	2,288.6	25.34	25.34 (19.59, 32.78)
Single Sinuva Stent Use (273 day lag period)			
Female	1,477.7	62.94	62.94 (51.36, 77.12)
Male	1,701.5	48.19	48.19 (38.81, 59.84)
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)			
Female	1,528.3	61.51	61.51 (50.25, 75.29)
Male	1,777.3	48.39	48.39 (39.17, 59.78)
Single Sinuva Stent Use			
Female	2,065.3	50.84	50.84 (41.99, 61.56)
Male	2,382.7	37.35	37.35 (30.35, 45.98)
Single Sinuva Stent Use (fixed follow-up)			
Female	2,127.2	49.36	49.36 (40.77, 59.76)
Male	2,480.9	37.49	37.49 (30.59, 45.94)
Single stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	*****	4.94	4.94 (2.22, 11.00)
Male	*****	5.53	5.53 (2.77, 11.06)

Table 3. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Sex

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Single Sinuva Stent Use			
Female	1,282.3	12.48	12.48 (7.64, 20.37)
Male	1,475.3	8.13	8.13 (4.62, 14.32)
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	*****	4.68	4.68 (2.10, 10.43)
Male	*****	5.25	5.25 (2.63, 10.50)
Single Sinuva Stent Use			
Female	1,318.7	12.13	12.13 (7.43, 19.81)
Male	1,517.3	7.91	7.91 (4.49, 13.93)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use Cohort (28 day lag period)			
Female	*****	4.51	4.51 (2.26, 9.02)
Male	*****	5.74	5.74 (3.26, 10.11)
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)			
Female	*****	4.32	4.32 (2.16, 8.64)
Male	*****	5.91	5.91 (3.43, 10.17)
Single Propel Stent Use			
Female	*****	4.27	4.27 (2.14, 8.55)
Male	*****	4.99	4.99 (2.76, 9.00)
Single Propel Stent Use Cohort (fixed follow-up)			
Female	*****	4.10	4.10 (2.05, 8.20)
Male	*****	5.18	5.18 (2.94, 9.11)
Single Sinuva Stent Use (28 day lag period)			
Female	2,082.3	10.57	10.57 (6.96, 16.05)
Male	2,373.1	8.01	8.01 (5.11, 12.55)
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)			
Female	2,143.2	10.26	10.26 (6.76, 15.59)
Male	2,473.3	8.09	8.09 (5.22, 12.53)
Single Sinuva Stent Use			
Female	2,147.6	10.71	10.71 (7.12, 16.12)
Male	2,446.3	7.77	7.77 (4.95, 12.18)
Single Sinuva Stent Use (fixed follow-up)			
Female	2,209.5	10.41	10.41 (6.92, 15.67)
Male	2,548.5	7.85	7.85 (5.06, 12.16)
Single stent cohorts - Outcome: Ocular Hypertension			
Primary analysis cohorts (14-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,232.4	32.46	32.46 (23.81, 44.25)
Male	1,475.3	20.33	20.33 (14.22, 29.08)
Single Sinuva Stent Use			
Female	1,271.8	51.89	51.89 (40.77, 66.05)
Male	1,482.7	29.68	29.68 (22.08, 39.88)
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			

Table 3. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Sex

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Female	1,266.5	32.37	32.37 (23.84, 43.97)
Male	1,515.0	19.14	19.14 (13.30, 27.55)
Single Sinuva Stent Use			
Female	1,289.5	51.18	51.18 (40.21, 65.15)
Male	1,503.7	29.26	29.26 (21.77, 39.32)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (14 day lag period)			
Female	1,791.8	27.91	27.91 (21.15, 36.82)
Male	2,133.2	15.47	15.47 (11.00, 21.76)
Single Propel Stent Use (fixed follow-up, 14 day lag period)			
Female	1,870.4	27.27	27.27 (20.72, 35.88)
Male	2,239.5	16.52	16.52 (11.97, 22.80)
Single Propel Stent Use			
Female	1,840.7	27.71	27.71 (21.06, 36.46)
Male	2,192.4	15.51	15.51 (11.08, 21.70)
Single Propel Stent Use (fixed follow-up)			
Female	1,919.7	27.09	27.09 (20.64, 35.55)
Male	2,299.5	16.09	16.09 (11.66, 22.21)
Single Sinuva Stent Use (14 day lag period)			
Female	2,044.5	46.47	46.47 (38.00, 56.82)
Male	2,375.7	22.31	22.31 (17.04, 29.20)
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)			
Female	2,105.9	45.11	45.11 (36.89, 55.16)
Male	2,473.0	22.64	22.64 (17.43, 29.42)
Single Sinuva Stent Use			
Female	2,075.9	46.25	46.25 (37.86, 56.49)
Male	2,412.4	21.97	21.97 (16.78, 28.76)
Single Sinuva Stent Use (fixed follow-up)			
Female	2,137.8	44.91	44.91 (36.77, 54.85)
Male	2,510.7	22.30	22.30 (17.16, 28.98)
Single stent cohorts - Outcome: Diminished Visual Acuity Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,202.5	29.10	29.10 (20.90, 40.54)
Male	1,437.5	22.26	22.26 (15.74, 31.48)
Single Sinuva Stent Use			
Female	1,271.0	30.69	30.69 (22.42, 42.00)
Male	1,465.0	23.21	23.21 (16.58, 32.48)
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	1,266.5	31.58	31.58 (23.17, 43.06)
Male	1,513.9	21.14	21.14 (14.95, 29.89)
Single Sinuva Stent Use			
Female	1,306.2	29.86	29.86 (21.81, 40.87)
Male	1,505.5	24.58	24.58 (17.81, 33.92)

Table 3. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Sex

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (28 day lag period)			
Female	1,742.5	29.84	29.84 (22.74, 39.16)
Male	2,067.9	20.79	20.79 (15.42, 28.04)
Single Propel Stent Use (fixed follow-up, 28 day lag period)			
Female	1,821.2	29.10	29.10 (22.23, 38.09)
Male	2,176.2	21.60	21.60 (16.23, 28.74)
Single Propel Stent Use			
Female	1,837.0	29.94	29.94 (22.99, 39.00)
Male	2,181.1	21.09	21.09 (15.80, 28.16)
Single Propel Stent Use (fixed follow-up)			
Female	1,916.5	29.22	29.22 (22.49, 37.97)
Male	2,291.2	20.95	20.95 (15.79, 27.80)
Single Sinuva Stent Use (28 day lag period)			
Female	2,043.7	35.72	35.72 (28.40, 44.93)
Male	2,341.9	24.34	24.34 (18.77, 31.55)
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)			
Female	2,104.2	35.17	35.17 (28.00, 44.17)
Male	2,439.2	24.60	24.60 (19.10, 31.68)
Single Sinuva Stent Use			
Female	2,108.6	34.62	34.62 (27.52, 43.55)
Male	2,412.8	24.87	24.87 (19.31, 32.03)
Single Sinuva Stent Use (fixed follow-up)			
Female	2,170.0	34.10	34.10 (27.15, 42.83)
Male	2,512.2	24.68	24.68 (19.24, 31.65)
Single stent cohorts - Outcome: Nasal Septal Perforation			
Primary analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	*****	4.68	4.68 (2.10, 10.42)
Male	*****	3.28	3.28 (1.36, 7.88)
Single Sinuva Stent Use			
Female	*****	3.78	3.78 (1.57, 9.09)
Male	*****	2.63	2.63 (0.99, 7.01)
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
Female	*****	0.00	0.00 (0.00, 0.00)
Male	*****	0.66	0.66 (0.09, 4.66)
Single Sinuva Stent Use			
Female	*****	0.76	0.76 (0.11, 5.36)
Male	*****	0.66	0.66 (0.09, 4.66)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use			
Female	*****	3.73	3.73 (1.78, 7.83)
Male	*****	2.26	2.26 (0.94, 5.43)

Table 3. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Sex

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Single Propel Stent Use (fixed follow-up)			
Female	*****	3.58	3.58 (1.71, 7.51)
Male	*****	2.15	2.15 (0.90, 5.17)
Single Propel Stent Use (1 day lag period)			
Female	*****	0.53	0.53 (0.08, 3.79)
Male	*****	0.45	0.45 (0.06, 3.21)
Single Propel Stent Use (fixed follow-up, 1 day lag period)			
Female	*****	0.51	0.51 (0.07, 3.63)
Male	*****	0.43	0.43 (0.06, 3.05)
Single Sinuva Stent Use			
Female	*****	2.31	2.31 (0.96, 5.55)
Male	*****	1.63	1.63 (0.61, 4.33)
Single Sinuva Stent Use (fixed follow-up)			
Female	*****	2.25	2.25 (0.94, 5.40)
Male	*****	1.56	1.56 (0.59, 4.16)
Single Sinuva Stent Use (1 day lag period)			
Female	*****	0.46	0.46 (0.07, 3.28)
Male	*****	0.41	0.41 (0.06, 2.88)
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)			
Female	*****	0.45	0.45 (0.06, 3.19)
Male	*****	0.39	0.39 (0.05, 2.77)
Repeat stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days			
Female	*****	59.58	59.58 (22.36, 158.76)
Male	*****	69.52	69.52 (28.94, 167.03)
Sinuva Repeat Stent within 730 days			
Female	*****	55.75	55.75 (20.92, 148.55)
Male	*****	63.33	63.33 (26.36, 152.17)
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days			
Female	*****	60.46	60.46 (27.16, 134.58)
Male	*****	55.86	55.86 (25.09, 124.33)
Sinuva Repeat Stent within 365 days (fixed follow-up)			
Female	*****	56.71	56.71 (25.48, 126.24)
Male	*****	53.79	53.79 (24.17, 119.73)
Sinuva Repeat Stent within 730 days			
Female	*****	56.51	56.51 (25.39, 125.79)
Male	*****	51.68	51.68 (23.22, 115.04)
Sinuva Repeat Stent within 730 days (fixed follow-up)			
Female	*****	53.22	53.22 (23.91, 118.47)
Male	*****	49.89	49.89 (22.42, 111.06)
Repeat stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days			

Table 3. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Sex

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Female	*****	22.39	22.39 (5.60, 89.52)
Male	*****	0.00	0.00 (0.00, 0.00)
Sinuva Repeat Stent within 730 days			
Female	*****	20.70	20.70 (5.18, 82.78)
Male	*****	0.00	0.00 (0.00, 0.00)
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days			
Female	*****	14.07	14.07 (3.52, 56.25)
Male	*****	0.00	0.00 (0.00, 0.00)
Sinuva Repeat Stent within 365 days (fixed follow-up)			
Female	*****	13.46	13.46 (3.37, 53.84)
Male	*****	0.00	0.00 (0.00, 0.00)
Sinuva Repeat Stent within 730 days			
Female	*****	13.05	13.05 (3.26, 52.18)
Male	*****	0.00	0.00 (0.00, 0.00)
Sinuva Repeat Stent within 730 days (fixed follow-up)			
Female	*****	12.53	12.53 (3.13, 50.11)
Male	*****	0.00	0.00 (0.00, 0.00)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Single stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	306	306	0
25-40 years	1,260	1,260	0
41-64 years	1,839	1,839	14
≥ 65 years	519	519	47
Single Sinuva Stent Use			
18-24 years	168	168	0
25-40 years	714	714	0
41-64 years	1,374	1,374	22
≥ 65 years	1,137	1,137	110
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	306	306	0
25-40 years	1,260	1,260	0
41-64 years	1,839	1,839	19
≥ 65 years	519	519	44
Single Sinuva Stent Use			
18-24 years	168	168	0
25-40 years	714	714	0
41-64 years	1,374	1,374	12
≥ 65 years	1,137	1,137	98
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (273 day lag period)			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	54
Single Propel Stent Use (fixed follow-up, 273 day lag period)			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	58
Single Propel Stent Use			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	80
Single Propel Stent Use (fixed follow-up)			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
≥ 65 years	519	519	83
Single Sinuva Stent Use (273 day lag period)			
18-24 years	168	168	0
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	145
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)			
18-24 years	168	168	0
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	149
Single Sinuva Stent Use			
18-24 years	168	168	0
25-40 years	714	714	0
41-64 years	1,374	1,374	25
≥ 65 years	1,137	1,137	169
Single Sinuva Stent Use (fixed follow-up)			
18-24 years	168	168	0
25-40 years	714	714	0
41-64 years	1,374	1,374	26
≥ 65 years	1,137	1,137	172
Single stent cohorts - Outcome: Glaucoma Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	*****
Single Sinuva Stent Use			
18-24 years	168	168	*****
Single stent cohorts - Outcome: Glaucoma Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	*****
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	*****
Single Sinuva Stent Use			
18-24 years	168	168	*****
25-40 years	714	714	*****

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	17
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use Cohort (28 day lag period)			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	*****
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	*****
Single Propel Stent Use			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	*****
Single Propel Stent Use Cohort (fixed follow-up)			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	*****
Single Sinuva Stent Use (28 day lag period)			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	30
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	31
Single Sinuva Stent Use			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	30
Single Sinuva Stent Use (fixed follow-up)			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	31

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Single stent cohorts - Outcome: Ocular Hypertension			
Primary analysis cohorts (14-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	306	306	*****
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	32
≥ 65 years	519	519	25
Single Sinuva Stent Use			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	69
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	306	306	*****
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	32
≥ 65 years	519	519	25
Single Sinuva Stent Use			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	71
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (14 day lag period)			
18-24 years	306	306	*****
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	39
≥ 65 years	519	519	29
Single Propel Stent Use (fixed follow-up, 14 day lag period)			
18-24 years	306	306	*****
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	41
≥ 65 years	519	519	32
Single Propel Stent Use			
18-24 years	306	306	*****
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	39
≥ 65 years	519	519	31
Single Propel Stent Use (fixed follow-up)			
18-24 years	306	306	*****
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	41

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
≥ 65 years	519	519	33
Single Sinuva Stent Use (14 day lag period)			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	95
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	97
Single Sinuva Stent Use			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	97
Single Sinuva Stent Use (fixed follow-up)			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	99
Single stent cohorts - Outcome: Diminished Visual Acuity			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	306	306	*****
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	27
≥ 65 years	519	519	20
Single Sinuva Stent Use			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	22
≥ 65 years	1,137	1,137	37
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	306	306	*****
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	31
≥ 65 years	519	519	20
Single Sinuva Stent Use			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	21

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
≥ 65 years	1,137	1,137	39
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (28 day lag period)			
18-24 years	306	306	*****
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	42
≥ 65 years	519	519	25
Single Propel Stent Use (fixed follow-up, 28 day lag period)			
18-24 years	306	306	*****
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	45
≥ 65 years	519	519	27
Single Propel Stent Use			
18-24 years	306	306	*****
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	47
≥ 65 years	519	519	25
Single Propel Stent Use (fixed follow-up)			
18-24 years	306	306	*****
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	48
≥ 65 years	519	519	27
Single Sinuva Stent Use (28 day lag period)			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	42
≥ 65 years	1,137	1,137	66
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	44
≥ 65 years	1,137	1,137	68
Single Sinuva Stent Use			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	41
≥ 65 years	1,137	1,137	67
Single Sinuva Stent Use (fixed follow-up)			
18-24 years	168	168	*****
25-40 years	714	714	*****
41-64 years	1,374	1,374	42
≥ 65 years	1,137	1,137	69

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Single stent cohorts - Outcome: Nasal Septal Perforation			
Primary analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	*****
Single Sinuva Stent Use			
18-24 years	168	168	0
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	*****
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	306	306	0
25-40 years	1,260	1,260	0
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	*****
Single Sinuva Stent Use			
18-24 years	168	168	0
25-40 years	714	714	*****
41-64 years	1,374	1,374	0
≥ 65 years	1,137	1,137	*****
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	*****
Single Propel Stent Use (fixed follow-up)			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	*****
Single Propel Stent Use (1 day lag period)			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****
≥ 65 years	519	519	0
Single Propel Stent Use (fixed follow-up, 1 day lag period)			
18-24 years	306	306	0
25-40 years	1,260	1,260	*****
41-64 years	1,839	1,839	*****

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
≥ 65 years	519	519	0
Single Sinuva Stent Use			
18-24 years	168	168	0
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	*****
Single Sinuva Stent Use (fixed follow-up)			
18-24 years	168	168	0
25-40 years	714	714	*****
41-64 years	1,374	1,374	*****
≥ 65 years	1,137	1,137	*****
Single Sinuva Stent Use (1 day lag period)			
18-24 years	168	168	0
25-40 years	714	714	*****
41-64 years	1,374	1,374	0
≥ 65 years	1,137	1,137	*****
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)			
18-24 years	168	168	0
25-40 years	714	714	*****
41-64 years	1,374	1,374	0
≥ 65 years	1,137	1,137	*****
Repeat stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days			
18-24 years	11	11	0
25-40 years	48	48	0
41-64 years	101	101	*****
≥ 65 years	71	71	*****
Sinuva Repeat Stent within 730 days			
18-24 years	12	12	0
25-40 years	51	51	0
41-64 years	110	110	*****
≥ 65 years	85	85	*****
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days			
18-24 years	11	11	0
25-40 years	48	48	0
41-64 years	101	101	*****
≥ 65 years	71	71	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)			
18-24 years	11	11	0
25-40 years	48	48	0
41-64 years	101	101	*****
≥ 65 years	71	71	*****

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Sinuva Repeat Stent within 730 days			
18-24 years	12	12	0
25-40 years	51	51	0
41-64 years	110	110	*****
≥ 65 years	85	85	*****
Sinuva Repeat Stent within 730 days (fixed follow-up)			
18-24 years	12	12	0
25-40 years	51	51	0
41-64 years	110	110	*****
≥ 65 years	85	85	*****
Repeat stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days			
18-24 years	11	11	0
25-40 years	48	48	0
41-64 years	101	101	*****
≥ 65 years	71	71	*****
Sinuva Repeat Stent within 730 days			
18-24 years	12	12	0
25-40 years	51	51	0
41-64 years	110	110	*****
≥ 65 years	85	85	*****
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days			
18-24 years	11	11	0
25-40 years	48	48	0
41-64 years	101	101	*****
≥ 65 years	71	71	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)			
18-24 years	11	11	0
25-40 years	48	48	0
41-64 years	101	101	*****
≥ 65 years	71	71	*****
Sinuva Repeat Stent within 730 days			
18-24 years	12	12	0
25-40 years	51	51	0
41-64 years	110	110	*****
≥ 65 years	85	85	*****
Sinuva Repeat Stent within 730 days (fixed follow-up)			
18-24 years	12	12	0
25-40 years	51	51	0
41-64 years	110	110	*****
≥ 65 years	85	85	*****

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Single stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	140.3	0.00	0.00 (0.00, 0.00)
25-40 years	460.8	0.00	0.00 (0.00, 0.00)
41-64 years	834.9	16.77	16.77 (9.93, 28.31)
≥ 65 years	267.2	175.93	175.93 (132.18, 234.15)
Single Sinuva Stent Use			
18-24 years	79.2	0.00	0.00 (0.00, 0.00)
25-40 years	379.3	0.00	0.00 (0.00, 0.00)
41-64 years	839.4	26.21	26.21 (17.26, 39.81)
≥ 65 years	797.7	137.90	137.90 (114.39, 166.23)
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	226.0	0.00	0.00 (0.00, 0.00)
25-40 years	847.6	0.00	0.00 (0.00, 0.00)
41-64 years	1,315.0	14.45	14.45 (9.22, 22.65)
≥ 65 years	395.6	111.22	111.22 (82.77, 149.45)
Single Sinuva Stent Use			
18-24 years	129.2	0.00	0.00 (0.00, 0.00)
25-40 years	564.0	0.00	0.00 (0.00, 0.00)
41-64 years	1,137.1	10.55	10.55 (5.99, 18.58)
≥ 65 years	962.4	101.83	101.83 (83.54, 124.12)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (273 day lag period)			
18-24 years	201.5	0.00	0.00 (0.00, 0.00)
25-40 years	*****	1.51	1.51 (0.21, 10.72)
41-64 years	*****	14.21	14.21 (8.83, 22.85)
≥ 65 years	340.3	158.69	158.69 (121.54, 207.20)
Single Propel Stent Use (fixed follow-up, 273 day lag period)			
18-24 years	210.9	0.00	0.00 (0.00, 0.00)
25-40 years	*****	1.46	1.46 (0.21, 10.40)
41-64 years	*****	14.15	14.15 (8.92, 22.46)
≥ 65 years	377.2	153.75	153.75 (118.87, 198.88)
Single Propel Stent Use			
18-24 years	332.5	0.00	0.00 (0.00, 0.00)
25-40 years	*****	0.84	0.84 (0.12, 5.93)
41-64 years	*****	12.90	12.90 (8.72, 19.09)
≥ 65 years	556.0	143.90	143.90 (115.58, 179.15)
Single Propel Stent Use (fixed follow-up)			
18-24 years	345.1	0.00	0.00 (0.00, 0.00)
25-40 years	*****	0.81	0.81 (0.11, 5.77)
41-64 years	*****	12.79	12.79 (8.71, 18.79)
≥ 65 years	603.5	137.54	137.54 (110.91, 170.55)

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Single Sinuva Stent Use (273 day lag period)			
18-24 years	112.0	0.00	0.00 (0.00, 0.00)
25-40 years	*****	1.75	1.75 (0.25, 12.40)
41-64 years	*****	22.35	22.35 (15.53, 32.16)
≥ 65 years	1,197.1	121.13	121.13 (102.93, 142.54)
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)			
18-24 years	119.7	0.00	0.00 (0.00, 0.00)
25-40 years	*****	1.68	1.68 (0.24, 11.94)
41-64 years	*****	22.08	22.08 (15.44, 31.58)
≥ 65 years	1,232.3	120.91	120.91 (102.98, 141.97)
Single Sinuva Stent Use			
18-24 years	185.7	0.00	0.00 (0.00, 0.00)
25-40 years	866.7	0.00	0.00 (0.00, 0.00)
41-64 years	1,812.5	13.79	13.79 (9.32, 20.41)
≥ 65 years	1,583.1	106.75	106.75 (91.81, 124.12)
Single Sinuva Stent Use (fixed follow-up)			
18-24 years	195.3	0.00	0.00 (0.00, 0.00)
25-40 years	896.6	0.00	0.00 (0.00, 0.00)
41-64 years	1,889.1	13.76	13.76 (9.37, 20.21)
≥ 65 years	1,627.0	105.72	105.72 (91.04, 122.76)
Single stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	215.5	0.00	0.00 (0.00, 0.00)
25-40 years	*****	3.79	3.79 (1.22, 11.75)
41-64 years	*****	3.99	3.99 (1.66, 9.59)
≥ 65 years	*****	15.01	15.01 (6.74, 33.42)
Single Sinuva Stent Use			
18-24 years	*****	8.09	8.09 (1.14, 57.45)
25-40 years	*****	1.84	1.84 (0.26, 13.08)
41-64 years	*****	7.26	7.26 (3.63, 14.51)
≥ 65 years	*****	18.20	18.20 (11.47, 28.89)
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	226.0	0.00	0.00 (0.00, 0.00)
25-40 years	*****	3.55	3.55 (1.14, 11.00)
41-64 years	*****	3.79	3.79 (1.58, 9.11)
≥ 65 years	*****	14.47	14.47 (6.50, 32.22)
Single Sinuva Stent Use			
18-24 years	*****	7.76	7.76 (1.09, 55.13)
25-40 years	*****	1.77	1.77 (0.25, 12.59)
41-64 years	*****	7.92	7.92 (4.12, 15.22)

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
≥ 65 years	1,006.9	16.88	16.88 (10.50, 27.16)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use Cohort (28 day lag period)			
18-24 years	315.7	0.00	0.00 (0.00, 0.00)
25-40 years	*****	2.68	2.68 (0.86, 8.30)
41-64 years	*****	3.78	3.78 (1.80, 7.94)
≥ 65 years	*****	17.35	17.35 (9.33, 32.24)
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)			
18-24 years	328.4	0.00	0.00 (0.00, 0.00)
25-40 years	*****	2.60	2.60 (0.84, 8.07)
41-64 years	*****	3.60	3.60 (1.72, 7.55)
≥ 65 years	*****	17.54	17.54 (9.71, 31.68)
Single Propel Stent Use			
18-24 years	332.5	0.00	0.00 (0.00, 0.00)
25-40 years	*****	2.51	2.51 (0.81, 7.80)
41-64 years	*****	3.59	3.59 (1.71, 7.54)
≥ 65 years	*****	14.91	14.91 (7.76, 28.66)
Single Propel Stent Use Cohort (fixed follow-up)			
18-24 years	345.1	0.00	0.00 (0.00, 0.00)
25-40 years	*****	2.44	2.44 (0.79, 7.58)
41-64 years	*****	3.43	3.43 (1.63, 7.19)
≥ 65 years	*****	15.27	15.27 (8.21, 28.37)
Single Sinuva Stent Use (28 day lag period)			
18-24 years	*****	5.66	5.66 (0.80, 40.22)
25-40 years	*****	1.20	1.20 (0.17, 8.53)
41-64 years	*****	5.10	5.10 (2.65, 9.81)
≥ 65 years	1,683.3	17.82	17.82 (12.46, 25.49)
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)			
18-24 years	*****	5.37	5.37 (0.76, 38.14)
25-40 years	*****	1.16	1.16 (0.16, 8.25)
41-64 years	*****	4.89	4.89 (2.54, 9.40)
≥ 65 years	1,729.6	17.92	17.92 (12.60, 25.49)
Single Sinuva Stent Use			
18-24 years	*****	5.40	5.40 (0.76, 38.32)
25-40 years	*****	1.15	1.15 (0.16, 8.20)
41-64 years	*****	5.49	5.49 (2.96, 10.21)
≥ 65 years	1,721.9	17.42	17.42 (12.18, 24.92)
Single Sinuva Stent Use (fixed follow-up)			
18-24 years	*****	5.13	5.13 (0.72, 36.42)
25-40 years	*****	1.12	1.12 (0.16, 7.92)
41-64 years	*****	5.27	5.27 (2.83, 9.79)

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
≥ 65 years	1,769.0	17.52	17.52 (12.32, 24.92)
Single stent cohorts - Outcome: Ocular Hypertension			
Primary analysis cohorts (14-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	*****	13.64	13.64 (4.40, 42.30)
25-40 years	*****	12.26	12.26 (6.59, 22.78)
41-64 years	1,273.9	25.12	25.12 (17.76, 35.52)
≥ 65 years	398.1	62.80	62.80 (42.44, 92.94)
Single Sinuva Stent Use			
18-24 years	*****	7.94	7.94 (1.12, 56.35)
25-40 years	*****	10.89	10.89 (4.89, 24.24)
41-64 years	*****	30.69	30.69 (21.93, 42.96)
≥ 65 years	969.9	71.14	71.14 (56.19, 90.07)
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	*****	13.32	13.32 (4.30, 41.30)
25-40 years	*****	11.86	11.86 (6.38, 22.04)
41-64 years	1,307.9	24.47	24.47 (17.30, 34.60)
≥ 65 years	404.9	61.75	61.75 (41.72, 91.39)
Single Sinuva Stent Use			
18-24 years	*****	7.77	7.77 (1.09, 55.18)
25-40 years	*****	10.68	10.68 (4.80, 23.78)
41-64 years	*****	28.48	28.48 (20.14, 40.27)
≥ 65 years	979.2	72.51	72.51 (57.46, 91.50)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (14 day lag period)			
18-24 years	*****	9.28	9.28 (2.99, 28.78)
25-40 years	*****	10.44	10.44 (5.93, 18.38)
41-64 years	1,876.3	20.79	20.79 (15.19, 28.45)
≥ 65 years	575.6	50.38	50.38 (35.01, 72.50)
Single Propel Stent Use (fixed follow-up, 14 day lag period)			
18-24 years	*****	8.93	8.93 (2.88, 27.70)
25-40 years	*****	10.14	10.14 (5.76, 17.86)
41-64 years	1,968.8	20.82	20.82 (15.33, 28.28)
≥ 65 years	621.9	51.45	51.45 (36.39, 72.76)
Single Propel Stent Use			
18-24 years	*****	9.05	9.05 (2.92, 28.05)
25-40 years	*****	10.11	10.11 (5.74, 17.79)
41-64 years	1,926.7	20.24	20.24 (14.79, 27.71)
≥ 65 years	587.4	52.78	52.78 (37.12, 75.04)
Single Propel Stent Use (fixed follow-up)			
18-24 years	*****	8.72	8.72 (2.81, 27.02)
25-40 years	*****	9.82	9.82 (5.58, 17.30)
41-64 years	2,019.4	20.30	20.30 (14.95, 27.57)

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
≥ 65 years	634.1	52.04	52.04 (37.00, 73.21)
Single Sinuva Stent Use (14 day lag period)			
18-24 years	*****	5.57	5.57 (0.78, 39.52)
25-40 years	*****	10.68	10.68 (5.56, 20.53)
41-64 years	*****	24.43	24.43 (18.12, 32.94)
≥ 65 years	1,637.7	58.01	58.01 (47.44, 70.93)
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)			
18-24 years	*****	5.28	5.28 (0.74, 37.51)
25-40 years	*****	10.32	10.32 (5.37, 19.83)
41-64 years	*****	23.97	23.97 (17.83, 32.20)
≥ 65 years	1,681.5	57.69	57.69 (47.28, 70.39)
Single Sinuva Stent Use			
18-24 years	*****	5.43	5.43 (0.77, 38.56)
25-40 years	*****	10.46	10.46 (5.44, 20.11)
41-64 years	*****	23.51	23.51 (17.37, 31.81)
≥ 65 years	1,657.3	58.53	58.53 (47.97, 71.41)
Single Sinuva Stent Use (fixed follow-up)			
18-24 years	*****	5.16	5.16 (0.73, 36.64)
25-40 years	*****	10.11	10.11 (5.26, 19.43)
41-64 years	*****	23.08	23.08 (17.12, 31.12)
≥ 65 years	1,701.6	58.18	58.18 (47.78, 70.85)
Single stent cohorts - Outcome: Diminished Visual Acuity			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	*****	4.66	4.66 (0.66, 33.05)
25-40 years	*****	24.22	24.22 (15.45, 37.97)
41-64 years	1,247.6	21.64	21.64 (14.84, 31.56)
≥ 65 years	393.0	50.89	50.89 (32.83, 78.88)
Single Sinuva Stent Use			
18-24 years	*****	8.09	8.09 (1.14, 57.46)
25-40 years	*****	24.23	24.23 (14.07, 41.72)
41-64 years	1,096.1	20.07	20.07 (13.22, 30.48)
≥ 65 years	979.7	37.77	37.77 (27.36, 52.13)
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	*****	8.91	8.91 (2.23, 35.63)
25-40 years	*****	22.66	22.66 (14.46, 35.53)
41-64 years	1,308.9	23.68	23.68 (16.66, 33.68)
≥ 65 years	408.7	48.93	48.93 (31.57, 75.85)
Single Sinuva Stent Use			
18-24 years	*****	7.77	7.77 (1.09, 55.13)
25-40 years	*****	26.97	26.97 (16.26, 44.73)
41-64 years	1,129.0	18.60	18.60 (12.13, 28.53)
≥ 65 years	997.7	39.09	39.09 (28.56, 53.50)

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (28 day lag period)			
18-24 years	*****	9.55	9.55 (3.08, 29.62)
25-40 years	*****	22.67	22.67 (15.32, 33.54)
41-64 years	1,829.2	22.96	22.96 (16.97, 31.07)
≥ 65 years	564.2	44.31	44.31 (29.94, 65.57)
Single Propel Stent Use (fixed follow-up, 28 day lag period)			
18-24 years	*****	9.18	9.18 (2.96, 28.47)
25-40 years	*****	22.01	22.01 (14.87, 32.57)
41-64 years	1,922.8	23.40	23.40 (17.47, 31.35)
≥ 65 years	612.0	44.12	44.12 (30.26, 64.33)
Single Propel Stent Use			
18-24 years	*****	12.16	12.16 (4.56, 32.39)
25-40 years	*****	21.26	21.26 (14.36, 31.46)
41-64 years	1,921.4	24.46	24.46 (18.38, 32.56)
≥ 65 years	591.6	42.26	42.26 (28.56, 62.54)
Single Propel Stent Use (fixed follow-up)			
18-24 years	*****	11.71	11.71 (4.39, 31.19)
25-40 years	*****	20.66	20.66 (13.96, 30.58)
41-64 years	2,015.7	23.81	23.81 (17.95, 31.60)
≥ 65 years	640.3	42.17	42.17 (28.92, 61.49)
Single Sinuva Stent Use (28 day lag period)			
18-24 years	*****	5.67	5.67 (0.80, 40.22)
25-40 years	*****	25.82	25.82 (16.83, 39.59)
41-64 years	1,741.5	24.12	24.12 (17.82, 32.63)
≥ 65 years	1,654.2	39.90	39.90 (31.35, 50.78)
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)			
18-24 years	*****	5.37	5.37 (0.76, 38.15)
25-40 years	*****	24.93	24.93 (16.25, 38.23)
41-64 years	1,817.2	24.21	24.21 (18.02, 32.54)
≥ 65 years	1,697.6	40.06	40.06 (31.58, 50.80)
Single Sinuva Stent Use			
18-24 years	*****	5.40	5.40 (0.76, 38.33)
25-40 years	*****	28.38	28.38 (19.02, 42.34)
41-64 years	1,798.3	22.80	22.80 (16.79, 30.97)
≥ 65 years	1,692.3	39.59	39.59 (31.16, 50.30)
Single Sinuva Stent Use (fixed follow-up)			
18-24 years	*****	5.13	5.13 (0.72, 36.43)
25-40 years	*****	27.41	27.41 (18.37, 40.90)
41-64 years	1,875.1	22.40	22.40 (16.55, 30.31)
≥ 65 years	1,736.6	39.73	39.73 (31.38, 50.31)
Single stent cohorts - Outcome: Nasal Septal Perforation			
Primary analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
18-24 years	226.0	0.00	0.00 (0.00, 0.00)
25-40 years	*****	2.36	2.36 (0.59, 9.45)
41-64 years	*****	6.07	6.07 (3.04, 12.14)
≥ 65 years	*****	2.41	2.41 (0.34, 17.08)
Single Sinuva Stent Use			
18-24 years	129.2	0.00	0.00 (0.00, 0.00)
25-40 years	*****	5.34	5.34 (1.72, 16.56)
41-64 years	*****	1.75	1.75 (0.44, 7.01)
≥ 65 years	*****	3.95	3.95 (1.48, 10.53)
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
18-24 years	225.7	0.00	0.00 (0.00, 0.00)
25-40 years	845.6	0.00	0.00 (0.00, 0.00)
41-64 years	*****	0.76	0.76 (0.11, 5.38)
≥ 65 years	*****	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use			
18-24 years	129.0	0.00	0.00 (0.00, 0.00)
25-40 years	*****	1.78	1.78 (0.25, 12.62)
41-64 years	1,140.4	0.00	0.00 (0.00, 0.00)
≥ 65 years	*****	0.99	0.99 (0.14, 7.00)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use			
18-24 years	332.5	0.00	0.00 (0.00, 0.00)
25-40 years	*****	2.51	2.51 (0.81, 7.79)
41-64 years	*****	4.10	4.10 (2.05, 8.21)
≥ 65 years	*****	1.64	1.64 (0.23, 11.65)
Single Propel Stent Use (fixed follow-up)			
18-24 years	345.1	0.00	0.00 (0.00, 0.00)
25-40 years	*****	2.44	2.44 (0.79, 7.57)
41-64 years	*****	3.91	3.91 (1.96, 7.83)
≥ 65 years	*****	1.51	1.51 (0.21, 10.74)
Single Propel Stent Use (1 day lag period)			
18-24 years	331.9	0.00	0.00 (0.00, 0.00)
25-40 years	*****	0.84	0.84 (0.12, 5.95)
41-64 years	*****	0.51	0.51 (0.07, 3.64)
≥ 65 years	608.5	0.00	0.00 (0.00, 0.00)
Single Propel Stent Use (fixed follow-up, 1 day lag period)			
18-24 years	344.5	0.00	0.00 (0.00, 0.00)
25-40 years	*****	0.81	0.81 (0.11, 5.78)
41-64 years	*****	0.49	0.49 (0.07, 3.47)
≥ 65 years	660.1	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use			
18-24 years	185.7	0.00	0.00 (0.00, 0.00)
25-40 years	*****	3.48	3.48 (1.12, 10.78)

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
41-64 years	*****	1.09	1.09 (0.27, 4.36)
≥ 65 years	*****	2.30	2.30 (0.86, 6.12)
Single Sinuva Stent Use (fixed follow-up)			
18-24 years	195.3	0.00	0.00 (0.00, 0.00)
25-40 years	*****	3.36	3.36 (1.08, 10.41)
41-64 years	*****	1.05	1.05 (0.26, 4.19)
≥ 65 years	*****	2.23	2.23 (0.84, 5.95)
Single Sinuva Stent Use (1 day lag period)			
18-24 years	185.3	0.00	0.00 (0.00, 0.00)
25-40 years	*****	1.16	1.16 (0.16, 8.21)
41-64 years	1,831.8	0.00	0.00 (0.00, 0.00)
≥ 65 years	*****	0.57	0.57 (0.08, 4.07)
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)			
18-24 years	195.0	0.00	0.00 (0.00, 0.00)
25-40 years	*****	1.12	1.12 (0.16, 7.94)
41-64 years	1,909.2	0.00	0.00 (0.00, 0.00)
≥ 65 years	*****	0.56	0.56 (0.08, 3.96)
Repeat stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days			
18-24 years	3.4	0.00	0.00 (0.00, 0.00)
25-40 years	21.8	0.00	0.00 (0.00, 0.00)
41-64 years	*****	14.87	14.87 (2.09, 105.54)
≥ 65 years	*****	171.64	171.64 (85.84, 343.22)
Sinuva Repeat Stent within 730 days			
18-24 years	3.4	0.00	0.00 (0.00, 0.00)
25-40 years	21.8	0.00	0.00 (0.00, 0.00)
41-64 years	*****	13.85	13.85 (1.95, 98.32)
≥ 65 years	*****	150.07	150.07 (75.05, 300.08)
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days			
18-24 years	3.9	0.00	0.00 (0.00, 0.00)
25-40 years	31.5	0.00	0.00 (0.00, 0.00)
41-64 years	*****	18.87	18.87 (4.72, 75.46)
≥ 65 years	*****	153.19	153.19 (82.42, 284.71)
Sinuva Repeat Stent within 365 days (fixed follow-up)			
18-24 years	3.9	0.00	0.00 (0.00, 0.00)
25-40 years	32.4	0.00	0.00 (0.00, 0.00)
41-64 years	*****	17.61	17.61 (4.40, 70.42)
≥ 65 years	*****	148.28	148.28 (79.78, 275.59)
Sinuva Repeat Stent within 730 days			
18-24 years	3.9	0.00	0.00 (0.00, 0.00)
25-40 years	31.5	0.00	0.00 (0.00, 0.00)
41-64 years	*****	17.59	17.59 (4.40, 70.33)

Table 4. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Age Group

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
≥ 65 years	*****	136.67	136.67 (73.54, 254.02)
Sinuva Repeat Stent within 730 days (fixed follow-up)			
18-24 years	3.9	0.00	0.00 (0.00, 0.00)
25-40 years	32.4	0.00	0.00 (0.00, 0.00)
41-64 years	*****	16.49	16.49 (4.12, 65.93)
≥ 65 years	*****	132.71	132.71 (71.40, 246.65)
Repeat stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days			
18-24 years	6.4	0.00	0.00 (0.00, 0.00)
25-40 years	36.6	0.00	0.00 (0.00, 0.00)
41-64 years	*****	12.28	12.28 (1.73, 87.18)
≥ 65 years	*****	15.72	15.72 (2.21, 111.58)
Sinuva Repeat Stent within 730 days			
18-24 years	6.4	0.00	0.00 (0.00, 0.00)
25-40 years	37.2	0.00	0.00 (0.00, 0.00)
41-64 years	*****	11.15	11.15 (1.57, 79.16)
≥ 65 years	*****	13.29	13.29 (1.87, 94.38)
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days			
18-24 years	9.0	0.00	0.00 (0.00, 0.00)
25-40 years	52.3	0.00	0.00 (0.00, 0.00)
41-64 years	*****	7.42	7.42 (1.05, 52.71)
≥ 65 years	*****	9.77	9.77 (1.38, 69.39)
Sinuva Repeat Stent within 365 days (fixed follow-up)			
18-24 years	9.0	0.00	0.00 (0.00, 0.00)
25-40 years	53.8	0.00	0.00 (0.00, 0.00)
41-64 years	*****	7.07	7.07 (1.00, 50.21)
≥ 65 years	*****	9.47	9.47 (1.33, 67.20)
Sinuva Repeat Stent within 730 days			
18-24 years	9.0	0.00	0.00 (0.00, 0.00)
25-40 years	52.9	0.00	0.00 (0.00, 0.00)
41-64 years	*****	6.81	6.81 (0.96, 48.36)
≥ 65 years	*****	8.48	8.48 (1.19, 60.18)
Sinuva Repeat Stent within 730 days (fixed follow-up)			
18-24 years	9.0	0.00	0.00 (0.00, 0.00)
25-40 years	54.4	0.00	0.00 (0.00, 0.00)
41-64 years	*****	6.51	6.51 (0.92, 46.24)
≥ 65 years	*****	8.20	8.20 (1.15, 58.19)

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Single stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	52	52	*****
2018	619	619	15
2019	498	498	*****
2020	*****	*****	*****
2021	820	820	21
2022	997	997	14
2023	879	879	0
2024	*****	*****	0
Single Sinuva Stent Use			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	19
2020	1,258	1,258	53
2021	1,026	1,026	47
2022	356	356	*****
2023	190	190	*****
2024	*****	*****	0
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	52	52	*****
2018	619	619	12
2019	498	498	*****
2020	*****	*****	*****
2021	820	820	12
2022	997	997	24
2023	879	879	*****
2024	*****	*****	0
Single Propel Stent Use			

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2017	0	0	0
2018	*****	*****	*****
2019	423	423	*****
2020	1,258	1,258	44
2021	1,026	1,026	35
2022	356	356	19
2023	190	190	*****
2024	*****	*****	0
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (273 day lag period)			
2017	52	52	*****
2018	619	619	26
2019	498	498	*****
2020	*****	*****	*****
2021	820	820	19
2022	997	997	14
2023	879	879	0
2024	*****	*****	0
Single Propel Stent Use (fixed follow-up, 273 day lag period)			
2017	52	52	*****
2018	619	619	26
2019	498	498	*****
2020	*****	*****	*****
2021	820	820	22
2022	997	997	14
2023	879	879	0
2024	*****	*****	0
Single Propel Stent Use			
2017	52	52	*****
2018	619	619	28
2019	498	498	11

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2020	*****	*****	*****
2021	820	820	25
2022	997	997	30
2023	879	879	*****
2024	*****	*****	0
Single Propel Stent Use (fixed follow-up)			
2017	52	52	*****
2018	619	619	28
2019	498	498	12
2020	*****	*****	*****
2021	820	820	28
2022	997	997	30
2023	879	879	*****
2024	*****	*****	0
Single Sinuva Stent Use (273 day lag period)			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	25
2020	1,258	1,258	82
2021	1,026	1,026	53
2022	356	356	*****
2023	190	190	*****
2024	*****	*****	0
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	26
2020	1,258	1,258	84
2021	1,026	1,026	55
2022	356	356	*****
2023	190	190	*****

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2024	*****	*****	0
Single Sinuva Stent Use			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	24
2020	1,258	1,258	76
2021	1,026	1,026	64
2022	356	356	*****
2023	190	190	*****
2024	*****	*****	0
Single Sinuva Stent Use (fixed follow-up)			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	25
2020	1,258	1,258	77
2021	1,026	1,026	66
2022	356	356	*****
2023	190	190	*****
2024	*****	*****	0
Single stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	52	52	0
2018	619	619	*****
2019	498	498	*****
2020	*****	*****	0
2021	820	820	*****
2022	997	997	*****
2023	879	879	*****
2024	*****	*****	0
Single Sinuva Stent Use			

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2017	0	0	0
2018	*****	*****	*****
2019	423	423	*****
2020	1,258	1,258	*****
2021	1,026	1,026	12
2022	356	356	*****
2023	190	190	0
2024	*****	*****	0
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	52	52	0
2018	619	619	*****
2019	498	498	*****
2020	*****	*****	0
2021	820	820	*****
2022	997	997	*****
2023	879	879	*****
2024	*****	*****	0
Single Sinuva Stent Use			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	*****
2020	1,258	1,258	*****
2021	1,026	1,026	11
2022	356	356	*****
2023	190	190	0
2024	*****	*****	0
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use Cohort (28 day lag period)			
2017	52	52	0
2018	619	619	*****

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2019	498	498	*****
2020	*****	*****	0
2021	820	820	*****
2022	997	997	*****
2023	879	879	*****
2024	*****	*****	0
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)			
2017	52	52	0
2018	619	619	*****
2019	498	498	*****
2020	*****	*****	0
2021	820	820	*****
2022	997	997	*****
2023	879	879	*****
2024	*****	*****	0
Single Propel Stent Use			
2017	52	52	0
2018	619	619	*****
2019	498	498	*****
2020	*****	*****	0
2021	820	820	*****
2022	997	997	*****
2023	879	879	*****
2024	*****	*****	0
Single Propel Stent Use Cohort (fixed follow-up)			
2017	52	52	0
2018	619	619	*****
2019	498	498	*****
2020	*****	*****	0
2021	820	820	*****
2022	997	997	*****

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2023	879	879	*****
2024	*****	*****	0
Single Sinuva Stent Use (28 day lag period)			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	*****
2020	1,258	1,258	*****
2021	1,026	1,026	19
2022	356	356	*****
2023	190	190	0
2024	*****	*****	0
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	*****
2020	1,258	1,258	*****
2021	1,026	1,026	20
2022	356	356	*****
2023	190	190	0
2024	*****	*****	0
Single Sinuva Stent Use			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	*****
2020	1,258	1,258	*****
2021	1,026	1,026	19
2022	356	356	*****
2023	190	190	0
2024	*****	*****	0
Single Sinuva Stent Use (fixed follow-up)			
2017	0	0	0

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2018	*****	*****	*****
2019	423	423	*****
2020	1,258	1,258	*****
2021	1,026	1,026	20
2022	356	356	*****
2023	190	190	0
2024	*****	*****	0
Single stent cohorts - Outcome: Ocular Hypertension			
Primary analysis cohorts (14-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	52	52	*****
2018	619	619	11
2019	498	498	*****
2020	*****	*****	0
2021	820	820	20
2022	997	997	25
2023	879	879	*****
2024	*****	*****	0
Single Sinuva Stent Use			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	*****
2020	1,258	1,258	37
2021	1,026	1,026	34
2022	356	356	19
2023	190	190	*****
2024	*****	*****	0
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	52	52	*****
2018	619	619	11

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2019	498	498	*****
2020	*****	*****	0
2021	820	820	19
2022	997	997	25
2023	879	879	*****
2024	*****	*****	0
Single Sinuva Stent Use			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	*****
2020	1,258	1,258	38
2021	1,026	1,026	34
2022	356	356	19
2023	190	190	*****
2024	*****	*****	0
Single Propel Stent Use (14 day lag period)			
2017	52	52	*****
2018	619	619	16
2019	498	498	*****
2020	*****	*****	0
2021	820	820	22
2022	997	997	25
2023	879	879	*****
2024	*****	*****	0
Single Propel Stent Use (fixed follow-up, 14 day lag period)			
2017	52	52	*****
2018	619	619	16
2019	498	498	*****
2020	*****	*****	0
2021	820	820	27
2022	997	997	25

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2023	879	879	*****
2024	*****	*****	0
Single Propel Stent Use			
2017	52	52	*****
2018	619	619	16
2019	498	498	*****
2020	*****	*****	0
2021	820	820	23
2022	997	997	25
2023	879	879	*****
2024	*****	*****	0
Single Propel Stent Use (fixed follow-up)			
2017	52	52	*****
2018	619	619	16
2019	498	498	*****
2020	*****	*****	0
2021	820	820	27
2022	997	997	25
2023	879	879	*****
2024	*****	*****	0
Single Sinuva Stent Use (14 day lag period)			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	12
2020	1,258	1,258	61
2021	1,026	1,026	41
2022	356	356	20
2023	190	190	*****
2024	*****	*****	0
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)			
2017	0	0	0

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2018	*****	*****	*****
2019	423	423	12
2020	1,258	1,258	61
2021	1,026	1,026	44
2022	356	356	20
2023	190	190	*****
2024	*****	*****	0
Single Sinuva Stent Use			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	12
2020	1,258	1,258	61
2021	1,026	1,026	42
2022	356	356	20
2023	190	190	*****
2024	*****	*****	0
Single Sinuva Stent Use (fixed follow-up)			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	12
2020	1,258	1,258	61
2021	1,026	1,026	45
2022	356	356	20
2023	190	190	*****
2024	*****	*****	0
Single stent cohorts - Outcome: Diminished Visual Acuity			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	52	52	*****
2018	619	619	*****
2019	498	498	14

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2020	*****	*****	0
2021	820	820	14
2022	997	997	23
2023	879	879	*****
2024	*****	*****	0
Single Sinuva Stent Use			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	*****
2020	1,258	1,258	30
2021	1,026	1,026	23
2022	356	356	*****
2023	190	190	*****
2024	*****	*****	0
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	52	52	*****
2018	619	619	*****
2019	498	498	15
2020	*****	*****	0
2021	820	820	13
2022	997	997	26
2023	879	879	*****
2024	*****	*****	0
Single Sinuva Stent Use			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	*****
2020	1,258	1,258	31
2021	1,026	1,026	24
2022	356	356	*****

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2023	190	190	*****
2024	*****	*****	0
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (28 day lag period)			
2017	52	52	*****
2018	619	619	*****
2019	498	498	20
2020	*****	*****	0
2021	820	820	25
2022	997	997	27
2023	879	879	*****
2024	*****	*****	0
Single Propel Stent Use (fixed follow-up, 28 day lag period)			
2017	52	52	*****
2018	619	619	*****
2019	498	498	21
2020	*****	*****	0
2021	820	820	28
2022	997	997	28
2023	879	879	*****
2024	*****	*****	0
Single Propel Stent Use			
2017	52	52	*****
2018	619	619	*****
2019	498	498	22
2020	*****	*****	0
2021	820	820	25
2022	997	997	29
2023	879	879	*****
2024	*****	*****	0
Single Propel Stent Use (fixed follow-up)			

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2017	52	52	*****
2018	619	619	*****
2019	498	498	22
2020	*****	*****	0
2021	820	820	27
2022	997	997	30
2023	879	879	*****
2024	*****	*****	0
Single Sinuva Stent Use (28 day lag period)			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	19
2020	1,258	1,258	54
2021	1,026	1,026	42
2022	356	356	*****
2023	190	190	*****
2024	*****	*****	0
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	20
2020	1,258	1,258	54
2021	1,026	1,026	44
2022	356	356	*****
2023	190	190	*****
2024	*****	*****	0
Single Sinuva Stent Use			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	20
2020	1,258	1,258	53

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2021	1,026	1,026	43
2022	356	356	*****
2023	190	190	*****
2024	*****	*****	0
Single Sinuva Stent Use (fixed follow-up)			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	20
2020	1,258	1,258	53
2021	1,026	1,026	45
2022	356	356	*****
2023	190	190	*****
2024	*****	*****	0
Single stent cohorts - Outcome: Nasal Septal Perforation			
Primary analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	52	52	0
2018	619	619	*****
2019	498	498	*****
2020	*****	*****	0
2021	820	820	*****
2022	997	997	*****
2023	879	879	*****
2024	*****	*****	0
Single Sinuva Stent Use			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	0
2020	1,258	1,258	*****
2021	1,026	1,026	*****
2022	356	356	0

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2023	190	190	*****
2024	*****	*****	0
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	52	52	0
2018	619	619	0
2019	498	498	0
2020	*****	*****	0
2021	820	820	0
2022	997	997	*****
2023	879	879	0
2024	*****	*****	0
Single Sinuva Stent Use			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	0
2020	1,258	1,258	0
2021	1,026	1,026	*****
2022	356	356	0
2023	190	190	0
2024	*****	*****	0
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use			
2017	52	52	0
2018	619	619	*****
2019	498	498	*****
2020	*****	*****	0
2021	820	820	*****
2022	997	997	*****
2023	879	879	*****
2024	*****	*****	0

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Single Propel Stent Use (fixed follow-up)			
2017	52	52	0
2018	619	619	*****
2019	498	498	*****
2020	*****	*****	0
2021	820	820	*****
2022	997	997	*****
2023	879	879	*****
2024	*****	*****	0
Single Propel Stent Use (1 day lag period)			
2017	52	52	0
2018	619	619	0
2019	498	498	*****
2020	*****	*****	0
2021	820	820	0
2022	997	997	*****
2023	879	879	0
2024	*****	*****	0
Single Propel Stent Use (fixed follow-up, 1 day lag period)			
2017	52	52	0
2018	619	619	0
2019	498	498	*****
2020	*****	*****	0
2021	820	820	0
2022	997	997	*****
2023	879	879	0
2024	*****	*****	0
Single Sinuva Stent Use			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	0

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2020	1,258	1,258	*****
2021	1,026	1,026	*****
2022	356	356	0
2023	190	190	*****
2024	*****	*****	0
Single Sinuva Stent Use (fixed follow-up)			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	0
2020	1,258	1,258	*****
2021	1,026	1,026	*****
2022	356	356	0
2023	190	190	*****
2024	*****	*****	0
Single Sinuva Stent Use (1 day lag period)			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	0
2020	1,258	1,258	0
2021	1,026	1,026	*****
2022	356	356	0
2023	190	190	0
2024	*****	*****	0
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)			
2017	0	0	0
2018	*****	*****	*****
2019	423	423	0
2020	1,258	1,258	0
2021	1,026	1,026	*****
2022	356	356	0
2023	190	190	0

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2024	*****	*****	0
Repeat stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days			
2017	0	0	0
2018	*****	*****	*****
2019	27	27	*****
2020	65	65	*****
2021	88	88	*****
2022	31	31	*****
2023	*****	*****	0
2024	0	0	0
Sinuva Repeat Stent within 730 days			
2017	0	0	0
2018	*****	*****	*****
2019	27	27	*****
2020	69	69	*****
2021	102	102	*****
2022	38	38	*****
2023	*****	*****	0
2024	0	0	0
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days			
2017	0	0	0
2018	*****	*****	*****
2019	27	27	*****
2020	65	65	*****
2021	88	88	*****
2022	31	31	*****
2023	*****	*****	0
2024	0	0	0

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
Sinuva Repeat Stent within 365 days (fixed follow-up)			
2017	0	0	0
2018	*****	*****	*****
2019	27	27	*****
2020	65	65	*****
2021	88	88	*****
2022	31	31	*****
2023	*****	*****	0
2024	0	0	0
Sinuva Repeat Stent within 730 days			
2017	0	0	0
2018	*****	*****	*****
2019	27	27	*****
2020	69	69	*****
2021	102	102	*****
2022	38	38	*****
2023	*****	*****	0
2024	0	0	0
Sinuva Repeat Stent within 730 days (fixed follow-up)			
2017	0	0	0
2018	*****	*****	*****
2019	27	27	*****
2020	69	69	*****
2021	102	102	*****
2022	38	38	*****
2023	*****	*****	0
2024	0	0	0
Repeat stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days			
2017	0	0	0

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2018	*****	*****	0
2019	27	27	*****
2020	65	65	0
2021	88	88	0
2022	31	31	*****
2023	*****	*****	0
2024	0	0	0
Sinuva Repeat Stent within 730 days			
2017	0	0	0
2018	*****	*****	0
2019	27	27	*****
2020	69	69	0
2021	102	102	0
2022	38	38	*****
2023	*****	*****	0
2024	0	0	0
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days			
2017	0	0	0
2018	*****	*****	0
2019	27	27	*****
2020	65	65	0
2021	88	88	0
2022	31	31	*****
2023	*****	*****	0
2024	0	0	0
Sinuva Repeat Stent within 365 days (fixed follow-up)			
2017	0	0	0
2018	*****	*****	0
2019	27	27	*****
2020	65	65	0

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Number of Patients	Number of Exposure Episodes	Number of Exposure Episodes with an Event
2021	88	88	0
2022	31	31	*****
2023	*****	*****	0
2024	0	0	0
Sinuva Repeat Stent within 730 days			
2017	0	0	0
2018	*****	*****	0
2019	27	27	*****
2020	69	69	0
2021	102	102	0
2022	38	38	*****
2023	*****	*****	0
2024	0	0	0
Sinuva Repeat Stent within 730 days (fixed follow-up)			
2017	0	0	0
2018	*****	*****	0
2019	27	27	*****
2020	69	69	0
2021	102	102	0
2022	38	38	*****
2023	*****	*****	0
2024	0	0	0

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Single stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	*****	53.82	53.82 (13.46, 215.22)
2018	444.2	33.77	33.77 (20.36, 56.02)
2019	*****	21.34	21.34 (10.67, 42.67)
2020	*****	27.14	27.14 (3.82, 192.66)
2021	490.1	42.85	42.85 (27.94, 65.72)
2022	314.8	44.47	44.47 (26.34, 75.09)
2023	5.2	0.00	0.00 (0.00, 0.00)
2024	0.0	NaN	NaN
Single Sinuva Stent Use			
2017	0.0	NaN	NaN
2018	*****	30.63	30.63 (9.88, 94.97)
2019	307.5	61.78	61.78 (39.41, 96.86)
2020	901.3	58.80	58.80 (44.92, 76.97)
2021	655.2	71.73	71.73 (53.90, 95.47)
2022	*****	68.58	68.58 (35.68, 131.81)
2023	*****	428.19	428.19 (60.31, 3,039.89)
2024	0.0	NaN	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	*****	45.11	45.11 (11.28, 180.36)
2018	535.8	22.39	22.39 (12.72, 39.43)
2019	*****	9.16	9.16 (3.44, 24.40)
2020	*****	22.86	22.86 (3.22, 162.29)
2021	639.2	18.77	18.77 (10.66, 33.06)
2022	790.1	30.37	30.37 (20.36, 45.32)
2023	*****	27.24	27.24 (13.62, 54.47)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Propel Stent Use			
2017	0.0	NaN	NaN

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2018	*****	25.54	25.54 (8.24, 79.19)
2019	*****	16.64	16.64 (7.47, 37.04)
2020	1,096.2	40.14	40.14 (29.87, 53.94)
2021	853.1	41.03	41.03 (29.46, 57.14)
2022	291.5	65.19	65.19 (41.58, 102.20)
2023	*****	40.65	40.65 (13.11, 126.04)
2024	0.1	0.00	0.00 (0.00, 0.00)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (273 day lag period)			
2017	*****	29.30	29.30 (7.33, 117.17)
2018	779.1	33.37	33.37 (22.72, 49.01)
2019	*****	15.61	15.61 (8.40, 29.02)
2020	*****	30.05	30.05 (4.23, 213.35)
2021	562.7	33.77	33.77 (21.54, 52.94)
2022	311.9	44.88	44.88 (26.58, 75.79)
2023	4.9	0.00	0.00 (0.00, 0.00)
2024	0.0	NaN	NaN
Single Propel Stent Use (fixed follow-up, 273 day lag period)			
2017	*****	29.30	29.30 (7.33, 117.17)
2018	791.2	32.86	32.86 (22.38, 48.27)
2019	*****	16.44	16.44 (9.11, 29.69)
2020	*****	30.42	30.42 (7.61, 121.63)
2021	625.2	35.19	35.19 (23.17, 53.44)
2022	318.4	43.97	43.97 (26.04, 74.24)
2023	5.2	0.00	0.00 (0.00, 0.00)
2024	0.0	NaN	NaN
Single Propel Stent Use			
2017	*****	25.06	25.06 (6.27, 100.20)
2018	938.5	29.84	29.84 (20.60, 43.21)
2019	763.4	14.41	14.41 (7.98, 26.02)
2020	*****	52.20	52.20 (13.06, 208.74)
2021	974.2	25.66	25.66 (17.34, 37.98)

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2022	938.4	31.97	31.97 (22.35, 45.72)
2023	*****	27.56	27.56 (13.78, 55.11)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Propel Stent Use (fixed follow-up)			
2017	*****	25.06	25.06 (6.27, 100.20)
2018	947.5	29.55	29.55 (20.40, 42.80)
2019	791.5	15.16	15.16 (8.61, 26.70)
2020	*****	25.84	25.84 (6.46, 103.31)
2021	1,064.0	26.32	26.32 (18.17, 38.11)
2022	957.4	31.34	31.34 (21.91, 44.82)
2023	*****	27.22	27.22 (13.61, 54.43)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use (273 day lag period)			
2017	0.0	NaN	NaN
2018	*****	29.83	29.83 (12.41, 71.66)
2019	521.6	47.93	47.93 (32.39, 70.93)
2020	1,483.7	55.27	55.27 (44.51, 68.62)
2021	877.0	60.43	60.43 (46.17, 79.10)
2022	*****	70.79	70.79 (36.83, 136.06)
2023	*****	471.29	471.29 (66.39, 3,345.84)
2024	0.0	NaN	NaN
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)			
2017	0.0	NaN	NaN
2018	*****	27.91	27.91 (11.62, 67.06)
2019	534.7	48.62	48.62 (33.11, 71.41)
2020	1,532.9	54.80	54.80 (44.25, 67.86)
2021	922.3	59.63	59.63 (45.78, 77.67)
2022	*****	67.08	67.08 (34.90, 128.93)
2023	*****	428.19	428.19 (60.31, 3,039.89)
2024	0.0	NaN	NaN
Single Sinuva Stent Use			
2017	0.0	NaN	NaN

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2018	*****	20.19	20.19 (7.58, 53.78)
2019	632.4	37.95	37.95 (25.44, 56.62)
2020	1,844.6	41.20	41.20 (32.91, 51.59)
2021	1,356.3	47.19	47.19 (36.93, 60.29)
2022	*****	66.45	66.45 (44.15, 99.99)
2023	*****	42.69	42.69 (13.77, 132.37)
2024	0.1	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use (fixed follow-up)			
2017	0.0	NaN	NaN
2018	*****	19.08	19.08 (7.16, 50.85)
2019	648.1	38.57	38.57 (26.06, 57.09)
2020	1,893.8	40.66	40.66 (32.52, 50.83)
2021	1,419.0	46.51	46.51 (36.54, 59.20)
2022	*****	63.26	63.26 (42.04, 95.20)
2023	*****	40.61	40.61 (13.10, 125.90)
2024	0.1	0.00	0.00 (0.00, 0.00)
Single stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	44.3	0.00	0.00 (0.00, 0.00)
2018	*****	7.57	7.57 (2.84, 20.18)
2019	*****	4.66	4.66 (1.16, 18.61)
2020	44.0	0.00	0.00 (0.00, 0.00)
2021	*****	3.22	3.22 (0.80, 12.86)
2022	*****	6.59	6.59 (2.74, 15.84)
2023	*****	4.28	4.28 (0.60, 30.42)
2024	0.0	NaN	NaN
Single Sinuva Stent Use			
2017	0.0	NaN	NaN
2018	*****	26.21	26.21 (8.45, 81.26)
2019	*****	2.80	2.80 (0.39, 19.87)
2020	*****	8.22	8.22 (4.27, 15.79)

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2021	843.2	14.23	14.23 (8.08, 25.06)
2022	*****	10.47	10.47 (3.38, 32.47)
2023	60.8	0.00	0.00 (0.00, 0.00)
2024	0.0	NaN	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	45.0	0.00	0.00 (0.00, 0.00)
2018	*****	7.43	7.43 (2.79, 19.80)
2019	*****	4.57	4.57 (1.14, 18.27)
2020	44.7	0.00	0.00 (0.00, 0.00)
2021	*****	3.11	3.11 (0.78, 12.44)
2022	*****	6.25	6.25 (2.60, 15.03)
2023	*****	3.38	3.38 (0.48, 24.00)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use			
2017	0.0	NaN	NaN
2018	*****	25.68	25.68 (8.28, 79.62)
2019	*****	2.75	2.75 (0.39, 19.53)
2020	*****	8.09	8.09 (4.21, 15.54)
2021	869.0	12.66	12.66 (7.01, 22.86)
2022	*****	13.38	13.38 (5.02, 35.65)
2023	74.7	0.00	0.00 (0.00, 0.00)
2024	0.1	0.00	0.00 (0.00, 0.00)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use Cohort (28 day lag period)			
2017	81.3	0.00	0.00 (0.00, 0.00)
2018	*****	5.34	5.34 (2.22, 12.84)
2019	*****	6.64	6.64 (2.76, 15.95)
2020	40.3	0.00	0.00 (0.00, 0.00)
2021	*****	4.24	4.24 (1.59, 11.30)
2022	*****	5.69	5.69 (2.37, 13.68)
2023	*****	4.34	4.34 (0.61, 30.81)

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2024	0.0	NaN	NaN
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)			
2017	81.3	0.00	0.00 (0.00, 0.00)
2018	*****	5.29	5.29 (2.20, 12.71)
2019	*****	6.39	6.39 (2.66, 15.35)
2020	78.8	0.00	0.00 (0.00, 0.00)
2021	*****	4.83	4.83 (2.01, 11.61)
2022	*****	5.57	5.57 (2.32, 13.39)
2023	*****	4.28	4.28 (0.60, 30.42)
2024	0.0	NaN	NaN
Single Propel Stent Use			
2017	82.5	0.00	0.00 (0.00, 0.00)
2018	*****	5.24	5.24 (2.18, 12.60)
2019	*****	6.52	6.52 (2.71, 15.65)
2020	41.2	0.00	0.00 (0.00, 0.00)
2021	*****	3.04	3.04 (0.98, 9.42)
2022	*****	5.25	5.25 (2.18, 12.61)
2023	*****	3.42	3.42 (0.48, 24.28)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Propel Stent Use Cohort (fixed follow-up)			
2017	82.5	0.00	0.00 (0.00, 0.00)
2018	*****	5.20	5.20 (2.16, 12.48)
2019	*****	6.28	6.28 (2.61, 15.09)
2020	80.3	0.00	0.00 (0.00, 0.00)
2021	*****	3.70	3.70 (1.39, 9.87)
2022	*****	5.14	5.14 (2.14, 12.36)
2023	*****	3.38	3.38 (0.48, 23.98)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use (28 day lag period)			
2017	0.0	NaN	NaN
2018	*****	15.44	15.44 (4.98, 47.86)
2019	*****	1.57	1.57 (0.22, 11.13)

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2020	*****	8.01	8.01 (4.83, 13.29)
2021	1,357.7	13.99	13.99 (8.93, 21.94)
2022	*****	8.95	8.95 (2.89, 27.77)
2023	57.8	0.00	0.00 (0.00, 0.00)
2024	0.0	NaN	NaN
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)			
2017	0.0	NaN	NaN
2018	*****	14.56	14.56 (4.70, 45.15)
2019	*****	1.53	1.53 (0.22, 10.85)
2020	*****	7.80	7.80 (4.70, 12.94)
2021	1,421.1	14.07	14.07 (9.08, 21.81)
2022	*****	8.54	8.54 (2.75, 26.47)
2023	60.8	0.00	0.00 (0.00, 0.00)
2024	0.0	NaN	NaN
Single Sinuva Stent Use			
2017	0.0	NaN	NaN
2018	*****	15.12	15.12 (4.88, 46.88)
2019	*****	1.54	1.54 (0.22, 10.95)
2020	*****	7.85	7.85 (4.73, 13.02)
2021	1,403.2	13.54	13.54 (8.64, 21.23)
2022	*****	11.09	11.09 (4.16, 29.55)
2023	71.2	0.00	0.00 (0.00, 0.00)
2024	0.1	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use (fixed follow-up)			
2017	0.0	NaN	NaN
2018	*****	14.30	14.30 (4.61, 44.33)
2019	*****	1.50	1.50 (0.21, 10.67)
2020	*****	7.65	7.65 (4.61, 12.68)
2021	1,468.3	13.62	13.62 (8.79, 21.11)
2022	*****	10.58	10.58 (3.97, 28.19)
2023	74.8	0.00	0.00 (0.00, 0.00)
2024	0.1	0.00	0.00 (0.00, 0.00)

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Single stent cohorts - Outcome: Ocular Hypertension			
Primary analysis cohorts (14-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	*****	22.48	22.48 (3.17, 159.60)
2018	530.1	20.75	20.75 (11.49, 37.47)
2019	*****	9.22	9.22 (3.46, 24.57)
2020	44.3	0.00	0.00 (0.00, 0.00)
2021	621.2	32.19	32.19 (20.77, 49.90)
2022	771.6	32.40	32.40 (21.89, 47.95)
2023	*****	34.32	34.32 (17.86, 65.97)
2024	0.1	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use			
2017	0.0	NaN	NaN
2018	*****	52.72	52.72 (23.69, 117.36)
2019	*****	25.20	25.20 (13.11, 48.42)
2020	1,089.6	33.96	33.96 (24.60, 46.87)
2021	843.0	40.33	40.33 (28.82, 56.45)
2022	284.5	66.79	66.79 (42.60, 104.72)
2023	*****	75.24	75.24 (31.32, 180.76)
2024	0.0	0.00	0.00 (0.00, 0.00)
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	*****	22.26	22.26 (3.14, 158.04)
2018	535.5	20.54	20.54 (11.38, 37.10)
2019	*****	11.44	11.44 (4.76, 27.49)
2020	44.7	0.00	0.00 (0.00, 0.00)
2021	632.4	30.05	30.05 (19.17, 47.11)
2022	792.2	31.56	31.56 (21.32, 46.70)
2023	*****	30.57	30.57 (15.91, 58.76)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use			
2017	0.0	NaN	NaN

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2018	*****	52.14	52.14 (23.42, 116.05)
2019	*****	19.41	19.41 (9.25, 40.72)
2020	1,097.3	34.63	34.63 (25.20, 47.59)
2021	855.7	39.73	39.73 (28.39, 55.61)
2022	291.0	65.29	65.29 (41.64, 102.35)
2023	*****	81.82	81.82 (36.76, 182.13)
2024	0.1	0.00	0.00 (0.00, 0.00)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (14 day lag period)			
2017	*****	24.85	24.85 (6.21, 99.36)
2018	935.0	17.11	17.11 (10.48, 27.93)
2019	*****	11.86	11.86 (6.17, 22.80)
2020	40.7	0.00	0.00 (0.00, 0.00)
2021	946.5	23.24	23.24 (15.31, 35.30)
2022	904.5	27.64	27.64 (18.68, 40.91)
2023	*****	34.76	34.76 (18.08, 66.80)
2024	0.1	0.00	0.00 (0.00, 0.00)
Single Propel Stent Use (fixed follow-up, 14 day lag period)			
2017	*****	24.85	24.85 (6.21, 99.36)
2018	944.2	16.95	16.95 (10.38, 27.66)
2019	*****	11.42	11.42 (5.94, 21.95)
2020	79.6	0.00	0.00 (0.00, 0.00)
2021	1,031.7	26.17	26.17 (17.95, 38.16)
2022	923.7	27.06	27.06 (18.29, 40.05)
2023	*****	34.32	34.32 (17.86, 65.96)
2024	0.1	0.00	0.00 (0.00, 0.00)
Single Propel Stent Use			
2017	*****	24.64	24.64 (6.16, 98.52)
2018	944.4	16.94	16.94 (10.38, 27.66)
2019	*****	13.09	13.09 (7.04, 24.33)
2020	41.2	0.00	0.00 (0.00, 0.00)
2021	969.2	23.73	23.73 (15.77, 35.71)

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2022	941.8	26.54	26.54 (17.94, 39.28)
2023	*****	30.93	30.93 (16.09, 59.44)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Propel Stent Use (fixed follow-up)			
2017	*****	24.64	24.64 (6.16, 98.52)
2018	953.4	16.78	16.78 (10.28, 27.39)
2019	*****	12.61	12.61 (6.79, 23.44)
2020	80.3	0.00	0.00 (0.00, 0.00)
2021	1,054.9	25.59	25.59 (17.55, 37.32)
2022	961.6	26.00	26.00 (17.57, 38.48)
2023	*****	30.55	30.55 (15.89, 58.71)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use (14 day lag period)			
2017	0.0	NaN	NaN
2018	*****	46.84	46.84 (24.37, 90.02)
2019	631.1	19.01	19.01 (10.80, 33.48)
2020	1,847.0	33.03	33.03 (25.70, 42.45)
2021	1,351.1	30.35	30.35 (22.34, 41.21)
2022	335.6	59.59	59.59 (38.44, 92.36)
2023	*****	79.16	79.16 (32.95, 190.19)
2024	0.0	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)			
2017	0.0	NaN	NaN
2018	*****	44.17	44.17 (22.98, 84.90)
2019	647.6	18.53	18.53 (10.52, 32.63)
2020	1,897.1	32.15	32.15 (25.02, 41.33)
2021	1,411.4	31.17	31.17 (23.20, 41.89)
2022	352.5	56.73	56.73 (36.60, 87.94)
2023	*****	75.23	75.23 (31.31, 180.75)
2024	0.0	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use			
2017	0.0	NaN	NaN

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2018	*****	41.16	41.16 (20.58, 82.30)
2019	636.8	18.84	18.84 (10.70, 33.18)
2020	1,865.3	32.70	32.70 (25.44, 42.03)
2021	1,373.2	30.58	30.58 (22.60, 41.39)
2022	348.7	57.36	57.36 (37.01, 88.92)
2023	*****	85.96	85.96 (38.62, 191.34)
2024	0.1	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use (fixed follow-up)			
2017	0.0	NaN	NaN
2018	*****	38.87	38.87 (19.44, 77.72)
2019	653.3	18.37	18.37 (10.43, 32.34)
2020	1,915.3	31.85	31.85 (24.78, 40.93)
2021	1,434.4	31.37	31.37 (23.42, 42.02)
2022	366.1	54.64	54.64 (35.25, 84.69)
2023	*****	81.73	81.73 (36.72, 181.93)
2024	0.1	0.00	0.00 (0.00, 0.00)
Single stent cohorts - Outcome: Diminished Visual Acuity			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	*****	22.95	22.95 (3.23, 162.91)
2018	*****	18.98	18.98 (10.21, 35.27)
2019	425.9	32.87	32.87 (19.47, 55.50)
2020	44.0	0.00	0.00 (0.00, 0.00)
2021	617.1	22.69	22.69 (13.44, 38.30)
2022	750.3	30.65	30.65 (20.37, 46.13)
2023	*****	21.54	21.54 (8.97, 51.75)
2024	0.0	NaN	NaN
Single Sinuva Stent Use			
2017	0.0	NaN	NaN
2018	*****	8.66	8.66 (1.22, 61.46)
2019	*****	22.58	22.58 (11.29, 45.15)
2020	1,083.9	27.68	27.68 (19.35, 39.58)

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2021	837.5	27.46	27.46 (18.25, 41.33)
2022	*****	35.20	35.20 (18.94, 65.43)
2023	*****	16.48	16.48 (2.32, 117.01)
2024	0.0	NaN	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	*****	22.53	22.53 (3.17, 159.95)
2018	*****	14.89	14.89 (7.45, 29.77)
2019	432.7	34.67	34.67 (20.90, 57.51)
2020	44.7	0.00	0.00 (0.00, 0.00)
2021	637.9	20.38	20.38 (11.83, 35.10)
2022	789.2	32.94	32.94 (22.43, 48.38)
2023	*****	30.63	30.63 (15.94, 58.87)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use			
2017	0.0	NaN	NaN
2018	*****	8.49	8.49 (1.20, 60.31)
2019	*****	22.25	22.25 (11.13, 44.49)
2020	1,101.6	28.14	28.14 (19.79, 40.02)
2021	861.8	27.85	27.85 (18.67, 41.55)
2022	*****	30.28	30.28 (15.76, 58.20)
2023	*****	40.74	40.74 (13.14, 126.33)
2024	0.1	0.00	0.00 (0.00, 0.00)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (28 day lag period)			
2017	*****	12.57	12.57 (1.77, 89.22)
2018	*****	18.31	18.31 (11.38, 29.45)
2019	740.1	27.02	27.02 (17.43, 41.89)
2020	40.3	0.00	0.00 (0.00, 0.00)
2021	928.0	26.94	26.94 (18.20, 39.87)
2022	864.8	31.22	31.22 (21.41, 45.53)
2023	*****	21.82	21.82 (9.08, 52.43)

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2024	0.0	NaN	NaN
Single Propel Stent Use (fixed follow-up, 28 day lag period)			
2017	*****	12.57	12.57 (1.77, 89.22)
2018	*****	18.13	18.13 (11.27, 29.16)
2019	769.5	27.29	27.29 (17.79, 41.86)
2020	78.8	0.00	0.00 (0.00, 0.00)
2021	1,016.5	27.55	27.55 (19.02, 39.90)
2022	883.0	31.71	31.71 (21.90, 45.93)
2023	*****	21.54	21.54 (8.97, 51.75)
2024	0.0	NaN	NaN
Single Propel Stent Use			
2017	*****	12.37	12.37 (1.74, 87.80)
2018	*****	15.84	15.84 (9.55, 26.27)
2019	750.7	29.31	29.31 (19.30, 44.51)
2020	41.2	0.00	0.00 (0.00, 0.00)
2021	971.5	25.73	25.73 (17.39, 38.08)
2022	936.1	30.98	30.98 (21.53, 44.58)
2023	*****	30.99	30.99 (16.12, 59.56)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Propel Stent Use (fixed follow-up)			
2017	*****	12.37	12.37 (1.74, 87.80)
2018	*****	15.69	15.69 (9.46, 26.03)
2019	779.6	28.22	28.22 (18.58, 42.86)
2020	80.3	0.00	0.00 (0.00, 0.00)
2021	1,061.2	25.44	25.44 (17.45, 37.10)
2022	955.3	31.40	31.40 (21.96, 44.92)
2023	*****	30.61	30.61 (15.93, 58.83)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use (28 day lag period)			
2017	0.0	NaN	NaN
2018	*****	10.18	10.18 (2.55, 40.71)
2019	621.0	30.60	30.60 (19.52, 47.97)

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2020	1,839.4	29.36	29.36 (22.48, 38.33)
2021	1,340.7	31.33	31.33 (23.15, 42.39)
2022	*****	36.31	36.31 (20.62, 63.94)
2023	*****	17.34	17.34 (2.44, 123.08)
2024	0.0	NaN	NaN
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)			
2017	0.0	NaN	NaN
2018	*****	9.61	9.61 (2.40, 38.43)
2019	637.3	31.38	31.38 (20.24, 48.64)
2020	1,889.6	28.58	28.58 (21.89, 37.31)
2021	1,401.3	31.40	31.40 (23.37, 42.19)
2022	*****	37.53	37.53 (21.79, 64.64)
2023	*****	16.48	16.48 (2.32, 117.01)
2024	0.0	NaN	NaN
Single Sinuva Stent Use			
2017	0.0	NaN	NaN
2018	*****	9.98	9.98 (2.50, 39.91)
2019	630.6	31.72	31.72 (20.46, 49.16)
2020	1,879.8	28.19	28.19 (21.54, 36.90)
2021	1,383.9	31.07	31.07 (23.04, 41.89)
2022	*****	33.67	33.67 (19.12, 59.29)
2023	*****	42.80	42.80 (13.80, 132.69)
2024	0.1	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use (fixed follow-up)			
2017	0.0	NaN	NaN
2018	*****	9.44	9.44 (2.36, 37.75)
2019	647.1	30.91	30.91 (19.94, 47.91)
2020	1,929.8	27.46	27.46 (20.98, 35.95)
2021	1,446.2	31.12	31.12 (23.23, 41.67)
2022	*****	34.82	34.82 (20.22, 59.97)
2023	*****	40.70	40.70 (13.13, 126.19)
2024	0.1	0.00	0.00 (0.00, 0.00)

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Single stent cohorts - Outcome: Nasal Septal Perforation			
Primary analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	45.0	0.00	0.00 (0.00, 0.00)
2018	*****	3.71	3.71 (0.93, 14.84)
2019	*****	4.57	4.57 (1.14, 18.26)
2020	44.7	0.00	0.00 (0.00, 0.00)
2021	*****	1.56	1.56 (0.22, 11.05)
2022	*****	1.25	1.25 (0.18, 8.86)
2023	*****	16.95	16.95 (7.05, 40.72)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use			
2017	0.0	NaN	NaN
2018	*****	8.48	8.48 (1.19, 60.22)
2019	363.4	0.00	0.00 (0.00, 0.00)
2020	*****	3.59	3.59 (1.35, 9.56)
2021	*****	2.29	2.29 (0.57, 9.17)
2022	300.7	0.00	0.00 (0.00, 0.00)
2023	*****	27.24	27.24 (6.81, 108.92)
2024	0.1	0.00	0.00 (0.00, 0.00)
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):			
Single Propel Stent Use			
2017	45.0	0.00	0.00 (0.00, 0.00)
2018	540.5	0.00	0.00 (0.00, 0.00)
2019	439.1	0.00	0.00 (0.00, 0.00)
2020	44.7	0.00	0.00 (0.00, 0.00)
2021	642.9	0.00	0.00 (0.00, 0.00)
2022	*****	1.25	1.25 (0.18, 8.87)
2023	*****	0.00	0.00 (0.00, 0.00)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use			
2017	0.0	NaN	NaN

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2018	*****	8.49	8.49 (1.20, 60.26)
2019	363.2	0.00	0.00 (0.00, 0.00)
2020	1,117.9	0.00	0.00 (0.00, 0.00)
2021	*****	1.15	1.15 (0.16, 8.14)
2022	300.3	0.00	0.00 (0.00, 0.00)
2023	74.2	0.00	0.00 (0.00, 0.00)
2024	0.1	0.00	0.00 (0.00, 0.00)
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use			
2017	82.5	0.00	0.00 (0.00, 0.00)
2018	*****	2.09	2.09 (0.52, 8.36)
2019	*****	3.90	3.90 (1.26, 12.10)
2020	41.2	0.00	0.00 (0.00, 0.00)
2021	*****	1.01	1.01 (0.14, 7.18)
2022	*****	1.05	1.05 (0.15, 7.43)
2023	*****	17.14	17.14 (7.14, 41.19)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Propel Stent Use (fixed follow-up)			
2017	82.5	0.00	0.00 (0.00, 0.00)
2018	*****	2.07	2.07 (0.52, 8.28)
2019	*****	3.76	3.76 (1.21, 11.66)
2020	80.3	0.00	0.00 (0.00, 0.00)
2021	*****	0.92	0.92 (0.13, 6.56)
2022	*****	1.03	1.03 (0.14, 7.28)
2023	*****	16.94	16.94 (7.05, 40.69)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Propel Stent Use (1 day lag period)			
2017	82.4	0.00	0.00 (0.00, 0.00)
2018	959.7	0.00	0.00 (0.00, 0.00)
2019	*****	1.30	1.30 (0.18, 9.21)
2020	41.1	0.00	0.00 (0.00, 0.00)
2021	989.2	0.00	0.00 (0.00, 0.00)

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2022	*****	1.05	1.05 (0.15, 7.45)
2023	290.0	0.00	0.00 (0.00, 0.00)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Propel Stent Use (fixed follow-up, 1 day lag period)			
2017	82.4	0.00	0.00 (0.00, 0.00)
2018	968.7	0.00	0.00 (0.00, 0.00)
2019	*****	1.25	1.25 (0.18, 8.88)
2020	80.2	0.00	0.00 (0.00, 0.00)
2021	1,081.8	0.00	0.00 (0.00, 0.00)
2022	*****	1.03	1.03 (0.14, 7.30)
2023	293.7	0.00	0.00 (0.00, 0.00)
2024	0.4	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use			
2017	0.0	NaN	NaN
2018	*****	4.94	4.94 (0.70, 35.09)
2019	649.6	0.00	0.00 (0.00, 0.00)
2020	*****	2.08	2.08 (0.78, 5.54)
2021	*****	1.41	1.41 (0.35, 5.65)
2022	362.8	0.00	0.00 (0.00, 0.00)
2023	*****	28.62	28.62 (7.16, 114.42)
2024	0.1	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use (fixed follow-up)			
2017	0.0	NaN	NaN
2018	*****	4.68	4.68 (0.66, 33.21)
2019	666.2	0.00	0.00 (0.00, 0.00)
2020	*****	2.03	2.03 (0.76, 5.40)
2021	*****	1.35	1.35 (0.34, 5.40)
2022	380.2	0.00	0.00 (0.00, 0.00)
2023	*****	27.21	27.21 (6.80, 108.80)
2024	0.1	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use (1 day lag period)			
2017	0.0	NaN	NaN

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2018	*****	4.95	4.95 (0.70, 35.12)
2019	649.2	0.00	0.00 (0.00, 0.00)
2020	1,928.4	0.00	0.00 (0.00, 0.00)
2021	*****	0.71	0.71 (0.10, 5.02)
2022	361.8	0.00	0.00 (0.00, 0.00)
2023	70.7	0.00	0.00 (0.00, 0.00)
2024	0.1	0.00	0.00 (0.00, 0.00)
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)			
2017	0.0	NaN	NaN
2018	*****	4.68	4.68 (0.66, 33.23)
2019	665.8	0.00	0.00 (0.00, 0.00)
2020	1,978.5	0.00	0.00 (0.00, 0.00)
2021	*****	0.68	0.68 (0.10, 4.80)
2022	379.2	0.00	0.00 (0.00, 0.00)
2023	74.3	0.00	0.00 (0.00, 0.00)
2024	0.1	0.00	0.00 (0.00, 0.00)
Repeat stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days			
2017	0.0	NaN	NaN
2018	*****	127.40	127.40 (17.95, 904.44)
2019	*****	51.62	51.62 (7.27, 366.45)
2020	*****	41.14	41.14 (10.29, 164.49)
2021	*****	76.01	76.01 (28.53, 202.54)
2022	*****	94.40	94.40 (13.30, 670.21)
2023	0.0	NaN	NaN
2024	0.0	NaN	NaN
Sinuva Repeat Stent within 730 days			
2017	0.0	NaN	NaN
2018	*****	127.40	127.40 (17.95, 904.44)
2019	*****	51.62	51.62 (7.27, 366.45)
2020	*****	40.39	40.39 (10.10, 161.49)

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2021	*****	64.29	64.29 (24.13, 171.31)
2022	*****	85.22	85.22 (12.00, 605.00)
2023	0.0	NaN	NaN
2024	0.0	NaN	NaN
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days			
2017	0.0	NaN	NaN
2018	*****	135.43	135.43 (33.87, 541.52)
2019	*****	28.14	28.14 (3.96, 199.74)
2020	*****	51.24	51.24 (19.23, 136.52)
2021	*****	59.01	59.01 (22.15, 157.23)
2022	*****	95.32	95.32 (13.43, 676.68)
2023	0.0	NaN	NaN
2024	0.0	NaN	NaN
Sinuva Repeat Stent within 365 days (fixed follow-up)			
2017	0.0	NaN	NaN
2018	*****	135.43	135.43 (33.87, 541.52)
2019	*****	28.14	28.14 (3.96, 199.74)
2020	*****	47.57	47.57 (17.86, 126.76)
2021	*****	55.28	55.28 (20.75, 147.29)
2022	*****	94.40	94.40 (13.30, 670.21)
2023	0.0	NaN	NaN
2024	0.0	NaN	NaN
Sinuva Repeat Stent within 730 days			
2017	0.0	NaN	NaN
2018	*****	135.43	135.43 (33.87, 541.52)
2019	*****	28.14	28.14 (3.96, 199.74)
2020	*****	50.65	50.65 (19.01, 134.96)
2021	*****	49.15	49.15 (18.45, 130.96)
2022	*****	86.16	86.16 (12.14, 611.71)
2023	0.0	NaN	NaN
2024	0.0	NaN	NaN

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
Sinuva Repeat Stent within 730 days (fixed follow-up)			
2017	0.0	NaN	NaN
2018	*****	135.43	135.43 (33.87, 541.52)
2019	*****	28.14	28.14 (3.96, 199.74)
2020	*****	47.07	47.07 (17.67, 125.41)
2021	*****	46.53	46.53 (17.46, 123.99)
2022	*****	85.22	85.22 (12.00, 605.00)
2023	0.0	NaN	NaN
2024	0.0	NaN	NaN
Repeat stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days			
2017	0.0	NaN	NaN
2018	9.0	0.00	0.00 (0.00, 0.00)
2019	*****	44.90	44.90 (6.32, 318.75)
2020	58.1	0.00	0.00 (0.00, 0.00)
2021	71.7	0.00	0.00 (0.00, 0.00)
2022	*****	39.49	39.49 (5.56, 280.36)
2023	1.7	0.00	0.00 (0.00, 0.00)
2024	0.0	NaN	NaN
Sinuva Repeat Stent within 730 days			
2017	0.0	NaN	NaN
2018	9.0	0.00	0.00 (0.00, 0.00)
2019	*****	44.90	44.90 (6.32, 318.75)
2020	61.3	0.00	0.00 (0.00, 0.00)
2021	82.8	0.00	0.00 (0.00, 0.00)
2022	*****	32.67	32.67 (4.60, 231.93)
2023	2.5	0.00	0.00 (0.00, 0.00)
2024	0.0	NaN	NaN
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days			
2017	0.0	NaN	NaN

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2018	17.4	0.00	0.00 (0.00, 0.00)
2019	*****	25.22	25.22 (3.55, 179.01)
2020	98.3	0.00	0.00 (0.00, 0.00)
2021	112.1	0.00	0.00 (0.00, 0.00)
2022	*****	34.38	34.38 (4.84, 244.05)
2023	1.7	0.00	0.00 (0.00, 0.00)
2024	0.0	NaN	NaN
Sinuva Repeat Stent within 365 days (fixed follow-up)			
2017	0.0	NaN	NaN
2018	17.4	0.00	0.00 (0.00, 0.00)
2019	*****	25.22	25.22 (3.55, 179.01)
2020	103.1	0.00	0.00 (0.00, 0.00)
2021	118.1	0.00	0.00 (0.00, 0.00)
2022	*****	33.49	33.49 (4.72, 237.74)
2023	1.7	0.00	0.00 (0.00, 0.00)
2024	0.0	NaN	NaN
Sinuva Repeat Stent within 730 days			
2017	0.0	NaN	NaN
2018	17.4	0.00	0.00 (0.00, 0.00)
2019	*****	25.22	25.22 (3.55, 179.01)
2020	101.7	0.00	0.00 (0.00, 0.00)
2021	131.5	0.00	0.00 (0.00, 0.00)
2022	*****	29.38	29.38 (4.14, 208.58)
2023	2.5	0.00	0.00 (0.00, 0.00)
2024	0.0	NaN	NaN
Sinuva Repeat Stent within 730 days (fixed follow-up)			
2017	0.0	NaN	NaN
2018	17.4	0.00	0.00 (0.00, 0.00)
2019	*****	25.22	25.22 (3.55, 179.01)
2020	106.4	0.00	0.00 (0.00, 0.00)
2021	137.5	0.00	0.00 (0.00, 0.00)
2022	*****	28.16	28.16 (3.97, 199.94)

Table 5. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024, by Year

	Total Years at Risk	Event Rate per 1000 Patient-Years at Risk	Event Rate per 1000 Patient-Years at Risk (95% Confidence Interval)
2023	2.5	0.00	0.00 (0.00, 0.00)
2024	0.0	NaN	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

****NaN = Not a number

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

		Number of Episodes by Episode Length	
		0-91 days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	1,955	49.8%
Single Sinuva Stent Use	3,393	1,055	31.1%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	649	16.5%
Single Sinuva Stent Use	3,393	318	9.4%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (273 day lag period)	3,924	2,051	52.3%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	3,924	1,955	49.8%
Single Propel Stent Use	3,924	768	19.6%
Single Propel Stent Use (fixed follow-up)	3,924	649	16.5%
Single Sinuva Stent Use (273 day lag period)	3,393	1,136	33.5%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	3,393	1,055	31.1%
Single Sinuva Stent Use	3,393	412	12.1%
Single Sinuva Stent Use (fixed follow-up)	3,393	318	9.4%
Single stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	810	20.6%
Single Sinuva Stent Use	3,393	394	11.6%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	637	16.2%
Single Sinuva Stent Use	3,393	305	9.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use Cohort (28 day lag period)	3,924	931	23.7%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	3,924	810	20.6%
Single Propel Stent Use	3,924	758	19.3%
Single Propel Stent Use Cohort (fixed follow-up)	3,924	637	16.2%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

		Number of Episodes by Episode Length	
		0-91 days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (28 day lag period)	3,393	486	14.3%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	394	11.6%
Single Sinuva Stent Use	3,393	399	11.8%
Single Sinuva Stent Use (fixed follow-up)	3,393	305	9.0%
Single stent cohorts - Outcome: Ocular Hypertension			
Primary analysis cohorts (14-day lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	738	18.8%
Single Sinuva Stent Use	3,393	385	11.3%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	651	16.6%
Single Sinuva Stent Use	3,393	333	9.8%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (14 day lag period)	3,924	856	21.8%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	3,924	738	18.8%
Single Propel Stent Use	3,924	769	19.6%
Single Propel Stent Use (fixed follow-up)	3,924	651	16.6%
Single Sinuva Stent Use (14 day lag period)	3,393	477	14.1%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	3,393	385	11.3%
Single Sinuva Stent Use	3,393	426	12.6%
Single Sinuva Stent Use (fixed follow-up)	3,393	333	9.8%
Single stent cohorts - Outcome: Diminished Visual Acuity			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	819	20.9%
Single Sinuva Stent Use	3,393	415	12.2%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	654	16.7%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

		Number of Episodes by Episode Length	
		0-91 days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	3,393	326	9.6%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use (28 day lag period)	3,924	939	23.9%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	3,924	819	20.9%
Single Propel Stent Use	3,924	775	19.8%
Single Propel Stent Use (fixed follow-up)	3,924	654	16.7%
Single Sinuva Stent Use (28 day lag period)	3,393	506	14.9%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	415	12.2%
Single Sinuva Stent Use	3,393	420	12.4%
Single Sinuva Stent Use (fixed follow-up)	3,393	326	9.6%
Single stent cohorts - Outcome: Nasal Septal Perforation **Primary analysis cohorts (no lag period with fixed one year follow-up):**			
Single Propel Stent Use	3,924	640	16.3%
Single Sinuva Stent Use	3,393	305	9.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):			
Single Propel Stent Use	3,924	639	16.3%
Single Sinuva Stent Use	3,393	303	8.9%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):			
Single Propel Stent Use	3,924	761	19.4%
Single Propel Stent Use (fixed follow-up)	3,924	640	16.3%
Single Propel Stent Use (1 day lag period)	3,924	760	19.4%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	3,924	639	16.3%
Single Sinuva Stent Use	3,393	399	11.8%
Single Sinuva Stent Use (fixed follow-up)	3,393	305	9.0%
Single Sinuva Stent Use (1 day lag period)	3,393	397	11.7%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

		Number of Episodes by Episode Length	
		0-91 days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	3,393	303	8.9%
Repeat stent cohorts - Outcome: Cataract			
Primary analysis cohorts (273-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days	231	70	30.3%
Sinuva Repeat Stent within 730 days	258	83	32.2%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days	231	76	32.9%
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	70	30.3%
Sinuva Repeat Stent within 730 days	258	89	34.5%
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	83	32.2%
Repeat stent cohorts - Outcome: Glaucoma			
Primary analysis cohorts (28-day lag period with fixed one year follow-up):			
Sinuva Repeat Stent within 365 days	231	28	12.1%
Sinuva Repeat Stent within 730 days	258	30	11.6%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):			
Sinuva Repeat Stent within 365 days	231	33	14.3%
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	28	12.1%
Sinuva Repeat Stent within 730 days	258	36	14.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	30	11.6%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	265	6.8%	287	7.3%
Single Sinuva Stent Use	267	7.9%	206	6.1%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	568	14.5%	423	10.8%
Single Sinuva Stent Use	286	8.4%	252	7.4%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	256	6.5%	283	7.2%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	265	6.8%	287	7.3%
Single Propel Stent Use	560	14.3%	417	10.6%
Single Propel Stent Use (fixed follow-up)	568	14.5%	423	10.8%
Single Sinuva Stent Use (273 day lag period)	262	7.7%	203	6.0%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	267	7.9%	206	6.1%
Single Sinuva Stent Use	280	8.3%	253	7.5%
Single Sinuva Stent Use (fixed follow-up)	286	8.4%	252	7.4%
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	535	13.6%	377	9.6%
Single Sinuva Stent Use	230	6.8%	243	7.2%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	559	14.2%	416	10.6%
Single Sinuva Stent Use	248	7.3%	235	6.9%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use Cohort (28 day lag period)	524	13.4%	369	9.4%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	535	13.6%	377	9.6%
Single Propel Stent Use	551	14.0%	410	10.4%
Single Propel Stent Use Cohort (fixed follow-up)	559	14.2%	416	10.6%
Single Sinuva Stent Use (28 day lag period)	229	6.7%	236	7.0%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	230	6.8%	243	7.2%
Single Sinuva Stent Use	243	7.2%	236	7.0%
Single Sinuva Stent Use (fixed follow-up)	248	7.3%	235	6.9%
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	564	14.4%	396	10.1%
Single Sinuva Stent Use	257	7.6%	237	7.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	574	14.6%	413	10.5%
Single Sinuva Stent Use	268	7.9%	248	7.3%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	555	14.1%	388	9.9%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	564	14.4%	396	10.1%
Single Propel Stent Use	566	14.4%	407	10.4%
Single Propel Stent Use (fixed follow-up)	574	14.6%	413	10.5%
Single Sinuva Stent Use (14 day lag period)	254	7.5%	233	6.9%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	257	7.6%	237	7.0%
Single Sinuva Stent Use	263	7.8%	249	7.3%
Single Sinuva Stent Use (fixed follow-up)	268	7.9%	248	7.3%
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	547	13.9%	385	9.8%
Single Sinuva Stent Use	230	6.8%	252	7.4%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	565	14.4%	426	10.9%
Single Sinuva Stent Use	253	7.5%	241	7.1%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	536	13.7%	377	9.6%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	547	13.9%	385	9.8%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use	556	14.2%	420	10.7%
Single Propel Stent Use (fixed follow-up)	565	14.4%	426	10.9%
Single Sinuva Stent Use (28 day lag period)	229	6.7%	245	7.2%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	230	6.8%	252	7.4%
Single Sinuva Stent Use	247	7.3%	242	7.1%
Single Sinuva Stent Use (fixed follow-up)	253	7.5%	241	7.1%
Single stent cohorts - Outcome: Nasal Septal Perforation				
Primary analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	552	14.1%	414	10.6%
Single Sinuva Stent Use	239	7.0%	231	6.8%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	557	14.2%	413	10.5%
Single Sinuva Stent Use	237	7.0%	232	6.8%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	544	13.9%	408	10.4%
Single Propel Stent Use (fixed follow-up)	552	14.1%	414	10.6%
Single Propel Stent Use (1 day lag period)	549	14.0%	407	10.4%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	557	14.2%	413	10.5%
Single Sinuva Stent Use	234	6.9%	232	6.8%
Single Sinuva Stent Use (fixed follow-up)	239	7.0%	231	6.8%
Single Sinuva Stent Use (1 day lag period)	233	6.9%	232	6.8%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	237	7.0%	232	6.8%
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	21	9.1%	20	8.7%
Sinuva Repeat Stent within 730 days	24	9.3%	21	8.1%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	21	9.1%	21	9.1%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 365 days (fixed follow-up)	21	9.1%	20	8.7%
Sinuva Repeat Stent within 730 days	24	9.3%	22	8.5%
Sinuva Repeat Stent within 730 days (fixed follow-up)	24	9.3%	21	8.1%
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	13	5.6%	21	9.1%
Sinuva Repeat Stent within 730 days	17	6.6%	25	9.7%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	13	5.6%	22	9.5%
Sinuva Repeat Stent within 365 days (fixed follow-up)	13	5.6%	21	9.1%
Sinuva Repeat Stent within 730 days	17	6.6%	25	9.7%
Sinuva Repeat Stent within 730 days (fixed follow-up)	17	6.6%	25	9.7%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length					
	274-364 days		365-455 days		456-546 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract						
Primary analysis cohorts (273-day lag period with fixed one year follow-up):						
Single Propel Stent Use	1,417	36.1%	0	0.0%	0	0.0%
Single Sinuva Stent Use	1,865	55.0%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	2,284	58.2%	0	0.0%	0	0.0%
Single Sinuva Stent Use	2,537	74.8%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (273 day lag period)	217	5.5%	211	5.4%	152	3.9%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	226	5.8%	221	5.6%	165	4.2%
Single Propel Stent Use	334	8.5%	247	6.3%	277	7.1%
Single Propel Stent Use (fixed follow-up)	344	8.8%	256	6.5%	280	7.1%
Single Sinuva Stent Use (273 day lag period)	208	6.1%	207	6.1%	209	6.2%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	217	6.4%	217	6.4%	216	6.4%
Single Sinuva Stent Use	263	7.8%	251	7.4%	189	5.6%
Single Sinuva Stent Use (fixed follow-up)	272	8.0%	256	7.5%	191	5.6%
Single stent cohorts - Outcome: Glaucoma						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Single Propel Stent Use	2,202	56.1%	0	0.0%	0	0.0%
Single Sinuva Stent Use	2,526	74.4%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	2,312	58.9%	0	0.0%	0	0.0%
Single Sinuva Stent Use	2,605	76.8%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use Cohort (28 day lag period)	305	7.8%	254	6.5%	256	6.5%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	312	8.0%	260	6.6%	259	6.6%
Single Propel Stent Use	330	8.4%	245	6.2%	275	7.0%
Single Propel Stent Use Cohort (fixed follow-up)	341	8.7%	251	6.4%	279	7.1%
Single Sinuva Stent Use (28 day lag period)	260	7.7%	211	6.2%	186	5.5%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length					
	274-364 days		365-455 days		456-546 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	261	7.7%	215	6.3%	188	5.5%
Single Sinuva Stent Use	257	7.6%	235	6.9%	169	5.0%
Single Sinuva Stent Use (fixed follow-up)	266	7.8%	237	7.0%	171	5.0%
Single stent cohorts - Outcome: Ocular Hypertension						
Primary analysis cohorts (14-day lag period with fixed one year follow-up):						
Single Propel Stent Use	2,226	56.7%	0	0.0%	0	0.0%
Single Sinuva Stent Use	2,514	74.1%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	2,286	58.3%	0	0.0%	0	0.0%
Single Sinuva Stent Use	2,544	75.0%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (14 day lag period)	318	8.1%	248	6.3%	262	6.7%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	329	8.4%	253	6.4%	265	6.8%
Single Propel Stent Use	336	8.6%	244	6.2%	272	6.9%
Single Propel Stent Use (fixed follow-up)	348	8.9%	251	6.4%	275	7.0%
Single Sinuva Stent Use (14 day lag period)	274	8.1%	229	6.7%	164	4.8%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	279	8.2%	232	6.8%	167	4.9%
Single Sinuva Stent Use	260	7.7%	237	7.0%	171	5.0%
Single Sinuva Stent Use (fixed follow-up)	270	8.0%	240	7.1%	173	5.1%
Single stent cohorts - Outcome: Diminished Visual Acuity						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Single Propel Stent Use	2,173	55.4%	0	0.0%	0	0.0%
Single Sinuva Stent Use	2,496	73.6%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	2,279	58.1%	0	0.0%	0	0.0%
Single Sinuva Stent Use	2,573	75.8%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (28 day lag period)	309	7.9%	260	6.6%	257	6.5%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	317	8.1%	267	6.8%	260	6.6%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length					
	274-364 days		365-455 days		456-546 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use	334	8.5%	247	6.3%	274	7.0%
Single Propel Stent Use (fixed follow-up)	346	8.8%	254	6.5%	278	7.1%
Single Sinuva Stent Use (28 day lag period)	264	7.8%	219	6.5%	192	5.7%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	266	7.8%	224	6.6%	194	5.7%
Single Sinuva Stent Use	260	7.7%	240	7.1%	177	5.2%
Single Sinuva Stent Use (fixed follow-up)	270	8.0%	243	7.2%	179	5.3%
Single stent cohorts - Outcome: Nasal Septal Perforation						
Primary analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	2,318	59.1%	0	0.0%	0	0.0%
Single Sinuva Stent Use	2,618	77.2%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):						
Single Propel Stent Use	2,315	59.0%	0	0.0%	0	0.0%
Single Sinuva Stent Use	2,621	77.2%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use	329	8.4%	245	6.2%	276	7.0%
Single Propel Stent Use (fixed follow-up)	340	8.7%	251	6.4%	280	7.1%
Single Propel Stent Use (1 day lag period)	327	8.3%	246	6.3%	275	7.0%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	338	8.6%	252	6.4%	279	7.1%
Single Sinuva Stent Use	251	7.4%	229	6.7%	167	4.9%
Single Sinuva Stent Use (fixed follow-up)	260	7.7%	231	6.8%	169	5.0%
Single Sinuva Stent Use (1 day lag period)	251	7.4%	230	6.8%	166	4.9%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	260	7.7%	231	6.8%	169	5.0%
Repeat stent cohorts - Outcome: Cataract						
Primary analysis cohorts (273-day lag period with fixed one year follow-up):						
Sinuva Repeat Stent within 365 days	120	51.9%	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	130	50.4%	0	0.0%	0	0.0%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):						
Sinuva Repeat Stent within 365 days	15	6.5%	*****	*****	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	16	6.9%	*****	*****	*****	*****

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length					
	274-364 days		365-455 days		456-546 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days	17	6.6%	*****	*****	*****	*****
Sinuva Repeat Stent within 730 days (fixed follow-up)	18	7.0%	*****	*****	*****	*****
Repeat stent cohorts - Outcome: Glaucoma						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Sinuva Repeat Stent within 365 days	169	73.2%	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	186	72.1%	0	0.0%	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):						
Sinuva Repeat Stent within 365 days	12	5.2%	22	9.5%	14	6.1%
Sinuva Repeat Stent within 365 days (fixed follow-up)	12	5.2%	22	9.5%	13	5.6%
Sinuva Repeat Stent within 730 days	17	6.6%	23	8.9%	17	6.6%
Sinuva Repeat Stent within 730 days (fixed follow-up)	17	6.6%	23	8.9%	16	6.2%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length			
	547-637 days		638-729 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	106	2.7%	648	16.5%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	115	2.9%	690	17.6%
Single Propel Stent Use	215	5.5%	1,106	28.2%
Single Propel Stent Use (fixed follow-up)	224	5.7%	1,180	30.1%
Single Sinuva Stent Use (273 day lag period)	213	6.3%	955	28.1%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	216	6.4%	999	29.4%
Single Sinuva Stent Use	200	5.9%	1,545	45.5%
Single Sinuva Stent Use (fixed follow-up)	209	6.2%	1,609	47.4%
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use Cohort (28 day lag period)	200	5.1%	1,085	27.7%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	210	5.4%	1,161	29.6%
Single Propel Stent Use	208	5.3%	1,147	29.2%
Single Propel Stent Use Cohort (fixed follow-up)	217	5.5%	1,224	31.2%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length			
	547-637 days		638-729 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (28 day lag period)	176	5.2%	1,609	47.4%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	187	5.5%	1,675	49.4%
Single Sinuva Stent Use	186	5.5%	1,668	49.2%
Single Sinuva Stent Use (fixed follow-up)	195	5.7%	1,736	51.2%
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	198	5.0%	1,099	28.0%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	206	5.2%	1,173	29.9%
Single Propel Stent Use	203	5.2%	1,127	28.7%
Single Propel Stent Use (fixed follow-up)	212	5.4%	1,200	30.6%
Single Sinuva Stent Use (14 day lag period)	177	5.2%	1,585	46.7%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	188	5.5%	1,648	48.6%
Single Sinuva Stent Use	177	5.2%	1,610	47.5%
Single Sinuva Stent Use (fixed follow-up)	186	5.5%	1,675	49.4%
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length			
	547-637 days		638-729 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use (28 day lag period)	192	4.9%	1,054	26.9%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	201	5.1%	1,128	28.7%
Single Propel Stent Use	206	5.2%	1,112	28.3%
Single Propel Stent Use (fixed follow-up)	214	5.5%	1,187	30.2%
Single Sinuva Stent Use (28 day lag period)	188	5.5%	1,550	45.7%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	198	5.8%	1,614	47.6%
Single Sinuva Stent Use	198	5.8%	1,609	47.4%
Single Sinuva Stent Use (fixed follow-up)	206	6.1%	1,675	49.4%
Single stent cohorts - Outcome: Nasal Septal Perforation				
Primary analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	208	5.3%	1,153	29.4%
Single Propel Stent Use (fixed follow-up)	217	5.5%	1,230	31.3%
Single Propel Stent Use (1 day lag period)	208	5.3%	1,152	29.4%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	217	5.5%	1,229	31.3%
Single Sinuva Stent Use	190	5.6%	1,691	49.8%
Single Sinuva Stent Use (fixed follow-up)	199	5.9%	1,759	51.8%
Single Sinuva Stent Use (1 day lag period)	192	5.7%	1,692	49.9%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	202	6.0%	1,759	51.8%
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length			
	547-637 days		638-729 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	15	6.5%	62	26.8%
Sinuva Repeat Stent within 365 days (fixed follow-up)	16	6.9%	65	28.1%
Sinuva Repeat Stent within 730 days	17	6.6%	64	24.8%
Sinuva Repeat Stent within 730 days (fixed follow-up)	18	7.0%	67	26.0%
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	15	6.5%	100	43.3%
Sinuva Repeat Stent within 365 days (fixed follow-up)	16	6.9%	106	45.9%
Sinuva Repeat Stent within 730 days	16	6.2%	107	41.5%
Sinuva Repeat Stent within 730 days (fixed follow-up)	17	6.6%	113	43.8%

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length								
	730+ days		Distribution of At-Risk Time in Days, by Episode						
	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single stent cohorts - Outcome: Cataract									
Primary analysis cohorts (273-day lag period with fixed one year follow-up):									
Single Propel Stent Use	0	0.0%	0	0	94	364	364	158.5	162.3
Single Sinuva Stent Use	0	0.0%	0	25	343	364	364	225.6	157.9
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):									
Single Propel Stent Use	0	0.0%	1	146	358	364	364	259.2	126.5
Single Sinuva Stent Use	0	0.0%	1	269	364	364	364	300.6	109.2
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):									
Single Propel Stent Use (273 day lag period)	0	0.0%	0	0	66	421	729	223.5	275.1
Single Propel Stent Use (fixed follow-up, 273 day lag period)	0	0.0%	0	0	94	448	729	236.7	278.6
Single Propel Stent Use	0	0.0%	1	127	330	691	729	374.5	266.2
Single Propel Stent Use (fixed follow-up)	0	0.0%	1	146	358	718	729	392.0	263.0
Single Sinuva Stent Use (273 day lag period)	0	0.0%	0	0	310	681	729	342.2	294.6
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	0	0.0%	0	25	343	697	729	355.8	293.0
Single Sinuva Stent Use	0	0.0%	1	236	564	729	729	478.8	263.6
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	1	269	597	729	729	496.1	253.5
Single stent cohorts - Outcome: Glaucoma									
Primary analysis cohorts (28-day lag period with fixed one year follow-up):									
Single Propel Stent Use	0	0.0%	0	121	340	364	364	247.6	136.1
Single Sinuva Stent Use	0	0.0%	0	268	364	364	364	296.9	115.9
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):									
Single Propel Stent Use	0	0.0%	1	149	364	364	364	261.0	126.1
Single Sinuva Stent Use	0	0.0%	1	295	364	364	364	305.3	106.5
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):									
Single Propel Stent Use Cohort (28 day lag period)	0	0.0%	0	102	311	680	729	359.5	274.2
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	0	0.0%	0	121	340	713	729	377.2	271.7
Single Propel Stent Use	0	0.0%	1	130	339	708	729	379.5	267.5
Single Propel Stent Use Cohort (fixed follow-up)	0	0.0%	1	149	368	729	729	397.5	264.0

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length								
	730+ days		Distribution of At-Risk Time in Days, by Episode						
	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use (28 day lag period)	0	0.0%	0	233	596	729	729	479.6	270.7
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	0	268	627	729	729	497.0	260.9
Single Sinuva Stent Use	0	0.0%	1	261	624	729	729	494.5	262.5
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	1	295	655	729	729	512.2	251.3
Single stent cohorts - Outcome: Ocular Hypertension									
Primary analysis cohorts (14-day lag period with fixed one year follow-up):									
Single Propel Stent Use	0	0.0%	0	130	344	364	364	252.0	132.0
Single Sinuva Stent Use	0	0.0%	0	261	364	364	364	296.5	114.3
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):									
Single Propel Stent Use	0	0.0%	1	144	358	364	364	258.9	126.7
Single Sinuva Stent Use	0	0.0%	1	272	364	364	364	300.7	109.7
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):									
Single Propel Stent Use (14 day lag period)	0	0.0%	0	112	316	686	729	365.3	270.8
Single Propel Stent Use (fixed follow-up, 14 day lag period)	0	0.0%	0	130	344	714	729	382.6	268.1
Single Propel Stent Use	0	0.0%	1	126	330	699	729	375.4	267.3
Single Propel Stent Use (fixed follow-up)	0	0.0%	1	144	358	727	729	392.7	264.0
Single Sinuva Stent Use (14 day lag period)	0	0.0%	0	226	578	729	729	475.8	269.5
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	0	0.0%	0	261	613	729	729	492.9	259.9
Single Sinuva Stent Use	0	0.0%	1	239	591	729	729	483.2	265.6
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	1	272	627	729	729	500.4	255.4
Single stent cohorts - Outcome: Diminished Visual Acuity									
Primary analysis cohorts (28-day lag period with fixed one year follow-up):									
Single Propel Stent Use	0	0.0%	0	119	330	364	364	245.7	136.3
Single Sinuva Stent Use	0	0.0%	0	259	364	364	364	294.5	117.2
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):									
Single Propel Stent Use	0	0.0%	1	146	355	364	364	258.8	126.7

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length								
	730+ days		Distribution of At-Risk Time in Days, by Episode						
	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use	0	0.0%	1	285	364	364	364	302.7	108.5
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):									
Single Propel Stent Use (28 day lag period)	0	0.0%	0	100	302	667	729	354.7	272.9
Single Propel Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	0	119	330	695	729	372.1	270.7
Single Propel Stent Use	0	0.0%	1	126	329	694	729	374.0	266.7
Single Propel Stent Use (fixed follow-up)	0	0.0%	1	146	355	723	729	391.7	263.4
Single Sinuva Stent Use (28 day lag period)	0	0.0%	0	224	570	729	729	472.1	271.0
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	0	259	600	729	729	489.1	261.7
Single Sinuva Stent Use	0	0.0%	1	249	597	729	729	486.7	263.6
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	1	285	627	729	729	504.0	253.0
Single stent cohorts - Outcome: Nasal Septal Perforation									
Primary analysis cohorts (no lag period with fixed one year follow-up):									
Single Propel Stent Use	0	0.0%	1	149	364	364	364	261.2	126.4
Single Sinuva Stent Use	0	0.0%	1	299	364	364	364	306.0	106.4
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):									
Single Propel Stent Use	0	0.0%	0	148	364	364	364	261.2	126.4
Single Sinuva Stent Use	0	0.0%	0	300	364	364	364	306.4	105.9
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):									
Single Propel Stent Use	0	0.0%	1	131	342	712	729	380.3	267.9
Single Propel Stent Use (fixed follow-up)	0	0.0%	1	149	369	729	729	398.3	264.4
Single Propel Stent Use (1 day lag period)	0	0.0%	0	131	342	712	729	380.4	268.0
Single Propel Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	0	148	369	729	729	398.3	264.4
Single Sinuva Stent Use	0	0.0%	1	267	633	729	729	497.8	262.4
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	1	299	666	729	729	515.4	251.0
Single Sinuva Stent Use (1 day lag period)	0	0.0%	0	267	633	729	729	498.2	262.0

Table 6. Summary of Time from Start of Follow-Up to End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes by Episode Length								
	730+ days		Distribution of At-Risk Time in Days, by Episode						
	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	0	300	666	729	729	515.9	250.5
Repeat stent cohorts - Outcome: Cataract									
Primary analysis cohorts (273-day lag period with fixed one year follow-up):									
Sinuva Repeat Stent within 365 days	0	0.0%	0	0	297	364	364	219.9	157.0
Sinuva Repeat Stent within 730 days	0	0.0%	0	0	277	364	364	213.3	158.1
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):									
Sinuva Repeat Stent within 365 days	0	0.0%	0	0	241	663	729	326.8	292.7
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0	297	686	729	343.7	291.8
Sinuva Repeat Stent within 730 days	0	0.0%	0	0	233	635	729	314.7	290.2
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	0	0	277	659	729	329.8	289.9
Repeat stent cohorts - Outcome: Glaucoma									
Primary analysis cohorts (28-day lag period with fixed one year follow-up):									
Sinuva Repeat Stent within 365 days	0	0.0%	0	239	364	364	364	297.4	114.3
Sinuva Repeat Stent within 730 days	0	0.0%	0	239	364	364	364	295.2	114.2
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):									
Sinuva Repeat Stent within 365 days	0	0.0%	0	227	542	729	729	471.7	263.9
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	239	584	729	729	489.9	257.2
Sinuva Repeat Stent within 730 days	0	0.0%	0	227	522	729	729	462.5	263.5
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	0	239	549	729	729	479.8	256.8

********Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 7. Summary of Reasons for End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024[1,2]

		Censoring Reason			
		End of Exposure Episode[3]		Occurrence of Outcome of Interest[4]	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract					
Primary analysis cohorts (273-day lag period with fixed one year follow-up):					
Single Propel Stent Use	3,924	1,194	30.4%	61	1.6%
Single Sinuva Stent Use	3,393	1,648	48.6%	132	3.9%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):					
Single Propel Stent Use	3,924	1,944	49.5%	63	1.6%
Single Sinuva Stent Use	3,393	2,265	66.8%	110	3.2%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):					
Single Propel Stent Use (273 day lag period)	3,924	579	14.8%	72	1.8%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	3,924	614	15.6%	77	2.0%
Single Propel Stent Use	3,924	899	22.9%	106	2.7%
Single Propel Stent Use (fixed follow-up)	3,924	963	24.5%	110	2.8%
Single Sinuva Stent Use (273 day lag period)	3,393	724	21.3%	175	5.2%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	3,393	761	22.4%	180	5.3%
Single Sinuva Stent Use	3,393	1,341	39.5%	194	5.7%
Single Sinuva Stent Use (fixed follow-up)	3,393	1,395	41.1%	198	5.8%
Single stent cohorts - Outcome: Glaucoma					
Primary analysis cohorts (28-day lag period with fixed one year follow-up):					
Single Propel Stent Use	3,924	1,893	48.2%	14	0.4%
Single Sinuva Stent Use	3,393	2,267	66.8%	28	0.8%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):					
Single Propel Stent Use	3,924	1,975	50.3%	14	0.4%
Single Sinuva Stent Use	3,393	2,339	68.9%	28	0.8%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):					
Single Propel Stent Use Cohort (28 day lag period)	3,924	890	22.7%	20	0.5%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	3,924	949	24.2%	21	0.5%

Table 7. Summary of Reasons for End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024[1,2]

		Censoring Reason			
		End of Exposure Episode[3]		Occurrence of Outcome of Interest[4]	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use	3,924	939	23.9%	19	0.5%
Single Propel Stent Use Cohort (fixed follow-up)	3,924	1,005	25.6%	20	0.5%
Single Sinuva Stent Use (28 day lag period)	3,393	1,385	40.8%	41	1.2%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	1,441	42.5%	42	1.2%
Single Sinuva Stent Use	3,393	1,456	42.9%	42	1.2%
Single Sinuva Stent Use (fixed follow-up)	3,393	1,513	44.6%	43	1.3%
Single stent cohorts - Outcome: Ocular Hypertension					
Primary analysis cohorts (14-day lag period with fixed one year follow-up):					
Single Propel Stent Use	3,924	1,899	48.4%	70	1.8%
Single Sinuva Stent Use	3,393	2,237	65.9%	110	3.2%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):					
Single Propel Stent Use	3,924	1,944	49.5%	70	1.8%
Single Sinuva Stent Use	3,393	2,276	67.1%	110	3.2%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):					
Single Propel Stent Use (14 day lag period)	3,924	892	22.7%	83	2.1%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	3,924	952	24.3%	88	2.2%
Single Propel Stent Use	3,924	916	23.3%	85	2.2%
Single Propel Stent Use (fixed follow-up)	3,924	979	24.9%	89	2.3%
Single Sinuva Stent Use (14 day lag period)	3,393	1,360	40.1%	148	4.4%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	3,393	1,415	41.7%	151	4.5%
Single Sinuva Stent Use	3,393	1,396	41.1%	149	4.4%
Single Sinuva Stent Use (fixed follow-up)	3,393	1,451	42.8%	152	4.5%
Single stent cohorts - Outcome: Diminished Visual Acuity					
Primary analysis cohorts (28-day lag period with fixed one year follow-up):					
Single Propel Stent Use	3,924	1,860	47.4%	67	1.7%
Single Sinuva Stent Use	3,393	2,232	65.8%	73	2.2%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):					

Table 7. Summary of Reasons for End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024[1,2]

	Censoring Reason				
		End of Exposure Episode[3]		Occurrence of Outcome of Interest[4]	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use	3,924	1,937	49.4%	72	1.8%
Single Sinuva Stent Use	3,393	2,303	67.9%	76	2.2%

Table 7. Summary of Reasons for End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024[1,2]

		Censoring Reason			
		End of Exposure Episode[3]		Occurrence of Outcome of Interest[4]	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):					
Single Propel Stent Use (28 day lag period)	3,924	863	22.0%	95	2.4%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	3,924	919	23.4%	100	2.5%
Single Propel Stent Use	3,924	909	23.2%	101	2.6%
Single Propel Stent Use (fixed follow-up)	3,924	974	24.8%	104	2.7%
Single Sinuva Stent Use (28 day lag period)	3,393	1,319	38.9%	130	3.8%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	1,373	40.5%	134	3.9%
Single Sinuva Stent Use	3,393	1,391	41.0%	133	3.9%
Single Sinuva Stent Use (fixed follow-up)	3,393	1,447	42.6%	136	4.0%
Single stent cohorts - Outcome: Nasal Septal Perforation					
Primary analysis cohorts (no lag period with fixed one year follow-up):					
Single Propel Stent Use	3,924	1,982	50.5%	11	0.3%
Single Sinuva Stent Use	3,393	2,358	69.5%	*****	*****
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):					
Single Propel Stent Use	3,924	1,982	50.5%	*****	*****
Single Sinuva Stent Use	3,393	2,362	69.6%	*****	*****
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):					
Single Propel Stent Use	3,924	943	24.0%	12	0.3%
Single Propel Stent Use (fixed follow-up)	3,924	1,010	25.7%	12	0.3%
Single Propel Stent Use (1 day lag period)	3,924	942	24.0%	*****	*****
Single Propel Stent Use (fixed follow-up, 1 day lag period)	3,924	1,008	25.7%	*****	*****
Single Sinuva Stent Use	3,393	1,478	43.6%	*****	*****
Single Sinuva Stent Use (fixed follow-up)	3,393	1,536	45.3%	*****	*****
Single Sinuva Stent Use (1 day lag period)	3,393	1,478	43.6%	*****	*****

Table 7. Summary of Reasons for End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024[1,2]

		Censoring Reason			
		End of Exposure Episode[3]		Occurrence of Outcome of Interest[4]	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	3,393	1,535	45.2%	*****	*****
Repeat stent cohorts - Outcome: Cataract					
Primary analysis cohorts (273-day lag period with fixed one year follow-up):					
Sinuva Repeat Stent within 365 days	231	104	45.0%	*****	*****
Sinuva Repeat Stent within 730 days	258	112	43.4%	*****	*****
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):					
Sinuva Repeat Stent within 365 days	231	47	20.3%	12	5.2%
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	49	21.2%	12	5.2%
Sinuva Repeat Stent within 730 days	258	49	19.0%	12	4.7%
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	51	19.8%	12	4.7%
Repeat stent cohorts - Outcome: Glaucoma					
Primary analysis cohorts (28-day lag period with fixed one year follow-up):					
Sinuva Repeat Stent within 365 days	231	157	68.0%	*****	*****
Sinuva Repeat Stent within 730 days	258	169	65.5%	*****	*****
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):					
Sinuva Repeat Stent within 365 days	231	84	36.4%	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	89	38.5%	*****	*****
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):					
Sinuva Repeat Stent within 730 days	258	88	34.1%	*****	*****
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	93	36.0%	*****	*****

Table 7. Summary of Reasons for End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024[1,2]

	Censoring Reason					
	Occurrence of User-Defined Censoring Criteria[5]		Disenrollment[6]		End of Data[7]	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract						
Primary analysis cohorts (273-day lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	2,481	63.2%	1,595	40.6%
Single Sinuva Stent Use	0	0.0%	1,504	44.3%	769	22.7%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	1,802	45.9%	1,110	28.3%
Single Sinuva Stent Use	0	0.0%	955	28.1%	443	13.1%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (273 day lag period)	153	3.9%	2,876	73.3%	1,935	49.3%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	0	0.0%	2,983	76.0%	1,990	50.7%
Single Propel Stent Use	149	3.8%	2,570	65.5%	1,696	43.2%
Single Propel Stent Use (fixed follow-up)	0	0.0%	2,651	67.6%	1,728	44.0%
Single Sinuva Stent Use (273 day lag period)	129	3.8%	2,199	64.8%	1,360	40.1%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	0	0.0%	2,283	67.3%	1,405	41.4%
Single Sinuva Stent Use	126	3.7%	1,614	47.6%	856	25.2%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	1,682	49.6%	890	26.2%
Single stent cohorts - Outcome: Glaucoma						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	1,889	48.1%	1,174	29.9%
Single Sinuva Stent Use	0	0.0%	1,031	30.4%	485	14.3%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	1,816	46.3%	1,124	28.6%
Single Sinuva Stent Use	0	0.0%	961	28.3%	451	13.3%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use Cohort (28 day lag period)	151	3.8%	2,647	67.5%	1,765	45.0%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	0	0.0%	2,737	69.8%	1,802	45.9%
Single Propel Stent Use	151	3.8%	2,605	66.4%	1,734	44.2%

Table 7. Summary of Reasons for End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024[1,2]

	Censoring Reason					
	Occurrence of User-Defined Censoring Criteria[5]		Disenrollment[6]		End of Data[7]	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use Cohort (fixed follow-up)	0	0.0%	2,689	68.5%	1,767	45.0%
Single Sinuva Stent Use (28 day lag period)	127	3.7%	1,704	50.2%	927	27.3%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	1,774	52.3%	962	28.4%
Single Sinuva Stent Use	126	3.7%	1,643	48.4%	888	26.2%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	1,711	50.4%	922	27.2%
Single stent cohorts - Outcome: Ocular Hypertension						
Primary analysis cohorts (14-day lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	1,835	46.8%	1,141	29.1%
Single Sinuva Stent Use	0	0.0%	982	28.9%	457	13.5%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	1,800	45.9%	1,109	28.3%
Single Sinuva Stent Use	0	0.0%	945	27.9%	438	12.9%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (14 day lag period)	150	3.8%	2,596	66.2%	1,725	44.0%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	0	0.0%	2,679	68.3%	1,760	44.9%
Single Propel Stent Use	149	3.8%	2,574	65.6%	1,706	43.5%
Single Propel Stent Use (fixed follow-up)	0	0.0%	2,656	67.7%	1,739	44.3%
Single Sinuva Stent Use (14 day lag period)	127	3.7%	1,635	48.2%	878	25.9%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	0	0.0%	1,703	50.2%	912	26.9%
Single Sinuva Stent Use	126	3.7%	1,601	47.2%	856	25.2%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	1,669	49.2%	890	26.2%
Single stent cohorts - Outcome: Diminished Visual Acuity						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	1,872	47.7%	1,165	29.7%
Single Sinuva Stent Use	0	0.0%	1,022	30.1%	480	14.1%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	1,797	45.8%	1,115	28.4%

Table 7. Summary of Reasons for End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024[1,2]

	Censoring Reason					
	Occurrence of User-Defined Censoring Criteria[5]		Disenrollment[6]		End of Data[7]	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	0	0.00%	955	28.10%	443	13.1
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (28 day lag period)	151	3.8%	2,606	66.4%	1,734	44.2%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	2,694	68.7%	1,769	45.1%
Single Propel Stent Use	151	3.8%	2,558	65.2%	1,700	43.3%
Single Propel Stent Use (fixed follow-up)	0	0.0%	2,641	67.3%	1,732	44.1%
Single Sinuva Stent Use (28 day lag period)	127	3.7%	1,685	49.7%	914	26.9%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	1,753	51.7%	947	27.9%
Single Sinuva Stent Use	126	3.7%	1,621	47.8%	872	25.7%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	1,688	49.7%	905	26.7%
Single stent cohorts - Outcome: Nasal Septal Perforation **Primary analysis cohorts (no lag period with fixed one year follow-up):**						
Single Propel Stent Use	0	0.0%	1,812	46.2%	1,123	28.6%
Single Sinuva Stent Use	0	0.0%	961	28.3%	451	13.3%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	1,823	46.5%	1,131	28.8%
Single Sinuva Stent Use	0	0.0%	965	28.4%	453	13.4%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use	151	3.8%	2,607	66.4%	1,738	44.3%
Single Propel Stent Use (fixed follow-up)	0	0.0%	2,691	68.6%	1,771	45.1%
Single Propel Stent Use (1 day lag period)	151	3.8%	2,618	66.7%	1,746	44.5%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	2,702	68.9%	1,779	45.3%
Single Sinuva Stent Use	126	3.7%	1,654	48.7%	899	26.5%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	1,722	50.8%	933	27.5%
Single Sinuva Stent Use (1 day lag period)	126	3.7%	1,662	49.0%	902	26.6%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	1,730	51.0%	936	27.6%

Table 7. Summary of Reasons for End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024[1,2]

	Censoring Reason					
	Occurrence of User-Defined Censoring Criteria[5]		Disenrollment[6]		End of Data[7]	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Repeat stent cohorts - Outcome: Cataract						
Primary analysis cohorts (273-day lag period with fixed one year follow-up):						
Sinuva Repeat Stent within 365 days	0	0.0%	113	48.9%	69	29.9%
Sinuva Repeat Stent within 730 days	0	0.0%	131	50.8%	82	31.8%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):						
Sinuva Repeat Stent within 365 days	*****	*****	153	66.2%	102	44.2%
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	159	68.8%	109	47.2%
Sinuva Repeat Stent within 730 days	*****	*****	176	68.2%	119	46.1%
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	183	70.9%	127	49.2%
Repeat stent cohorts - Outcome: Glaucoma						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Sinuva Repeat Stent within 365 days	0	0.0%	69	29.9%	41	17.7%
Sinuva Repeat Stent within 730 days	0	0.0%	84	32.6%	51	19.8%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):						
Sinuva Repeat Stent within 365 days	*****	*****	130	56.3%	80	34.6%
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	134	58.0%	84	36.4%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):						
Sinuva Repeat Stent within 730 days	*****	*****	151	58.5%	96	37.2%
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	156	60.5%	101	39.1%

Table 7. Summary of Reasons for End of At-Risk Period for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024[1,2]

	Censoring Reason					
	Occurrence of User-Defined Censoring Criteria[5]		Disenrollment[6]		End of Data[7]	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

[1]An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

[2]All reasons for censoring may not be displayed to prevent publication of small cells.

[3]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

[4]Represents episodes censored due to occurrence of request-defined event.

[5]Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

[6]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

[7]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to End of Exposure Episode by Episode Length	
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Exposure Episode[1]	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	1,194	0	0.0%
Single Sinuva Stent Use	3,393	1,648	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	1,944	0	0.0%
Single Sinuva Stent Use	3,393	2,265	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	3,924	579	0	0.0%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	3,924	614	0	0.0%
Single Propel Stent Use	3,924	899	0	0.0%
Single Propel Stent Use (fixed follow-up)	3,924	963	0	0.0%
Single Sinuva Stent Use (273 day lag period)	3,393	724	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	3,393	761	0	0.0%
Single Sinuva Stent Use	3,393	1,341	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	3,393	1,395	0	0.0%
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	1,893	0	0.0%
Single Sinuva Stent Use	3,393	2,267	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	1,975	0	0.0%
Single Sinuva Stent Use	3,393	2,339	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use Cohort (28 day lag period)	3,924	890	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to End of Exposure Episode by Episode Length	
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Exposure Episode[1]	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	3,924	949	0	0.0%
Single Propel Stent Use	3,924	939	0	0.0%
Single Propel Stent Use Cohort (fixed follow-up)	3,924	1,005	0	0.0%
Single Sinuva Stent Use (28 day lag period)	3,393	1,385	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	1,441	0	0.0%
Single Sinuva Stent Use	3,393	1,456	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Sinuva Stent Use (fixed follow-up)	3,393	1,513	0	0.0%
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	1,899	0	0.0%
Single Sinuva Stent Use	3,393	2,237	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	1,944	0	0.0%
Single Sinuva Stent Use	3,393	2,276	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	3,924	892	0	0.0%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	3,924	952	0	0.0%
Single Propel Stent Use	3,924	916	0	0.0%
Single Propel Stent Use (fixed follow-up)	3,924	979	0	0.0%
Single Sinuva Stent Use (14 day lag period)	3,393	1,360	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	3,393	1,415	0	0.0%
Single Sinuva Stent Use	3,393	1,396	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	3,393	1,451	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to End of Exposure Episode by Episode Length	
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Exposure Episode[1]	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	1,860	0	0.0%
Single Sinuva Stent Use	3,393	2,232	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	1,937	0	0.0%
Single Sinuva Stent Use	3,393	2,303	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	3,924	863	0	0.0%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	3,924	919	0	0.0%
Single Propel Stent Use	3,924	909	0	0.0%
Single Propel Stent Use (fixed follow-up)	3,924	974	0	0.0%
Single Sinuva Stent Use (28 day lag period)	3,393	1,319	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	1,373	0	0.0%
Single Sinuva Stent Use	3,393	1,391	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	3,393	1,447	0	0.0%
Single stent cohorts - Outcome: Nasal Septal Perforation				
Primary analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	1,982	0	0.0%
Single Sinuva Stent Use	3,393	2,358	0	0.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	1,982	0	0.0%
Single Sinuva Stent Use	3,393	2,362	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to End of Exposure Episode by Episode Length	
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Exposure Episode[1]	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	3,924	943	0	0.0%
Single Propel Stent Use (fixed follow-up)	3,924	1,010	0	0.0%
Single Propel Stent Use (1 day lag period)	3,924	942	0	0.0%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	3,924	1,008	0	0.0%
Single Sinuva Stent Use	3,393	1,478	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	3,393	1,536	0	0.0%
Single Sinuva Stent Use (1 day lag period)	3,393	1,478	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	3,393	1,535	0	0.0%
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	231	104	0	0.0%
Sinuva Repeat Stent within 730 days	258	112	0	0.0%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	231	47	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	49	0	0.0%
Sinuva Repeat Stent within 730 days	258	49	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	51	0	0.0%
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	231	157	0	0.0%
Sinuva Repeat Stent within 730 days	258	169	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	231	84	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	89	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to End of Exposure Episode by Episode Length	
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Exposure Episode[1]	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days	258	88	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	93	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (273 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use Cohort (28 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use	0	0.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use Cohort (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (28 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (14 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (28 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single stent cohorts - Outcome: Nasal Septal Perforation				
Primary analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Propel Stent Use (1 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (1 day lag period)	0	0.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	0	0.0%
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	0	0.0%
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	1,194	100.0%	0	0.0%
Single Sinuva Stent Use	1,648	100.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	1,944	100.0%	0	0.0%
Single Sinuva Stent Use	2,265	100.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (273 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	1,893	100.0%	0	0.0%
Single Sinuva Stent Use	2,267	100.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	1,975	100.0%	0	0.0%
Single Sinuva Stent Use	2,339	100.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use Cohort (28 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag peric	0	0.0%	0	0.0%
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use Cohort (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (28 day lag period)	0	0.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	1,899	100.0%	0	0.0%
Single Sinuva Stent Use	2,237	100.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	1,944	100.0%	0	0.0%
Single Sinuva Stent Use	2,276	100.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (14 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	1,860	100.0%	0	0.0%
Single Sinuva Stent Use	2,232	100.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	1,937	100.0%	0	0.0%
Single Sinuva Stent Use	2,303	100.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (28 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single stent cohorts - Outcome: Nasal Septal Perforation				
Primary analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	1,982	100.0%	0	0.0%
Single Sinuva Stent Use	2,358	100.0%	0	0.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	1,982	100.0%	0	0.0%
Single Sinuva Stent Use	2,362	100.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Propel Stent Use (1 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (1 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	0	0.0%
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	104	100.0%	0	0.0%
Sinuva Repeat Stent within 730 days	112	100.0%	0	0.0%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	0	0.0%
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	157	100.0%	0	0.0%
Sinuva Repeat Stent within 730 days	169	100.0%	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (273 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use Cohort (28 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use	0	0.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use Cohort (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (28 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (14 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (28 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single stent cohorts - Outcome: Nasal Septal Perforation				
Primary analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Propel Stent Use (1 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (1 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	0	0.0%
Repeat stent cohorts - Outcome: Cataract				

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	0	0.0%
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	579	100.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	614	100.0%	0	0.0%
Single Propel Stent Use	899	100.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	963	100.0%	0	0.0%
Single Sinuva Stent Use (273 day lag period)	724	100.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	761	100.0%	0	0.0%
Single Sinuva Stent Use	1,341	100.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	1,395	100.0%	0	0.0%
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use Cohort (28 day lag period)	890	100.0%	0	0.0%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	949	100.0%	0	0.0%
Single Propel Stent Use	939	100.0%	0	0.0%
Single Propel Stent Use Cohort (fixed follow-up)	1,005	100.0%	0	0.0%
Single Sinuva Stent Use (28 day lag period)	1,385	100.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	1,441	100.0%	0	0.0%
Single Sinuva Stent Use	1,456	100.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	1,513	100.0%	0	0.0%
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	892	100.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	952	100.0%	0	0.0%
Single Propel Stent Use	916	100.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	979	100.0%	0	0.0%
Single Sinuva Stent Use (14 day lag period)	1,360	100.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	1,415	100.0%	0	0.0%
Single Sinuva Stent Use	1,396	100.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	1,451	100.0%	0	0.0%
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	863	100.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	919	100.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use	909	100.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	974	100.0%	0	0.0%
Single Sinuva Stent Use (28 day lag period)	1,319	100.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	1,373	100.0%	0	0.0%
Single Sinuva Stent Use	1,391	100.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	1,447	100.0%	0	0.0%
Single stent cohorts - Outcome: Nasal Septal Perforation				
Primary analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	943	100.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	1,010	100.0%	0	0.0%
Single Propel Stent Use (1 day lag period)	942	100.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	1,008	100.0%	0	0.0%
Single Sinuva Stent Use	1,478	100.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	1,536	100.0%	0	0.0%
Single Sinuva Stent Use (1 day lag period)	1,478	100.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	1,535	100.0%	0	0.0%
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	47	100.0%	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	49	100.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length				
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days	49	100.0%	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	51	100.0%	0	0.0%
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	84	100.0%	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	89	100.0%	0	0.0%
Sinuva Repeat Stent within 730 days	88	100.0%	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	93	100.0%	0	0.0%

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single stent cohorts - Outcome: Cataract							
Primary analysis cohorts (273-day lag period with fixed one year follow-up):							
Single Propel Stent Use	364	364	364	364	364	364.0	0.0
Single Sinuva Stent Use	364	364	364	364	364	364.0	0.0
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	364	364	364	364	364	364.0	0.0
Single Sinuva Stent Use	364	364	364	364	364	364.0	0.0
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use (273 day lag period)	729	729	729	729	729	729.0	0.0
Single Propel Stent Use (fixed follow-up, 273 day lag period)	729	729	729	729	729	729.0	0.0
Single Propel Stent Use	729	729	729	729	729	729.0	0.0
Single Propel Stent Use (fixed follow-up)	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use (273 day lag period)	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use (fixed follow-up)	729	729	729	729	729	729.0	0.0
Single stent cohorts - Outcome: Glaucoma							
Primary analysis cohorts (28-day lag period with fixed one year follow-up):							
Single Propel Stent Use	364	364	364	364	364	364.0	0.0
Single Sinuva Stent Use	364	364	364	364	364	364.0	0.0
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	364	364	364	364	364	364.0	0.0
Single Sinuva Stent Use	364	364	364	364	364	364.0	0.0
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use Cohort (28 day lag period)	729	729	729	729	729	729.0	0.0
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	729	729	729	729	729	729.0	0.0
Single Propel Stent Use	729	729	729	729	729	729.0	0.0
Single Propel Stent Use Cohort (fixed follow-up)	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use (28 day lag period)	729	729	729	729	729	729.0	0.0

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use (fixed follow-up)	729	729	729	729	729	729.0	0.0
Single stent cohorts - Outcome: Ocular Hypertension							
Primary analysis cohorts (14-day lag period with fixed one year follow-up):							
Single Propel Stent Use	364	364	364	364	364	364.0	0.0
Single Sinuva Stent Use	364	364	364	364	364	364.0	0.0
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	364	364	364	364	364	364.0	0.0
Single Sinuva Stent Use	364	364	364	364	364	364.0	0.0
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use (14 day lag period)	729	729	729	729	729	729.0	0.0
Single Propel Stent Use (fixed follow-up, 14 day lag period)	729	729	729	729	729	729.0	0.0
Single Propel Stent Use	729	729	729	729	729	729.0	0.0
Single Propel Stent Use (fixed follow-up)	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use (14 day lag period)	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use (fixed follow-up)	729	729	729	729	729	729.0	0.0
Single stent cohorts - Outcome: Diminished Visual Acuity							
Primary analysis cohorts (28-day lag period with fixed one year follow-up):							
Single Propel Stent Use	364	364	364	364	364	364.0	0.0
Single Sinuva Stent Use	364	364	364	364	364	364.0	0.0
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	364	364	364	364	364	364.0	0.0
Single Sinuva Stent Use	364	364	364	364	364	364.0	0.0
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use (28 day lag period)	729	729	729	729	729	729.0	0.0
Single Propel Stent Use (fixed follow-up, 28 day lag period)	729	729	729	729	729	729.0	0.0

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Propel Stent Use	729	729	729	729	729	729.0	0.0
Single Propel Stent Use (fixed follow-up)	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use (28 day lag period)	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use (fixed follow-up)	729	729	729	729	729	729.0	0.0
Single stent cohorts - Outcome: Nasal Septal Perforation							
Primary analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	364	364	364	364	364	364.0	0.0
Single Sinuva Stent Use	364	364	364	364	364	364.0	0.0
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):							
Single Propel Stent Use	364	364	364	364	364	364.0	0.0
Single Sinuva Stent Use	364	364	364	364	364	364.0	0.0
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use	729	729	729	729	729	729.0	0.0
Single Propel Stent Use (fixed follow-up)	729	729	729	729	729	729.0	0.0
Single Propel Stent Use (1 day lag period)	729	729	729	729	729	729.0	0.0
Single Propel Stent Use (fixed follow-up, 1 day lag period)	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use (fixed follow-up)	729	729	729	729	729	729.0	0.0
Single Sinuva Stent Use (1 day lag period)	729	729	729	729	729	729.0	0.0

Table 8. Summary of Time from Start of Follow-up to End of At-Risk Period due to End of Exposure Episode for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to End of Exposure Episode by Episode Length							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	729	729	729	729	729	729.0	0.0
Repeat stent cohorts - Outcome: Cataract							
Primary analysis cohorts (273-day lag period with fixed one year follow-up):							
Sinuva Repeat Stent within 365 days	364	364	364	364	364	364.0	0.0
Sinuva Repeat Stent within 730 days	364	364	364	364	364	364.0	0.0
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):							
Sinuva Repeat Stent within 365 days	729	729	729	729	729	729.0	0.0
Sinuva Repeat Stent within 365 days (fixed follow-up)	729	729	729	729	729	729.0	0.0
Sinuva Repeat Stent within 730 days	729	729	729	729	729	729.0	0.0
Sinuva Repeat Stent within 730 days (fixed follow-up)	729	729	729	729	729	729.0	0.0
Repeat stent cohorts - Outcome: Glaucoma							
Primary analysis cohorts (28-day lag period with fixed one year follow-up):							
Sinuva Repeat Stent within 365 days	364	364	364	364	364	364.0	0.0
Sinuva Repeat Stent within 730 days	364	364	364	364	364	364.0	0.0
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):							
Sinuva Repeat Stent within 365 days	729	729	729	729	729	729.0	0.0
Sinuva Repeat Stent within 365 days (fixed follow-up)	729	729	729	729	729	729.0	0.0
Sinuva Repeat Stent within 730 days	729	729	729	729	729	729.0	0.0
Sinuva Repeat Stent within 730 days (fixed follow-up)	729	729	729	729	729	729.0	0.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

[1]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length	
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest[1]	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	61	16	26.2%
Single Sinuva Stent Use	3,393	132	28	21.2%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	63	16	25.4%
Single Sinuva Stent Use	3,393	110	20	18.2%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	3,924	72	16	22.2%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	3,924	77	16	20.8%
Single Propel Stent Use	3,924	106	16	15.1%
Single Propel Stent Use (fixed follow-up)	3,924	110	16	14.5%
Single Sinuva Stent Use (273 day lag period)	3,393	175	28	16.0%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	3,393	180	28	15.6%
Single Sinuva Stent Use	3,393	194	20	10.3%
Single Sinuva Stent Use (fixed follow-up)	3,393	198	20	10.1%
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	14	*****	*****
Single Sinuva Stent Use	3,393	28	*****	*****
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	14	*****	*****
Single Sinuva Stent Use	3,393	28	*****	*****

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length	
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest[1]	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use Cohort (28 day lag period)	3,924	20	*****	*****
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	3,924	21	*****	*****
Single Propel Stent Use	3,924	19	*****	*****
Single Propel Stent Use Cohort (fixed follow-up)	3,924	20	*****	*****
Single Sinuva Stent Use (28 day lag period)	3,393	41	*****	*****
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	42	*****	*****
Single Sinuva Stent Use	3,393	42	*****	*****
Single Sinuva Stent Use (fixed follow-up)	3,393	43	*****	*****
Single stent cohorts - Outcome: Ocular Hypertension **Primary analysis cohorts (14-day lag period with fixed one year follow-up):**				
Single Propel Stent Use	3,924	70	22	31.4%
Single Sinuva Stent Use	3,393	110	40	36.4%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	70	19	27.1%
Single Sinuva Stent Use	3,393	110	37	33.6%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	3,924	83	20	24.1%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	3,924	88	22	25.0%
Single Propel Stent Use	3,924	85	18	21.2%
Single Propel Stent Use (fixed follow-up)	3,924	89	19	21.3%
Single Sinuva Stent Use (14 day lag period)	3,393	148	39	26.4%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	3,393	151	40	26.5%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length	
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest[1]	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	3,393	149	36	24.2%
Single Sinuva Stent Use (fixed follow-up)	3,393	152	37	24.3%
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	67	20	29.9%
Single Sinuva Stent Use	3,393	73	30	41.1%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	72	24	33.3%
Single Sinuva Stent Use	3,393	76	28	36.8%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	3,924	95	19	20.0%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	3,924	100	20	20.0%
Single Propel Stent Use	3,924	101	24	23.8%
Single Propel Stent Use (fixed follow-up)	3,924	104	24	23.1%
Single Sinuva Stent Use (28 day lag period)	3,393	130	29	22.3%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	134	30	22.4%
Single Sinuva Stent Use	3,393	133	28	21.1%
Single Sinuva Stent Use (fixed follow-up)	3,393	136	28	20.6%
Single stent cohorts - Outcome: Nasal Septal Perforation				
Primary analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	11	*****	*****

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length	
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest[1]	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	3,393	*****	*****	*****
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	*****	0	0.0%
Single Sinuva Stent Use	3,393	*****	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	3,924	12	*****	*****
Single Propel Stent Use (fixed follow-up)	3,924	12	*****	*****
Single Propel Stent Use (1 day lag period)	3,924	*****	0	0.0%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	3,924	*****	0	0.0%
Single Sinuva Stent Use	3,393	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up)	3,393	*****	*****	*****
Single Sinuva Stent Use (1 day lag period)	3,393	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	3,393	*****	0	0.0%
Repeat stent cohorts - Outcome: Cataract **Primary analysis cohorts (273-day lag period with fixed one year follow-up):**				
Sinuva Repeat Stent within 365 days	231	*****	*****	*****
Sinuva Repeat Stent within 730 days	258	*****	*****	*****
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	231	12	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	12	*****	*****
Sinuva Repeat Stent within 730 days	258	12	*****	*****

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length	
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of Outcome of Interest[1]	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	12	*****	*****
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	231	*****	*****	*****
Sinuva Repeat Stent within 730 days	258	*****	*****	*****
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	231	*****	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	*****	*****	*****
Sinuva Repeat Stent within 730 days	258	*****	*****	*****
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	*****	*****	*****

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	16	26.2%	17	27.9%
Single Sinuva Stent Use	35	26.5%	40	30.3%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	21	33.3%	13	20.6%
Single Sinuva Stent Use	49	44.5%	22	20.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	13	18.1%	16	22.2%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	16	20.8%	17	22.1%
Single Propel Stent Use	20	18.9%	13	12.3%
Single Propel Stent Use (fixed follow-up)	21	19.1%	13	11.8%
Single Sinuva Stent Use (273 day lag period)	32	18.3%	39	22.3%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	35	19.4%	40	22.2%
Single Sinuva Stent Use	48	24.7%	22	11.3%
Single Sinuva Stent Use (fixed follow-up)	49	24.7%	22	11.1%
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	*****	*****	*****	*****
Single Sinuva Stent Use	11	39.3%	*****	*****
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	*****	*****	*****	*****
Single Sinuva Stent Use	11	39.3%	*****	*****

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use Cohort (28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use Cohort (fixed follow-up)	*****	*****	*****	*****
Single Sinuva Stent Use (28 day lag period)	11	26.8%	*****	*****
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	11	26.2%	*****	*****
Single Sinuva Stent Use	11	26.2%	*****	*****
Single Sinuva Stent Use (fixed follow-up)	11	25.6%	*****	*****
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	26	37.1%	11	15.7%
Single Sinuva Stent Use	33	30.0%	12	10.9%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	29	41.4%	*****	*****
Single Sinuva Stent Use	35	31.8%	18	16.4%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	25	30.1%	11	13.3%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	26	29.5%	11	12.5%
Single Propel Stent Use	28	32.9%	*****	*****
Single Propel Stent Use (fixed follow-up)	29	32.6%	*****	*****
Single Sinuva Stent Use (14 day lag period)	33	22.3%	12	8.1%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	33	21.9%	12	7.9%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	35	23.5%	18	12.1%
Single Sinuva Stent Use (fixed follow-up)	35	23.0%	18	11.8%
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	17	25.4%	16	23.9%
Single Sinuva Stent Use	13	17.8%	13	17.8%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	19	26.4%	17	23.6%
Single Sinuva Stent Use	18	23.7%	12	15.8%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	17	17.9%	16	16.8%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	17	17.0%	16	16.0%
Single Propel Stent Use	18	17.8%	17	16.8%
Single Propel Stent Use (fixed follow-up)	19	18.3%	17	16.3%
Single Sinuva Stent Use (28 day lag period)	13	10.0%	13	10.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	13	9.7%	13	9.7%
Single Sinuva Stent Use	17	12.8%	12	9.0%
Single Sinuva Stent Use (fixed follow-up)	18	13.2%	12	8.8%
Single stent cohorts - Outcome: Nasal Septal Perforation				
Primary analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	*****	*****	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	*****	*****	*****	*****
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	*****	*****	0	0.0%
Single Sinuva Stent Use	*****	*****	*****	*****
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up)	*****	*****	0	0.0%
Single Propel Stent Use (1 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	*****	*****	0	0.0%
Single Sinuva Stent Use	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up)	*****	*****	*****	*****
Single Sinuva Stent Use (1 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	*****	*****	*****	*****
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	*****	*****	*****	*****
Sinuva Repeat Stent within 730 days	*****	*****	*****	*****
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	*****	*****	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	*****	*****	*****	*****
Sinuva Repeat Stent within 730 days	*****	*****	*****	*****

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days (fixed follow-up)	*****	*****	*****	*****
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	12	19.7%	0	0.0%
Single Sinuva Stent Use	29	22.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	13	20.6%	0	0.0%
Single Sinuva Stent Use	19	17.3%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	12	16.7%	*****	*****
Single Propel Stent Use (fixed follow-up, 273 day lag period)	12	15.6%	*****	*****
Single Propel Stent Use	13	12.3%	*****	*****
Single Propel Stent Use (fixed follow-up)	13	11.8%	12	10.9%
Single Sinuva Stent Use (273 day lag period)	29	16.6%	*****	*****
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	29	16.1%	*****	*****
Single Sinuva Stent Use	19	9.8%	24	12.4%
Single Sinuva Stent Use (fixed follow-up)	19	9.6%	27	13.6%
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	*****	*****	0	0.0%
Single Sinuva Stent Use	*****	*****	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	*****	*****	0	0.0%
Single Sinuva Stent Use	*****	*****	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use Cohort (28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use Cohort (fixed follow-up)	*****	*****	*****	*****
Single Sinuva Stent Use (28 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up)	*****	*****	*****	*****
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	11	15.7%	0	0.0%
Single Sinuva Stent Use	25	22.7%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	*****	*****	0	0.0%
Single Sinuva Stent Use	20	18.2%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 14 day lag period)	11	12.5%	*****	*****
Single Propel Stent Use	12	14.1%	*****	*****
Single Propel Stent Use (fixed follow-up)	13	14.6%	*****	*****
Single Sinuva Stent Use (14 day lag period)	23	15.5%	17	11.5%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	25	16.6%	17	11.3%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	19	12.8%	16	10.7%
Single Sinuva Stent Use (fixed follow-up)	20	13.2%	17	11.2%
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	14	20.9%	0	0.0%
Single Sinuva Stent Use	17	23.3%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	12	16.7%	0	0.0%
Single Sinuva Stent Use	18	23.7%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	13	13.7%	12	12.6%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	14	14.0%	13	13.0%
Single Propel Stent Use	11	10.9%	12	11.9%
Single Propel Stent Use (fixed follow-up)	12	11.5%	13	12.5%
Single Sinuva Stent Use (28 day lag period)	16	12.3%	24	18.5%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	17	12.7%	25	18.7%
Single Sinuva Stent Use	17	12.8%	17	12.8%
Single Sinuva Stent Use (fixed follow-up)	18	13.2%	18	13.2%
Single stent cohorts - Outcome: Nasal Septal Perforation				
Primary analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Propel Stent Use (1 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (1 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	0	0.0%
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	*****	*****	0	0.0%
Sinuva Repeat Stent within 730 days	*****	*****	0	0.0%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	*****	*****	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	*****	*****	0	0.0%
Sinuva Repeat Stent within 730 days	*****	*****	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days (fixed follow-up)	*****	*****	0	0.0%
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	*****	*****	0	0.0%
Sinuva Repeat Stent within 730 days	*****	*****	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	*****	*****	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	*****	*****	0	0.0%
Sinuva Repeat Stent within 730 days	*****	*****	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	*****	*****	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 273 day lag period)	*****	*****	*****	*****
Single Propel Stent Use	15	14.2%	12	11.3%
Single Propel Stent Use (fixed follow-up)	15	13.6%	12	10.9%
Single Sinuva Stent Use (273 day lag period)	14	8.0%	16	9.1%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	14	7.8%	16	8.9%
Single Sinuva Stent Use	31	16.0%	23	11.9%
Single Sinuva Stent Use (fixed follow-up)	31	15.7%	23	11.6%
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use Cohort (28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use Cohort (fixed follow-up)	*****	*****	*****	*****
Single Sinuva Stent Use (28 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up)	*****	*****	*****	*****
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 14 day lag period)	*****	*****	*****	*****
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up)	*****	*****	*****	*****
Single Sinuva Stent Use (14 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	*****	*****	*****	*****

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	11	7.4%	*****	*****
Single Sinuva Stent Use (fixed follow-up)	11	7.2%	*****	*****
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up)	*****	*****	*****	*****
Single Sinuva Stent Use (28 day lag period)	11	8.5%	13	10.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	11	8.2%	13	9.7%
Single Sinuva Stent Use	19	14.3%	12	9.0%
Single Sinuva Stent Use (fixed follow-up)	19	14.0%	12	8.8%
Single stent cohorts - Outcome: Nasal Septal Perforation				
Primary analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up)	*****	*****	0	0.0%
Single Propel Stent Use (1 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	*****	*****	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (1 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	0	0.0%
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	*****	*****
Sinuva Repeat Stent within 730 days	0	0.0%	*****	*****

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	*****	*****
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up)	*****	*****	0	0.0%
Single Sinuva Stent Use (273 day lag period)	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	*****	*****	0	0.0%
Single Sinuva Stent Use	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	*****	*****	0	0.0%
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use Cohort (28 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use Cohort (fixed follow-up)	*****	*****	0	0.0%
Single Sinuva Stent Use (28 day lag period)	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	*****	*****	0	0.0%
Single Sinuva Stent Use	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	*****	*****	0	0.0%
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up)	*****	*****	0	0.0%
Single Sinuva Stent Use (14 day lag period)	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	*****	*****	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	*****	*****	0	0.0%
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up)	*****	*****	0	0.0%
Single Sinuva Stent Use (28 day lag period)	11	8.5%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	12	9.0%	0	0.0%
Single Sinuva Stent Use	11	8.3%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	11	8.1%	0	0.0%
Single stent cohorts - Outcome: Nasal Septal Perforation				
Primary analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	0	0.0%	0	0.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Propel Stent Use (1 day lag period)	0	0.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	0.0%	0	0.0%
Single Sinuva Stent Use (1 day lag period)	0	0.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	0	0.0%	0	0.0%
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	*****	*****	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	*****	*****	0	0.0%
Sinuva Repeat Stent within 730 days	*****	*****	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length			
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days (fixed follow-up)	*****	*****	0	0.0%
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0.0%	0	0.0%

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single stent cohorts - Outcome: Cataract							
Primary analysis cohorts (273-day lag period with fixed one year follow-up):							
Single Propel Stent Use	6	76	166	246	364	166.0	104.3
Single Sinuva Stent Use	1	105	200	267	362	187.2	98.7
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	7	85	149	253	349	165.6	100.5
Single Sinuva Stent Use	1	109	148	231	358	166.5	97.0
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use (273 day lag period)	6	102	212	330	701	237.7	176.3
Single Propel Stent Use (fixed follow-up, 273 day lag period)	6	102	209	328	701	239.4	177.7
Single Propel Stent Use	7	132	293	491	721	320.3	209.4
Single Propel Stent Use (fixed follow-up)	7	132	293	487	721	321.0	207.1
Single Sinuva Stent Use (273 day lag period)	1	137	253	409	729	285.4	190.7
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	1	144	253	401	729	285.3	190.5
Single Sinuva Stent Use	1	135	319	509	715	321.5	197.9
Single Sinuva Stent Use (fixed follow-up)	1	135	325	507	715	322.3	197.0
Single stent cohorts - Outcome: Glaucoma							
Primary analysis cohorts (28-day lag period with fixed one year follow-up):							
Single Propel Stent Use	13	62	89	170	308	120.8	92.7
Single Sinuva Stent Use	1	86	144	276	362	165.2	111.7
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	41	90	117	198	336	148.8	92.7
Single Sinuva Stent Use	1	95	163	247	357	166.8	108.3

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use Cohort (28 day lag period)	13	70	151	423	713	246.3	219.7
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	13	72	170	430	713	266.9	234.0
Single Propel Stent Use	41	96	160	443	636	249.7	195.5
Single Propel Stent Use Cohort (fixed follow-up)	41	98	179	451	706	272.6	215.9
Single Sinuva Stent Use (28 day lag period)	1	97	260	421	691	282.0	204.3
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	1	97	276	449	691	291.4	210.8
Single Sinuva Stent Use	1	122	247	423	719	290.0	208.3
Single Sinuva Stent Use (fixed follow-up)	1	122	288	449	719	299.7	215.3
Single stent cohorts - Outcome: Ocular Hypertension							
Primary analysis cohorts (14-day lag period with fixed one year follow-up):							
Single Propel Stent Use	3	76	121	211	351	146.2	99.0
Single Sinuva Stent Use	2	70	139	253	364	158.9	108.0
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	4	86	134	219	364	154.3	98.6
Single Sinuva Stent Use	6	81	131	239	364	154.8	104.9
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use (14 day lag period)	3	92	154	335	700	229.4	189.4
Single Propel Stent Use (fixed follow-up, 14 day lag period)	3	92	154	336	700	226.2	187.7
Single Propel Stent Use	4	105	167	336	714	237.8	190.6
Single Propel Stent Use (fixed follow-up)	4	105	167	349	714	236.9	188.9
Single Sinuva Stent Use (14 day lag period)	2	88	194	372	728	256.4	195.3
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	2	87	195	372	728	256.1	194.6

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use	6	94	192	379	725	252.8	192.7
Single Sinuva Stent Use (fixed follow-up)	6	94	193	379	725	252.7	192.1
Single stent cohorts - Outcome: Diminished Visual Acuity							
Primary analysis cohorts (28-day lag period with fixed one year follow-up):							
Single Propel Stent Use	2	83	168	263	364	169.3	105.3
Single Sinuva Stent Use	14	56	147	273	357	162.4	107.8
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	1	62	153	235	353	153.8	104.9
Single Sinuva Stent Use	8	63	129	253	349	157.7	109.0
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use (28 day lag period)	2	123	233	427	728	284.3	202.7
Single Propel Stent Use (fixed follow-up, 28 day lag period)	2	125	262	431	728	292.2	208.2
Single Propel Stent Use	1	100	224	392	709	261.3	196.0
Single Propel Stent Use (fixed follow-up)	1	101	225	393	709	262.0	194.4
Single Sinuva Stent Use (28 day lag period)	14	138	313	479	708	323.2	207.4
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	14	138	313	479	718	324.7	208.2
Single Sinuva Stent Use	8	114	316	482	717	320.7	213.1
Single Sinuva Stent Use (fixed follow-up)	8	115	316	481	717	319.9	211.7
Single stent cohorts - Outcome: Nasal Septal Perforation							
Primary analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	1	1	1	1	158	15.3	47.3

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length						
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use	1	1	1	1	208	39.6	78.3
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):							
Single Propel Stent Use	157	157	157	157	157	157.0	NaN
Single Sinuva Stent Use	140	140	174	207	207	173.5	47.4
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use	1	1	1	1	544	59.3	159.2
Single Propel Stent Use (fixed follow-up)	1	1	1	1	544	59.3	159.2
Single Propel Stent Use (1 day lag period)	157	157	350	543	543	350.0	272.9
Single Propel Stent Use (fixed follow-up, 1 day lag period)	157	157	350	543	543	350.0	272.9
Single Sinuva Stent Use	1	1	1	1	208	39.6	78.3
Single Sinuva Stent Use (fixed follow-up)	1	1	1	1	208	39.6	78.3
Single Sinuva Stent Use (1 day lag period)	140	140	174	207	207	173.5	47.4
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	140	140	174	207	207	173.5	47.4
Repeat stent cohorts - Outcome: Cataract **Primary analysis cohorts (273-day lag period with fixed one year follow-up):**							
Sinuva Repeat Stent within 365 days	42	148	197	228	324	183.9	81.0
Sinuva Repeat Stent within 730 days	42	148	197	228	324	183.9	81.0
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):							
Sinuva Repeat Stent within 365 days	42	154	223	466	716	306.7	233.9
Sinuva Repeat Stent within 365 days (fixed follow-up)	42	154	223	466	716	306.7	233.9
Sinuva Repeat Stent within 730 days	42	154	223	466	716	306.7	233.9

Table 9. Summary of Time from Start of Follow-up to End of At-Risk Period due to Occurrence of Outcome of Interest for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

Number of Episodes Censored due to Occurrence of Outcome of Interest by Episode Length	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Sinuva Repeat Stent within 730 days (fixed follow-up)	42	154	223	466	716	306.7	233.9
Repeat stent cohorts - Outcome: Glaucoma							
Primary analysis cohorts (28-day lag period with fixed one year follow-up):							
Sinuva Repeat Stent within 365 days	1	1	179	356	356	178.5	251.0
Sinuva Repeat Stent within 730 days	1	1	179	356	356	178.5	251.0
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):							
Sinuva Repeat Stent within 365 days	1	1	179	356	356	178.5	251.0
Sinuva Repeat Stent within 365 days (fixed follow-up)	1	1	179	356	356	178.5	251.0
Sinuva Repeat Stent within 730 days	1	1	179	356	356	178.5	251.0
Sinuva Repeat Stent within 730 days (fixed follow-up)	1	1	179	356	356	178.5	251.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

[1]Represents episodes censored due to occurrence of request-defined event.

NaN: Not a number

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria[1]	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	0	0	NaN
Single Sinuva Stent Use	3,393	0	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	0	0	NaN
Single Sinuva Stent Use	3,393	0	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	3,924	151	134	88.7%
Single Propel Stent Use Cohort (fixed follow-up)	3,924	0	0	NaN
Single Propel Stent Use Cohort (28 day lag period)	3,924	151	132	87.4%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	3,924	0	0	NaN
Single Sinuva Stent Use	3,393	127	105	82.7%
Single Sinuva Stent Use (fixed follow-up)	3,393	0	0	NaN
Single Sinuva Stent Use (28 day lag period)	3,393	126	104	82.5%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	0	0	NaN
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	0	0	NaN
Single Sinuva Stent Use	3,393	0	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	0	0	NaN
Single Sinuva Stent Use	3,393	0	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria[1]	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	3,924	153	141	92.2%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	3,924	0	0	NaN
Single Propel Stent Use	3,924	149	130	87.2%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (fixed follow-up)	3,924	0	0	NaN
Single Sinuva Stent Use (273 day lag period)	3,393	129	117	90.7%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	3,393	0	0	NaN
Single Sinuva Stent Use	3,393	126	104	82.5%
Single Sinuva Stent Use (fixed follow-up)	3,393	0	0	NaN
Single stent cohorts - Outcome: Nasal Septal perforation **Primary analysis cohorts (no lag period with fixed one year follow-up):**				
Single Propel Stent Use	3,924	0	0	NaN
Single Sinuva Stent Use	3,393	0	0	NaN
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	0	0	NaN
Single Sinuva Stent Use	3,393	0	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	3,924	151	132	87.4%
Single Propel Stent Use (fixed follow-up)	3,924	0	0	NaN
Single Propel Stent Use (1 day lag period)	3,924	151	132	87.4%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	3,924	0	0	NaN
Single Sinuva Stent Use	3,393	126	104	82.5%

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria[1]	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (fixed follow-up)	3,393	0	0	NaN
Single Sinuva Stent Use (1 day lag period)	3,393	126	104	82.5%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	3,393	0	0	NaN
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	0	0	NaN
Single Sinuva Stent Use	3,393	0	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	0	0	NaN
Single Sinuva Stent Use	3,393	0	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	3,924	151	134	88.7%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	3,924	0	0	NaN
Single Propel Stent Use	3,924	151	132	87.4%
Single Propel Stent Use (fixed follow-up)	3,924	0	0	NaN
Single Sinuva Stent Use (28 day lag period)	3,393	127	105	82.7%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	0	0	NaN
Single Sinuva Stent Use	3,393	126	104	82.5%
Single Sinuva Stent Use (fixed follow-up)	3,393	0	0	NaN
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	0	0	NaN
Single Sinuva Stent Use	3,393	0	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria[1]	Number of Episodes	Percent of Total Episodes
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	3,924	0	0	NaN
Single Sinuva Stent Use	3,393	0	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	3,924	150	132	88.0%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	3,924	0	0	NaN
Single Propel Stent Use	3,924	149	130	87.2%
Single Propel Stent Use (fixed follow-up)	3,924	0	0	NaN
Single Sinuva Stent Use (14 day lag period)	3,393	127	105	82.7%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	3,393	0	0	NaN
Single Sinuva Stent Use	3,393	126	104	82.5%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Sinuva Stent Use (fixed follow-up)	3,393	0	0	NaN
Repeat stent cohorts - Outcome: Glaucoma **Primary analysis cohorts (28-day lag period with fixed one year follow-up):**				
Sinuva Repeat Stent within 365 days	231	0	0	NaN
Sinuva Repeat Stent within 730 days	258	0	0	NaN
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	231	*****	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	0	0	NaN
Sinuva Repeat Stent within 730 days	258	*****	*****	*****

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
			0-91 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria[1]	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	0	0	NaN
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	231	0	0	NaN
Sinuva Repeat Stent within 730 days	258	0	0	NaN
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	231	*****	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	0	0	NaN
Sinuva Repeat Stent within 730 days	258	*****	*****	*****
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	0	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use Cohort (fixed follow-up)	0	NaN	0	NaN
Single Propel Stent Use Cohort (28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (28 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use		NaN	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 273 day lag period)	0	NaN	0	NaN
Single Propel Stent Use	*****	*****	*****	*****
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (273 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single stent cohorts - Outcome: Nasal Septal perforation **Primary analysis cohorts (no lag period with fixed one year follow-up):**				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Propel Stent Use (1 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 1 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	*****	*****

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (1 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	0	NaN	0	NaN
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (28 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use		NaN	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 14 day lag period)	0	NaN	0	NaN
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (14 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	*****	*****
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days	0	NaN	0	NaN
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	0.0%	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days	0	0.0%	*****	*****

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	92-182 days		183-273 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	NaN	0	NaN
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days	0	NaN	0	NaN
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	NaN	0	NaN
Sinuva Repeat Stent within 365 days (fixed follow-up)	*****	*****	*****	*****
Sinuva Repeat Stent within 730 days	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	0	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use Cohort (fixed follow-up)	0	NaN	0	NaN
Single Propel Stent Use Cohort (28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (28 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 273 day lag period)	0	NaN	0	NaN
Single Propel Stent Use	*****	*****	*****	*****
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (fixed follow-up)	*****	*****	*****	*****
Single Sinuva Stent Use (273 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use (fixed follow-up)	*****	*****	*****	*****
Single stent cohorts - Outcome: Nasal Septal perforation **Primary analysis cohorts (no lag period with fixed one year follow-up):**				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Propel Stent Use (1 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 1 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	*****	*****

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (1 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	0	NaN	0	NaN
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (28 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 14 day lag period)	0	NaN	0	NaN
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (14 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	*****	*****
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days	0	NaN	0	NaN
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	*****	*****	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days	*****	*****	*****	*****

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	274-364 days		365-455 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	NaN	0	NaN
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days	0	NaN	0	NaN
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	NaN	0	NaN
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	0	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use Cohort (fixed follow-up)	0	NaN	0	NaN
Single Propel Stent Use Cohort (28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (28 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN		NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 273 day lag period)	0	NaN	0	NaN
Single Propel Stent Use	*****	*****	*****	*****
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (fixed follow-up)	*****	*****	*****	*****
Single Sinuva Stent Use (273 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use (fixed follow-up)	*****	*****	*****	*****
Single stent cohorts - Outcome: Nasal Septal perforation **Primary analysis cohorts (no lag period with fixed one year follow-up):**				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Propel Stent Use (1 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 1 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	*****	*****

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (1 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	0	NaN	0	NaN
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (28 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN		NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up, 14 day lag period)	0	NaN	0	NaN
Single Propel Stent Use	*****	*****	*****	*****
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (14 day lag period)	*****	*****	*****	*****
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	*****	*****
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days	0	NaN	0	NaN
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	*****	*****	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days	*****	*****	0	0.0%

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	456-546 days		547-637 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	NaN	0	NaN
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days	0	NaN	0	NaN
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	NaN	0	NaN
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	0	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	*****	*****	0	0.0%
Single Propel Stent Use Cohort (fixed follow-up)	0	NaN	0	NaN
Single Propel Stent Use Cohort (28 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (28 day lag period)	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (273 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	0	NaN	0	NaN
Single Propel Stent Use	*****	*****	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (273 day lag period)	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single stent cohorts - Outcome: Nasal Septal perforation **Primary analysis cohorts (no lag period with fixed one year follow-up):**				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Propel Stent Use (1 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	0	0.0%

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (1 day lag period)	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	0	NaN	0	NaN
Single stent cohorts - Outcome: Diminished Visual Acuity				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (28 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single Propel Stent Use	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (28 day lag period)	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Single stent cohorts - Outcome: Ocular Hypertension				
Primary analysis cohorts (14-day lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):				
Single Propel Stent Use	0	NaN	0	NaN
Single Sinuva Stent Use	0	NaN	0	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Propel Stent Use (14 day lag period)	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	0	NaN	0	NaN
Single Propel Stent Use	*****	*****	0	0.0%
Single Propel Stent Use (fixed follow-up)	0	NaN	0	NaN
Single Sinuva Stent Use (14 day lag period)	*****	*****	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	0	NaN	0	NaN
Single Sinuva Stent Use	*****	*****	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):				
Single Sinuva Stent Use (fixed follow-up)	0	NaN	0	NaN
Repeat stent cohorts - Outcome: Glaucoma				
Primary analysis cohorts (28-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	NaN	0	NaN
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	NaN	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length			
	638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	NaN	0	NaN
Repeat stent cohorts - Outcome: Cataract				
Primary analysis cohorts (273-day lag period with fixed one year follow-up):				
Sinuva Repeat Stent within 365 days	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days	0	NaN	0	NaN
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):				
Sinuva Repeat Stent within 365 days	0	NaN	0	NaN
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	NaN	0	NaN
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	0	0	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length						
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single stent cohorts - Outcome: Glaucoma							
Primary analysis cohorts (28-day lag period with fixed one year follow-up):							
Single Propel Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use	0	0	0	15	666	51.6	138.5
Single Propel Stent Use Cohort (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Propel Stent Use Cohort (28 day lag period)	1	1	1	43	694	61.4	145.7
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use	0	0	0	0	712	58.6	144.6
Single Sinuva Stent Use (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use (28 day lag period)	1	1	1	1	656	59.9	141.7
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single stent cohorts - Outcome: Cataract							
Primary analysis cohorts (273-day lag period with fixed one year follow-up):							
Single Propel Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length						
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use (273 day lag period)	0	0	0	0	522	25.7	91.2
Single Propel Stent Use (fixed follow-up, 273 day lag period)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Propel Stent Use	1	1	1	42	694	61.3	146.6
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use (273 day lag period)	0	0	0	0	671	29.7	105.3
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use	1	1	1	1	656	59.9	141.7
Single Sinuva Stent Use (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single stent cohorts - Outcome: Nasal Septal perforation							
Primary analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):							
Single Propel Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use	1	1	1	43	694	61.4	145.7
Single Propel Stent Use (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Propel Stent Use (1 day lag period)	0	0	0	42	693	60.4	145.7
Single Propel Stent Use (fixed follow-up, 1 day lag period)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use	1	1	1	1	656	59.9	141.7

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length						
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use (1 day lag period)	0	0	0	0	655	58.9	141.7
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single stent cohorts - Outcome: Diminished Visual Acuity							
Primary analysis cohorts (28-day lag period with fixed one year follow-up):							
Single Propel Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use (28 day lag period)	0	0	0	15	666	51.6	138.5
Single Propel Stent Use (fixed follow-up, 28 day lag period)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Propel Stent Use	1	1	1	43	694	61.4	145.7
Single Propel Stent Use (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use (28 day lag period)	0	0	0	0	712	58.6	144.6
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use	1	1	1	1	656	59.9	141.7
Single Sinuva Stent Use (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single stent cohorts - Outcome: Ocular Hypertension							
Primary analysis cohorts (14-day lag period with fixed one year follow-up):							
Single Propel Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length						
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use (14 day lag period)	0	0	0	29	680	56.2	142.6
Single Propel Stent Use (fixed follow-up, 14 day lag period)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Propel Stent Use	1	1	1	43	694	61.7	146.6
Single Propel Stent Use (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use (14 day lag period)	0	0	0	0	726	61.4	149.2
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Single Sinuva Stent Use	1	1	1	1	656	59.9	141.7
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Sinuva Stent Use (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Repeat stent cohorts - Outcome: Glaucoma							
Primary analysis cohorts (28-day lag period with fixed one year follow-up):							
Sinuva Repeat Stent within 365 days	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Sinuva Repeat Stent within 730 days	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):							
Sinuva Repeat Stent within 365 days	0	0	61	284	477	158.3	184.8
Sinuva Repeat Stent within 365 days (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Sinuva Repeat Stent within 730 days	0	0	36	284	477	142.5	181.3

Table 10. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Occurrence of User-Defined Censoring Criteria for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Occurrence of User-Defined Censoring Criteria by Episode Length						
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Sinuva Repeat Stent within 730 days (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Repeat stent cohorts - Outcome: Cataract							
Primary analysis cohorts (273-day lag period with fixed one year follow-up):							
Sinuva Repeat Stent within 365 days	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Sinuva Repeat Stent within 730 days	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):							
Sinuva Repeat Stent within 365 days	0	0	0	39	232	44.2	82.1
Sinuva Repeat Stent within 365 days (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Sinuva Repeat Stent within 730 days	0	0	0	39	232	39.8	78.6
Sinuva Repeat Stent within 730 days (fixed follow-up)	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

[1]Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

*****Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to Disenrollment by Episode Length			
			0-91 days		92-182 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Disenrollment[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Glaucoma						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,889	756	40.0%	496	26.3%
Single Sinuva Stent Use	3,393	1,031	363	35.2%	204	19.8%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,816	597	32.9%	519	28.6%
Single Sinuva Stent Use	3,393	961	283	29.4%	220	22.9%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use	3,924	2,647	743	28.1%	484	18.3%
Single Propel Stent Use Cohort (fixed follow-up)	3,924	2,737	756	27.6%	496	18.1%
Single Propel Stent Use Cohort (28 day lag period)	3,924	2,605	586	22.5%	508	19.5%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag	3,924	2,689	597	22.2%	519	19.3%
Single Sinuva Stent Use	3,393	1,704	350	20.5%	197	11.6%
Single Sinuva Stent Use (fixed follow-up)	3,393	1,774	363	20.5%	204	11.5%
Single Sinuva Stent Use (28 day lag period)	3,393	1,643	273	16.6%	212	12.9%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	1,711	283	16.5%	220	12.9%
Single stent cohorts - Outcome: Cataract						
Primary analysis cohorts (273-day lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	2,481	1,816	73.2%	228	9.2%
Single Sinuva Stent Use	3,393	1,504	963	64.0%	216	14.4%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,802	597	33.1%	513	28.5%
Single Sinuva Stent Use	3,393	955	283	29.6%	220	23.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (273 day lag period)	3,924	2,876	1,772	61.6%	219	7.6%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	3,924	2,983	1,816	60.9%	228	7.6%

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to Disenrollment by Episode Length			
			0-91 days		92-182 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Disenrollment[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use	3,924	2,570	586	22.8%	503	19.6%
Single Propel Stent Use (fixed follow-up)	3,924	2,651	597	22.5%	513	19.4%
Single Sinuva Stent Use (273 day lag period)	3,393	2,199	928	42.2%	211	9.6%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	3,393	2,283	963	42.2%	216	9.5%
Single Sinuva Stent Use	3,393	1,614	273	16.9%	212	13.1%
Single Sinuva Stent Use (fixed follow-up)	3,393	1,682	283	16.8%	220	13.1%
Single stent cohorts - Outcome: Nasal Septal perforation						
Primary analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,812	594	32.8%	517	28.5%
Single Sinuva Stent Use	3,393	961	283	29.4%	221	23.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,823	603	33.1%	521	28.6%
Single Sinuva Stent Use	3,393	965	288	29.8%	219	22.7%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use	3,924	2,607	583	22.4%	506	19.4%
Single Propel Stent Use (fixed follow-up)	3,924	2,691	594	22.1%	517	19.2%
Single Propel Stent Use (1 day lag period)	3,924	2,618	592	22.6%	510	19.5%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	3,924	2,702	603	22.3%	521	19.3%
Single Sinuva Stent Use	3,393	1,654	273	16.5%	213	12.9%
Single Sinuva Stent Use (fixed follow-up)	3,393	1,722	283	16.4%	221	12.8%
Single Sinuva Stent Use (1 day lag period)	3,393	1,662	278	16.7%	211	12.7%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	3,393	1,730	288	16.6%	219	12.7%
Single stent cohorts - Outcome: Diminished Visual Acuity						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,872	753	40.2%	494	26.4%
Single Sinuva Stent Use	3,393	1,022	362	35.4%	202	19.8%

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to Disenrollment by Episode Length			
			0-91 days		92-182 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Disenrollment[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,797	594	33.1%	512	28.5%
Single Sinuva Stent Use	3,393	950	283	29.8%	218	22.9%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (28 day lag period)	3,924	2,606	740	28.4%	482	18.5%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	3,924	2,694	753	28.0%	494	18.3%
Single Propel Stent Use	3,924	2,558	583	22.8%	501	19.6%
Single Propel Stent Use (fixed follow-up)	3,924	2,641	594	22.5%	512	19.4%
Single Sinuva Stent Use (28 day lag period)	3,393	1,685	349	20.7%	195	11.6%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	1,753	362	20.7%	202	11.5%
Single Sinuva Stent Use	3,393	1,621	273	16.8%	210	13.0%
Single Sinuva Stent Use (fixed follow-up)	3,393	1,688	283	16.8%	218	12.9%
Single stent cohorts - Outcome: Ocular Hypertension **Primary analysis cohorts (14-day lag period with fixed one year follow-up):**						
Single Propel Stent Use	3,924	1,835	677	36.9%	504	27.5%
Single Sinuva Stent Use	3,393	982	324	33.0%	210	21.4%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,800	596	33.1%	513	28.5%
Single Sinuva Stent Use	3,393	945	281	29.7%	216	22.9%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (14 day lag period)	3,924	2,596	665	25.6%	494	19.0%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	3,924	2,679	677	25.3%	504	18.8%
Single Propel Stent Use	3,924	2,574	585	22.7%	503	19.5%
Single Propel Stent Use (fixed follow-up)	3,924	2,656	596	22.4%	513	19.3%
Single Sinuva Stent Use (14 day lag period)	3,393	1,635	312	19.1%	203	12.4%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	3,393	1,703	324	19.0%	210	12.3%

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to Disenrollment by Episode Length			
			0-91 days		92-182 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Disenrollment[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	3,393	1,601	271	16.9%	208	13.0%
Single Sinuva Stent Use (fixed follow-up)	3,393	1,669	281	16.8%	216	12.9%
Repeat stent cohorts - Outcome: Glaucoma						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Sinuva Repeat Stent within 365 days	231	69	25	36.2%	12	17.4%
Sinuva Repeat Stent within 730 days	258	84	27	32.1%	16	19.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):						
Sinuva Repeat Stent within 365 days	231	130	25	19.2%	12	9.2%
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	134	25	18.7%	12	9.0%
Sinuva Repeat Stent within 730 days	258	151	27	17.9%	16	10.6%
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	156	27	17.3%	16	10.3%
Repeat stent cohorts - Outcome: Cataract						
Primary analysis cohorts (273-day lag period with fixed one year follow-up):						
Sinuva Repeat Stent within 365 days	231	113	66	58.4%	18	15.9%
Sinuva Repeat Stent within 730 days	258	131	79	60.3%	21	16.0%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):						
Sinuva Repeat Stent within 365 days	231	153	65	42.5%	17	11.1%
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	159	66	41.5%	18	11.3%
Sinuva Repeat Stent within 730 days	258	176	77	43.8%	20	11.4%
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	183	79	43.2%	21	11.5%

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Disenrollment by Episode Length							
	183-273 days		274-364 days		365-455 days		456-546 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Glaucoma								
Primary analysis cohorts (28-day lag period with fixed one year follow-up):								
Single Propel Stent Use	351	18.6%	286	15.1%	0	0.0%	0	0.0%
Single Sinuva Stent Use	229	22.2%	235	22.8%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):								
Single Propel Stent Use	385	21.2%	315	17.3%	0	0.0%	0	0.0%
Single Sinuva Stent Use	219	22.8%	239	24.9%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):								
Single Propel Stent Use	340	12.8%	277	10.5%	228	8.6%	225	8.5%
Single Propel Stent Use Cohort (fixed follow-up)	351	12.8%	286	10.4%	238	8.7%	229	8.4%
Single Propel Stent Use Cohort (28 day lag period)	377	14.5%	301	11.6%	220	8.4%	247	9.5%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	385	14.3%	315	11.7%	229	8.5%	253	9.4%
Single Sinuva Stent Use	218	12.8%	231	13.6%	191	11.2%	159	9.3%
Single Sinuva Stent Use (fixed follow-up)	229	12.9%	235	13.2%	197	11.1%	164	9.2%
Single Sinuva Stent Use (28 day lag period)	212	12.9%	229	13.9%	211	12.8%	148	9.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	219	12.8%	239	14.0%	216	12.6%	153	8.9%
Single stent cohorts - Outcome: Cataract								
Primary analysis cohorts (273-day lag period with fixed one year follow-up):								
Single Propel Stent Use	247	10.0%	190	7.7%	0	0.0%	0	0.0%
Single Sinuva Stent Use	151	10.0%	174	11.6%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):								
Single Propel Stent Use	382	21.2%	310	17.2%	0	0.0%	0	0.0%
Single Sinuva Stent Use	217	22.7%	235	24.6%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):								
Single Propel Stent Use (273 day lag period)	242	8.4%	180	6.3%	177	6.2%	139	4.8%
Single Propel Stent Use (fixed follow-up, 273 day lag	247	8.3%	190	6.4%	191	6.4%	152	5.1%
Single Propel Stent Use	374	14.6%	297	11.6%	216	8.4%	237	9.2%
Single Propel Stent Use (fixed follow-up)	382	14.4%	310	11.7%	225	8.5%	242	9.1%

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Disenrollment by Episode Length							
	183-273 days		274-364 days		365-455 days		456-546 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (273 day lag period)	146	6.6%	163	7.4%	182	8.3%	173	7.9%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	151	6.6%	174	7.6%	193	8.5%	180	7.9%
Single Sinuva Stent Use	210	13.0%	225	13.9%	208	12.9%	142	8.8%
Single Sinuva Stent Use (fixed follow-up)	217	12.9%	235	14.0%	213	12.7%	147	8.7%
Single stent cohorts - Outcome: Nasal Septal perforation								
Primary analysis cohorts (no lag period with fixed one year follow-up):								
Single Propel Stent Use	385	21.2%	316	17.4%	0	0.0%	0	0.0%
Single Sinuva Stent Use	217	22.6%	240	25.0%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):								
Single Propel Stent Use	385	21.1%	314	17.2%	0	0.0%	0	0.0%
Single Sinuva Stent Use	218	22.6%	240	24.9%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):								
Single Propel Stent Use	377	14.5%	302	11.6%	221	8.5%	249	9.6%
Single Propel Stent Use (fixed follow-up)	385	14.3%	316	11.7%	230	8.5%	255	9.5%
Single Propel Stent Use (1 day lag period)	377	14.4%	300	11.5%	221	8.4%	248	9.5%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	385	14.2%	314	11.6%	230	8.5%	254	9.4%
Single Sinuva Stent Use	210	12.7%	230	13.9%	210	12.7%	149	9.0%
Single Sinuva Stent Use (fixed follow-up)	217	12.6%	240	13.9%	215	12.5%	154	8.9%
Single Sinuva Stent Use (1 day lag period)	211	12.7%	230	13.8%	210	12.6%	149	9.0%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	218	12.6%	240	13.9%	215	12.4%	154	8.9%
Single stent cohorts - Outcome: Diminished Visual Acuity								
Primary analysis cohorts (28-day lag period with fixed one year follow-up):								
Single Propel Stent Use	345	18.4%	280	15.0%	0	0.0%	0	0.0%
Single Sinuva Stent Use	227	22.2%	231	22.6%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):								
Single Propel Stent Use	381	21.2%	310	17.3%	0	0.0%	0	0.0%
Single Sinuva Stent Use	216	22.7%	233	24.5%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):								

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Disenrollment by Episode Length							
	183-273 days		274-364 days		365-455 days		456-546 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use (28 day lag period)	334	12.8%	271	10.4%	224	8.6%	223	8.6%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	345	12.8%	280	10.4%	234	8.7%	227	8.4%
Single Propel Stent Use	373	14.6%	296	11.6%	212	8.3%	244	9.5%
Single Propel Stent Use (fixed follow-up)	381	14.4%	310	11.7%	221	8.4%	250	9.5%
Single Sinuva Stent Use (28 day lag period)	216	12.8%	227	13.5%	179	10.6%	158	9.4%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	227	12.9%	231	13.2%	185	10.6%	163	9.3%
Single Sinuva Stent Use	209	12.9%	223	13.8%	204	12.6%	141	8.7%
Single Sinuva Stent Use (fixed follow-up)	216	12.8%	233	13.8%	209	12.4%	146	8.6%
Single stent cohorts - Outcome: Ocular Hypertension								
Primary analysis cohorts (14-day lag period with fixed one year follow-up):								
Single Propel Stent Use	361	19.7%	293	16.0%	0	0.0%	0	0.0%
Single Sinuva Stent Use	213	21.7%	235	23.9%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):								
Single Propel Stent Use	378	21.0%	313	17.4%	0	0.0%	0	0.0%
Single Sinuva Stent Use	217	23.0%	231	24.4%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):								
Single Propel Stent Use (14 day lag period)	350	13.5%	282	10.9%	219	8.4%	233	9.0%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	361	13.5%	293	10.9%	228	8.5%	237	8.8%
Single Propel Stent Use	370	14.4%	299	11.6%	215	8.4%	243	9.4%
Single Propel Stent Use (fixed follow-up)	378	14.2%	313	11.8%	224	8.4%	248	9.3%
Single Sinuva Stent Use (14 day lag period)	203	12.4%	229	14.0%	195	11.9%	139	8.5%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	213	12.5%	235	13.8%	200	11.7%	145	8.5%
Single Sinuva Stent Use	210	13.1%	221	13.8%	203	12.7%	144	9.0%
Single Sinuva Stent Use (fixed follow-up)	217	13.0%	231	13.8%	208	12.5%	149	8.9%
Repeat stent cohorts - Outcome: Glaucoma								
Primary analysis cohorts (28-day lag period with fixed one year follow-up):								
Sinuva Repeat Stent within 365 days	21	30.4%	11	15.9%	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	25	29.8%	16	19.0%	0	0.0%	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):								

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Disenrollment by Episode Length							
	183-273 days		274-364 days		365-455 days		456-546 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sinuva Repeat Stent within 365 days	21	16.2%	*****	*****	20	15.4%	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	21	15.7%	11	8.2%	21	15.7%	12	9.0%
Sinuva Repeat Stent within 730 days	24	15.9%	15	9.9%	21	13.9%	14	9.3%
Sinuva Repeat Stent within 730 days (fixed follow-up)	25	16.0%	16	10.3%	22	14.1%	14	9.0%
Repeat stent cohorts - Outcome: Cataract								
Primary analysis cohorts (273-day lag period with fixed one year follow-up):								
Sinuva Repeat Stent within 365 days	15	13.3%	14	12.4%	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	16	12.2%	15	11.5%	0	0.0%	0	0.0%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):								
Sinuva Repeat Stent within 365 days	15	9.8%	13	8.5%	11	7.2%	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	15	9.4%	14	8.8%	12	7.5%	*****	*****
Sinuva Repeat Stent within 730 days	16	9.1%	14	8.0%	15	8.5%	*****	*****
Sinuva Repeat Stent within 730 days (fixed follow-up)	16	8.7%	15	8.2%	16	8.7%	*****	*****

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Disenrollment by Episode Length					
	547-637 days		638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Glaucoma						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use	172	6.5%	178	6.7%	0	0.0%
Single Propel Stent Use Cohort (fixed follow-up)	186	6.8%	195	7.1%	0	0.0%
Single Propel Stent Use Cohort (28 day lag period)	180	6.9%	186	7.1%	0	0.0%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	190	7.1%	201	7.5%	0	0.0%
Single Sinuva Stent Use	158	9.3%	200	11.7%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	171	9.6%	211	11.9%	0	0.0%
Single Sinuva Stent Use (28 day lag period)	166	10.1%	192	11.7%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	177	10.3%	204	11.9%	0	0.0%
Single stent cohorts - Outcome: Cataract						
Primary analysis cohorts (273-day lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (273 day lag period)	90	3.1%	57	2.0%	0	0.0%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	98	3.3%	61	2.0%	0	0.0%
Single Propel Stent Use	179	7.0%	178	6.9%	0	0.0%
Single Propel Stent Use (fixed follow-up)	189	7.1%	193	7.3%	0	0.0%
Single Sinuva Stent Use (273 day lag period)	182	8.3%	214	9.7%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	186	8.1%	220	9.6%	0	0.0%

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Disenrollment by Episode Length					
	547-637 days		638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	161	10.0%	183	11.3%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	172	10.2%	195	11.6%	0	0.0%
Single stent cohorts - Outcome: Nasal Septal perforation						
Primary analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use	181	6.9%	188	7.2%	0	0.0%
Single Propel Stent Use (fixed follow-up)	191	7.1%	203	7.5%	0	0.0%
Single Propel Stent Use (1 day lag period)	181	6.9%	189	7.2%	0	0.0%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	192	7.1%	203	7.5%	0	0.0%
Single Sinuva Stent Use	172	10.4%	197	11.9%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	183	10.6%	209	12.1%	0	0.0%
Single Sinuva Stent Use (1 day lag period)	174	10.5%	199	12.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	186	10.8%	210	12.1%	0	0.0%
Single stent cohorts - Outcome: Diminished Visual Acuity						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag p						
Single Propel Stent Use (28 day lag period)	162	6.2%	170	6.5%	0	0.0%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	175	6.5%	186	6.9%	0	0.0%
Single Propel Stent Use	173	6.8%	176	6.9%	0	0.0%
Single Propel Stent Use (fixed follow-up)	182	6.9%	191	7.2%	0	0.0%

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Disenrollment by Episode Length					
	547-637 days		638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (28 day lag period)	160	9.5%	201	11.9%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	172	9.8%	211	12.0%	0	0.0%
Single Sinuva Stent Use	168	10.4%	193	11.9%	0	0.0%
Single Sinuva Stent Use (fixed follow-up)	178	10.5%	205	12.1%	0	0.0%
Single stent cohorts - Outcome: Ocular Hypertension						
Primary analysis cohorts (14-day lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (14 day lag period)	168	6.5%	185	7.1%	0	0.0%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	180	6.7%	199	7.4%	0	0.0%
Single Propel Stent Use	173	6.7%	186	7.2%	0	0.0%
Single Propel Stent Use (fixed follow-up)	183	6.9%	201	7.6%	0	0.0%
Single Sinuva Stent Use (14 day lag period)	157	9.6%	197	12.0%	0	0.0%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	169	9.9%	207	12.2%	0	0.0%
Single Sinuva Stent Use	156	9.7%	188	11.7%	0	0.0%

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to Disenrollment by Episode Length					
	547-637 days		638-729 days		730+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use (fixed follow-up)	167	10.0%	200	12.0%	0	0.0%
Repeat stent cohorts - Outcome: Glaucoma						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):						
Sinuva Repeat Stent within 365 days	14	10.8%	16	12.3%	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	15	11.2%	17	12.7%	0	0.0%
Sinuva Repeat Stent within 730 days	15	9.9%	19	12.6%	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	16	10.3%	20	12.8%	0	0.0%
Repeat stent cohorts - Outcome: Cataract						
Primary analysis cohorts (273-day lag period with fixed one year follow-up):						
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%	0	0.0%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):						
Sinuva Repeat Stent within 365 days	*****	*****	12	7.8%	0	0.0%
Sinuva Repeat Stent within 365 days (fixed follow-up)	*****	*****	13	8.2%	0	0.0%
Sinuva Repeat Stent within 730 days	*****	*****	12	6.8%	0	0.0%
Sinuva Repeat Stent within 730 days (fixed follow-up)	*****	*****	13	7.1%	0	0.0%

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single stent cohorts - Outcome: Glaucoma							
Primary analysis cohorts (28-day lag period with fixed one year follow-up):							
Single Propel Stent Use	0	43	126	222	364	138.5	107.0
Single Sinuva Stent Use	0	55	159	267	364	161.4	114.8
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	1	67	147	239	364	156.4	102.4
Single Sinuva Stent Use	1	76	172	272	362	174.5	108.9
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use	0	77	207	424	729	258.2	210.7
Single Propel Stent Use Cohort (fixed follow-up)	0	78	212	430	729	261.9	212.6
Single Propel Stent Use Cohort (28 day lag period)	1	103	229	438	729	277.7	205.6
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	1	105	233	443	729	280.7	206.9
Single Sinuva Stent Use	0	127	305	513	727	322.5	221.2
Single Sinuva Stent Use (fixed follow-up)	0	127	305	516	729	323.9	222.0
Single Sinuva Stent Use (28 day lag period)	1	148	318	511	729	335.5	213.1
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	1	149	319	515	729	337.1	214.2
Single stent cohorts - Outcome: Cataract							
Primary analysis cohorts (273-day lag period with fixed one year follow-up):							
Single Propel Stent Use	0	0	0	108	364	65.3	104.9
Single Sinuva Stent Use	0	0	14	164	363	86.2	113.0
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	1	66	147	238	364	155.8	102.2
Single Sinuva Stent Use	1	76	169	271	362	173.6	108.7
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use (273 day lag period)	0	0	0	245	728	135.4	191.8
Single Propel Stent Use (fixed follow-up, 273 day lag period)	0	0	0	253	728	139.3	194.3
Single Propel Stent Use	1	101	226	434	729	275.5	205.0
Single Propel Stent Use (fixed follow-up)	1	103	230	440	729	278.5	206.5
Single Sinuva Stent Use (273 day lag period)	0	0	166	463	729	245.1	247.6
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	0	0	168	460	729	245.0	247.1
Single Sinuva Stent Use	1	145	317	502	729	332.0	212.6

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use (fixed follow-up)	1	147	317	511	729	333.8	213.8
Single stent cohorts - Outcome: Nasal Septal perforation							
Primary analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	1	67	148	239	364	156.7	102.5
Single Sinuva Stent Use	1	76	172	272	362	174.4	108.9
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):							
Single Propel Stent Use	0	66	147	239	364	156.1	102.9
Single Sinuva Stent Use	0	75	171	271	364	173.8	109.0
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use	1	104	231	441	729	278.8	205.9
Single Propel Stent Use (fixed follow-up)	1	105	235	446	729	281.7	207.2
Single Propel Stent Use (1 day lag period)	0	102	230	441	729	278.2	206.6
Single Propel Stent Use (fixed follow-up, 1 day lag period)	0	104	234	447	729	281.1	207.8
Single Sinuva Stent Use	1	149	320	515	729	337.4	213.8
Single Sinuva Stent Use (fixed follow-up)	1	151	321	523	729	338.9	214.8
Single Sinuva Stent Use (1 day lag period)	0	150	320	515	729	337.2	214.2
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	0	150	320	522	729	338.7	215.2
Single stent cohorts - Outcome: Diminished Visual Acuity							
Primary analysis cohorts (28-day lag period with fixed one year follow-up):							
Single Propel Stent Use	0	42	125	220	364	137.7	106.7
Single Sinuva Stent Use	0	54	159	267	364	160.8	114.8
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	1	66	147	238	364	156.0	102.3
Single Sinuva Stent Use	1	76	169	271	362	173.6	108.9
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use (28 day lag period)	0	75	203	420	729	255.4	209.8
Single Propel Stent Use (fixed follow-up, 28 day lag period)	0	77	209	424	729	259.0	211.5
Single Propel Stent Use	1	101	226	434	729	275.3	204.7
Single Propel Stent Use (fixed follow-up)	1	103	230	440	729	278.2	206.0
Single Sinuva Stent Use (28 day lag period)	0	125	303	520	727	322.7	222.4
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	0	126	303	523	727	323.8	223.0

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use	1	147	318	514	729	335.5	214.3
Single Sinuva Stent Use (fixed follow-up)	1	148	318	523	729	337.0	215.3
Single stent cohorts - Outcome: Ocular Hypertension							
Primary analysis cohorts (14-day lag period with fixed one year follow-up):							
Single Propel Stent Use	0	53	135	231	364	146.4	105.0
Single Sinuva Stent Use	0	64	164	269	363	166.5	112.3
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):							
Single Propel Stent Use	1	66	147	237	364	155.9	102.4
Single Sinuva Stent Use	1	76	170	270	362	173.2	108.7
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):							
Single Propel Stent Use (14 day lag period)	0	89	215	430	729	266.8	208.9
Single Propel Stent Use (fixed follow-up, 14 day lag period)	0	91	220	435	729	269.9	210.3
Single Propel Stent Use	1	101	227	436	729	276.7	205.9
Single Propel Stent Use (fixed follow-up)	1	103	231	442	729	279.7	207.3
Single Sinuva Stent Use (14 day lag period)	0	134	305	509	729	326.9	218.4
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	0	134	307	518	729	328.3	219.2
Single Sinuva Stent Use	1	145	316	507	729	333.1	213.6
Single Sinuva Stent Use (fixed follow-up)	1	147	316	513	729	334.9	214.7
Repeat stent cohorts - Outcome: Glaucoma							
Primary analysis cohorts (28-day lag period with fixed one year follow-up):							
Sinuva Repeat Stent within 365 days	0	64	169	236	360	158.2	104.3
Sinuva Repeat Stent within 730 days	0	66	176	244	360	166.8	106.3
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):							
Sinuva Repeat Stent within 365 days	0	155	329	522	728	339.1	221.0
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	156	344	532	728	343.8	220.9
Sinuva Repeat Stent within 730 days	0	155	309	522	728	337.7	219.4

Table 11. Summary of Time from Start of Follow-Up to End of At-Risk Period due to Disenrollment for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	161	315	522	728	341.2	218.9
Repeat stent cohorts - Outcome: Cataract							
Primary analysis cohorts (273-day lag period with fixed one year follow-up):							
Sinuva Repeat Stent within 365 days	0	0	16	193	359	95.5	117.3
Sinuva Repeat Stent within 730 days	0	0	16	180	359	90.3	114.0
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):							
Sinuva Repeat Stent within 365 days	0	0	156	421	721	221.6	235.2
Sinuva Repeat Stent within 365 days (fixed follow-up)	0	0	159	435	724	227.5	236.7
Sinuva Repeat Stent within 730 days	0	0	139	419	721	215.1	232.2
Sinuva Repeat Stent within 730 days (fixed follow-up)	0	0	144	428	724	219.3	233.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

[1]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

Table 12. Summary of Time from Start of Follow-Up to End of At-Risk Period due to End of Data for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to End of Data by Episode Length			
			0-91 days		92-182 days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Data[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Glaucoma						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,174	448	38.2%	319	27.2%
Single Sinuva Stent Use	3,393	485	130	26.8%	92	19.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,124	356	31.7%	322	28.6%
Single Sinuva Stent Use	3,393	451	97	21.5%	91	20.2%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use Cohort (28 day lag period)	3,924	1,765	441	25.0%	317	18.0%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	3,924	1,802	448	24.9%	319	17.7%
Single Propel Stent Use	3,924	1,734	350	20.2%	320	18.5%
Single Propel Stent Use Cohort (fixed follow-up)	3,924	1,767	356	20.1%	322	18.2%
Single Sinuva Stent Use (28 day lag period)	3,393	927	123	13.3%	90	9.7%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	962	130	13.5%	92	9.6%
Single Sinuva Stent Use	3,393	888	91	10.2%	89	10.0%
Single Sinuva Stent Use (fixed follow-up)	3,393	922	97	10.5%	91	9.9%
Single stent cohorts - Outcome: Cataract						
Primary analysis cohorts (273-day lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,595	1,123	70.4%	149	9.3%
Single Sinuva Stent Use	3,393	769	450	58.5%	113	14.7%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,110	356	32.1%	319	28.7%
Single Sinuva Stent Use	3,393	443	97	21.9%		20.3%

Table 12. Summary of Time from Start of Follow-Up to End of At-Risk Period due to End of Data for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to End of Data by Episode Length			
			0-91 days		92-182 days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Data[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (273 day lag period)	3,924	1,935	1,106	57.2%	147	7.6%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	3,924	1,990	1,123	56.4%	149	7.5%
Single Propel Stent Use	3,924	1,696	350	20.6%	317	18.7%
Single Propel Stent Use (fixed follow-up)	3,924	1,728	356	20.6%	319	18.5%
Single Sinuva Stent Use (273 day lag period)	3,393	1,360	436	32.1%	111	8.2%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	3,393	1,405	450	32.0%	113	8.0%
Single Sinuva Stent Use	3,393	856	91	10.6%	88	10.3%
Single Sinuva Stent Use (fixed follow-up)	3,393	890	97	10.9%	90	10.1%
Single stent cohorts - Outcome: Nasal Septal Perforation **Primary analysis cohorts (no lag period with fixed one year follow-up):**						
Single Propel Stent Use	3,924	1,123	355	31.6%	321	28.6%
Single Sinuva Stent Use	3,393	451	97	21.5%	91	20.2%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,131	360	31.8%	326	28.8%
Single Sinuva Stent Use	3,393	453	98	21.6%	92	20.3%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use	3,924	1,738	349	20.1%	319	18.4%
Single Propel Stent Use (fixed follow-up)	3,924	1,771	355	20.0%	321	18.1%
Single Propel Stent Use (1 day lag period)	3,924	1,746	354	20.3%	324	18.6%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	3,924	1,779	360	20.2%	326	18.3%
Single Sinuva Stent Use	3,393	899	91	10.1%	89	9.9%
Single Sinuva Stent Use (fixed follow-up)	3,393	933	97	10.4%	91	9.8%
Single Sinuva Stent Use (1 day lag period)	3,393	902	92	10.2%	90	10.0%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	3,393	936	98	10.5%	92	9.8%

Table 12. Summary of Time from Start of Follow-Up to End of At-Risk Period due to End of Data for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to End of Data by Episode Length			
			0-91 days		92-182 days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Data[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Diminished Visual Acuity						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,165	445	38.2%	318	27.3%
Single Sinuva Stent Use	3,393	480	129	26.9%	90	18.8%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,115	353	31.7%	318	28.5%
Single Sinuva Stent Use	3,393	443	97	21.9%	89	20.1%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (28 day lag period)	3,924	1,734	438	25.3%	316	18.2%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	3,924	1,769	445	25.2%	318	18.0%
Single Propel Stent Use	3,924	1,700	347	20.4%	316	18.6%
Single Propel Stent Use (fixed follow-up)	3,924	1,732	353	20.4%	318	18.4%
Single Sinuva Stent Use (28 day lag period)	3,393	914	122	13.3%	88	9.6%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	3,393	947	129	13.6%	90	9.5%
Single Sinuva Stent Use	3,393	872	91	10.4%	87	10.0%
Single Sinuva Stent Use (fixed follow-up)	3,393	905	97	10.7%	89	9.8%
Single stent cohorts - Outcome: Ocular Hypertension						
Primary analysis cohorts (14-day lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,141	396	34.7%	326	28.6%
Single Sinuva Stent Use	3,393	457	120	26.3%	82	17.9%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):						
Single Propel Stent Use	3,924	1,109	355	32.0%	317	28.6%
Single Sinuva Stent Use	3,393	438	96	21.9%	87	19.9%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):						
Single Propel Stent Use (14 day lag period)	3,924	1,725	389	22.6%	324	18.8%

Table 12. Summary of Time from Start of Follow-Up to End of At-Risk Period due to End of Data for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

			Number of Episodes Censored due to End of Data by Episode Length			
			0-91 days		92-182 days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Data[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use (fixed follow-up, 14 day lag period)	3,924	1,760	396	22.5%	326	18.5%
Single Propel Stent Use	3,924	1,706	349	20.5%	315	18.5%
Single Propel Stent Use (fixed follow-up)	3,924	1,739	355	20.4%	317	18.2%
Single Sinuva Stent Use (14 day lag period)	3,393	878	113	12.9%	80	9.1%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	3,393	912	120	13.2%	82	9.0%
Single Sinuva Stent Use	3,393	856	90	10.5%	85	9.9%
Single Sinuva Stent Use (fixed follow-up)	3,393	890	96	10.8%	87	9.8%
Repeat stent cohorts - Outcome: Glaucoma						
Primary analysis cohorts (28-day lag period with fixed one year follow-up):						
Sinuva Repeat Stent within 365 days	231	41	15	36.6%	*****	*****
Sinuva Repeat Stent within 730 days	258	51	17	33.3%	*****	*****
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):						
Sinuva Repeat Stent within 365 days	231	80	15	18.8%	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	84	15	17.9%	*****	*****
Sinuva Repeat Stent within 730 days	258	96	17	17.7%	*****	*****
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	101	17	16.8%	*****	*****
Repeat stent cohorts - Outcome: Cataract						
Primary analysis cohorts (273-day lag period with fixed one year follow-up):						
Sinuva Repeat Stent within 365 days	231	69	40	58.0%	*****	*****
Sinuva Repeat Stent within 730 days	258	82	49	59.8%	*****	*****
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):						
Sinuva Repeat Stent within 365 days	231	102	39	38.2%	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	231	109	40	36.7%	*****	*****
Sinuva Repeat Stent within 730 days	258	119	47	39.5%	*****	*****
Sinuva Repeat Stent within 730 days (fixed follow-up)	258	127	49	38.6%	11	8.7%

Table 12. Summary of Time from Start of Follow-Up to End of At-Risk Period due to End of Data for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to End of Data by Episode Length							
	183-273 days		274-364 days		365-455 days		456-546 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single stent cohorts - Outcome: Glaucoma								
Primary analysis cohorts (28-day lag period with fixed one year follow-up):								
Single Propel Stent Use	206	17.5%	201	17.1%	0	0.0%	0	0.0%
Single Sinuva Stent Use	129	26.6%	134	27.6%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):								
Single Propel Stent Use	239	21.3%	207	18.4%	0	0.0%	0	0.0%
Single Sinuva Stent Use	123	27.3%	140	31.0%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):								
Single Propel Stent Use Cohort (28 day lag period)	203	11.5%	196	11.1%	157	8.9%	177	10.0%
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	206	11.4%	201	11.2%	159	8.8%	177	9.8%
Single Propel Stent Use	237	13.7%	200	11.5%	148	8.5%	187	10.8%
Single Propel Stent Use Cohort (fixed follow-up)	239	13.5%	207	11.7%	150	8.5%	187	10.6%
Single Sinuva Stent Use (28 day lag period)	126	13.6%	132	14.2%	109	11.8%	99	10.7%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	129	13.4%	134	13.9%	111	11.5%	102	10.6%
Single Sinuva Stent Use	121	13.6%	136	15.3%	110	12.4%	91	10.2%
Single Sinuva Stent Use (fixed follow-up)	123	13.3%	140	15.2%	112	12.1%	93	10.1%
Single stent cohorts - Outcome: Cataract								
Primary analysis cohorts (273-day lag period with fixed one year follow-up):								
Single Propel Stent Use	181	11.3%	142	8.9%	0	0.0%	0	0.0%
Single Sinuva Stent Use	91	11.8%	115	15.0%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):								
Single Propel Stent Use	236	21.3%	199	17.9%	0	0.0%	0	0.0%
Single Sinuva Stent Use	122	27.5%	134	30.2%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):								
Single Propel Stent Use (273 day lag period)	181	9.4%	136	7.0%	145	7.5%	106	5.5%
Single Propel Stent Use (fixed follow-up, 273 day lag period)	181	9.1%	142	7.1%	152	7.6%	117	5.9%
Single Propel Stent Use	234	13.8%	193	11.4%	144	8.5%	177	10.4%

Table 12. Summary of Time from Start of Follow-Up to End of At-Risk Period due to End of Data for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to End of Data by Episode Length							
	183-273 days		274-364 days		365-455 days		456-546 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Propel Stent Use (fixed follow-up)	236	13.7%	199	11.5%	146	8.4%	177	10.2%
Single Sinuva Stent Use (273 day lag period)	89	6.5%	107	7.9%	131	9.6%	127	9.3%
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	91	6.5%	115	8.2%	138	9.8%	131	9.3%
Single Sinuva Stent Use	120	14.0%	130	15.2%	108	12.6%	83	9.7%
Single Sinuva Stent Use (fixed follow-up)	122	13.7%	134	15.1%	110	12.4%	85	9.6%
Single stent cohorts - Outcome: Nasal Septal Perforation								
Primary analysis cohorts (no lag period with fixed one year follow-up):								
Single Propel Stent Use	240	21.4%	207	18.4%	0	0.0%	0	0.0%
Single Sinuva Stent Use	123	27.3%	140	31.0%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):								
Single Propel Stent Use	238	21.0%	207	18.3%	0	0.0%	0	0.0%
Single Sinuva Stent Use	123	27.2%	140	30.9%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):								
Single Propel Stent Use	238	13.7%	200	11.5%	149	8.6%	187	10.8%
Single Propel Stent Use (fixed follow-up)	240	13.6%	207	11.7%	151	8.5%	187	10.6%
Single Propel Stent Use (1 day lag period)	236	13.5%	200	11.5%	148	8.5%	188	10.8%
Single Propel Stent Use (fixed follow-up, 1 day lag period)	238	13.4%	207	11.6%	150	8.4%	188	10.6%
Single Sinuva Stent Use	121	13.5%	136	15.1%	111	12.3%	92	10.2%
Single Sinuva Stent Use (fixed follow-up)	123	13.2%	140	15.0%	113	12.1%	94	10.1%
Single Sinuva Stent Use (1 day lag period)	121	13.4%	136	15.1%	110	12.2%	92	10.2%
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	123	13.1%	140	15.0%	112	12.0%	94	10.0%
Single stent cohorts - Outcome: Diminished Visual Acuity								
Primary analysis cohorts (28-day lag period with fixed one year follow-up):								
Single Propel Stent Use	205	17.6%	197	16.9%	0	0.0%	0	0.0%
Single Sinuva Stent Use	129	26.9%	132	27.5%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):								
Single Propel Stent Use	239	21.4%	205	18.4%	0	0.0%	0	0.0%

Table 12. Summary of Time from Start of Follow-Up to End of At-Risk Period due to End of Data for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to End of Data by Episode Length							
	183-273 days		274-364 days		365-455 days		456-546 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva Stent Use	120	27.1%	137	30.9%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):								
Single Propel Stent Use (28 day lag period)	202	11.6%	192	11.1%	155	8.9%	173	10.0%
Single Propel Stent Use (fixed follow-up, 28 day lag period)	205	11.6%	197	11.1%	157	8.9%	173	9.8%
Single Propel Stent Use	237	13.9%	198	11.6%	143	8.4%	181	10.6%
Single Propel Stent Use (fixed follow-up)	239	13.8%	205	11.8%	145	8.4%	181	10.5%
Single Sinuva Stent Use (28 day lag period)	126	13.8%	130	14.2%	101	11.1%	100	10.9%
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	129	13.6%	132	13.9%	103	10.9%	103	10.9%
Single Sinuva Stent Use	118	13.5%	133	15.3%	108	12.4%	85	9.7%
Single Sinuva Stent Use (fixed follow-up)	120	13.3%	137	15.1%	110	12.2%	87	9.6%
Single stent cohorts - Outcome: Ocular Hypertension **Primary analysis cohorts (14-day lag period with fixed one year follow-up):**								
Single Propel Stent Use	215	18.8%	204	17.9%	0	0.0%	0	0.0%
Single Sinuva Stent Use	119	26.0%	136	29.8%	0	0.0%	0	0.0%
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):								
Single Propel Stent Use	234	21.1%	203	18.3%	0	0.0%	0	0.0%
Single Sinuva Stent Use	121	27.6%	134	30.6%	0	0.0%	0	0.0%
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):								
Single Propel Stent Use (14 day lag period)	213	12.3%	198	11.5%	143	8.3%	176	10.2%
Single Propel Stent Use (fixed follow-up, 14 day lag period)	215	12.2%	204	11.6%	145	8.2%	176	10.0%
Single Propel Stent Use	232	13.6%	196	11.5%	147	8.6%	182	10.7%
Single Propel Stent Use (fixed follow-up)	234	13.5%	203	11.7%	149	8.6%	182	10.5%
Single Sinuva Stent Use (14 day lag period)	117	13.3%	133	15.1%	109	12.4%	84	9.6%
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	119	13.0%	136	14.9%	111	12.2%	87	9.5%
Single Sinuva Stent Use	119	13.9%	130	15.2%	107	12.5%	86	10.0%
Single Sinuva Stent Use (fixed follow-up)	121	13.6%	134	15.1%	109	12.2%	88	9.9%

Table 12. Summary of Time from Start of Follow-Up to End of At-Risk Period due to End of Data for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to End of Data by Episode Length							
	183-273 days		274-364 days		365-455 days		456-546 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Repeat stent cohorts - Outcome: Glaucoma								
Primary analysis cohorts (28-day lag period with fixed one year follow-up):								
Sinuva Repeat Stent within 365 days	*****	*****	*****	*****	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	13	25.5%	*****	*****	0	0.0%	0	0.0%
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):								
Sinuva Repeat Stent within 365 days	*****	*****	*****	*****	*****	*****	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	*****	*****	*****	*****	*****	*****	*****	*****
Sinuva Repeat Stent within 730 days	12	12.5%	*****	*****	*****	*****	11	11.5%
Sinuva Repeat Stent within 730 days (fixed follow-up)	13	12.9%	*****	*****	11	10.9%	11	10.9%
Repeat stent cohorts - Outcome: Cataract								
Primary analysis cohorts (273-day lag period with fixed one year follow-up):								
Sinuva Repeat Stent within 365 days	*****	*****	11	15.9%	0	0.0%	0	0.0%
Sinuva Repeat Stent within 730 days	*****	*****	12	14.6%	0	0.0%	0	0.0%
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):								
Sinuva Repeat Stent within 365 days	*****	*****	*****	*****	*****	*****	*****	*****
Sinuva Repeat Stent within 365 days (fixed follow-up)	*****	*****	11	10.1%	*****	*****	*****	*****
Sinuva Repeat Stent within 730 days	*****	*****	11	9.2%	11	9.2%	*****	*****
Sinuva Repeat Stent within 730 days (fixed follow-up)	*****	*****	12	9.4%	12	9.4%	*****	*****

Table 12. Summary of Time from Start of Follow-Up to End of At-Risk Period due to End of Data for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to End of Data by Episode Length												
	547-637 days		638-729 days		730+ days		Distribution of At-Risk Time in Days, by Episode						
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single stent cohorts - Outcome: Glaucoma													
Primary analysis cohorts (28-day lag period with fixed one year follow-up):													
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%	0	46	130	232	364	143.1	108.5
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%	0	79	198	282	360	183.7	110.9
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):													
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%	1	71	154	246	364	160.5	103.9
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%	2	100	212	295	362	198.4	106.3
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):													
Single Propel Stent Use Cohort (28 day lag period)	131	7.4%	143	8.1%	0	0.0%	0	92	234	462	729	279.5	216.3
Single Propel Stent Use Cohort (fixed follow-up, 28 day lag period)	138	7.7%	154	8.5%	0	0.0%	0	94	238	466	729	282.2	218.0
Single Propel Stent Use	138	8.0%	154	8.9%	0	0.0%	1	116	260	477	729	298.8	211.5
Single Propel Stent Use Cohort (fixed follow-up)	144	8.1%	162	9.2%	0	0.0%	1	117	261	479	729	300.7	212.7
Single Sinuva Stent Use (28 day lag period)	108	11.7%	140	15.1%	0	0.0%	0	197	356	568	728	368.6	215.8
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	116	12.1%	148	15.4%	0	0.0%	0	197	359	570	729	370.0	217.2
Single Sinuva Stent Use	110	12.4%	140	15.8%	0	0.0%	2	217	369	564	729	381.1	208.2
Single Sinuva Stent Use (fixed follow-up)	118	12.8%	148	16.1%	0	0.0%	2	216	373	570	729	382.6	210.0
Single stent cohorts - Outcome: Cataract													
Primary analysis cohorts (273-day lag period with fixed one year follow-up):													
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%	0	0	0	136	364	73.0	109.4
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%	0	0	46	191	363	102.6	118.7
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):													
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%	1	68	151	245	364	159.0	103.5

Table 12. Summary of Time from Start of Follow-Up to End of At-Risk Period due to End of Data for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to End of Data by Episode Length												
	547-637 days		638-729 days		730+ days		Distribution of At-Risk Time in Days, by Episode						
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%	2	97	211	290	361	196.8	106.3
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):													
Single Propel Stent Use (273 day lag period)	76	3.9%	38	2.0%	0	0.0%	0	0	30	286	728	153.3	198.6
Single Propel Stent Use (fixed follow-up, 273 day lag period)	82	4.1%	44	2.2%	0	0.0%	0	0	36	296	728	158.5	202.4
Single Propel Stent Use	134	7.9%	147	8.7%	0	0.0%	1	114	252	472	729	295.4	211.2
Single Propel Stent Use (fixed follow-up)	140	8.1%	155	9.0%	0	0.0%	1	114	254	476	729	297.4	212.6
Single Sinuva Stent Use (273 day lag period)	156	11.5%	203	14.9%	0	0.0%	0	28	304	557	729	311.6	257.0
Single Sinuva Stent Use (fixed follow-up, 273 day lag period)	158	11.2%	209	14.9%	0	0.0%	0	27	306	555	729	311.5	256.5
Single Sinuva Stent Use	105	12.3%	131	15.3%	0	0.0%	2	212	361	561	729	376.1	208.2
Single Sinuva Stent Use (fixed follow-up)	113	12.7%	139	15.6%	0	0.0%	2	212	367	564	729	377.9	210.1
Single stent cohorts - Outcome: Nasal Septal Perforation **Primary analysis cohorts (no lag period with fixed one year follow-up):**													
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%	1	71	154	246	364	160.8	103.9
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%	2	100	212	295	362	198.4	106.3
Sensitivity analysis cohorts (1-day lag period with fixed one year follow-up):													
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%	0	71	153	246	364	160.5	104.6
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%	1	99	211	294	364	197.9	106.4
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):													
Single Propel Stent Use	140	8.1%	156	9.0%	0	0.0%	1	118	261	478	729	300.0	211.9
Single Propel Stent Use (fixed follow-up)	146	8.2%	164	9.3%	0	0.0%	1	119	261	479	729	301.9	213.1
Single Propel Stent Use (1 day lag period)	136	7.8%	160	9.2%	0	0.0%	0	117	260	478	729	299.8	212.8
Single Propel Stent Use (fixed follow-up, 1 day lag period)	142	8.0%	168	9.4%	0	0.0%	0	118	260	481	729	301.7	214.0
Single Sinuva Stent Use	115	12.8%	144	16.0%	0	0.0%	2	219	373	565	729	383.6	208.4
Single Sinuva Stent Use (fixed follow-up)	123	13.2%	152	16.3%	0	0.0%	2	219	375	572	729	385.0	210.2
Single Sinuva Stent Use (1 day lag period)	117	13.0%	144	16.0%	0	0.0%	1	221	373	567	729	383.2	208.7

Table 12. Summary of Time from Start of Follow-Up to End of At-Risk Period due to End of Data for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to End of Data by Episode Length						Distribution of At-Risk Time in Days, by Episode						
	547-637 days		638-729 days		730+ days								
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva Stent Use (fixed follow-up, 1 day lag period)	125	13.4%	152	16.2%	0	0.0%	1	220	375	572	729	384.6	210.5
Single stent cohorts - Outcome: Diminished Visual Acuity													
Primary analysis cohorts (28-day lag period with fixed one year follow-up):													
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%	0	46	130	232	364	142.5	108.2
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%	0	79	198	282	360	183.6	111.3
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):													
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%	1	71	154	246	364	160.6	104.0
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%	2	97	212	295	362	197.9	106.5
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):													
Single Propel Stent Use (28 day lag period)	123	7.1%	135	7.8%	0	0.0%	0	90	233	454	729	275.9	214.9
Single Propel Stent Use (fixed follow-up, 28 day l	129	7.3%	145	8.2%	0	0.0%	0	91	233	458	729	278.4	216.5
Single Propel Stent Use	133	7.8%	145	8.5%	0	0.0%	1	115	254	472	729	295.8	210.4
Single Propel Stent Use (fixed follow-up)	138	8.0%	153	8.8%	0	0.0%	1	116	258	476	729	297.7	211.6
Single Sinuva Stent Use (28 day lag period)	108	11.8%	139	15.2%	0	0.0%	0	197	354	569	728	368.9	216.5
Single Sinuva Stent Use (fixed follow-up, 28 day lag period)	115	12.1%	146	15.4%	0	0.0%	0	197	358	570	728	369.7	217.7
Single Sinuva Stent Use	112	12.8%	138	15.8%	0	0.0%	2	217	369	565	729	381.2	208.8
Single Sinuva Stent Use (fixed follow-up)	119	13.1%	146	16.1%	0	0.0%	2	216	372	571	729	382.6	210.6
Single stent cohorts - Outcome: Ocular Hypertension													
Primary analysis cohorts (14-day lag period with fixed one year follow-up):													
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%	0	59	142	238	364	151.8	107.5
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%	0	87	205	286	364	189.8	109.4
Sensitivity analysis cohorts (no lag period with fixed one year follow-up):													
Single Propel Stent Use	0	0.0%	0	0.0%	0	0.0%	1	68	151	246	364	159.5	103.8
Single Sinuva Stent Use	0	0.0%	0	0.0%	0	0.0%	2	97	212	290	362	197.0	106.4
Secondary analysis cohorts (maximum of two years follow-up, with or without lag period):													
Single Propel Stent Use (14 day lag period)	125	7.2%	157	9.1%	0	0.0%	0	102	247	466	729	288.6	215.3

Table 12. Summary of Time from Start of Follow-Up to End of At-Risk Period due to End of Data for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to End of Data by Episode Length						Distribution of At-Risk Time in Days, by Episode						
	547-637 days		638-729 days		730+ days								
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Propel Stent Use (fixed follow-up, 14 day lag period)	131	7.4%	167	9.5%	0	0.0%	0	103	248	472	729	291.0	216.7
Single Propel Stent Use	132	7.7%	153	9.0%	0	0.0%	1	115	255	476	729	297.6	211.9
Single Propel Stent Use (fixed follow-up)	138	7.9%	161	9.3%	0	0.0%	1	115	260	478	729	299.5	213.1
Single Sinuva Stent Use (14 day lag period)	97	11.0%	145	16.5%	0	0.0%	0	205	361	562	729	373.5	213.6
Single Sinuva Stent Use (fixed follow-up, 14 day lag period)	104	11.4%	153	16.8%	0	0.0%	0	205	364	573	729	374.8	215.1
Single Sinuva Stent Use	102	11.9%	137	16.0%	0	0.0%	2	214	368	563	729	379.2	209.1
Single Sinuva Stent Use (fixed follow-up)	110	12.4%	145	16.3%	0	0.0%	2	214	369	568	729	380.9	211.0
Repeat stent cohorts - Outcome: Glaucoma													
Primary analysis cohorts (28-day lag period with fixed one year follow-up):													
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%	0	0.0%	9	64	169	239	351	162.4	104.1
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%	0	0.0%	0	64	170	255	351	167.7	106.6
Secondary analysis cohorts (28-day lag period with maximum of two years follow-up):													
Sinuva Repeat Stent within 365 days	12	15.0%	*****	*****	0	0.0%	9	163	358	573	726	356.4	224.6
Sinuva Repeat Stent within 365 days (fixed follow-up)	13	15.5%	11	13.1%	0	0.0%	9	170	369	575	726	363.1	223.7
Sinuva Repeat Stent within 730 days	13	13.5%	13	13.5%	0	0.0%	0	168	345	573	726	356.5	225.3
Sinuva Repeat Stent within 730 days (fixed follow-up)	14	13.9%	14	13.9%	0	0.0%	0	170	351	575	726	361.0	223.7
Repeat stent cohorts - Outcome: Cataract													
Primary analysis cohorts (273-day lag period with fixed one year follow-up):													
Sinuva Repeat Stent within 365 days	0	0.0%	0	0.0%	0	0.0%	0	0	37	212	359	106.0	125.6
Sinuva Repeat Stent within 730 days	0	0.0%	0	0.0%	0	0.0%	0	0	34	193	359	99.8	121.9
Secondary analysis cohorts (273-day lag period with maximum of two years follow-up):													
Sinuva Repeat Stent within 365 days	13	12.7%	*****	*****	0	0.0%	0	0	224	486	711	264.2	248.7
Sinuva Repeat Stent within 365 days (fixed follow-up)	14	12.8%	11	10.1%	0	0.0%	0	0	233	494	724	273.3	249.4
Sinuva Repeat Stent within 730 days	14	11.8%	*****	*****	0	0.0%	0	0	212	471	711	253.3	244.2

Table 12. Summary of Time from Start of Follow-Up to End of At-Risk Period due to End of Data for Exposures of Interest in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Number of Episodes Censored due to End of Data by Episode Length												
	547-637 days		638-729 days		730+ days		Distribution of At-Risk Time in Days, by Episode						
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Sinuva Repeat Stent within 730 days (fixed follow-up)	15	11.8%	11	8.7%	0	0.0%	0	0	221	471	724	259.8	245.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

[1]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

Table 13. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Single Sinuva Stent Use Cohort		Single Propel Stent Use Cohort		Sinuva Repeat Stent (within 365 days) Cohort**		Sinuva Repeat Stent (within 730 days) Cohort**	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	337,208,449	N/A	337,208,449	N/A	337,208,449	N/A	337,208,449	N/A
Had required coverage type (medical and/or drug coverage)	252,813,339	84,395,110	252,813,339	84,395,110	252,813,339	84,395,110	252,813,339	84,395,110
Enrolled during specified age range	193,990,173	58,823,166	193,990,173	58,823,166	193,990,173	58,823,166	193,990,173	58,823,166
Had requestable medical charts	193,990,173	0	193,990,173	0	193,990,173	0	193,990,173	0
Met demographic requirements (sex, race, and Hispanic origin)	193,926,399	63,774	193,926,399	63,774	193,926,399	63,774	193,926,399	63,774
Members with a valid index event								
Had any cohort-defining claim during the query period	4,405	193,921,994	5,016	193,921,383	*****	*****	*****	*****
Claim recorded during specified age range	4,372	33	4,944	72	*****	*****	*****	*****
Episode defining index claim recorded during the query period	4,372	0	4,944	0	*****	*****	*****	*****
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	3,988	384	4,357	587	263	*****	300	*****
Met inclusion and exclusion criteria[1]	3,393	595	3,924	433	231	32	258	42
Evidence of any of the outcomes: Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	N/A	595	N/A	433	N/A	32	N/A	42
Met event incidence criteria	3,393	0	3,924	0	231	0	258	0
Had sufficient post-index continuous enrollment	3,393	0	3,924	0	231	0	258	0
Had index episode of at least required length	3,393	0	3,924	0	231	0	258	0

Table 13. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database (SDD) from December 1, 2017 to January 31, 2024

	Single Sinuva Stent Use Cohort		Single Propel Stent Use Cohort		Sinuva Repeat Stent (within 365 days) Cohort**		Sinuva Repeat Stent (within 730 days) Cohort**	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Had index episode longer than blackout period	3,393	0	3,924	0	231	0	258	0
Did not have an event during blackout period	3,393	0	3,924	0	231	0	258	0
Final cohort								
Number of members	3,393	N/A	3,924	N/A	231	N/A	258	N/A
Number of episodes	3,393	N/A	3,924	N/A	231	N/A	258	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

[1]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

N/A: Not applicable

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (July 22, 2024)

Masked DP ID	DP Start Date	DP End Date[1]
DP01	01/01/2004	07/31/2023
DP02	01/01/2005	07/31/2022
DP03	01/01/2008	08/31/2023
DP04	01/01/2006	10/31/2023
DP05	01/01/2000	01/31/2024
DP06	01/01/2000	12/31/2021
DP07	01/01/2000	04/30/2023
DP08	01/01/2000	08/31/2022
DP09	01/01/2000	01/31/2024
DP10	01/01/2000	10/31/2022
DP11	01/01/2007	10/31/2023
DP12	01/01/2014	12/31/2021
DP13	01/01/2008	01/31/2024
DP14	01/01/2010	06/30/2023

[1]End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
Sinuva	
mometasone furoate	Sinuva
Propel	
mometasone furoate 0.37 MG Drug Implant [Propel]	PROPEL
mometasone furoate 0.37 MG Drug Implant [Propel]	PROPEL Contour
mometasone furoate 0.37 MG Drug Implant [Propel]	PROPEL Mini
mometasone furoate 0.37 MG Drug Implant [Propel]	PROPEL Mini SDS

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
	Sinuva		
C9122	Mometasone furoate sinus implant, 10 mcg (Sinuva)	Procedure	HCPCS
J7401	Mometasone furoate sinus implant, 10 mcg	Procedure	HCPCS
J7402	Mometasone furoate sinus implant, (Sinuva), 10 mcg	Procedure	HCPCS
	Propel		
S1090	Mometasone furoate sinus implant, 370 micrograms	Procedure	HCPCS
S1091	Stent, noncoronary, temporary, with delivery system (Propel)	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
	Cataracts		
13.41	Phacoemulsification and aspiration of cataract	Procedure	ICD-9-CM
13.42	Mechanical phacofragmentation and aspiration of cataract by posterior route	Procedure	ICD-9-CM
13.43	Mechanical phacofragmentation and other aspiration of cataract	Procedure	ICD-9-CM
13.6	Other cataract extraction	Procedure	ICD-9-CM
13.64	Discission of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.66	Mechanical fragmentation of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.69	Other cataract extraction	Procedure	ICD-9-CM
366.00	Unspecified nonsenile cataract	Diagnosis	ICD-9-CM
366.02	Posterior subcapsular polar cataract, nonsenile	Diagnosis	ICD-9-CM
366.09	Other and combined forms of nonsenile cataract	Diagnosis	ICD-9-CM
366.12	Incipient cataract	Diagnosis	ICD-9-CM
366.14	Posterior subcapsular polar senile cataract	Diagnosis	ICD-9-CM
366.15	Cortical senile cataract	Diagnosis	ICD-9-CM
366.19	Other and combined forms of senile cataract	Diagnosis	ICD-9-CM
366.30	Unspecified cataracta complicata	Diagnosis	ICD-9-CM
366.4	Cataract associated with other disorders	Diagnosis	ICD-9-CM
366.50	Unspecified after-cataract	Diagnosis	ICD-9-CM
366.52	Other after-cataract, not obscuring vision	Diagnosis	ICD-9-CM
366.8	Other cataract	Diagnosis	ICD-9-CM
366.9	Unspecified cataract	Diagnosis	ICD-9-CM
66820	Discission of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid); stab incision technique (Ziegler or Wheeler knife)	Procedure	CPT-4
66821	Discission of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid); laser surgery (eg, YAG laser) (1 or more stages)	Procedure	CPT-4
66825	Repositioning of intraocular lens prosthesis, requiring an incision (separate procedure)	Procedure	CPT-4
66830	Removal of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid) with corneo-scleral section, with or without iridectomy (iridocapsulotomy, iridocapsulectomy)	Procedure	CPT-4
66840	Removal of lens material; aspiration technique, 1 or more stages	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
66850	Removal of lens material; phacofragmentation technique (mechanical or ultrasonic) (eg, phacoemulsification), with aspiration	Procedure	CPT-4
66852	Removal of lens material; pars plana approach, with or without vitrectomy	Procedure	CPT-4
66920	Removal of lens material; intracapsular	Procedure	CPT-4
66930	Removal of lens material; intracapsular, for dislocated lens	Procedure	CPT-4
66940	Removal of lens material; extracapsular (other than 66840, 66850, 66852)	Procedure	CPT-4
66982	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental	Procedure	CPT-4
66983	Intracapsular cataract extraction with insertion of intraocular lens prosthesis (1 stage procedure)	Procedure	CPT-4
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or	Procedure	CPT-4
H25.011	Cortical age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.012	Cortical age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.013	Cortical age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.019	Cortical age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.041	Posterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.042	Posterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.043	Posterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.049	Posterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.9	Unspecified age-related cataract	Diagnosis	ICD-10-CM
H26.001	Unspecified infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.002	Unspecified infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
H26.003	Unspecified infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.009	Unspecified infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.051	Posterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.052	Posterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.053	Posterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.059	Posterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.09	Other infantile and juvenile cataract	Diagnosis	ICD-10-CM
H26.20	Unspecified complicated cataract	Diagnosis	ICD-10-CM
H26.30	Drug-induced cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.31	Drug-induced cataract, right eye	Diagnosis	ICD-10-CM
H26.32	Drug-induced cataract, left eye	Diagnosis	ICD-10-CM
H26.33	Drug-induced cataract, bilateral	Diagnosis	ICD-10-CM
H26.40	Unspecified secondary cataract	Diagnosis	ICD-10-CM
H26.491	Other secondary cataract, right eye	Diagnosis	ICD-10-CM
H26.492	Other secondary cataract, left eye	Diagnosis	ICD-10-CM
H26.493	Other secondary cataract, bilateral	Diagnosis	ICD-10-CM
H26.499	Other secondary cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.8	Other specified cataract	Diagnosis	ICD-10-CM
H26.9	Unspecified cataract	Diagnosis	ICD-10-CM
	Diminished Visual Acuity		
368.1	Subjective visual disturbances	Diagnosis	ICD-9-CM
368.10	Unspecified subjective visual disturbance	Diagnosis	ICD-9-CM
368.11	Sudden visual loss	Diagnosis	ICD-9-CM
368.12	Transient visual loss	Diagnosis	ICD-9-CM
368.13	Visual discomfort	Diagnosis	ICD-9-CM
368.14	Visual distortions of shape and size	Diagnosis	ICD-9-CM
368.15	Other visual distortions and entoptic phenomena	Diagnosis	ICD-9-CM
368.2	Diplopia	Diagnosis	ICD-9-CM
368.3	Other disorders of binocular vision	Diagnosis	ICD-9-CM
368.30	Unspecified binocular vision disorder	Diagnosis	ICD-9-CM
368.31	Suppression of binocular vision	Diagnosis	ICD-9-CM
368.32	Simultaneous visual perception without fusion	Diagnosis	ICD-9-CM
368.33	Fusion with defective stereopsis	Diagnosis	ICD-9-CM
368.34	Abnormal retinal correspondence	Diagnosis	ICD-9-CM
368.4	Visual field defects	Diagnosis	ICD-9-CM
368.40	Unspecified visual field defect	Diagnosis	ICD-9-CM
368.41	Scotoma involving central area in visual field	Diagnosis	ICD-9-CM
368.42	Scotoma of blind spot area in visual field	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
368.43	Sector or arcuate defects in visual field	Diagnosis	ICD-9-CM
368.44	Other localized visual field defect	Diagnosis	ICD-9-CM
368.45	Generalized contraction or constriction in visual field	Diagnosis	ICD-9-CM
368.46	Homonymous bilateral field defects in visual field	Diagnosis	ICD-9-CM
368.47	Heteronymous bilateral field defects in visual field	Diagnosis	ICD-9-CM
368.5	Color vision deficiencies	Diagnosis	ICD-9-CM
368.51	Protan defect in color vision	Diagnosis	ICD-9-CM
368.52	Deutan defect in color vision	Diagnosis	ICD-9-CM
368.53	Tritan defect in color vision	Diagnosis	ICD-9-CM
368.55	Acquired color vision deficiencies	Diagnosis	ICD-9-CM
368.59	Other color vision deficiencies	Diagnosis	ICD-9-CM
368.6	Night blindness	Diagnosis	ICD-9-CM
368.60	Unspecified night blindness	Diagnosis	ICD-9-CM
368.62	Acquired night blindness	Diagnosis	ICD-9-CM
368.63	Abnormal dark adaptation curve	Diagnosis	ICD-9-CM
368.69	Other night blindness	Diagnosis	ICD-9-CM
368.8	Other specified visual disturbances	Diagnosis	ICD-9-CM
368.9	Unspecified visual disturbance	Diagnosis	ICD-9-CM
H53.10	Unspecified subjective visual disturbances	Diagnosis	ICD-10-CM
H53.11	Day blindness	Diagnosis	ICD-10-CM
H53.121	Transient visual loss, right eye	Diagnosis	ICD-10-CM
H53.122	Transient visual loss, left eye	Diagnosis	ICD-10-CM
H53.123	Transient visual loss, bilateral	Diagnosis	ICD-10-CM
H53.129	Transient visual loss, unspecified eye	Diagnosis	ICD-10-CM
H53.131	Sudden visual loss, right eye	Diagnosis	ICD-10-CM
H53.132	Sudden visual loss, left eye	Diagnosis	ICD-10-CM
H53.133	Sudden visual loss, bilateral	Diagnosis	ICD-10-CM
H53.139	Sudden visual loss, unspecified eye	Diagnosis	ICD-10-CM
H53.141	Visual discomfort, right eye	Diagnosis	ICD-10-CM
H53.142	Visual discomfort, left eye	Diagnosis	ICD-10-CM
H53.143	Visual discomfort, bilateral	Diagnosis	ICD-10-CM
H53.149	Visual discomfort, unspecified	Diagnosis	ICD-10-CM
H53.15	Visual distortions of shape and size	Diagnosis	ICD-10-CM
H53.19	Other subjective visual disturbances	Diagnosis	ICD-10-CM
H53.2	Diplopia	Diagnosis	ICD-10-CM
H53.30	Unspecified disorder of binocular vision	Diagnosis	ICD-10-CM
H53.31	Abnormal retinal correspondence	Diagnosis	ICD-10-CM
H53.32	Fusion with defective stereopsis	Diagnosis	ICD-10-CM
H53.33	Simultaneous visual perception without fusion	Diagnosis	ICD-10-CM
H53.34	Suppression of binocular vision	Diagnosis	ICD-10-CM
H53.40	Unspecified visual field defects	Diagnosis	ICD-10-CM
H53.411	Scotoma involving central area, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
H53.412	Scotoma involving central area, left eye	Diagnosis	ICD-10-CM
H53.413	Scotoma involving central area, bilateral	Diagnosis	ICD-10-CM
H53.419	Scotoma involving central area, unspecified	Diagnosis	ICD-10-CM
H53.421	Scotoma of blind spot area, right eye	Diagnosis	ICD-10-CM
H53.422	Scotoma of blind spot area, left eye	Diagnosis	ICD-10-CM
H53.423	Scotoma of blind spot area, bilateral	Diagnosis	ICD-10-CM
H53.429	Scotoma of blind spot area, unspecified eye	Diagnosis	ICD-10-CM
H53.431	Sector or arcuate defects, right eye	Diagnosis	ICD-10-CM
H53.432	Sector or arcuate defects, left eye	Diagnosis	ICD-10-CM
H53.433	Sector or arcuate defects, bilateral	Diagnosis	ICD-10-CM
H53.439	Sector or arcuate defects, unspecified eye	Diagnosis	ICD-10-CM
H53.451	Other localized visual field defect, right eye	Diagnosis	ICD-10-CM
H53.452	Other localized visual field defect, left eye	Diagnosis	ICD-10-CM
H53.453	Other localized visual field defect, bilateral	Diagnosis	ICD-10-CM
H53.459	Other localized visual field defect, unspecified eye	Diagnosis	ICD-10-CM
H53.461	Homonymous bilateral field defects, right side	Diagnosis	ICD-10-CM
H53.462	Homonymous bilateral field defects, left side	Diagnosis	ICD-10-CM
H53.469	Homonymous bilateral field defects, unspecified side	Diagnosis	ICD-10-CM
H53.47	Heteronymous bilateral field defects	Diagnosis	ICD-10-CM
H53.481	Generalized contraction of visual field, right	Diagnosis	ICD-10-CM
H53.482	Generalized contraction of visual field, left eye	Diagnosis	ICD-10-CM
H53.483	Generalized contraction of visual field, bilateral	Diagnosis	ICD-10-CM
H53.489	Generalized contraction of visual field, unspecified eye	Diagnosis	ICD-10-CM
H53.50	Unspecified color vision deficiencies	Diagnosis	ICD-10-CM
H53.52	Acquired color vision deficiency	Diagnosis	ICD-10-CM
H53.53	Deuteranomaly	Diagnosis	ICD-10-CM
H53.54	Protanomaly	Diagnosis	ICD-10-CM
H53.55	Tritanomaly	Diagnosis	ICD-10-CM
H53.59	Other color vision deficiencies	Diagnosis	ICD-10-CM
H53.60	Unspecified night blindness	Diagnosis	ICD-10-CM
H53.61	Abnormal dark adaptation curve	Diagnosis	ICD-10-CM
H53.62	Acquired night blindness	Diagnosis	ICD-10-CM
H53.69	Other night blindness	Diagnosis	ICD-10-CM
H53.71	Glare sensitivity	Diagnosis	ICD-10-CM
H53.72	Impaired contrast sensitivity	Diagnosis	ICD-10-CM
H53.8	Other visual disturbances	Diagnosis	ICD-10-CM
H53.9	Unspecified visual disturbance	Diagnosis	ICD-10-CM
R44.1	Visual hallucinations	Diagnosis	ICD-10-CM
365.1	Open-angle glaucoma	Diagnosis	ICD-9-CM
365.10	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
365.14	Open-angle glaucoma of childhood	Diagnosis	ICD-9-CM
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM
365.3	Corticosteroid-induced glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM
365.32	Corticosteroid-induced glaucoma, residual	Diagnosis	ICD-9-CM
365.7	Glaucoma stage	Diagnosis	ICD-9-CM
365.70	Glaucoma stage, unspecified	Diagnosis	ICD-9-CM
365.71	Mild stage glaucoma	Diagnosis	ICD-9-CM
365.72	Moderate stage glaucoma	Diagnosis	ICD-9-CM
365.73	Severe stage glaucoma	Diagnosis	ICD-9-CM
365.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
G8306	Primary open-angle glaucoma patient with intraocular pressure above the target range goal documented to have received plan of care	Procedure	HCPCS
G8307	Primary open-angle glaucoma patient with intraocular pressure at or below goal, no plan of care necessary	Procedure	HCPCS
G8308	Primary open-angle glaucoma patient with intraocular pressure above the target range goal, and not documented to have received plan of care during the reporting year	Procedure	HCPCS
H40.1	Open-angle glaucoma	Diagnosis	ICD-10-CM
H40.10	Unspecified open-angle glaucoma	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.11	Primary open-angle glaucoma	Diagnosis	ICD-10-CM
H40.111	Primary open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.112	Primary open-angle glaucoma, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.113	Primary open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.119	Primary open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.12	Low-tension glaucoma	Diagnosis	ICD-10-CM
H40.121	Low-tension glaucoma, right eye	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.122	Low-tension glaucoma, left eye	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.123	Low-tension glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.129	Low-tension glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.15	Residual stage of open-angle glaucoma	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
	Glaucoma		
H40.152	Residual stage of open-angle glaucoma, left	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma,	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.6	Glaucoma secondary to drugs	Diagnosis	ICD-10-CM
H40.60	Glaucoma secondary to drugs, unspecified eye	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61	Glaucoma secondary to drugs, right eye	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62	Glaucoma secondary to drugs, left eye	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63	Glaucoma secondary to drugs, bilateral	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H44.51	Absolute glaucoma	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.23	Glaucomatous optic atrophy	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
	Nasal Septal Perforation		
30220	Insertion Nasal Septal Prosthesis Button	Procedure	CPT-4
30630	Repair nasal septal perforations	Procedure	CPT-4
L8047	Nasal Septal Prosthesis	Procedure	HCPCS
	Ocular Hypertension		
365.0	Borderline glaucoma (glaucoma suspect)	Diagnosis	ICD-9-CM
365.00	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM
365.05	Open angle with borderline findings, high risk	Diagnosis	ICD-9-CM
H40.00	Preglaucoma, unspecified	Diagnosis	ICD-10-CM
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.01	Open angle with borderline findings, low risk	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.02	Open angle with borderline findings, high risk	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.04	Steroid responder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.05	Ocular hypertension	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
	Cataracts		
085J3ZZ	Destruction of Right Lens, Percutaneous Approach	Procedure	ICD-10-PCS
085K3ZZ	Destruction of Left Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08BJ3ZZ	Excision of Right Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08BK3ZZ	Excision of Left Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08DJ3ZZ	Extraction of Right Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08DK3ZZ	Extraction of Left Lens, Percutaneous Approach	Procedure	ICD-10-PCS
13.41	Phacoemulsification and aspiration of cataract	Procedure	ICD-9-CM
13.42	Mechanical phacofragmentation and aspiration of cataract by posterior	Procedure	ICD-9-CM
13.43	Mechanical phacofragmentation and other aspiration of cataract	Procedure	ICD-9-CM
13.6	Other cataract extraction	Procedure	ICD-9-CM
13.64	Discission of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.65	Excision of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.66	Mechanical fragmentation of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.69	Other cataract extraction	Procedure	ICD-9-CM
366	Cataract	Diagnosis	ICD-9-CM
366.00	Unspecified nonsenile cataract	Diagnosis	ICD-9-CM
366.01	Anterior subcapsular polar cataract, nonsenile	Diagnosis	ICD-9-CM
366.02	Posterior subcapsular polar cataract, nonsenile	Diagnosis	ICD-9-CM
366.03	Cortical, lamellar, or zonular cataract, nonsenile	Diagnosis	ICD-9-CM
366.04	Nuclear cataract, nonsenile	Diagnosis	ICD-9-CM
366.09	Other and combined forms of nonsenile cataract	Diagnosis	ICD-9-CM
366.1	Senile cataract	Diagnosis	ICD-9-CM
366.10	Unspecified senile cataract	Diagnosis	ICD-9-CM
366.11	Pseudoexfoliation of lens capsule	Diagnosis	ICD-9-CM
366.12	Incipient cataract	Diagnosis	ICD-9-CM
366.13	Anterior subcapsular polar senile cataract	Diagnosis	ICD-9-CM
366.14	Posterior subcapsular polar senile cataract	Diagnosis	ICD-9-CM
366.15	Cortical senile cataract	Diagnosis	ICD-9-CM
366.16	Nuclear sclerosis	Diagnosis	ICD-9-CM
366.17	Total or mature senile cataract	Diagnosis	ICD-9-CM
366.18	Hypermature senile cataract	Diagnosis	ICD-9-CM
366.19	Other and combined forms of senile cataract	Diagnosis	ICD-9-CM
366.2	Traumatic cataract	Diagnosis	ICD-9-CM
366.20	Unspecified traumatic cataract	Diagnosis	ICD-9-CM
366.21	Localized traumatic opacities of cataract	Diagnosis	ICD-9-CM
366.22	Total traumatic cataract	Diagnosis	ICD-9-CM
366.23	Partially resolved traumatic cataract	Diagnosis	ICD-9-CM
366.3	Cataract secondary to ocular disorders	Diagnosis	ICD-9-CM
366.30	Unspecified cataracta complicata	Diagnosis	ICD-9-CM
366.31	Cataract secondary to glaucomatous flecks (subcapsular)	Diagnosis	ICD-9-CM
366.32	Cataract in inflammatory ocular disorders	Diagnosis	ICD-9-CM
366.33	Cataract with ocular neovascularization	Diagnosis	ICD-9-CM
366.34	Cataract in degenerative ocular disorders	Diagnosis	ICD-9-CM
366.4	Cataract associated with other disorders	Diagnosis	ICD-9-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
366.50	Unspecified after-cataract	Diagnosis	ICD-9-CM
366.52	Other after-cataract, not obscuring vision	Diagnosis	ICD-9-CM
366.53	After-cataract, obscuring vision	Diagnosis	ICD-9-CM
366.8	Other cataract	Diagnosis	ICD-9-CM
366.9	Unspecified cataract	Diagnosis	ICD-9-CM
65860	Severing adhesions of anterior segment, laser technique (separate	Procedure	CPT-4
66820	Discission of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid); stab incision technique (Ziegler or Wheeler knife)	Procedure	CPT-4
66821	Discission of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid); laser surgery (eg, YAG laser) (1 or more stages)	Procedure	CPT-4
66825	Repositioning of intraocular lens prosthesis, requiring an incision (separate procedure)	Procedure	CPT-4
66830	Removal of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid) with corneo-scleral section, with or without iridectomy (iridocapsulotomy, iridocapsulectomy)	Procedure	CPT-4
66840	Removal of lens material; aspiration technique, 1 or more stages	Procedure	CPT-4
66850	Removal of lens material; phacofragmentation technique (mechanical or ultrasonic) (eg, phacoemulsification), with aspiration	Procedure	CPT-4
66852	Removal of lens material; pars plana approach, with or without vitrectomy	Procedure	CPT-4
66920	Removal of lens material; intracapsular	Procedure	CPT-4
66930	Removal of lens material; intracapsular, for dislocated lens	Procedure	CPT-4
66940	Removal of lens material; extracapsular (other than 66840, 66850, 66852)	Procedure	CPT-4
66982	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage	Procedure	CPT-4
66983	Intracapsular cataract extraction with insertion of intraocular lens prosthesis (1 stage procedure)	Procedure	CPT-4
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification)	Procedure	CPT-4
H25.011	Cortical age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.012	Cortical age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.013	Cortical age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.019	Cortical age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.031	Anterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.032	Anterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.033	Anterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.039	Anterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.041	Posterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
H25.042	Posterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.043	Posterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.049	Posterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.091	Other age-related incipient cataract, right eye	Diagnosis	ICD-10-CM
H25.092	Other age-related incipient cataract, left eye	Diagnosis	ICD-10-CM
H25.093	Other age-related incipient cataract, bilateral	Diagnosis	ICD-10-CM
H25.099	Other age-related incipient cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.10	Age-related nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.11	Age-related nuclear cataract, right eye	Diagnosis	ICD-10-CM
H25.12	Age-related nuclear cataract, left eye	Diagnosis	ICD-10-CM
H25.13	Age-related nuclear cataract, bilateral	Diagnosis	ICD-10-CM
H25.20	Age-related cataract, morgagnian type, unspecified eye	Diagnosis	ICD-10-CM
H25.21	Age-related cataract, morgagnian type, right eye	Diagnosis	ICD-10-CM
H25.22	Age-related cataract, morgagnian type, left eye	Diagnosis	ICD-10-CM
H25.23	Age-related cataract, morgagnian type, bilateral	Diagnosis	ICD-10-CM
H25.811	Combined forms of age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.812	Combined forms of age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.813	Combined forms of age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.819	Combined forms of age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.89	Other age-related cataract	Diagnosis	ICD-10-CM
H25.9	Unspecified age-related cataract	Diagnosis	ICD-10-CM
H26.001	Unspecified infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.002	Unspecified infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.003	Unspecified infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.009	Unspecified infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.011	Infantile and juvenile cortical, lamellar, or zonular cataract, right eye	Diagnosis	ICD-10-CM
H26.012	Infantile and juvenile cortical, lamellar, or zonular cataract, left eye	Diagnosis	ICD-10-CM
H26.013	Infantile and juvenile cortical, lamellar, or zonular cataract, bilateral	Diagnosis	ICD-10-CM
H26.019	Infantile and juvenile cortical, lamellar, or zonular cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.031	Infantile and juvenile nuclear cataract, right eye	Diagnosis	ICD-10-CM
H26.032	Infantile and juvenile nuclear cataract, left eye	Diagnosis	ICD-10-CM
H26.033	Infantile and juvenile nuclear cataract, bilateral	Diagnosis	ICD-10-CM
H26.039	Infantile and juvenile nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.041	Anterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.042	Anterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.043	Anterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.049	Anterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.051	Posterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.052	Posterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.053	Posterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.059	Posterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.061	Combined forms of infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.062	Combined forms of infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.063	Combined forms of infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.069	Combined forms of infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
H26.09	Other infantile and juvenile cataract	Diagnosis	ICD-10-CM
H26.101	Unspecified traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.102	Unspecified traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.103	Unspecified traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.109	Unspecified traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.111	Localized traumatic opacities, right eye	Diagnosis	ICD-10-CM
H26.112	Localized traumatic opacities, left eye	Diagnosis	ICD-10-CM
H26.113	Localized traumatic opacities, bilateral	Diagnosis	ICD-10-CM
H26.119	Localized traumatic opacities, unspecified eye	Diagnosis	ICD-10-CM
H26.121	Partially resolved traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.122	Partially resolved traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.123	Partially resolved traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.129	Partially resolved traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.131	Total traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.132	Total traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.133	Total traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.139	Total traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.20	Unspecified complicated cataract	Diagnosis	ICD-10-CM
H26.211	Cataract with neovascularization, right eye	Diagnosis	ICD-10-CM
H26.212	Cataract with neovascularization, left eye	Diagnosis	ICD-10-CM
H26.213	Cataract with neovascularization, bilateral	Diagnosis	ICD-10-CM
H26.219	Cataract with neovascularization, unspecified eye	Diagnosis	ICD-10-CM
H26.221	Cataract secondary to ocular disorders (degenerative) (inflammatory), right eye	Diagnosis	ICD-10-CM
H26.222	Cataract secondary to ocular disorders (degenerative) (inflammatory), left	Diagnosis	ICD-10-CM
H26.223	Cataract secondary to ocular disorders (degenerative) (inflammatory), bilateral	Diagnosis	ICD-10-CM
H26.229	Cataract secondary to ocular disorders (degenerative) (inflammatory), unspecified eye	Diagnosis	ICD-10-CM
H26.231	Glaucomatous flecks (subcapsular), right eye	Diagnosis	ICD-10-CM
H26.232	Glaucomatous flecks (subcapsular), left eye	Diagnosis	ICD-10-CM
H26.233	Glaucomatous flecks (subcapsular), bilateral	Diagnosis	ICD-10-CM
H26.239	Glaucomatous flecks (subcapsular), unspecified eye	Diagnosis	ICD-10-CM
H26.30	Drug-induced cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.31	Drug-induced cataract, right eye	Diagnosis	ICD-10-CM
H26.32	Drug-induced cataract, left eye	Diagnosis	ICD-10-CM
H26.33	Drug-induced cataract, bilateral	Diagnosis	ICD-10-CM
H26.40	Unspecified secondary cataract	Diagnosis	ICD-10-CM
H26.491	Other secondary cataract, right eye	Diagnosis	ICD-10-CM
H26.492	Other secondary cataract, left eye	Diagnosis	ICD-10-CM
H26.493	Other secondary cataract, bilateral	Diagnosis	ICD-10-CM
H26.499	Other secondary cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.8	Other specified cataract	Diagnosis	ICD-10-CM
H26.9	Unspecified cataract	Diagnosis	ICD-10-CM
H28	Cataract in diseases classified elsewhere	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
	Cataract Surgery		
085J3ZZ	Destruction of Right Lens, Percutaneous Approach	Procedure	ICD-10-PCS
085K3ZZ	Destruction of Left Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08BJ3ZZ	Excision of Right Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08BK3ZZ	Excision of Left Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08DJ3ZZ	Extraction of Right Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08DK3ZZ	Extraction of Left Lens, Percutaneous Approach	Procedure	ICD-10-PCS
13.41	Phacoemulsification and aspiration of cataract	Procedure	ICD-9-CM
13.42	Mechanical phacofragmentation and aspiration of cataract by posterior	Procedure	ICD-9-CM
13.43	Mechanical phacofragmentation and other aspiration of cataract	Procedure	ICD-9-CM
13.6	Other cataract extraction	Procedure	ICD-9-CM
13.64	Discission of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.65	Excision of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.66	Mechanical fragmentation of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.69	Other cataract extraction	Procedure	ICD-9-CM
65860	Severing adhesions of anterior segment, laser technique (separate	Procedure	CPT-4
66820	Discission of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid); stab incision technique (Ziegler or Wheeler knife)	Procedure	CPT-4
66821	Discission of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid); laser surgery (eg, YAG laser) (1 or more stages)	Procedure	CPT-4
66825	Repositioning of intraocular lens prosthesis, requiring an incision (separate procedure)	Procedure	CPT-4
66830	Removal of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid) with corneo-scleral section, with or without iridectomy (iridocapsulotomy, iridocapsulectomy)	Procedure	CPT-4
66840	Removal of lens material; aspiration technique, 1 or more stages	Procedure	CPT-4
66850	Removal of lens material; phacofragmentation technique (mechanical or ultrasonic) (eg, phacoemulsification), with aspiration	Procedure	CPT-4
66852	Removal of lens material; pars plana approach, with or without vitrectomy	Procedure	CPT-4
66920	Removal of lens material; intracapsular	Procedure	CPT-4
66930	Removal of lens material; intracapsular, for dislocated lens	Procedure	CPT-4
66940	Removal of lens material; extracapsular (other than 66840, 66850, 66852)	Procedure	CPT-4
66982	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage	Procedure	CPT-4
66983	Intracapsular cataract extraction with insertion of intraocular lens prosthesis (1 stage procedure)	Procedure	CPT-4
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification)	Procedure	CPT-4

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
	Diminished Visual Acuity		
368.1	Subjective visual disturbances	Diagnosis	ICD-9-CM
368.10	Unspecified subjective visual disturbance	Diagnosis	ICD-9-CM
368.11	Sudden visual loss	Diagnosis	ICD-9-CM
368.12	Transient visual loss	Diagnosis	ICD-9-CM
368.13	Visual discomfort	Diagnosis	ICD-9-CM
368.14	Visual distortions of shape and size	Diagnosis	ICD-9-CM
368.15	Other visual distortions and entoptic phenomena	Diagnosis	ICD-9-CM
368.2	Diplopia	Diagnosis	ICD-9-CM
368.3	Other disorders of binocular vision	Diagnosis	ICD-9-CM
368.30	Unspecified binocular vision disorder	Diagnosis	ICD-9-CM
368.31	Suppression of binocular vision	Diagnosis	ICD-9-CM
368.32	Simultaneous visual perception without fusion	Diagnosis	ICD-9-CM
368.33	Fusion with defective stereopsis	Diagnosis	ICD-9-CM
368.34	Abnormal retinal correspondence	Diagnosis	ICD-9-CM
368.4	Visual field defects	Diagnosis	ICD-9-CM
368.40	Unspecified visual field defect	Diagnosis	ICD-9-CM
368.41	Scotoma involving central area in visual field	Diagnosis	ICD-9-CM
368.42	Scotoma of blind spot area in visual field	Diagnosis	ICD-9-CM
368.43	Sector or arcuate defects in visual field	Diagnosis	ICD-9-CM
368.44	Other localized visual field defect	Diagnosis	ICD-9-CM
368.45	Generalized contraction or constriction in visual field	Diagnosis	ICD-9-CM
368.46	Homonymous bilateral field defects in visual field	Diagnosis	ICD-9-CM
368.47	Heteronymous bilateral field defects in visual field	Diagnosis	ICD-9-CM
368.5	Color vision deficiencies	Diagnosis	ICD-9-CM
368.51	Protan defect in color vision	Diagnosis	ICD-9-CM
368.52	Deutan defect in color vision	Diagnosis	ICD-9-CM
368.53	Tritan defect in color vision	Diagnosis	ICD-9-CM
368.55	Acquired color vision deficiencies	Diagnosis	ICD-9-CM
368.59	Other color vision deficiencies	Diagnosis	ICD-9-CM
368.6	Night blindness	Diagnosis	ICD-9-CM
368.60	Unspecified night blindness	Diagnosis	ICD-9-CM
368.62	Acquired night blindness	Diagnosis	ICD-9-CM
368.63	Abnormal dark adaptation curve	Diagnosis	ICD-9-CM
368.69	Other night blindness	Diagnosis	ICD-9-CM
368.8	Other specified visual disturbances	Diagnosis	ICD-9-CM
368.9	Unspecified visual disturbance	Diagnosis	ICD-9-CM
H53.10	Unspecified subjective visual disturbances	Diagnosis	ICD-10-CM
H53.11	Day blindness	Diagnosis	ICD-10-CM
H53.121	Transient visual loss, right eye	Diagnosis	ICD-10-CM
H53.122	Transient visual loss, left eye	Diagnosis	ICD-10-CM
H53.123	Transient visual loss, bilateral	Diagnosis	ICD-10-CM
H53.129	Transient visual loss, unspecified eye	Diagnosis	ICD-10-CM
H53.131	Sudden visual loss, right eye	Diagnosis	ICD-10-CM
H53.132	Sudden visual loss, left eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
H53.133	Sudden visual loss, bilateral	Diagnosis	ICD-10-CM
H53.139	Sudden visual loss, unspecified eye	Diagnosis	ICD-10-CM
H53.141	Visual discomfort, right eye	Diagnosis	ICD-10-CM
H53.142	Visual discomfort, left eye	Diagnosis	ICD-10-CM
H53.143	Visual discomfort, bilateral	Diagnosis	ICD-10-CM
H53.149	Visual discomfort, unspecified	Diagnosis	ICD-10-CM
H53.15	Visual distortions of shape and size	Diagnosis	ICD-10-CM
H53.19	Other subjective visual disturbances	Diagnosis	ICD-10-CM
H53.2	Diplopia	Diagnosis	ICD-10-CM
H53.30	Unspecified disorder of binocular vision	Diagnosis	ICD-10-CM
H53.31	Abnormal retinal correspondence	Diagnosis	ICD-10-CM
H53.32	Fusion with defective stereopsis	Diagnosis	ICD-10-CM
H53.33	Simultaneous visual perception without fusion	Diagnosis	ICD-10-CM
H53.34	Suppression of binocular vision	Diagnosis	ICD-10-CM
H53.40	Unspecified visual field defects	Diagnosis	ICD-10-CM
H53.411	Scotoma involving central area, right eye	Diagnosis	ICD-10-CM
H53.412	Scotoma involving central area, left eye	Diagnosis	ICD-10-CM
H53.413	Scotoma involving central area, bilateral	Diagnosis	ICD-10-CM
H53.419	Scotoma involving central area, unspecified eye	Diagnosis	ICD-10-CM
H53.421	Scotoma of blind spot area, right eye	Diagnosis	ICD-10-CM
H53.422	Scotoma of blind spot area, left eye	Diagnosis	ICD-10-CM
H53.423	Scotoma of blind spot area, bilateral	Diagnosis	ICD-10-CM
H53.429	Scotoma of blind spot area, unspecified eye	Diagnosis	ICD-10-CM
H53.431	Sector or arcuate defects, right eye	Diagnosis	ICD-10-CM
H53.432	Sector or arcuate defects, left eye	Diagnosis	ICD-10-CM
H53.433	Sector or arcuate defects, bilateral	Diagnosis	ICD-10-CM
H53.439	Sector or arcuate defects, unspecified eye	Diagnosis	ICD-10-CM
H53.451	Other localized visual field defect, right eye	Diagnosis	ICD-10-CM
H53.452	Other localized visual field defect, left eye	Diagnosis	ICD-10-CM
H53.453	Other localized visual field defect, bilateral	Diagnosis	ICD-10-CM
H53.459	Other localized visual field defect, unspecified eye	Diagnosis	ICD-10-CM
H53.461	Homonymous bilateral field defects, right side	Diagnosis	ICD-10-CM
H53.462	Homonymous bilateral field defects, left side	Diagnosis	ICD-10-CM
H53.469	Homonymous bilateral field defects, unspecified side	Diagnosis	ICD-10-CM
H53.47	Heteronymous bilateral field defects	Diagnosis	ICD-10-CM
H53.481	Generalized contraction of visual field, right eye	Diagnosis	ICD-10-CM
H53.482	Generalized contraction of visual field, left eye	Diagnosis	ICD-10-CM
H53.483	Generalized contraction of visual field, bilateral	Diagnosis	ICD-10-CM
H53.489	Generalized contraction of visual field, unspecified eye	Diagnosis	ICD-10-CM
H53.50	Unspecified color vision deficiencies	Diagnosis	ICD-10-CM
H53.52	Acquired color vision deficiency	Diagnosis	ICD-10-CM
H53.53	Deuteranomaly	Diagnosis	ICD-10-CM
H53.54	Protanomaly	Diagnosis	ICD-10-CM
H53.55	Tritanomaly	Diagnosis	ICD-10-CM
H53.59	Other color vision deficiencies	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
H53.60	Unspecified night blindness	Diagnosis	ICD-10-CM
H53.61	Abnormal dark adaptation curve	Diagnosis	ICD-10-CM
H53.62	Acquired night blindness	Diagnosis	ICD-10-CM
H53.69	Other night blindness	Diagnosis	ICD-10-CM
H53.71	Glare sensitivity	Diagnosis	ICD-10-CM
H53.72	Impaired contrast sensitivity	Diagnosis	ICD-10-CM
H53.8	Other visual disturbances	Diagnosis	ICD-10-CM
H53.9	Unspecified visual disturbance	Diagnosis	ICD-10-CM
R44.1	Visual hallucinations	Diagnosis	ICD-10-CM
	Eye Laser Surgery		
65860	Severing adhesions of anterior segment, laser technique (separate	Procedure	CPT-4
66761	Iridotomy/iridectomy by laser surgery (eg, for glaucoma) (per session)	Procedure	CPT-4
66821	Discission of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid); laser surgery (eg, YAG laser) (1 or more stages)	Procedure	CPT-4
67031	Severing of vitreous strands, vitreous face adhesions, sheets, membranes or opacities, laser surgery (1 or more stages)	Procedure	CPT-4
67039	Vitrectomy, mechanical, pars plana approach; with focal endolaser photocoagulation	Procedure	CPT-4
67040	Vitrectomy, mechanical, pars plana approach; with endolaser panretinal photocoagulation	Procedure	CPT-4
67043	Vitrectomy, mechanical, pars plana approach; with removal of subretinal membrane (eg, choroidal neovascularization), includes, if performed, intraocular tamponade (ie, air, gas or silicone oil) and laser photocoagulation	Procedure	CPT-4
67108	Repair of retinal detachment; with vitrectomy, any method, including, when performed, air or gas tamponade, focal endolaser photocoagulation, cryotherapy, drainage of subretinal fluid, scleral buckling, and/or removal of lens by same technique	Procedure	CPT-4
67113	Repair of complex retinal detachment (eg, proliferative vitreoretinopathy, stage C-1 or greater, diabetic traction retinal detachment, retinopathy of prematurity, retinal tear of greater than 90 degrees), with vitrectomy and membrane peeling, including, when performed, air, gas, or silicone oil tamponade, cryotherapy, endolaser photocoagulation, drainage of subretinal fluid, scleral buckling, and/or removal of lens	Procedure	CPT-4
67145	Prophylaxis of retinal detachment (eg, retinal break, lattice degeneration) without drainage, 1 or more sessions; photocoagulation (laser or xenon arc)	Procedure	CPT-4
67220	Destruction of localized lesion of choroid (eg, choroidal neovascularization); photocoagulation (eg, laser), 1 or more sessions	Procedure	CPT-4
67825	Correction of trichiasis; epilation by other than forceps (eg, by electrosurgery, cryotherapy, laser surgery)	Procedure	CPT-4
68760	Closure of the lacrimal punctum; by thermocauterization, ligation, or laser surgery	Procedure	CPT-4
	Glaucoma		
365.1	Open-angle glaucoma	Diagnosis	ICD-9-CM
365.10	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM
365.13	Pigmentary open-angle glaucoma	Diagnosis	ICD-9-CM
365.14	Open-angle glaucoma of childhood	Diagnosis	ICD-9-CM
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM
365.2	Primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.21	Intermittent angle-closure glaucoma	Diagnosis	ICD-9-CM
365.22	Acute angle-closure glaucoma	Diagnosis	ICD-9-CM
365.23	Chronic angle-closure glaucoma	Diagnosis	ICD-9-CM
365.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-9-CM
365.3	Corticosteroid-induced glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM
365.32	Corticosteroid-induced glaucoma, residual stage	Diagnosis	ICD-9-CM
365.4	Glaucoma associated with congenital anomalies, dystrophies, and systemic syndromes	Diagnosis	ICD-9-CM
365.41	Glaucoma associated with chamber angle anomalies	Diagnosis	ICD-9-CM
365.42	Glaucoma associated with anomalies of iris	Diagnosis	ICD-9-CM
365.43	Glaucoma associated with other anterior segment anomalies	Diagnosis	ICD-9-CM
365.44	Glaucoma associated with systemic syndromes	Diagnosis	ICD-9-CM
365.5	Glaucoma associated with disorders of the lens	Diagnosis	ICD-9-CM
365.51	Phacolytic glaucoma	Diagnosis	ICD-9-CM
365.52	Pseudoexfoliation glaucoma	Diagnosis	ICD-9-CM
365.59	Glaucoma associated with other lens disorders	Diagnosis	ICD-9-CM
365.6	Glaucoma associated with other ocular disorders	Diagnosis	ICD-9-CM
365.60	Glaucoma associated with unspecified ocular disorder	Diagnosis	ICD-9-CM
365.61	Glaucoma associated with pupillary block	Diagnosis	ICD-9-CM
365.62	Glaucoma associated with ocular inflammations	Diagnosis	ICD-9-CM
365.63	Glaucoma associated with vascular disorders of eye	Diagnosis	ICD-9-CM
365.64	Glaucoma associated with tumors or cysts	Diagnosis	ICD-9-CM
365.65	Glaucoma associated with ocular trauma	Diagnosis	ICD-9-CM
365.7	Glaucoma stage	Diagnosis	ICD-9-CM
365.70	Glaucoma stage, unspecified	Diagnosis	ICD-9-CM
365.71	Mild stage glaucoma	Diagnosis	ICD-9-CM
365.72	Moderate stage glaucoma	Diagnosis	ICD-9-CM
365.73	Severe stage glaucoma	Diagnosis	ICD-9-CM
365.74	Indeterminate stage glaucoma	Diagnosis	ICD-9-CM
365.8	Other specified forms of glaucoma	Diagnosis	ICD-9-CM
365.81	Hypersecretion glaucoma	Diagnosis	ICD-9-CM
365.82	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-9-CM
365.83	Aqueous misdirection	Diagnosis	ICD-9-CM
365.89	Other specified glaucoma	Diagnosis	ICD-9-CM
365.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
G8306	Primary open-angle glaucoma patient with intraocular pressure above the target range goal documented to have received plan of care	Procedure	HCPCS

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
G8307	Primary open-angle glaucoma patient with intraocular pressure at or below goal, no plan of care necessary	Procedure	HCPCS
G8308	Primary open-angle glaucoma patient with intraocular pressure above the target range goal, and not documented to have received plan of care during the reporting year	Procedure	HCPCS
H26.23	Glaucomatous flecks (subcapsular)	Diagnosis	ICD-10-CM
H26.231	Glaucomatous flecks (subcapsular), right eye	Diagnosis	ICD-10-CM
H26.232	Glaucomatous flecks (subcapsular), left eye	Diagnosis	ICD-10-CM
H26.233	Glaucomatous flecks (subcapsular), bilateral	Diagnosis	ICD-10-CM
H26.239	Glaucomatous flecks (subcapsular), unspecified eye	Diagnosis	ICD-10-CM
H40.03	Anatomical narrow angle	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.1	Open-angle glaucoma	Diagnosis	ICD-10-CM
H40.10	Unspecified open-angle glaucoma	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.11	Primary open-angle glaucoma	Diagnosis	ICD-10-CM
H40.111	Primary open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.112	Primary open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.113	Primary open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.119	Primary open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.12	Low-tension glaucoma	Diagnosis	ICD-10-CM
H40.121	Low-tension glaucoma, right eye	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.122	Low-tension glaucoma, left eye	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.123	Low-tension glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.129	Low-tension glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.13	Pigmentary glaucoma	Diagnosis	ICD-10-CM
H40.131	Pigmentary glaucoma, right eye	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.132	Pigmentary glaucoma, left eye	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.133	Pigmentary glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.139	Pigmentary glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.14	Capsular glaucoma with pseudoexfoliation of lens	Diagnosis	ICD-10-CM
H40.141	Capsular glaucoma with pseudoexfoliation of lens, right eye	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.142	Capsular glaucoma with pseudoexfoliation of lens, left eye	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.143	Capsular glaucoma with pseudoexfoliation of lens, bilateral	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.149	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.15	Residual stage of open-angle glaucoma	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2	Primary angle-closure glaucoma	Diagnosis	ICD-10-CM
H40.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.21	Acute angle-closure glaucoma	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.22	Chronic angle-closure glaucoma	Diagnosis	ICD-10-CM
H40.221	Chronic angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.222	Chronic angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.223	Chronic angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.229	Chronic angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.23	Intermittent angle-closure glaucoma	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.3	Glaucoma secondary to eye trauma	Diagnosis	ICD-10-CM
H40.30	Glaucoma secondary to eye trauma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31	Glaucoma secondary to eye trauma, right eye	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32	Glaucoma secondary to eye trauma, left eye	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33	Glaucoma secondary to eye trauma, bilateral	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.4	Glaucoma secondary to eye inflammation	Diagnosis	ICD-10-CM
H40.40	Glaucoma secondary to eye inflammation, unspecified eye	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41	Glaucoma secondary to eye inflammation, right eye	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.42	Glaucoma secondary to eye inflammation, left eye	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43	Glaucoma secondary to eye inflammation, bilateral	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.5	Glaucoma secondary to other eye disorders	Diagnosis	ICD-10-CM
H40.50	Glaucoma secondary to other eye disorders, unspecified eye	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51	Glaucoma secondary to other eye disorders, right eye	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52	Glaucoma secondary to other eye disorders, left eye	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53	Glaucoma secondary to other eye disorders, bilateral	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.6	Glaucoma secondary to drugs	Diagnosis	ICD-10-CM
H40.60	Glaucoma secondary to drugs, unspecified eye	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61	Glaucoma secondary to drugs, right eye	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62	Glaucoma secondary to drugs, left eye	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63	Glaucoma secondary to drugs, bilateral	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.8	Other glaucoma	Diagnosis	ICD-10-CM
H40.81	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.82	Hypersecretion glaucoma	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.83	Aqueous misdirection	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.51	Absolute glaucoma	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.23	Glaucomatous optic atrophy	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
	Nasal Septal Perforation		
30220	Insertion Nasal Septal Prosthesis Button	Procedure	CPT-4
30630	Repair nasal septal perforations	Procedure	CPT-4
L8047	Nasal Septal Prosthesis	Procedure	HCPCS
	Ocular Hypertension		
365.0	Borderline glaucoma (glaucoma suspect)	Diagnosis	ICD-9-CM
365.00	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM
365.05	Open angle with borderline findings, high risk	Diagnosis	ICD-9-CM
H40.00	Preglaucoma, unspecified	Diagnosis	ICD-10-CM
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.01	Open angle with borderline findings, low risk	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.02	Open angle with borderline findings, high risk	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.04	Steroid responder	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.05	Ocular hypertension	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
	Trabeculoplasty		
65855	Trabeculoplasty by laser surgery	Procedure	CPT-4

Appendix F. List of Generic and Brand Names of Medical Products Used to Define Inclusion Criteria in this Request

Generic Name	Brand Name
Glaucoma	
apraclonidine HCl	Iopidine
apraclonidine HCl	apraclonidine
betaxolol HCl	Betoptic S
betaxolol HCl	betaxolol
bimatoprost	Durysta
bimatoprost	Lumigan
bimatoprost	bimatoprost
brimonidine tartrate	Alphagan P
brimonidine tartrate	Lumify
brimonidine tartrate	brimonidine
brimonidine tartrate/dorzolamide HCl/PF	brimonidine-dorzolamide (PF)
brimonidine tartrate/timolol maleate	Combigan
brimonidine tartrate/timolol maleate	brimonidine-timolol
brinzolamide	Azopt
brinzolamide	brinzolamide
brinzolamide/brimonidine tartrate	Simbrinza
carteolol HCl	carteolol
dorzolamide HCl	Trusopt
dorzolamide HCl	dorzolamide
dorzolamide HCl/PF	dorzolamide (PF)
dorzolamide HCl/timolol maleate	Cosopt
dorzolamide HCl/timolol maleate	dorzolamide-timolol
dorzolamide HCl/timolol maleate/PF	Cosopt (PF)
dorzolamide HCl/timolol maleate/PF	dorzolamide-timolol (PF)
echothiophate iodide	Phospholine Iodide
latanoprost	Xalatan
latanoprost	Xelpros
latanoprost	latanoprost
latanoprost/PF	latanoprost (PF)
latanoprostene bunod	Vyzulta
levobunolol HCl	Betagan
levobunolol HCl	levobunolol
methazolamide	Neptazane
methazolamide	methazolamide
metipranolol	metipranolol
netarsudil mesylate	Rhopressa
netarsudil mesylate/latanoprost	Rocklatan
pilocarpine HCl	Isopto Carpine
pilocarpine HCl	pilocarpine HCl
tafluprost/PF	Zioptan (PF)
timolol	Betimol
timolol maleate	Istalol
timolol maleate	Timoptic
timolol maleate	Timoptic-XE
timolol maleate	timolol maleate
timolol maleate/PF	Timoptic Ocudose (PF)
timolol maleate/PF	timolol maleate (PF)

Appendix F. List of Generic and Brand Names of Medical Products Used to Define Inclusion Criteria in this Request

Generic Name	Brand Name
timolol maleate/brimonidine tartrate/dorzolamide HCl/PF	timolol-brimonidi-dorzolam(PF)
timolol maleate/dorzolamide HCl/latanoprost/PF	timolol-dorzolamid-latanop(PF)
timolol maleate/latanoprost/PF	timolol-latanoprost(PF)
travoprost	Travatan Z
travoprost	travoprost
travoprost (benzalkonium)	travoprost (benzalkonium)
unoprostone isopropyl	Rescula

Appendix G. List of Generic and Brand Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Generic Name	Brand Name
Sinuva	
mometasone furoate	Sinuva
Propel	
mometasone furoate 0.37 MG Drug Implant [Propel]	PROPEL
mometasone furoate 0.37 MG Drug Implant [Propel]	PROPEL Contour
mometasone furoate 0.37 MG Drug Implant [Propel]	PROPEL Mini
mometasone furoate 0.37 MG Drug Implant [Propel]	PROPEL Mini SDS

Appendix H. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Exposure Censoring Criteria in this Request

Code	Description	Code Category	Code Type
	Sinuva		
C9122	10 mcg (Sinuva)	Procedure	HCPCS
J7401	10 mcg	Procedure	HCPCS
J7402	(Sinuva), 10 mcg	Procedure	HCPCS
	Propel		
S1090	370 micrograms	Procedure	HCPCS
S1091	delivery system (Propel)	Procedure	HCPCS

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
	Blepharitis		
373.0	Blepharitis	Diagnosis	ICD-9-CM
373.00	Blepharitis, unspecified	Diagnosis	ICD-9-CM
373.01	Ulcerative blepharitis	Diagnosis	ICD-9-CM
373.02	Squamous blepharitis	Diagnosis	ICD-9-CM
H01.0	Blepharitis	Diagnosis	ICD-10-CM
H01.00	Unspecified blepharitis	Diagnosis	ICD-10-CM
H01.001	Unspecified blepharitis right upper eyelid	Diagnosis	ICD-10-CM
H01.002	Unspecified blepharitis right lower eyelid	Diagnosis	ICD-10-CM
H01.003	Unspecified blepharitis right eye, unspecified eyelid	Diagnosis	ICD-10-CM
H01.004	Unspecified blepharitis left upper eyelid	Diagnosis	ICD-10-CM
H01.005	Unspecified blepharitis left lower eyelid	Diagnosis	ICD-10-CM
H01.006	Unspecified blepharitis left eye, unspecified eyelid	Diagnosis	ICD-10-CM
H01.009	Unspecified blepharitis unspecified eye, unspecified eyelid	Diagnosis	ICD-10-CM
H01.00A	Unspecified blepharitis right eye, upper and lower eyelids	Diagnosis	ICD-10-CM
H01.00B	Unspecified blepharitis left eye, upper and lower eyelids	Diagnosis	ICD-10-CM
H01.01	Ulcerative blepharitis	Diagnosis	ICD-10-CM
H01.011	Ulcerative blepharitis right upper eyelid	Diagnosis	ICD-10-CM
H01.012	Ulcerative blepharitis right lower eyelid	Diagnosis	ICD-10-CM
H01.013	Ulcerative blepharitis right eye, unspecified eyelid	Diagnosis	ICD-10-CM
H01.014	Ulcerative blepharitis left upper eyelid	Diagnosis	ICD-10-CM
H01.015	Ulcerative blepharitis left lower eyelid	Diagnosis	ICD-10-CM
H01.016	Ulcerative blepharitis left eye, unspecified eyelid	Diagnosis	ICD-10-CM
H01.019	Ulcerative blepharitis unspecified eye, unspecified eyelid	Diagnosis	ICD-10-CM
H01.01A	Ulcerative blepharitis right eye, upper and lower eyelids	Diagnosis	ICD-10-CM
H01.01B	Ulcerative blepharitis left eye, upper and lower eyelids	Diagnosis	ICD-10-CM
H01.02	Squamous blepharitis	Diagnosis	ICD-10-CM
H01.021	Squamous blepharitis right upper eyelid	Diagnosis	ICD-10-CM
H01.022	Squamous blepharitis right lower eyelid	Diagnosis	ICD-10-CM
H01.023	Squamous blepharitis right eye, unspecified eyelid	Diagnosis	ICD-10-CM
H01.024	Squamous blepharitis left upper eyelid	Diagnosis	ICD-10-CM
H01.025	Squamous blepharitis left lower eyelid	Diagnosis	ICD-10-CM
H01.026	Squamous blepharitis left eye, unspecified eyelid	Diagnosis	ICD-10-CM
H01.029	Squamous blepharitis unspecified eye, unspecified eyelid	Diagnosis	ICD-10-CM
H01.02A	Squamous blepharitis right eye, upper and lower eyelids	Diagnosis	ICD-10-CM
H01.02B	Squamous blepharitis left eye, upper and lower eyelids	Diagnosis	ICD-10-CM
	Cardiovascular Risk Factors		
401.0	Essential hypertension, malignant	Diagnosis	ICD-9-CM
401.1	Essential hypertension, benign	Diagnosis	ICD-9-CM
401.9	Unspecified essential hypertension	Diagnosis	ICD-9-CM
402.00	Malignant hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.10	Benign hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.90	Unspecified hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
403.00	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage	Diagnosis	ICD-9-CM
403.10	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.90	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
405.01	Secondary renovascular hypertension, malignant	Diagnosis	ICD-9-CM
405.09	Other secondary hypertension, malignant	Diagnosis	ICD-9-CM
405.11	Secondary renovascular hypertension, benign	Diagnosis	ICD-9-CM
405.19	Other secondary hypertension, benign	Diagnosis	ICD-9-CM
405.91	Secondary renovascular hypertension, unspecified	Diagnosis	ICD-9-CM
405.99	Other secondary hypertension, unspecified	Diagnosis	ICD-9-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I16.0	Hypertensive urgency	Diagnosis	ICD-10-CM
I16.1	Hypertensive emergency	Diagnosis	ICD-10-CM
I16.9	Hypertensive crisis, unspecified	Diagnosis	ICD-10-CM
	Cardiac and Vascular Diseases		
393	Chronic rheumatic pericarditis	Diagnosis	ICD-9-CM
397	Diseases of other endocardial structures	Diagnosis	ICD-9-CM
397.0	Diseases of tricuspid valve	Diagnosis	ICD-9-CM
397.1	Rheumatic diseases of pulmonary valve	Diagnosis	ICD-9-CM
397.9	Rheumatic diseases of endocardium, valve unspecified	Diagnosis	ICD-9-CM
398	Other rheumatic heart disease	Diagnosis	ICD-9-CM
398.0	Rheumatic myocarditis	Diagnosis	ICD-9-CM
398.9	Other and unspecified rheumatic heart diseases	Diagnosis	ICD-9-CM
398.90	Unspecified rheumatic heart disease	Diagnosis	ICD-9-CM
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
398.99	Other and unspecified rheumatic heart diseases	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
410	Acute myocardial infarction	Diagnosis	ICD-9-CM
410.0	Acute myocardial infarction of anterolateral wall	Diagnosis	ICD-9-CM
410.00	Acute myocardial infarction of anterolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.02	Acute myocardial infarction of anterolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.1	Acute myocardial infarction of other anterior wall	Diagnosis	ICD-9-CM
410.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.2	Acute myocardial infarction of inferolateral wall	Diagnosis	ICD-9-CM
410.20	Acute myocardial infarction of inferolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.22	Acute myocardial infarction of inferolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.3	Acute myocardial infarction of inferoposterior wall	Diagnosis	ICD-9-CM
410.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.4	Acute myocardial infarction of other inferior wall	Diagnosis	ICD-9-CM
410.40	Acute myocardial infarction of other inferior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.5	Acute myocardial infarction of other lateral wall	Diagnosis	ICD-9-CM
410.50	Acute myocardial infarction of other lateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.52	Acute myocardial infarction of other lateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.6	Acute myocardial infarction, true posterior wall infarction	Diagnosis	ICD-9-CM
410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	Diagnosis	ICD-9-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
410.7	Acute myocardial infarction, subendocardial infarction	Diagnosis	ICD-9-CM
410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.8	Acute myocardial infarction of other specified sites	Diagnosis	ICD-9-CM
410.80	Acute myocardial infarction of other specified sites, episode of care unspecified	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.82	Acute myocardial infarction of other specified sites, subsequent episode of care	Diagnosis	ICD-9-CM
410.9	Acute myocardial infarction, unspecified site	Diagnosis	ICD-9-CM
410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
410.92	Acute myocardial infarction, unspecified site, subsequent episode of care	Diagnosis	ICD-9-CM
411	Other acute and subacute forms of ischemic heart disease	Diagnosis	ICD-9-CM
411.0	Postmyocardial infarction syndrome	Diagnosis	ICD-9-CM
411.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
411.8	Other acute and subacute forms of ischemic heart disease	Diagnosis	ICD-9-CM
411.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
411.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
412	Old myocardial infarction	Diagnosis	ICD-9-CM
413	Angina pectoris	Diagnosis	ICD-9-CM
413.0	Angina decubitus	Diagnosis	ICD-9-CM
413.1	Prinzmetal angina	Diagnosis	ICD-9-CM
413.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
414	Other forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.0	Coronary atherosclerosis	Diagnosis	ICD-9-CM
414.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	Diagnosis	ICD-9-CM
414.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
414.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
414.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
414.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	Diagnosis	ICD-9-CM
414.1	Aneurysm and dissection of heart	Diagnosis	ICD-9-CM
414.10	Aneurysm of heart	Diagnosis	ICD-9-CM
414.11	Aneurysm of coronary vessels	Diagnosis	ICD-9-CM
414.12	Dissection of coronary artery	Diagnosis	ICD-9-CM
414.19	Other aneurysm of heart	Diagnosis	ICD-9-CM
414.2	Chronic total occlusion of coronary artery	Diagnosis	ICD-9-CM
414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.9	Unspecified chronic ischemic heart disease	Diagnosis	ICD-9-CM
420	Acute pericarditis	Diagnosis	ICD-9-CM
420.0	Acute pericarditis in diseases classified elsewhere	Diagnosis	ICD-9-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
420.9	Other and unspecified acute pericarditis	Diagnosis	ICD-9-CM
420.90	Unspecified acute pericarditis	Diagnosis	ICD-9-CM
420.91	Acute idiopathic pericarditis	Diagnosis	ICD-9-CM
420.99	Other acute pericarditis	Diagnosis	ICD-9-CM
421	Acute and subacute endocarditis	Diagnosis	ICD-9-CM
421.0	Acute and subacute bacterial endocarditis	Diagnosis	ICD-9-CM
421.1	Acute and subacute infective endocarditis in diseases classified elsewhere	Diagnosis	ICD-9-CM
421.9	Unspecified acute endocarditis	Diagnosis	ICD-9-CM
422	Acute myocarditis	Diagnosis	ICD-9-CM
422.0	Acute myocarditis in diseases classified elsewhere	Diagnosis	ICD-9-CM
422.9	Other and unspecified acute myocarditis	Diagnosis	ICD-9-CM
422.90	Unspecified acute myocarditis	Diagnosis	ICD-9-CM
422.91	Idiopathic myocarditis	Diagnosis	ICD-9-CM
422.92	Septic myocarditis	Diagnosis	ICD-9-CM
422.93	Toxic myocarditis	Diagnosis	ICD-9-CM
422.99	Other acute myocarditis	Diagnosis	ICD-9-CM
423	Other diseases of pericardium	Diagnosis	ICD-9-CM
423.0	Hemopericardium	Diagnosis	ICD-9-CM
423.1	Adhesive pericarditis	Diagnosis	ICD-9-CM
423.2	Constrictive pericarditis	Diagnosis	ICD-9-CM
423.3	Cardiac tamponade	Diagnosis	ICD-9-CM
423.8	Other specified diseases of pericardium	Diagnosis	ICD-9-CM
423.9	Unspecified disease of pericardium	Diagnosis	ICD-9-CM
424	Other diseases of endocardium	Diagnosis	ICD-9-CM
424.0	Mitral valve disorders	Diagnosis	ICD-9-CM
424.1	Aortic valve disorders	Diagnosis	ICD-9-CM
424.2	Tricuspid valve disorders, specified as nonrheumatic	Diagnosis	ICD-9-CM
424.3	Pulmonary valve disorders	Diagnosis	ICD-9-CM
424.9	Endocarditis, valve unspecified	Diagnosis	ICD-9-CM
424.90	Endocarditis, valve unspecified, unspecified cause	Diagnosis	ICD-9-CM
424.91	Endocarditis in diseases classified elsewhere	Diagnosis	ICD-9-CM
424.99	Other endocarditis, valve unspecified	Diagnosis	ICD-9-CM
425	Cardiomyopathy	Diagnosis	ICD-9-CM
425.0	Endomyocardial fibrosis	Diagnosis	ICD-9-CM
425.1	Hypertrophic cardiomyopathy	Diagnosis	ICD-9-CM
425.11	Hypertrophic obstructive cardiomyopathy	Diagnosis	ICD-9-CM
425.18	Other hypertrophic cardiomyopathy	Diagnosis	ICD-9-CM
425.2	Obscure cardiomyopathy of Africa	Diagnosis	ICD-9-CM
425.3	Endocardial fibroelastosis	Diagnosis	ICD-9-CM
425.4	Other primary cardiomyopathies	Diagnosis	ICD-9-CM
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
425.7	Nutritional and metabolic cardiomyopathy	Diagnosis	ICD-9-CM
425.8	Cardiomyopathy in other diseases classified elsewhere	Diagnosis	ICD-9-CM
425.9	Unspecified secondary cardiomyopathy	Diagnosis	ICD-9-CM
427.5	Cardiac arrest	Diagnosis	ICD-9-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
428	Heart failure	Diagnosis	ICD-9-CM
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.2	Systolic heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.3	Diastolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.4	Combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
429	Ill-defined descriptions and complications of heart disease	Diagnosis	ICD-9-CM
429.0	Unspecified myocarditis	Diagnosis	ICD-9-CM
429.1	Myocardial degeneration	Diagnosis	ICD-9-CM
429.2	Unspecified cardiovascular disease	Diagnosis	ICD-9-CM
429.3	Cardiomegaly	Diagnosis	ICD-9-CM
429.4	Functional disturbances following cardiac surgery	Diagnosis	ICD-9-CM
429.5	Rupture of chordae tendineae	Diagnosis	ICD-9-CM
429.6	Rupture of papillary muscle	Diagnosis	ICD-9-CM
429.7	Certain sequelae of myocardial infarction, not elsewhere classified	Diagnosis	ICD-9-CM
429.71	Acquired cardiac septal defect	Diagnosis	ICD-9-CM
429.79	Other certain sequelae of myocardial infarction, not elsewhere classified	Diagnosis	ICD-9-CM
429.8	Other ill-defined heart diseases	Diagnosis	ICD-9-CM
429.81	Other disorders of papillary muscle	Diagnosis	ICD-9-CM
429.82	Hyperkinetic heart disease	Diagnosis	ICD-9-CM
429.83	Takotsubo syndrome	Diagnosis	ICD-9-CM
429.89	Other ill-defined heart disease	Diagnosis	ICD-9-CM
429.9	Unspecified heart disease	Diagnosis	ICD-9-CM
440	Atherosclerosis	Diagnosis	ICD-9-CM
440.0	Atherosclerosis of aorta	Diagnosis	ICD-9-CM
440.1	Atherosclerosis of renal artery	Diagnosis	ICD-9-CM
440.2	Atherosclerosis of native arteries of the extremities	Diagnosis	ICD-9-CM
440.20	Atherosclerosis of native arteries of the extremities, unspecified	Diagnosis	ICD-9-CM
440.21	Atherosclerosis of native arteries of the extremities with intermittent claudication	Diagnosis	ICD-9-CM
440.22	Atherosclerosis of native arteries of the extremities with rest pain	Diagnosis	ICD-9-CM
440.23	Atherosclerosis of native arteries of the extremities with ulceration	Diagnosis	ICD-9-CM
440.24	Atherosclerosis of native arteries of the extremities with gangrene	Diagnosis	ICD-9-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
440.29	Other atherosclerosis of native arteries of the extremities	Diagnosis	ICD-9-CM
440.3	Atherosclerosis of bypass graft of extremities	Diagnosis	ICD-9-CM
440.30	Atherosclerosis of unspecified bypass graft of extremities	Diagnosis	ICD-9-CM
440.31	Atherosclerosis of autologous vein bypass graft of extremities	Diagnosis	ICD-9-CM
440.32	Atherosclerosis of nonautologous biological bypass graft of extremities	Diagnosis	ICD-9-CM
440.4	Chronic total occlusion of artery of the extremities	Diagnosis	ICD-9-CM
440.8	Atherosclerosis of other specified arteries	Diagnosis	ICD-9-CM
440.9	Generalized and unspecified atherosclerosis	Diagnosis	ICD-9-CM
996.03	Mechanical complication due to coronary bypass graft	Diagnosis	ICD-9-CM
I07.0	Rheumatic tricuspid stenosis	Diagnosis	ICD-10-CM
I07.1	Rheumatic tricuspid insufficiency	Diagnosis	ICD-10-CM
I07.2	Rheumatic tricuspid stenosis and insufficiency	Diagnosis	ICD-10-CM
I07.8	Other rheumatic tricuspid valve diseases	Diagnosis	ICD-10-CM
I07.9	Rheumatic tricuspid valve disease, unspecified	Diagnosis	ICD-10-CM
I08.1	Rheumatic disorders of both mitral and tricuspid valves	Diagnosis	ICD-10-CM
I08.2	Rheumatic disorders of both aortic and tricuspid valves	Diagnosis	ICD-10-CM
I08.3	Combined rheumatic disorders of mitral, aortic and tricuspid valves	Diagnosis	ICD-10-CM
I08.8	Other rheumatic multiple valve diseases	Diagnosis	ICD-10-CM
I08.9	Rheumatic multiple valve disease, unspecified	Diagnosis	ICD-10-CM
I09	Other rheumatic heart diseases	Diagnosis	ICD-10-CM
I09.0	Rheumatic myocarditis	Diagnosis	ICD-10-CM
I09.1	Rheumatic diseases of endocardium, valve unspecified	Diagnosis	ICD-10-CM
I09.2	Chronic rheumatic pericarditis	Diagnosis	ICD-10-CM
I09.8	Other specified rheumatic heart diseases	Diagnosis	ICD-10-CM
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I09.89	Other specified rheumatic heart diseases	Diagnosis	ICD-10-CM
I09.9	Rheumatic heart disease, unspecified	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I30.0	Acute nonspecific idiopathic pericarditis	Diagnosis	ICD-10-CM
I30.1	Infective pericarditis	Diagnosis	ICD-10-CM
I30.8	Other forms of acute pericarditis	Diagnosis	ICD-10-CM
I30.9	Acute pericarditis, unspecified	Diagnosis	ICD-10-CM
I31.0	Chronic adhesive pericarditis	Diagnosis	ICD-10-CM
I31.1	Chronic constrictive pericarditis	Diagnosis	ICD-10-CM
I31.2	Hemopericardium, not elsewhere classified	Diagnosis	ICD-10-CM
I31.3	Pericardial effusion (noninflammatory)	Diagnosis	ICD-10-CM
I31.4	Cardiac tamponade	Diagnosis	ICD-10-CM
I31.8	Other specified diseases of pericardium	Diagnosis	ICD-10-CM
I31.9	Disease of pericardium, unspecified	Diagnosis	ICD-10-CM
I32	Pericarditis in diseases classified elsewhere	Diagnosis	ICD-10-CM
I33.0	Acute and subacute infective endocarditis	Diagnosis	ICD-10-CM
I33.9	Acute and subacute endocarditis, unspecified	Diagnosis	ICD-10-CM
I34.0	Nonrheumatic mitral (valve) insufficiency	Diagnosis	ICD-10-CM
I34.1	Nonrheumatic mitral (valve) prolapse	Diagnosis	ICD-10-CM
I34.2	Nonrheumatic mitral (valve) stenosis	Diagnosis	ICD-10-CM
I34.8	Other nonrheumatic mitral valve disorders	Diagnosis	ICD-10-CM
I34.9	Nonrheumatic mitral valve disorder, unspecified	Diagnosis	ICD-10-CM
I35.0	Nonrheumatic aortic (valve) stenosis	Diagnosis	ICD-10-CM
I35.1	Nonrheumatic aortic (valve) insufficiency	Diagnosis	ICD-10-CM
I35.2	Nonrheumatic aortic (valve) stenosis with insufficiency	Diagnosis	ICD-10-CM
I35.8	Other nonrheumatic aortic valve disorders	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I35.9	Nonrheumatic aortic valve disorder, unspecified	Diagnosis	ICD-10-CM
I36.0	Nonrheumatic tricuspid (valve) stenosis	Diagnosis	ICD-10-CM
I36.1	Nonrheumatic tricuspid (valve) insufficiency	Diagnosis	ICD-10-CM
I36.2	Nonrheumatic tricuspid (valve) stenosis with insufficiency	Diagnosis	ICD-10-CM
I36.8	Other nonrheumatic tricuspid valve disorders	Diagnosis	ICD-10-CM
I36.9	Nonrheumatic tricuspid valve disorder, unspecified	Diagnosis	ICD-10-CM
I37.0	Nonrheumatic pulmonary valve stenosis	Diagnosis	ICD-10-CM
I37.1	Nonrheumatic pulmonary valve insufficiency	Diagnosis	ICD-10-CM
I37.2	Nonrheumatic pulmonary valve stenosis with insufficiency	Diagnosis	ICD-10-CM
I37.8	Other nonrheumatic pulmonary valve disorders	Diagnosis	ICD-10-CM
I37.9	Nonrheumatic pulmonary valve disorder, unspecified	Diagnosis	ICD-10-CM
I38	Endocarditis, valve unspecified	Diagnosis	ICD-10-CM
I39	Endocarditis and heart valve disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
I40.0	Infective myocarditis	Diagnosis	ICD-10-CM
I40.1	Isolated myocarditis	Diagnosis	ICD-10-CM
I40.8	Other acute myocarditis	Diagnosis	ICD-10-CM
I40.9	Acute myocarditis, unspecified	Diagnosis	ICD-10-CM
I41	Myocarditis in diseases classified elsewhere	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.1	Obstructive hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
I42.2	Other hypertrophic cardiomyopathy	Diagnosis	ICD-10-CM
I42.3	Endomyocardial (eosinophilic) disease	Diagnosis	ICD-10-CM
I42.4	Endocardial fibroelastosis	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I42.9	Cardiomyopathy, unspecified	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
I51.0	Cardiac septal defect, acquired	Diagnosis	ICD-10-CM
I51.1	Rupture of chordae tendineae, not elsewhere classified	Diagnosis	ICD-10-CM
I51.2	Rupture of papillary muscle, not elsewhere classified	Diagnosis	ICD-10-CM
I51.3	Intracardiac thrombosis, not elsewhere classified	Diagnosis	ICD-10-CM
I51.4	Myocarditis, unspecified	Diagnosis	ICD-10-CM
I51.5	Myocardial degeneration	Diagnosis	ICD-10-CM
I51.7	Cardiomegaly	Diagnosis	ICD-10-CM
I51.81	Takotsubo syndrome	Diagnosis	ICD-10-CM
I51.89	Other ill-defined heart diseases	Diagnosis	ICD-10-CM
I51.9	Heart disease, unspecified	Diagnosis	ICD-10-CM
I52	Other heart disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
I70.0	Atherosclerosis of aorta	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I70.201	Unspecified atherosclerosis of native arteries of extremities, right leg	Diagnosis	ICD-10-CM
I70.202	Unspecified atherosclerosis of native arteries of extremities, left leg	Diagnosis	ICD-10-CM
I70.203	Unspecified atherosclerosis of native arteries of extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.208	Unspecified atherosclerosis of native arteries of extremities, other extremity	Diagnosis	ICD-10-CM
I70.209	Unspecified atherosclerosis of native arteries of extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.211	Atherosclerosis of native arteries of extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.212	Atherosclerosis of native arteries of extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.213	Atherosclerosis of native arteries of extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.218	Atherosclerosis of native arteries of extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.219	Atherosclerosis of native arteries of extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.221	Atherosclerosis of native arteries of extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.222	Atherosclerosis of native arteries of extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.223	Atherosclerosis of native arteries of extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.228	Atherosclerosis of native arteries of extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.229	Atherosclerosis of native arteries of extremities with rest pain, unspecified	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I70.231	Atherosclerosis of native arteries of right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.232	Atherosclerosis of native arteries of right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.233	Atherosclerosis of native arteries of right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.234	Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.235	Atherosclerosis of native arteries of right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.238	Atherosclerosis of native arteries of right leg with ulceration of other part of lower right leg	Diagnosis	ICD-10-CM
I70.239	Atherosclerosis of native arteries of right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.241	Atherosclerosis of native arteries of left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.242	Atherosclerosis of native arteries of left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.243	Atherosclerosis of native arteries of left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.244	Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.245	Atherosclerosis of native arteries of left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.248	Atherosclerosis of native arteries of left leg with ulceration of other part of lower left leg	Diagnosis	ICD-10-CM
I70.249	Atherosclerosis of native arteries of left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.25	Atherosclerosis of native arteries of other extremities with ulceration	Diagnosis	ICD-10-CM
I70.261	Atherosclerosis of native arteries of extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.262	Atherosclerosis of native arteries of extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.263	Atherosclerosis of native arteries of extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.268	Atherosclerosis of native arteries of extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.269	Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.291	Other atherosclerosis of native arteries of extremities, right leg	Diagnosis	ICD-10-CM
I70.292	Other atherosclerosis of native arteries of extremities, left leg	Diagnosis	ICD-10-CM
I70.293	Other atherosclerosis of native arteries of extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.298	Other atherosclerosis of native arteries of extremities, other extremity	Diagnosis	ICD-10-CM
I70.299	Other atherosclerosis of native arteries of extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.301	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.302	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.303	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.308	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.309	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.311	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.312	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.313	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I70.318	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.319	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.321	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.322	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.323	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.328	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.329	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.331	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.332	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.333	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.334	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.335	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.338	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.339	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.341	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.342	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.343	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.344	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.345	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.348	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.349	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.35	Atherosclerosis of unspecified type of bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I70.361	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.362	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.363	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.368	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.369	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.391	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.392	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.393	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.398	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.399	Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.401	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.402	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.403	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.408	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.409	Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.411	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.412	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.413	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.418	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.419	Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.421	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.422	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I70.423	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.428	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.429	Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.431	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.432	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.433	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.434	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.435	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.438	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.439	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.441	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.442	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.443	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.444	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.445	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.448	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.449	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.45	Atherosclerosis of autologous vein bypass graft(s) of other extremity with	Diagnosis	ICD-10-CM
I70.461	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.462	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.463	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.468	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.469	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I70.491	Other atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.492	Other atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.493	Other atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.498	Other atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.499	Other atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.501	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.502	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.503	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.508	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.509	Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.511	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.512	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.513	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.518	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.519	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.521	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.522	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.523	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.528	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.529	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.531	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.532	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.533	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I70.534	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.535	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.538	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.539	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.541	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.542	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.543	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.544	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.545	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.548	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.549	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.55	Atherosclerosis of nonautologous biological bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.561	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.562	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.563	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.568	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.569	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.591	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.592	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.593	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.598	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.599	Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I70.601	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.602	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.603	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.608	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.609	Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.611	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.612	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM
I70.613	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.618	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.619	Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.621	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.622	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.623	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.628	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.629	Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.631	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.632	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of	Diagnosis	ICD-10-CM
I70.633	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.634	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.635	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.638	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.639	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.641	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I70.642	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.643	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.644	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.645	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.648	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.649	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.65	Atherosclerosis of nonbiological bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.661	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
I70.662	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.663	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.668	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.669	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.691	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.692	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.693	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.698	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.699	Other atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.701	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.702	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.703	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.708	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.709	Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.711	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, right leg	Diagnosis	ICD-10-CM
I70.712	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, left leg	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I70.713	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs	Diagnosis	ICD-10-CM
I70.718	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, other extremity	Diagnosis	ICD-10-CM
I70.719	Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity	Diagnosis	ICD-10-CM
I70.721	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, right leg	Diagnosis	ICD-10-CM
I70.722	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, left leg	Diagnosis	ICD-10-CM
I70.723	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, bilateral legs	Diagnosis	ICD-10-CM
I70.728	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, other extremity	Diagnosis	ICD-10-CM
I70.729	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, unspecified extremity	Diagnosis	ICD-10-CM
I70.731	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.732	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of	Diagnosis	ICD-10-CM
I70.733	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.734	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.735	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.738	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.739	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.741	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of	Diagnosis	ICD-10-CM
I70.742	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.743	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.744	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.745	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.748	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
I70.749	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.75	Atherosclerosis of other type of bypass graft(s) of other extremity with ulceration	Diagnosis	ICD-10-CM
I70.761	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I70.762	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
I70.763	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
I70.768	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
I70.769	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
I70.791	Other atherosclerosis of other type of bypass graft(s) of the extremities, right leg	Diagnosis	ICD-10-CM
I70.792	Other atherosclerosis of other type of bypass graft(s) of the extremities, left leg	Diagnosis	ICD-10-CM
I70.793	Other atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs	Diagnosis	ICD-10-CM
I70.798	Other atherosclerosis of other type of bypass graft(s) of the extremities, other extremity	Diagnosis	ICD-10-CM
I70.799	Other atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity	Diagnosis	ICD-10-CM
I70.8	Atherosclerosis of other arteries	Diagnosis	ICD-10-CM
I70.90	Unspecified atherosclerosis	Diagnosis	ICD-10-CM
I70.91	Generalized atherosclerosis	Diagnosis	ICD-10-CM
I70.92	Chronic total occlusion of artery of the extremities	Diagnosis	ICD-10-CM
I97.0	Postcardiotomy syndrome	Diagnosis	ICD-10-CM
I97.110	Postprocedural cardiac insufficiency following cardiac surgery	Diagnosis	ICD-10-CM
I97.111	Postprocedural cardiac insufficiency following other surgery	Diagnosis	ICD-10-CM
I97.120	Postprocedural cardiac arrest following cardiac surgery	Diagnosis	ICD-10-CM
I97.121	Postprocedural cardiac arrest following other surgery	Diagnosis	ICD-10-CM
I97.130	Postprocedural heart failure following cardiac surgery	Diagnosis	ICD-10-CM
I97.131	Postprocedural heart failure following other surgery	Diagnosis	ICD-10-CM
I97.190	Other postprocedural cardiac functional disturbances following cardiac surgery	Diagnosis	ICD-10-CM
I97.191	Other postprocedural cardiac functional disturbances following other surgery	Diagnosis	ICD-10-CM
M32.11	Endocarditis in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.12	Pericarditis in systemic lupus erythematosus	Diagnosis	ICD-10-CM
T82.211A	Breakdown (mechanical) of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.212A	Displacement of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.213A	Leakage of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.218A	Other mechanical complication of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
V45.81	Postprocedural aortocoronary bypass status	Diagnosis	ICD-9-CM
V45.82	Postprocedural percutaneous transluminal coronary angioplasty status	Diagnosis	ICD-9-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
	Cerebrovascular Diseases		
430	Subarachnoid hemorrhage	Diagnosis	ICD-9-CM
431	Intracerebral hemorrhage	Diagnosis	ICD-9-CM
432	Other and unspecified intracranial hemorrhage	Diagnosis	ICD-9-CM
432.0	Nontraumatic extradural hemorrhage	Diagnosis	ICD-9-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
432.1	Subdural hemorrhage	Diagnosis	ICD-9-CM
432.9	Unspecified intracranial hemorrhage	Diagnosis	ICD-9-CM
433	Occlusion and stenosis of precerebral arteries	Diagnosis	ICD-9-CM
433.0	Occlusion and stenosis of basilar artery	Diagnosis	ICD-9-CM
433.00	Occlusion and stenosis of basilar artery without mention of cerebral infarction	Diagnosis	ICD-9-CM
433.01	Occlusion and stenosis of basilar artery with cerebral infarction	Diagnosis	ICD-9-CM
433.1	Occlusion and stenosis of carotid artery	Diagnosis	ICD-9-CM
433.10	Occlusion and stenosis of carotid artery without mention of cerebral infarction	Diagnosis	ICD-9-CM
433.11	Occlusion and stenosis of carotid artery with cerebral infarction	Diagnosis	ICD-9-CM
433.2	Occlusion and stenosis of vertebral artery	Diagnosis	ICD-9-CM
433.20	Occlusion and stenosis of vertebral artery without mention of cerebral infarction	Diagnosis	ICD-9-CM
433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.3	Occlusion and stenosis of multiple and bilateral precerebral arteries	Diagnosis	ICD-9-CM
433.30	Occlusion and stenosis of multiple and bilateral precerebral arteries without mention of cerebral infarction	Diagnosis	ICD-9-CM
433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	Diagnosis	ICD-9-CM
433.8	Occlusion and stenosis of other specified precerebral artery	Diagnosis	ICD-9-CM
433.80	Occlusion and stenosis of other specified precerebral artery without mention of cerebral infarction	Diagnosis	ICD-9-CM
433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.9	Occlusion and stenosis of unspecified precerebral artery	Diagnosis	ICD-9-CM
433.90	Occlusion and stenosis of unspecified precerebral artery without mention of cerebral infarction	Diagnosis	ICD-9-CM
433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
434	Occlusion of cerebral arteries	Diagnosis	ICD-9-CM
434.0	Cerebral thrombosis	Diagnosis	ICD-9-CM
434.00	Cerebral thrombosis without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.01	Cerebral thrombosis with cerebral infarction	Diagnosis	ICD-9-CM
434.1	Cerebral embolism	Diagnosis	ICD-9-CM
434.10	Cerebral embolism without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.11	Cerebral embolism with cerebral infarction	Diagnosis	ICD-9-CM
434.9	Unspecified cerebral artery occlusion	Diagnosis	ICD-9-CM
434.90	Unspecified cerebral artery occlusion without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.91	Unspecified cerebral artery occlusion with cerebral infarction	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.03	Nontraumatic chronic subdural hemorrhage	Diagnosis	ICD-10-CM
I62.1	Nontraumatic extradural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I65.01	Occlusion and stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I65.02	Occlusion and stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I65.03	Occlusion and stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I65.09	Occlusion and stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I65.1	Occlusion and stenosis of basilar artery	Diagnosis	ICD-10-CM
I65.21	Occlusion and stenosis of right carotid artery	Diagnosis	ICD-10-CM
I65.22	Occlusion and stenosis of left carotid artery	Diagnosis	ICD-10-CM
I65.23	Occlusion and stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I65.29	Occlusion and stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I65.8	Occlusion and stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I65.9	Occlusion and stenosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
	Other Cardiovascular Disorders		
426	Conduction disorders	Diagnosis	ICD-9-CM
426.0	Atrioventricular block, complete	Diagnosis	ICD-9-CM
426.1	Atrioventricular block, other and unspecified	Diagnosis	ICD-9-CM
426.10	Unspecified atrioventricular block	Diagnosis	ICD-9-CM
426.11	First degree atrioventricular block	Diagnosis	ICD-9-CM
426.12	Mobitz (type) II atrioventricular block	Diagnosis	ICD-9-CM
426.13	Other second degree atrioventricular block	Diagnosis	ICD-9-CM
426.2	Left bundle branch hemiblock	Diagnosis	ICD-9-CM
426.3	Other left bundle branch block	Diagnosis	ICD-9-CM
426.4	Right bundle branch block	Diagnosis	ICD-9-CM
426.5	Bundle branch block, other and unspecified	Diagnosis	ICD-9-CM
426.50	Unspecified bundle branch block	Diagnosis	ICD-9-CM
426.51	Right bundle branch block and left posterior fascicular block	Diagnosis	ICD-9-CM
426.52	Right bundle branch block and left anterior fascicular block	Diagnosis	ICD-9-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
426.53	Other bilateral bundle branch block	Diagnosis	ICD-9-CM
426.54	Trifascicular block	Diagnosis	ICD-9-CM
426.6	Other heart block	Diagnosis	ICD-9-CM
426.7	Anomalous atrioventricular excitation	Diagnosis	ICD-9-CM
426.8	Other specified conduction disorders	Diagnosis	ICD-9-CM
426.81	Lown-Ganong-Levine syndrome	Diagnosis	ICD-9-CM
426.82	Long QT syndrome	Diagnosis	ICD-9-CM
426.89	Other specified conduction disorder	Diagnosis	ICD-9-CM
426.9	Unspecified conduction disorder	Diagnosis	ICD-9-CM
427	Cardiac dysrhythmias	Diagnosis	ICD-9-CM
427.0	Paroxysmal supraventricular tachycardia	Diagnosis	ICD-9-CM
427.1	Paroxysmal ventricular tachycardia	Diagnosis	ICD-9-CM
427.2	Unspecified paroxysmal tachycardia	Diagnosis	ICD-9-CM
427.3	Atrial fibrillation and flutter	Diagnosis	ICD-9-CM
427.31	Atrial fibrillation	Diagnosis	ICD-9-CM
427.32	Atrial flutter	Diagnosis	ICD-9-CM
427.4	Ventricular fibrillation and flutter	Diagnosis	ICD-9-CM
427.41	Ventricular fibrillation	Diagnosis	ICD-9-CM
427.42	Ventricular flutter	Diagnosis	ICD-9-CM
427.5	Cardiac arrest	Diagnosis	ICD-9-CM
427.6	Premature beats	Diagnosis	ICD-9-CM
427.60	Unspecified premature beats	Diagnosis	ICD-9-CM
427.61	Supraventricular premature beats	Diagnosis	ICD-9-CM
427.69	Other premature beats	Diagnosis	ICD-9-CM
427.8	Other specified cardiac dysrhythmias	Diagnosis	ICD-9-CM
427.81	Sinoatrial node dysfunction	Diagnosis	ICD-9-CM
427.89	Other specified cardiac dysrhythmias	Diagnosis	ICD-9-CM
427.9	Unspecified cardiac dysrhythmia	Diagnosis	ICD-9-CM
I44.0	Atrioventricular block, first degree	Diagnosis	ICD-10-CM
I44.1	Atrioventricular block, second degree	Diagnosis	ICD-10-CM
I44.2	Atrioventricular block, complete	Diagnosis	ICD-10-CM
I44.30	Unspecified atrioventricular block	Diagnosis	ICD-10-CM
I44.39	Other atrioventricular block	Diagnosis	ICD-10-CM
I44.4	Left anterior fascicular block	Diagnosis	ICD-10-CM
I44.5	Left posterior fascicular block	Diagnosis	ICD-10-CM
I44.60	Unspecified fascicular block	Diagnosis	ICD-10-CM
I44.69	Other fascicular block	Diagnosis	ICD-10-CM
I44.7	Left bundle-branch block, unspecified	Diagnosis	ICD-10-CM
I45.0	Right fascicular block	Diagnosis	ICD-10-CM
I45.10	Unspecified right bundle-branch block	Diagnosis	ICD-10-CM
I45.19	Other right bundle-branch block	Diagnosis	ICD-10-CM
I45.2	Bifascicular block	Diagnosis	ICD-10-CM
I45.3	Trifascicular block	Diagnosis	ICD-10-CM
I45.4	Nonspecific intraventricular block	Diagnosis	ICD-10-CM
I45.5	Other specified heart block	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I45.6	Pre-excitation syndrome	Diagnosis	ICD-10-CM
I45.81	Long QT syndrome	Diagnosis	ICD-10-CM
I45.89	Other specified conduction disorders	Diagnosis	ICD-10-CM
I45.9	Conduction disorder, unspecified	Diagnosis	ICD-10-CM
I47.0	Re-entry ventricular arrhythmia	Diagnosis	ICD-10-CM
I47.1	Supraventricular tachycardia	Diagnosis	ICD-10-CM
I47.2	Ventricular tachycardia	Diagnosis	ICD-10-CM
I47.9	Paroxysmal tachycardia, unspecified	Diagnosis	ICD-10-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
I48.92	Unspecified atrial flutter	Diagnosis	ICD-10-CM
I49.01	Ventricular fibrillation	Diagnosis	ICD-10-CM
I49.02	Ventricular flutter	Diagnosis	ICD-10-CM
I49.1	Atrial premature depolarization	Diagnosis	ICD-10-CM
I49.2	Junctional premature depolarization	Diagnosis	ICD-10-CM
I49.3	Ventricular premature depolarization	Diagnosis	ICD-10-CM
I49.40	Unspecified premature depolarization	Diagnosis	ICD-10-CM
I49.49	Other premature depolarization	Diagnosis	ICD-10-CM
I49.5	Sick sinus syndrome	Diagnosis	ICD-10-CM
I49.8	Other specified cardiac arrhythmias	Diagnosis	ICD-10-CM
I49.9	Cardiac arrhythmia, unspecified	Diagnosis	ICD-10-CM
	Corneal Abrasion		
918.1	Superficial injury of cornea	Diagnosis	ICD-9-CM
S05.0	Injury of conjunctiva and corneal abrasion without foreign body	Diagnosis	ICD-10-CM
S05.00	Injury of conjunctiva and corneal abrasion without foreign body, unspecified eye	Diagnosis	ICD-10-CM
S05.00XA	Injury of conjunctiva and corneal abrasion without foreign body, unspecified eye, initial encounter	Diagnosis	ICD-10-CM
S05.00XD	Injury of conjunctiva and corneal abrasion without foreign body, unspecified eye, subsequent encounter	Diagnosis	ICD-10-CM
S05.00XS	Injury of conjunctiva and corneal abrasion without foreign body, unspecified eye, sequela	Diagnosis	ICD-10-CM
S05.01	Injury of conjunctiva and corneal abrasion without foreign body, right eye	Diagnosis	ICD-10-CM
S05.01XA	Injury of conjunctiva and corneal abrasion without foreign body, right eye, initial encounter	Diagnosis	ICD-10-CM
S05.01XD	Injury of conjunctiva and corneal abrasion without foreign body, right eye, subsequent encounter	Diagnosis	ICD-10-CM
S05.01XS	Injury of conjunctiva and corneal abrasion without foreign body, right eye, sequela	Diagnosis	ICD-10-CM
S05.02	Injury of conjunctiva and corneal abrasion without foreign body, left eye	Diagnosis	ICD-10-CM
S05.02XA	Injury of conjunctiva and corneal abrasion without foreign body, left eye, initial encounter	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
S05.02XD	Injury of conjunctiva and corneal abrasion without foreign body, left eye, subsequent encounter	Diagnosis	ICD-10-CM
S05.02XS	Injury of conjunctiva and corneal abrasion without foreign body, left eye, sequela	Diagnosis	ICD-10-CM
	Corneal Graft		
996.51	Mechanical complication due to corneal graft	Diagnosis	ICD-9-CM
T85.3	Mechanical complication of other ocular prosthetic devices, implants and grafts	Diagnosis	ICD-10-CM
T85.31	Breakdown (mechanical) of other ocular prosthetic devices, implants and grafts	Diagnosis	ICD-10-CM
T85.318	Breakdown (mechanical) of other ocular prosthetic devices, implants and grafts	Diagnosis	ICD-10-CM
T85.318A	Breakdown (mechanical) of other ocular prosthetic devices, implants and grafts, initial encounter	Diagnosis	ICD-10-CM
T85.318D	Breakdown (mechanical) of other ocular prosthetic devices, implants and grafts, subsequent encounter	Diagnosis	ICD-10-CM
T85.318S	Breakdown (mechanical) of other ocular prosthetic devices, implants and grafts, sequela	Diagnosis	ICD-10-CM
T85.32	Displacement of other ocular prosthetic devices, implants and grafts	Diagnosis	ICD-10-CM
T85.328	Displacement of other ocular prosthetic devices, implants and grafts	Diagnosis	ICD-10-CM
T85.328A	Displacement of other ocular prosthetic devices, implants and grafts, initial encounter	Diagnosis	ICD-10-CM
T85.328D	Displacement of other ocular prosthetic devices, implants and grafts, subsequent encounter	Diagnosis	ICD-10-CM
T85.328S	Displacement of other ocular prosthetic devices, implants and grafts, sequela	Diagnosis	ICD-10-CM
T85.39	Other mechanical complication of other ocular prosthetic devices, implants and grafts	Diagnosis	ICD-10-CM
T85.398	Other mechanical complication of other ocular prosthetic devices, implants and grafts	Diagnosis	ICD-10-CM
T85.398A	Other mechanical complication of other ocular prosthetic devices, implants and grafts, initial encounter	Diagnosis	ICD-10-CM
T85.398D	Other mechanical complication of other ocular prosthetic devices, implants and grafts, subsequent encounter	Diagnosis	ICD-10-CM
T85.398S	Other mechanical complication of other ocular prosthetic devices, implants and grafts, sequela	Diagnosis	ICD-10-CM
T86.84	Complications of corneal transplant	Diagnosis	ICD-10-CM
T86.840	Corneal transplant rejection	Diagnosis	ICD-10-CM
T86.8401	Corneal transplant rejection, right eye	Diagnosis	ICD-10-CM
T86.8402	Corneal transplant rejection, left eye	Diagnosis	ICD-10-CM
T86.8403	Corneal transplant rejection, bilateral	Diagnosis	ICD-10-CM
T86.8409	Corneal transplant rejection, unspecified eye	Diagnosis	ICD-10-CM
T86.841	Corneal transplant failure	Diagnosis	ICD-10-CM
T86.8411	Corneal transplant failure, right eye	Diagnosis	ICD-10-CM
T86.8412	Corneal transplant failure, left eye	Diagnosis	ICD-10-CM
T86.8413	Corneal transplant failure, bilateral	Diagnosis	ICD-10-CM
T86.8419	Corneal transplant failure, unspecified eye	Diagnosis	ICD-10-CM
T86.842	Corneal transplant infection	Diagnosis	ICD-10-CM
T86.8421	Corneal transplant infection, right eye	Diagnosis	ICD-10-CM
T86.8422	Corneal transplant infection, left eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
T86.8423	Corneal transplant infection, bilateral	Diagnosis	ICD-10-CM
T86.8429	Corneal transplant infection, unspecified eye	Diagnosis	ICD-10-CM
T86.848	Other complications of corneal transplant	Diagnosis	ICD-10-CM
T86.8481	Other complications of corneal transplant, right eye	Diagnosis	ICD-10-CM
T86.8482	Other complications of corneal transplant, left eye	Diagnosis	ICD-10-CM
T86.8483	Other complications of corneal transplant, bilateral	Diagnosis	ICD-10-CM
T86.8489	Other complications of corneal transplant, unspecified eye	Diagnosis	ICD-10-CM
T86.849	Unspecified complication of corneal transplant	Diagnosis	ICD-10-CM
T86.8491	Unspecified complication of corneal transplant, right eye	Diagnosis	ICD-10-CM
T86.8492	Unspecified complication of corneal transplant, left eye	Diagnosis	ICD-10-CM
T86.8493	Unspecified complication of corneal transplant, bilateral	Diagnosis	ICD-10-CM
T86.8499	Unspecified complication of corneal transplant, unspecified eye	Diagnosis	ICD-10-CM
Z94.7	Corneal transplant status	Diagnosis	ICD-10-CM
	Chronic Kidney Disease		
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sjogren syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.11	Contrast-induced nephropathy	Diagnosis	ICD-10-CM
N14.19	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
	Diabetes		
249.00	Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.01	Secondary diabetes mellitus without mention of complication, uncontrolled	Diagnosis	ICD-9-CM
249.10	Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.11	Secondary diabetes mellitus with ketoacidosis, uncontrolled	Diagnosis	ICD-9-CM
249.20	Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.21	Secondary diabetes mellitus with hyperosmolarity, uncontrolled	Diagnosis	ICD-9-CM
249.30	Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.31	Secondary diabetes mellitus with other coma, uncontrolled	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.50	Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.51	Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled	Diagnosis	ICD-9-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
249.60	Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.61	Secondary diabetes mellitus with neurological manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.70	Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.71	Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled	Diagnosis	ICD-9-CM
249.80	Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.81	Secondary diabetes mellitus with other specified manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.90	Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.91	Secondary diabetes mellitus with unspecified complication, uncontrolled	Diagnosis	ICD-9-CM
250	Diabetes mellitus	Diagnosis	ICD-9-CM
250.0	Diabetes mellitus without mention of complication	Diagnosis	ICD-9-CM
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.1	Diabetes with ketoacidosis	Diagnosis	ICD-9-CM
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.2	Diabetes with hyperosmolarity	Diagnosis	ICD-9-CM
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.3	Diabetes with other coma	Diagnosis	ICD-9-CM
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.4	Diabetes with renal manifestations	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.5	Diabetes with ophthalmic manifestations	Diagnosis	ICD-9-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.6	Diabetes with neurological manifestations	Diagnosis	ICD-9-CM
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.7	Diabetes with peripheral circulatory disorders	Diagnosis	ICD-9-CM
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.8	Diabetes with other specified manifestations	Diagnosis	ICD-9-CM
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.9	Diabetes with unspecified complication	Diagnosis	ICD-9-CM
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy,	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-9-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.37X1	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E13.37X2	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E13.37X3	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E13.37X9	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
	Diabetic Retinopathy		
362.0	Diabetic retinopathy	Diagnosis	ICD-9-CM
362.01	Background diabetic retinopathy	Diagnosis	ICD-9-CM
362.02	Proliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.03	Nonproliferative diabetic retinopathy NOS	Diagnosis	ICD-9-CM
362.04	Mild nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.05	Moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.06	Severe nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
E08.31	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.32	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.33	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.34	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.35	Diabetes mellitus due to underlying condition with proliferative diabetic	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.352	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.353	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified	Diagnosis	ICD-10-CM
E08.354	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.355	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.31	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.32	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.33	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.34	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.35	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.352	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.353	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.354	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.355	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.31	Type 1 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.32	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.33	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.34	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.35	Type 1 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.352	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.353	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.354	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.355	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.31	Type 2 diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.32	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.33	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.34	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.35	Type 2 diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.352	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.353	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.354	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.355	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.31	Other specified diabetes mellitus with unspecified diabetic retinopathy	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.32	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.33	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.34	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.35	Other specified diabetes mellitus with proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.352	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.353	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.354	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.355	Other specified diabetes mellitus with stable proliferative diabetic retinopathy	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
	Endoscopic Sinus Surgery		
31032	Sinusotomy, maxillary (antrotomy); radical (Caldwell-Luc) with removal of antrochoanal polyps	Procedure	CPT-4
31051	Sinusotomy, sphenoid, with or without biopsy; with mucosal stripping or removal of polyp(s)	Procedure	CPT-4
31233	Nasal/sinus endoscopy, diagnostic with maxillary sinusoscopy (via inferior meatus or canine fossa puncture)	Procedure	CPT-4
31235	Nasal/sinus endoscopy, diagnostic with sphenoid sinusoscopy (via puncture of sphenoidal face or cannulation of ostium)	Procedure	CPT-4
31237	Nasal/sinus endoscopy, surgical; with biopsy, polypectomy or debridement (separate procedure)	Procedure	CPT-4
31238	Nasal/sinus endoscopy, surgical; with control of nasal hemorrhage	Procedure	CPT-4
31239	Nasal/sinus endoscopy, surgical; with dacryocystorhinostomy	Procedure	CPT-4
31240	Nasal/sinus endoscopy, surgical; with concha bullosa resection	Procedure	CPT-4
31241	Nasal/sinus endoscopy, surgical; with ligation of sphenopalatine artery	Procedure	CPT-4
31253	Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including frontal sinus exploration, with removal of tissue from frontal sinus, when performed	Procedure	CPT-4
31254	Nasal/sinus endoscopy, surgical with ethmoidectomy; partial (anterior)	Procedure	CPT-4
31255	Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior)	Procedure	CPT-4
31256	Nasal/sinus endoscopy, surgical, with maxillary antrostomy;	Procedure	CPT-4
31257	Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including sphenoidotomy	Procedure	CPT-4
31259	Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including sphenoidotomy, with removal of tissue from the sphenoid	Procedure	CPT-4
31267	Nasal/sinus endoscopy, surgical, with maxillary antrostomy; with removal of tissue from maxillary sinus	Procedure	CPT-4
31276	Nasal/sinus endoscopy, surgical, with frontal sinus exploration, including removal of tissue from frontal sinus, when performed	Procedure	CPT-4

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
31287	Nasal/sinus endoscopy, surgical, with sphenoidotomy;	Procedure	CPT-4
31288	Nasal/sinus endoscopy, surgical, with sphenoidotomy; with removal of tissue from the sphenoid sinus	Procedure	CPT-4
31295	Nasal/sinus endoscopy, surgical; with dilation of maxillary sinus ostium (eg, balloon dilation), transnasal or via canine fossa	Procedure	CPT-4
31296	Nasal/sinus endoscopy, surgical; with dilation of frontal sinus ostium (eg, balloon dilation)	Procedure	CPT-4
31297	Nasal/sinus endoscopy, surgical; with dilation of sphenoid sinus ostium (eg, balloon dilation)	Procedure	CPT-4
31298	Nasal/sinus endoscopy, surgical; with dilation of frontal and sphenoid sinus ostia (eg, balloon dilation)	Procedure	CPT-4
S2342	Nasal endoscopy for post-operative debridement following functional endoscopic sinus surgery, nasal and/or sinus cavity(s), unilateral or bilateral	Procedure	HCPCS
S2344	Nasal/sinus endoscopy, surgical; with enlargement of sinus ostium opening using inflatable device (i.e., balloon sinuplasty)	Procedure	HCPCS
	Episcleritis		
379.0	Scleritis and episcleritis	Diagnosis	ICD-9-CM
379.01	Episcleritis periodica fugax	Diagnosis	ICD-9-CM
379.02	Nodular episcleritis	Diagnosis	ICD-9-CM
379.09	Other scleritis and episcleritis	Diagnosis	ICD-9-CM
A18.51	Tuberculous episcleritis	Diagnosis	ICD-10-CM
B02.34	Zoster scleritis	Diagnosis	ICD-10-CM
H15.0	Scleritis	Diagnosis	ICD-10-CM
H15.00	Unspecified scleritis	Diagnosis	ICD-10-CM
H15.001	Unspecified scleritis, right eye	Diagnosis	ICD-10-CM
H15.002	Unspecified scleritis, left eye	Diagnosis	ICD-10-CM
H15.003	Unspecified scleritis, bilateral	Diagnosis	ICD-10-CM
H15.009	Unspecified scleritis, unspecified eye	Diagnosis	ICD-10-CM
H15.01	Anterior scleritis	Diagnosis	ICD-10-CM
H15.011	Anterior scleritis, right eye	Diagnosis	ICD-10-CM
H15.012	Anterior scleritis, left eye	Diagnosis	ICD-10-CM
H15.013	Anterior scleritis, bilateral	Diagnosis	ICD-10-CM
H15.019	Anterior scleritis, unspecified eye	Diagnosis	ICD-10-CM
H15.02	Brawny scleritis	Diagnosis	ICD-10-CM
H15.021	Brawny scleritis, right eye	Diagnosis	ICD-10-CM
H15.022	Brawny scleritis, left eye	Diagnosis	ICD-10-CM
H15.023	Brawny scleritis, bilateral	Diagnosis	ICD-10-CM
H15.029	Brawny scleritis, unspecified eye	Diagnosis	ICD-10-CM
H15.03	Posterior scleritis	Diagnosis	ICD-10-CM
H15.031	Posterior scleritis, right eye	Diagnosis	ICD-10-CM
H15.032	Posterior scleritis, left eye	Diagnosis	ICD-10-CM
H15.033	Posterior scleritis, bilateral	Diagnosis	ICD-10-CM
H15.039	Posterior scleritis, unspecified eye	Diagnosis	ICD-10-CM
H15.04	Scleritis with corneal involvement	Diagnosis	ICD-10-CM
H15.041	Scleritis with corneal involvement, right eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H15.042	Scleritis with corneal involvement, left eye	Diagnosis	ICD-10-CM
H15.043	Scleritis with corneal involvement, bilateral	Diagnosis	ICD-10-CM
H15.049	Scleritis with corneal involvement, unspecified eye	Diagnosis	ICD-10-CM
H15.09	Other scleritis	Diagnosis	ICD-10-CM
H15.091	Other scleritis, right eye	Diagnosis	ICD-10-CM
H15.092	Other scleritis, left eye	Diagnosis	ICD-10-CM
H15.093	Other scleritis, bilateral	Diagnosis	ICD-10-CM
H15.099	Other scleritis, unspecified eye	Diagnosis	ICD-10-CM
H15.1	Episcleritis	Diagnosis	ICD-10-CM
H15.10	Unspecified episcleritis	Diagnosis	ICD-10-CM
H15.101	Unspecified episcleritis, right eye	Diagnosis	ICD-10-CM
H15.102	Unspecified episcleritis, left eye	Diagnosis	ICD-10-CM
H15.103	Unspecified episcleritis, bilateral	Diagnosis	ICD-10-CM
H15.109	Unspecified episcleritis, unspecified eye	Diagnosis	ICD-10-CM
H15.11	Episcleritis periodica fugax	Diagnosis	ICD-10-CM
H15.111	Episcleritis periodica fugax, right eye	Diagnosis	ICD-10-CM
H15.112	Episcleritis periodica fugax, left eye	Diagnosis	ICD-10-CM
H15.113	Episcleritis periodica fugax, bilateral	Diagnosis	ICD-10-CM
H15.119	Episcleritis periodica fugax, unspecified eye	Diagnosis	ICD-10-CM
H15.12	Nodular episcleritis	Diagnosis	ICD-10-CM
H15.121	Nodular episcleritis, right eye	Diagnosis	ICD-10-CM
H15.122	Nodular episcleritis, left eye	Diagnosis	ICD-10-CM
H15.123	Nodular episcleritis, bilateral	Diagnosis	ICD-10-CM
H15.129	Nodular episcleritis, unspecified eye	Diagnosis	ICD-10-CM
	Fuchs Endothelial Dystrophy		
371.57	Endothelial corneal dystrophy	Diagnosis	ICD-9-CM
H18.51	Endothelial corneal dystrophy	Diagnosis	ICD-10-CM
H18.511	Endothelial corneal dystrophy, right eye	Diagnosis	ICD-10-CM
H18.512	Endothelial corneal dystrophy, left eye	Diagnosis	ICD-10-CM
H18.513	Endothelial corneal dystrophy, bilateral	Diagnosis	ICD-10-CM
H18.519	Endothelial corneal dystrophy, unspecified eye	Diagnosis	ICD-10-CM
	Heterochromic Cyclitis		
364.21	Fuchs' heterochromic cyclitis	Diagnosis	ICD-9-CM
H20.81	Fuchs' heterochromic cyclitis	Diagnosis	ICD-10-CM
H20.811	Fuchs' heterochromic cyclitis, right eye	Diagnosis	ICD-10-CM
H20.812	Fuchs' heterochromic cyclitis, left eye	Diagnosis	ICD-10-CM
H20.813	Fuchs' heterochromic cyclitis, bilateral	Diagnosis	ICD-10-CM
H20.819	Fuchs' heterochromic cyclitis, unspecified eye	Diagnosis	ICD-10-CM
	Keratitis		
054.42	Dendritic keratitis	Diagnosis	ICD-9-CM
054.43	Herpes simplex disciform keratitis	Diagnosis	ICD-9-CM
090.3	Syphilitic interstitial keratitis	Diagnosis	ICD-9-CM
098.43	Gonococcal keratitis	Diagnosis	ICD-9-CM
370	Keratitis	Diagnosis	ICD-9-CM
370.2	Superficial keratitis without conjunctivitis	Diagnosis	ICD-9-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
370.20	Unspecified superficial keratitis	Diagnosis	ICD-9-CM
370.21	Punctate keratitis	Diagnosis	ICD-9-CM
370.22	Macular keratitis	Diagnosis	ICD-9-CM
370.23	Filamentary keratitis	Diagnosis	ICD-9-CM
370.24	Photokeratitis	Diagnosis	ICD-9-CM
370.44	Keratitis or keratoconjunctivitis in exanthema	Diagnosis	ICD-9-CM
370.5	Interstitial and deep keratitis	Diagnosis	ICD-9-CM
370.50	Unspecified interstitial keratitis	Diagnosis	ICD-9-CM
370.52	Diffuse interstitial keratitis	Diagnosis	ICD-9-CM
370.54	Sclerosing keratitis	Diagnosis	ICD-9-CM
370.59	Other interstitial and deep keratitis	Diagnosis	ICD-9-CM
370.8	Other forms of keratitis	Diagnosis	ICD-9-CM
370.9	Unspecified keratitis	Diagnosis	ICD-9-CM
A18.52	Tuberculous keratitis	Diagnosis	ICD-10-CM
A50.31	Late congenital syphilitic interstitial keratitis	Diagnosis	ICD-10-CM
A54.33	Gonococcal keratitis	Diagnosis	ICD-10-CM
B00.52	Herpesviral keratitis	Diagnosis	ICD-10-CM
B01.81	Varicella keratitis	Diagnosis	ICD-10-CM
B02.33	Zoster keratitis	Diagnosis	ICD-10-CM
B05.81	Measles keratitis and keratoconjunctivitis	Diagnosis	ICD-10-CM
B60.13	Keratoconjunctivitis due to Acanthamoeba	Diagnosis	ICD-10-CM
H16	Keratitis	Diagnosis	ICD-10-CM
H16.1	Other and unspecified superficial keratitis without conjunctivitis	Diagnosis	ICD-10-CM
H16.10	Unspecified superficial keratitis	Diagnosis	ICD-10-CM
H16.101	Unspecified superficial keratitis, right eye	Diagnosis	ICD-10-CM
H16.102	Unspecified superficial keratitis, left eye	Diagnosis	ICD-10-CM
H16.103	Unspecified superficial keratitis, bilateral	Diagnosis	ICD-10-CM
H16.109	Unspecified superficial keratitis, unspecified eye	Diagnosis	ICD-10-CM
H16.11	Macular keratitis	Diagnosis	ICD-10-CM
H16.111	Macular keratitis, right eye	Diagnosis	ICD-10-CM
H16.112	Macular keratitis, left eye	Diagnosis	ICD-10-CM
H16.113	Macular keratitis, bilateral	Diagnosis	ICD-10-CM
H16.119	Macular keratitis, unspecified eye	Diagnosis	ICD-10-CM
H16.12	Filamentary keratitis	Diagnosis	ICD-10-CM
H16.121	Filamentary keratitis, right eye	Diagnosis	ICD-10-CM
H16.122	Filamentary keratitis, left eye	Diagnosis	ICD-10-CM
H16.123	Filamentary keratitis, bilateral	Diagnosis	ICD-10-CM
H16.129	Filamentary keratitis, unspecified eye	Diagnosis	ICD-10-CM
H16.13	Photokeratitis	Diagnosis	ICD-10-CM
H16.131	Photokeratitis, right eye	Diagnosis	ICD-10-CM
H16.132	Photokeratitis, left eye	Diagnosis	ICD-10-CM
H16.133	Photokeratitis, bilateral	Diagnosis	ICD-10-CM
H16.139	Photokeratitis, unspecified eye	Diagnosis	ICD-10-CM
H16.14	Punctate keratitis	Diagnosis	ICD-10-CM
H16.141	Punctate keratitis, right eye	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H16.142	Punctate keratitis, left eye	Diagnosis	ICD-10-CM
H16.143	Punctate keratitis, bilateral	Diagnosis	ICD-10-CM
H16.149	Punctate keratitis, unspecified eye	Diagnosis	ICD-10-CM
H16.291	Other keratoconjunctivitis, right eye	Diagnosis	ICD-10-CM
H16.292	Other keratoconjunctivitis, left eye	Diagnosis	ICD-10-CM
H16.293	Other keratoconjunctivitis, bilateral	Diagnosis	ICD-10-CM
H16.299	Other keratoconjunctivitis, unspecified eye	Diagnosis	ICD-10-CM
H16.3	Interstitial and deep keratitis	Diagnosis	ICD-10-CM
H16.30	Unspecified interstitial keratitis	Diagnosis	ICD-10-CM
H16.301	Unspecified interstitial keratitis, right eye	Diagnosis	ICD-10-CM
H16.302	Unspecified interstitial keratitis, left eye	Diagnosis	ICD-10-CM
H16.303	Unspecified interstitial keratitis, bilateral	Diagnosis	ICD-10-CM
H16.309	Unspecified interstitial keratitis, unspecified eye	Diagnosis	ICD-10-CM
H16.32	Diffuse interstitial keratitis	Diagnosis	ICD-10-CM
H16.321	Diffuse interstitial keratitis, right eye	Diagnosis	ICD-10-CM
H16.322	Diffuse interstitial keratitis, left eye	Diagnosis	ICD-10-CM
H16.323	Diffuse interstitial keratitis, bilateral	Diagnosis	ICD-10-CM
H16.329	Diffuse interstitial keratitis, unspecified eye	Diagnosis	ICD-10-CM
H16.33	Sclerosing keratitis	Diagnosis	ICD-10-CM
H16.331	Sclerosing keratitis, right eye	Diagnosis	ICD-10-CM
H16.332	Sclerosing keratitis, left eye	Diagnosis	ICD-10-CM
H16.333	Sclerosing keratitis, bilateral	Diagnosis	ICD-10-CM
H16.339	Sclerosing keratitis, unspecified eye	Diagnosis	ICD-10-CM
H16.39	Other interstitial and deep keratitis	Diagnosis	ICD-10-CM
H16.391	Other interstitial and deep keratitis, right eye	Diagnosis	ICD-10-CM
H16.392	Other interstitial and deep keratitis, left eye	Diagnosis	ICD-10-CM
H16.393	Other interstitial and deep keratitis, bilateral	Diagnosis	ICD-10-CM
H16.399	Other interstitial and deep keratitis, unspecified eye	Diagnosis	ICD-10-CM
H16.8	Other keratitis	Diagnosis	ICD-10-CM
H16.9	Unspecified keratitis	Diagnosis	ICD-10-CM
	Macular Degeneration		
362.50	Macular degeneration (senile) of retina, unspecified	Diagnosis	ICD-9-CM
362.51	Nonexudative senile macular degeneration of retina	Diagnosis	ICD-9-CM
362.52	Exudative senile macular degeneration of retina	Diagnosis	ICD-9-CM
362.53	Cystoid macular degeneration of retina	Diagnosis	ICD-9-CM
H35.30	Unspecified macular degeneration	Diagnosis	ICD-10-CM
H35.31	Nonexudative age-related macular degeneration	Diagnosis	ICD-10-CM
H35.311	Nonexudative age-related macular degeneration, right eye	Diagnosis	ICD-10-CM
H35.3110	Nonexudative age-related macular degeneration, right eye, stage unspecified	Diagnosis	ICD-10-CM
H35.3111	Nonexudative age-related macular degeneration, right eye, early dry stage	Diagnosis	ICD-10-CM
H35.3112	Nonexudative age-related macular degeneration, right eye, intermediate dry stage	Diagnosis	ICD-10-CM
H35.3113	Nonexudative age-related macular degeneration, right eye, advanced atrophic without subfoveal involvement	Diagnosis	ICD-10-CM
H35.3114	Nonexudative age-related macular degeneration, right eye, advanced atrophic with subfoveal involvement	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H35.312	Nonexudative age-related macular degeneration, left eye	Diagnosis	ICD-10-CM
H35.3120	Nonexudative age-related macular degeneration, left eye, stage unspecified	Diagnosis	ICD-10-CM
H35.3121	Nonexudative age-related macular degeneration, left eye, early dry stage	Diagnosis	ICD-10-CM
H35.3122	Nonexudative age-related macular degeneration, left eye, intermediate dry stage	Diagnosis	ICD-10-CM
H35.3123	Nonexudative age-related macular degeneration, left eye, advanced atrophic without subfoveal involvement	Diagnosis	ICD-10-CM
H35.3124	Nonexudative age-related macular degeneration, left eye, advanced atrophic with subfoveal involvement	Diagnosis	ICD-10-CM
H35.313	Nonexudative age-related macular degeneration, bilateral	Diagnosis	ICD-10-CM
H35.3130	Nonexudative age-related macular degeneration, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H35.3131	Nonexudative age-related macular degeneration, bilateral, early dry stage	Diagnosis	ICD-10-CM
H35.3132	Nonexudative age-related macular degeneration, bilateral, intermediate dry stage	Diagnosis	ICD-10-CM
H35.3133	Nonexudative age-related macular degeneration, bilateral, advanced atrophic without subfoveal involvement	Diagnosis	ICD-10-CM
H35.3134	Nonexudative age-related macular degeneration, bilateral, advanced atrophic with subfoveal involvement	Diagnosis	ICD-10-CM
H35.319	Nonexudative age-related macular degeneration, unspecified eye	Diagnosis	ICD-10-CM
H35.3190	Nonexudative age-related macular degeneration, unspecified eye, stage	Diagnosis	ICD-10-CM
H35.3191	Nonexudative age-related macular degeneration, unspecified eye, early dry stage	Diagnosis	ICD-10-CM
H35.3192	Nonexudative age-related macular degeneration, unspecified eye, intermediate dry stage	Diagnosis	ICD-10-CM
H35.3193	Nonexudative age-related macular degeneration, unspecified eye, advanced atrophic without subfoveal involvement	Diagnosis	ICD-10-CM
H35.3194	Nonexudative age-related macular degeneration, unspecified eye, advanced atrophic with subfoveal involvement	Diagnosis	ICD-10-CM
H35.32	Exudative age-related macular degeneration	Diagnosis	ICD-10-CM
H35.321	Exudative age-related macular degeneration, right eye	Diagnosis	ICD-10-CM
H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified	Diagnosis	ICD-10-CM
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization	Diagnosis	ICD-10-CM
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization	Diagnosis	ICD-10-CM
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar	Diagnosis	ICD-10-CM
H35.322	Exudative age-related macular degeneration, left eye	Diagnosis	ICD-10-CM
H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified	Diagnosis	ICD-10-CM
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization	Diagnosis	ICD-10-CM
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization	Diagnosis	ICD-10-CM
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar	Diagnosis	ICD-10-CM
H35.323	Exudative age-related macular degeneration, bilateral	Diagnosis	ICD-10-CM
H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization	Diagnosis	ICD-10-CM
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar	Diagnosis	ICD-10-CM
H35.329	Exudative age-related macular degeneration, unspecified eye	Diagnosis	ICD-10-CM
H35.3290	Exudative age-related macular degeneration, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H35.3291	Exudative age-related macular degeneration, unspecified eye, with active choroidal neovascularization	Diagnosis	ICD-10-CM
H35.3292	Exudative age-related macular degeneration, unspecified eye, with inactive choroidal neovascularization	Diagnosis	ICD-10-CM
H35.3293	Exudative age-related macular degeneration, unspecified eye, with inactive scar	Diagnosis	ICD-10-CM
H35.35	Cystoid macular degeneration	Diagnosis	ICD-10-CM
H35.351	Cystoid macular degeneration, right eye	Diagnosis	ICD-10-CM
H35.352	Cystoid macular degeneration, left eye	Diagnosis	ICD-10-CM
H35.353	Cystoid macular degeneration, bilateral	Diagnosis	ICD-10-CM
H35.359	Cystoid macular degeneration, unspecified eye	Diagnosis	ICD-10-CM
	Nasal Polyps		
471	Nasal polyps	Diagnosis	ICD-9-CM
471.0	Polyp of nasal cavity	Diagnosis	ICD-9-CM
471.1	Polypoid sinus degeneration	Diagnosis	ICD-9-CM
471.8	Other polyp of sinus	Diagnosis	ICD-9-CM
471.9	Unspecified nasal polyp	Diagnosis	ICD-9-CM
J33	Nasal polyp	Diagnosis	ICD-10-CM
J33.0	Polyp of nasal cavity	Diagnosis	ICD-10-CM
J33.1	Polypoid sinus degeneration	Diagnosis	ICD-10-CM
J33.8	Other polyp of sinus	Diagnosis	ICD-10-CM
J33.9	Nasal polyp, unspecified	Diagnosis	ICD-10-CM
	Retinitis Pigmentosa		
362.74	Pigmentary retinal dystrophy	Diagnosis	ICD-9-CM
H35.5	Hereditary retinal dystrophy	Diagnosis	ICD-10-CM
H35.50	Unspecified hereditary retinal dystrophy	Diagnosis	ICD-10-CM
H35.51	Vitreoretinal dystrophy	Diagnosis	ICD-10-CM
H35.52	Pigmentary retinal dystrophy	Diagnosis	ICD-10-CM
	Subconjunctival Hemorrhage		
372.72	Conjunctival hemorrhage	Diagnosis	ICD-9-CM
H11.3	Conjunctival hemorrhage	Diagnosis	ICD-10-CM
H11.30	Conjunctival hemorrhage, unspecified eye	Diagnosis	ICD-10-CM
H11.31	Conjunctival hemorrhage, right eye	Diagnosis	ICD-10-CM
H11.32	Conjunctival hemorrhage, left eye	Diagnosis	ICD-10-CM
H11.33	Conjunctival hemorrhage, bilateral	Diagnosis	ICD-10-CM
	Uveitis		
053.22	Herpes zoster iridocyclitis	Diagnosis	ICD-9-CM
054.44	Herpes simplex iridocyclitis	Diagnosis	ICD-9-CM
091.5	Early syphilis, uveitis due to secondary syphilis	Diagnosis	ICD-9-CM
091.50	Early syphilis, syphilitic uveitis, unspecified	Diagnosis	ICD-9-CM
091.52	Early syphilis, syphilitic iridocyclitis (secondary)	Diagnosis	ICD-9-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
098.41	Gonococcal iridocyclitis	Diagnosis	ICD-9-CM
360.11	Sympathetic uveitis	Diagnosis	ICD-9-CM
360.12	Panuveitis	Diagnosis	ICD-9-CM
364.0	Acute and subacute iridocyclitis	Diagnosis	ICD-9-CM
364.00	Unspecified acute and subacute iridocyclitis	Diagnosis	ICD-9-CM
364.01	Primary iridocyclitis	Diagnosis	ICD-9-CM
364.02	Recurrent iridocyclitis	Diagnosis	ICD-9-CM
364.03	Secondary iridocyclitis, infectious	Diagnosis	ICD-9-CM
364.04	Secondary iridocyclitis, noninfectious	Diagnosis	ICD-9-CM
364.1	Chronic iridocyclitis	Diagnosis	ICD-9-CM
364.10	Unspecified chronic iridocyclitis	Diagnosis	ICD-9-CM
364.11	Chronic iridocyclitis in diseases classified elsewhere	Diagnosis	ICD-9-CM
364.2	Certain types of iridocyclitis	Diagnosis	ICD-9-CM
364.23	Lens-induced iridocyclitis	Diagnosis	ICD-9-CM
364.3	Unspecified iridocyclitis	Diagnosis	ICD-9-CM
A18.54	Tuberculous iridocyclitis	Diagnosis	ICD-10-CM
A51.43	Secondary syphilitic oculopathy	Diagnosis	ICD-10-CM
A54.32	Gonococcal iridocyclitis	Diagnosis	ICD-10-CM
B00.51	Herpesviral iridocyclitis	Diagnosis	ICD-10-CM
B02.32	Zoster iridocyclitis	Diagnosis	ICD-10-CM
D86.83	Sarcoid iridocyclitis	Diagnosis	ICD-10-CM
H20	Iridocyclitis	Diagnosis	ICD-10-CM
H20.0	Acute and subacute iridocyclitis	Diagnosis	ICD-10-CM
H20.00	Unspecified acute and subacute iridocyclitis	Diagnosis	ICD-10-CM
H20.01	Primary iridocyclitis	Diagnosis	ICD-10-CM
H20.011	Primary iridocyclitis, right eye	Diagnosis	ICD-10-CM
H20.012	Primary iridocyclitis, left eye	Diagnosis	ICD-10-CM
H20.013	Primary iridocyclitis, bilateral	Diagnosis	ICD-10-CM
H20.019	Primary iridocyclitis, unspecified eye	Diagnosis	ICD-10-CM
H20.02	Recurrent acute iridocyclitis	Diagnosis	ICD-10-CM
H20.021	Recurrent acute iridocyclitis, right eye	Diagnosis	ICD-10-CM
H20.022	Recurrent acute iridocyclitis, left eye	Diagnosis	ICD-10-CM
H20.023	Recurrent acute iridocyclitis, bilateral	Diagnosis	ICD-10-CM
H20.029	Recurrent acute iridocyclitis, unspecified eye	Diagnosis	ICD-10-CM
H20.03	Secondary infectious iridocyclitis	Diagnosis	ICD-10-CM
H20.031	Secondary infectious iridocyclitis, right eye	Diagnosis	ICD-10-CM
H20.032	Secondary infectious iridocyclitis, left eye	Diagnosis	ICD-10-CM
H20.033	Secondary infectious iridocyclitis, bilateral	Diagnosis	ICD-10-CM
H20.039	Secondary infectious iridocyclitis, unspecified eye	Diagnosis	ICD-10-CM
H20.04	Secondary noninfectious iridocyclitis	Diagnosis	ICD-10-CM
H20.041	Secondary noninfectious iridocyclitis, right eye	Diagnosis	ICD-10-CM
H20.042	Secondary noninfectious iridocyclitis, left eye	Diagnosis	ICD-10-CM
H20.043	Secondary noninfectious iridocyclitis, bilateral	Diagnosis	ICD-10-CM
H20.049	Secondary noninfectious iridocyclitis, unspecified eye	Diagnosis	ICD-10-CM
H20.1	Chronic iridocyclitis	Diagnosis	ICD-10-CM

Appendix I. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H20.10	Chronic iridocyclitis, unspecified eye	Diagnosis	ICD-10-CM
H20.11	Chronic iridocyclitis, right eye	Diagnosis	ICD-10-CM
H20.12	Chronic iridocyclitis, left eye	Diagnosis	ICD-10-CM
H20.13	Chronic iridocyclitis, bilateral	Diagnosis	ICD-10-CM
H20.2	Lens-induced iridocyclitis	Diagnosis	ICD-10-CM
H20.20	Lens-induced iridocyclitis, unspecified eye	Diagnosis	ICD-10-CM
H20.21	Lens-induced iridocyclitis, right eye	Diagnosis	ICD-10-CM
H20.22	Lens-induced iridocyclitis, left eye	Diagnosis	ICD-10-CM
H20.23	Lens-induced iridocyclitis, bilateral	Diagnosis	ICD-10-CM
H20.8	Other iridocyclitis	Diagnosis	ICD-10-CM
H20.9	Unspecified iridocyclitis	Diagnosis	ICD-10-CM
H44.11	Panuveitis	Diagnosis	ICD-10-CM
H44.111	Panuveitis, right eye	Diagnosis	ICD-10-CM
H44.112	Panuveitis, left eye	Diagnosis	ICD-10-CM
H44.113	Panuveitis, bilateral	Diagnosis	ICD-10-CM
H44.119	Panuveitis, unspecified eye	Diagnosis	ICD-10-CM
H44.13	Sympathetic uveitis	Diagnosis	ICD-10-CM
H44.131	Sympathetic uveitis, right eye	Diagnosis	ICD-10-CM
H44.132	Sympathetic uveitis, left eye	Diagnosis	ICD-10-CM
H44.133	Sympathetic uveitis, bilateral	Diagnosis	ICD-10-CM
H44.139	Sympathetic uveitis, unspecified eye	Diagnosis	ICD-10-CM
	Vasculitis		
362.18	Retinal vasculitis	Diagnosis	ICD-9-CM
H35.06	Retinal vasculitis	Diagnosis	ICD-10-CM
H35.061	Retinal vasculitis, right eye	Diagnosis	ICD-10-CM
H35.062	Retinal vasculitis, left eye	Diagnosis	ICD-10-CM
H35.063	Retinal vasculitis, bilateral	Diagnosis	ICD-10-CM
H35.069	Retinal vasculitis, unspecified eye	Diagnosis	ICD-10-CM

Appendix J. List of Generic and Brand Names of Medical Products Used to Define Characteristics in this Request

Generic Name	Brand Name
Inhaled Steroids	
beclomethasone dipropionate	QNASL
beclomethasone dipropionate	Qvar
beclomethasone dipropionate	Qvar RediHaler
budesonide	Pulmicort
budesonide	Pulmicort Flexhaler
budesonide	budesonide
budesonide/formoterol fumarate	Symbicort
budesonide/formoterol fumarate	budesonide-formoterol
budesonide/glycopyrrolate/formoterol fumarate	Breztri Aerosphere
ciclesonide	Alvesco
ciclesonide	Zetonna
fluticasone furoate	Arnuity Ellipta
fluticasone furoate/umeclidinium bromide/vilanterol trifenat	Trelegy Ellipta
fluticasone furoate/vilanterol trifenatate	Breo Ellipta
fluticasone furoate/vilanterol trifenatate	fluticasone furoate-vilanterol
fluticasone propionate	ArmonAir Digihaler
fluticasone propionate	ArmonAir RespiClick
fluticasone propionate	Flovent Diskus
fluticasone propionate	Flovent HFA
fluticasone propionate	Xhance
fluticasone propionate	fluticasone propionate
fluticasone propionate/salmeterol xinafoate	Advair Diskus
fluticasone propionate/salmeterol xinafoate	Advair HFA
fluticasone propionate/salmeterol xinafoate	AirDuo Digihaler
fluticasone propionate/salmeterol xinafoate	AirDuo RespiClick
fluticasone propionate/salmeterol xinafoate	Wixela Inhub
fluticasone propionate/salmeterol xinafoate	fluticasone propion-salmeterol
mometasone furoate	Asmanex HFA
mometasone furoate	Asmanex Twisthaler
mometasone furoate/formoterol fumarate	Dulera
Intranasal Steroids	
azelastine HCl/fluticasone propionate	Dymista
azelastine HCl/fluticasone propionate	azelastine-fluticasone
azelastine/fluticasone/sodium chloride/sodium bicarbonate	Ticalast
beclomethasone dipropionate	Beconase AQ
budesonide	Rhinocort Allergy
budesonide	Rhinocort Aqua
budesonide	budesonide
ciclesonide	Omnaris
flunisolide	flunisolide
fluticasone furoate	Children's Flonase Sensimist
fluticasone furoate	Flonase Sensimist
fluticasone furoate	Veramyst
fluticasone propionate	24 Hour Allergy Relief
fluticasone propionate	Aller-Flo
fluticasone propionate	Allergy Relief (fluticasone)
fluticasone propionate	Children's Flonase Allergy Rlf

Appendix J. List of Generic and Brand Names of Medical Products Used to Define Characteristics in this Request

Generic Name	Brand Name
fluticasone propionate	Childrens 24 Hr Allergy Relief
fluticasone propionate	ClariSpray
fluticasone propionate	Flonase
fluticasone propionate	Flonase Allergy Relief
fluticasone propionate	fluticasone propionate
fluticasone propionate/sodium chloride/sodium bicarbonate	Ticanase
fluticasone propionate/sodium chloride/sodium bicarbonate	Ticaspray
mometasone furoate	Nasonex
mometasone furoate	mometasone
triamcinolone acetonide	24 Hour Nasal Allergy
triamcinolone acetonide	Aller-Cort
triamcinolone acetonide	Children's Nasacort
triamcinolone acetonide	Nasacort
triamcinolone acetonide	Nasacort Allergy
triamcinolone acetonide	Nasal Allergy
triamcinolone acetonide	triamcinolone acetonide
Oral Steroids	
budesonide	Entocort EC
budesonide	Ortikos
budesonide	Tarpeyo
budesonide	Uceris
budesonide	budesonide
cortisone acetate	cortisone
deflazacort	Emflaza
dexamethasone	Decadron
dexamethasone	DexPak 10 day
dexamethasone	DexPak 13 Day
dexamethasone	DexPak 6 Day
dexamethasone	Dexabliss
dexamethasone	Dexamethasone Intensol
dexamethasone	Dxevo
dexamethasone	Hemady
dexamethasone	HiDex
dexamethasone	LoCort
dexamethasone	TaperDex
dexamethasone	ZCort
dexamethasone	ZoDex
dexamethasone	ZonaCort
dexamethasone	dexamethasone
hydrocortisone	Alkindi Sprinkle
hydrocortisone	Cortef
hydrocortisone	hydrocortisone
methylprednisolone	Medrol
methylprednisolone	Medrol (Pak)
methylprednisolone	Methylpred DP
methylprednisolone	methylprednisolone
prednisolone	Millipred
prednisolone	Millipred DP

Appendix J. List of Generic and Brand Names of Medical Products Used to Define Characteristics in this Request

Generic Name	Brand Name
prednisolone	Prelone
prednisolone	prednisolone
prednisolone acetate	Flo-Pred
prednisolone sodium phosphate	Millipred
prednisolone sodium phosphate	Orapred ODT
prednisolone sodium phosphate	Pediapred
prednisolone sodium phosphate	Veripred 20
prednisolone sodium phosphate	prednisolone sodium phosphate
prednisone	Deltasone
prednisone	Prednisone Intensol
prednisone	Rayos
prednisone	prednisone

Appendix K. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool [version 13.1.2] to examine the association between single or repeat mometasone stent implants and adverse ocular events in the Sentinel Distributed Database (SDD). This is a follow-up assessment to cder_mpl1r_wp227.

Query period: December 1, 2017 - January 31, 2024
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index requirement: N/A
Post-episode requirement for Type 2 analyses: Days specified; optional
Enrollment gap: 45 days
Age groups: 18-24, 25-40, 41-64 and 65+ years
Stratifications: Age group, Sex, Calendar year
Censor output categorization: 0-91 92-182 183-273 274-364 365-455 456-546 547-637 638-729 730+
Envelope macro: No reclassification on inpatient Adate
Distribution of index-defining codes: Yes
Freeze data: No

			Exposure						
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Create Baseline Table?	Censor Treatment Episode at Evidence of:
1	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; Data Partner (DP) end date; Disenrollment; Occurrence of Glaucoma; Occurrence of a Sinuva event
2	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Glaucoma
3	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	757	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Glaucoma; Occurrence of a Sinuva event

Appendix K. Specifications Defining Parameters for this Request

	Exposure								
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Create Baseline Table?	Censor Treatment Episode at Evidence of:
4	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	757	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Glaucoma
5	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	364	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Glaucoma
6	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	392	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Glaucoma
7	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract; Occurrence of a Sinuva event
8	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract
9	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	1002	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract; Occurrence of a Sinuva event
10	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	1002	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract

Appendix K. Specifications Defining Parameters for this Request									
	Exposure								
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Create Baseline Table?	Censor Treatment Episode at Evidence of:
11	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	364	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract
12	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	637	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract
13	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Nasal Septal Perforation; Occurrence of a Sinuva event
14	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Nasal Septal Perforation
15	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	730	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Nasal Septal Perforation; Occurrence of a Sinuva event
16	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	730	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Nasal Septal Perforation
17	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	364	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Nasal Septal Perforation

Appendix K. Specifications Defining Parameters for this Request									
	Exposure								
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Create Baseline Table?	Censor Treatment Episode at Evidence of:
18	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	365	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Nasal Septal Perforation
19	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Diminished Visual Acuity; Occurrence of a Sinuva event
20	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Diminished Visual Acuity
21	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	757	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Diminished Visual Acuity; Occurrence of a Sinuva event
22	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	757	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Diminished Visual Acuity
23	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	364	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Diminished Visual Acuity
24	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	392	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Diminished Visual Acuity

Appendix K. Specifications Defining Parameters for this Request									
	Exposure								
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Create Baseline Table?	Censor Treatment Episode at Evidence of:
25	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Ocular Hypertension; Occurrence of a Sinuva event
26	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Ocular Hypertension
27	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	743	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Ocular Hypertension; Occurrence of a Sinuva event
28	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	743	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Ocular Hypertension
29	Propel: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	364	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Ocular Hypertension
30	Propel: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	378	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Ocular Hypertension
31	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Glaucoma; Occurrence of a Propel event

Appendix K. Specifications Defining Parameters for this Request									
			Exposure						
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Create Baseline Table?	Censor Treatment Episode at Evidence of:
32	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Glaucoma
33	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	757	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Glaucoma; Occurrence of a Propel event
34	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	757	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Glaucoma
35	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	3654	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Glaucoma
36	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	392	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Glaucoma
37	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract; Occurrence of a Propel event
38	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract

Appendix K. Specifications Defining Parameters for this Request									
			Exposure						
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Create Baseline Table?	Censor Treatment Episode at Evidence of:
39	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	1002	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract; Occurrence of a Propel event
40	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	1002	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract
41	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	364	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract
42	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	637	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract
43	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Nasal Septal Perforation; Occurrence of a Propel event
44	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Nasal Septal Perforation
45	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	730	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Nasal Septal Perforation; Occurrence of a Propel event

Appendix K. Specifications Defining Parameters for this Request									
			Exposure						
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Create Baseline Table?	Censor Treatment Episode at Evidence of:
46	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	730	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Nasal Septal Perforation
47	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	365	Washout lookback period should search for only evidence of a dispensing date	Yes	364	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Nasal Septal Perforation
48	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	365	Washout lookback period should search for only evidence of a dispensing date	Yes	365	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Nasal Septal Perforation
49	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Diminished Visual Acuity; Occurrence of a Propel event
50	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Diminished Visual Acuity
51	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	757	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Diminished Visual Acuity; Occurrence of a Propel event
52	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	757	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Diminished Visual Acuity

Appendix K. Specifications Defining Parameters for this Request

	Exposure								
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Create Baseline Table?	Censor Treatment Episode at Evidence of:
53	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	364	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Diminished Visual Acuity
54	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	392	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Diminished Visual Acuity
55	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Ocular Hypertension; Occurrence of a Propel event
56	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	729	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Ocular Hypertension
57	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	743	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Ocular Hypertension; Occurrence of a Propel event
58	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	743	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Ocular Hypertension
59	Sinuva: Single Implant (NDC or specific PX) See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	364	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Ocular Hypertension

Appendix K. Specifications Defining Parameters for this Request

	Exposure								
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Create Baseline Table?	Censor Treatment Episode at Evidence of:
60	Sinuva: Single Implant (NDC or specific PX) with lag period See Appendix L for details	First valid exposure episode during query period	183	Washout lookback period should search for only evidence of a dispensing date	Yes	378	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Ocular Hypertension
61	Sinuva: Repeat Implant See Appendix L for details	First valid exposure episode during query period	0	N/A	Yes	757	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Glaucoma; Occurrence of a Propel event
62	Sinuva: Repeat Implant See Appendix L for details	First valid exposure episode during query period	0	N/A	Yes	757	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract
63	Sinuva: Repeat Implant See Appendix L for details	First valid exposure episode during query period	0	N/A	Yes	392	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract
64	Sinuva: Repeat Implant See Appendix L for details	First valid exposure episode during query period	0	N/A	Yes	1002	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract; Occurrence of a Propel event
65	Sinuva: Repeat Implant See Appendix L for details	First valid exposure episode during query period	0	N/A	Yes	1002	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract
66	Sinuva: Repeat Implant See Appendix L for details	First valid exposure episode during query period	0	N/A	Yes	637	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract

Appendix K. Specifications Defining Parameters for this Request

	Exposure								
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Create Baseline Table?	Censor Treatment Episode at Evidence of:
67	Sinuva: Repeat Implant See Appendix L for details	First valid exposure episode during query period	0	N/A	Yes	757	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Glaucoma; Occurrence of a Propel event
68	Sinuva: Repeat Implant See Appendix L for details	First valid exposure episode during query period	0	N/A	Yes	757	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract
69	Sinuva: Repeat Implant See Appendix L for details	First valid exposure episode during query period	0	N/A	Yes	392	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract
70	Sinuva: Repeat Implant See Appendix L for details	First valid exposure episode during query period	0	N/A	Yes	1002	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract; Occurrence of a Propel event
71	Sinuva: Repeat Implant See Appendix L for details	First valid exposure episode during query period	0	N/A	Yes	1002	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract
72	Sinuva: Repeat Implant See Appendix L for details	First valid exposure episode during query period	0	N/A	Yes	637	Any care setting	Yes	Death; DP end date; Disenrollment; Occurrence of Cataract

Appendix K. Specifications Defining Parameters for this Request								
Scenario	Inclusion/Exclusion Group	Criteria	Care Setting	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	Minimum Days Supplied
1	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
2	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
3	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
4	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
5	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
6	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1

Appendix K. Specifications Defining Parameters for this Request								
Scenario	Inclusion/Exclusion Group	Criteria	Care Setting	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	Minimum Days Supplied
7	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
8	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
9	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
10	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
11	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
12	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1

Appendix K. Specifications Defining Parameters for this Request								
Scenario	Inclusion/Exclusion Group	Criteria	Care Setting	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	Minimum Days Supplied
13	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
14	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
15	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
16	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
17	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
18	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1

Appendix K. Specifications Defining Parameters for this Request								
Scenario	Inclusion/Exclusion Group	Criteria	Care Setting	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	Minimum Days Supplied
19	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
20	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
21	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
22	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
23	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
24	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1

Appendix K. Specifications Defining Parameters for this Request								
Scenario	Inclusion/Exclusion Group	Criteria	Care Setting	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	Minimum Days Supplied
25	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
26	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
27	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
28	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
29	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
30	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1

Appendix K. Specifications Defining Parameters for this Request								
Scenario	Inclusion/Exclusion Group	Criteria	Care Setting	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	Minimum Days Supplied
31	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
32	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
33	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
34	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
35	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
36	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1

Appendix K. Specifications Defining Parameters for this Request								
Scenario	Inclusion/Exclusion Group	Criteria	Care Setting	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	Minimum Days Supplied
37	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
38	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
39	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
40	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
41	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
42	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1

Appendix K. Specifications Defining Parameters for this Request								
Scenario	Inclusion/Exclusion Group	Criteria	Care Setting	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	Minimum Days Supplied
43	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
44	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
45	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
46	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
47	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
48	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1

Appendix K. Specifications Defining Parameters for this Request								
Scenario	Inclusion/Exclusion Group	Criteria	Care Setting	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	Minimum Days Supplied
49	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
50	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
51	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
52	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
53	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
54	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1

Appendix K. Specifications Defining Parameters for this Request								
Scenario	Inclusion/Exclusion Group	Criteria	Care Setting	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	Minimum Days Supplied
55	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
56	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
57	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
58	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
59	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
60	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1

Appendix K. Specifications Defining Parameters for this Request								
Scenario	Inclusion/Exclusion Group	Criteria	Care Setting	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	Minimum Days Supplied
61	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
62	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
63	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
64	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
65	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
66	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1

Appendix K. Specifications Defining Parameters for this Request								
Scenario	Inclusion/Exclusion Group	Criteria	Care Setting	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings	Number of Instances the Criteria Should Be Found in Evaluation Period	Minimum Days Supplied
67	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
68	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
69	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
70	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
71	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1
72	Glaucoma, Cataract, Nasal Septal perforation, Diminshed visual acuity, eye laser surgery, cataract surgery, and trabeculoplasty, Ocular Hypertension	Exclusion	Any care setting	-183	-1	Evaluation period should search for only evidence of a dispensing date	1	1

Appendix K. Specifications Defining Parameters for this Request							
Scenario	Event	Incident Event Washout Period	Care Setting	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Blackout Period	Risk Window Interval Start
1	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
2	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
3	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
4	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
5	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
6	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
7	Cataract	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
8	Cataract	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
9	Cataract	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	273
10	Cataract	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	273
11	Cataract	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
12	Cataract	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	273
13	Nasal Septal Perforation	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
14	Nasal Septal Perforation	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
15	Nasal Septal Perforation	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	1
16	Nasal Septal Perforation	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	1

Appendix K. Specifications Defining Parameters for this Request							
Scenario	Event	Incident Event Washout Period	Care Setting	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Blackout Period	Risk Window Interval Start
17	Nasal Septal Perforation	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
18	Nasal Septal Perforation	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	1
19	Diminished Visual Acuity	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
20	Diminished Visual Acuity	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
21	Diminished Visual Acuity	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
22	Diminished Visual Acuity	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
23	Diminished Visual Acuity	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
24	Diminished Visual Acuity	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
25	Ocular Hypertension	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
26	Ocular Hypertension	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
27	Ocular Hypertension	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	14
28	Ocular Hypertension	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	14
29	Ocular Hypertension	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
30	Ocular Hypertension	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	14
31	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
32	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A

Appendix K. Specifications Defining Parameters for this Request							
Scenario	Event	Incident Event Washout Period	Care Setting	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Blackout Period	Risk Window Interval Start
33	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
34	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
35	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
36	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
37	Cataract	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
38	Cataract	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
39	Cataract	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	273
40	Cataract	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	273
41	Cataract	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
42	Cataract	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	273
43	Nasal Septal Perforation	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
44	Nasal Septal Perforation	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
45	Nasal Septal Perforation	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	1
46	Nasal Septal Perforation	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	1
47	Nasal Septal Perforation	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
48	Nasal Septal Perforation	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	1

Appendix K. Specifications Defining Parameters for this Request							
Scenario	Event	Incident Event Washout Period	Care Setting	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Blackout Period	Risk Window Interval Start
49	Diminished Visual Acuity	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
50	Diminished Visual Acuity	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
51	Diminished Visual Acuity	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
52	Diminished Visual Acuity	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
53	Diminished Visual Acuity	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
54	Diminished Visual Acuity	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
55	Ocular Hypertension	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
56	Ocular Hypertension	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
57	Ocular Hypertension	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	14
58	Ocular Hypertension	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	14
59	Ocular Hypertension	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	N/A
60	Ocular Hypertension	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	14
61	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
62	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
63	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
64	Cataracts	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	273

Appendix K. Specifications Defining Parameters for this Request							
Scenario	Event	Incident Event Washout Period	Care Setting	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Blackout Period	Risk Window Interval Start
65	Cataracts	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	273
66	Cataracts	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	273
67	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
68	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
69	Glaucoma	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	28
70	Cataracts	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	273
71	Cataracts	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	273
72	Cataracts	183	Any care setting	N/A	De-duplicates occurrences of the same event group on the same day	N/A	273

International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), Current Procedural Terminology (CPT) codes are provided by Optum360.
National Drug Codes (NDCs) are checked against First Data Bank's FDB MedKnowledge®.
N/A: Not applicable

Appendix L. Combos for this Request

Orange highlighting = parameters used to define combo code output

Green highlighting = parameters used to define combination logic between groups specified in combo codes file

Combo (Figures attached below)

Index Exposure	Combination Group	Combination Description	Combination Order	Combination Code	Combination Code Behavior	Combination Encounter Type	Combination Principal Diagnosis
Sinuva Stent Implant	repsinuva_1	Rep Sinuva Stent 365days	N/A N/A	REPSINUVA1Y	RX: the virtual record will behave like a dispensing record	N/A	N/A
Sinuva Stent Implant	repsinuva_2	Rep Sinuva Stent 730days	N/A N/A	REPSINUVA2Y	RX: the virtual record will behave like a dispensing record	N/A	N/A
Sinuva Stent Implant	sinuva_1	Sinuva_RXPX	N/A N/A	SINUVARXPX1	RX: the virtual record will behave like a dispensing record	N/A	N/A
Sinuva Stent Implant	sinuva_2	Sinuva_RXnoPX	N/A N/A	SINUVARXNPX	RX: the virtual record will behave like a dispensing record	N/A	N/A
Sinuva Stent Implant	sinuva_3	Sinuva_PXRX	N/A N/A	SINUVAPXRX1	RX: the virtual record will behave like a dispensing record	N/A	N/A
Sinuva Stent Implant	sinuva_4	Sinuva_PXnoRX	N/A N/A	SINUVAPXNRX	RX: the virtual record will behave like a dispensing record	N/A	N/A
Propel Stent Implant	propel_1	Propel_RXPX	N/A N/A	PROPELRXPX1	RX: the virtual record will behave like a dispensing record	N/A	N/A
Propel Stent Implant	propel_2	Propel_RXnoPX	N/A N/A	PROPELRXNPX	RX: the virtual record will behave like a dispensing record	N/A	N/A
Propel Stent Implant	propel_3	Propel_PXRX	N/A N/A	PROPELPXRX1	RX: the virtual record will behave like a dispensing record	N/A	N/A
Propel Stent Implant	propel_4	Propel_PXnoRX	N/A N/A	PROPELPXNRX	RX: the virtual record will behave like a dispensing record	N/A	N/A

Combo Codes

Raw Group	Raw Care Setting	Raw Principal Diagnosis	Raw Lab Order	Raw Lab Result
Sinuva Stent Implant	Any	N/A	N/A	N/A
Propel Stent Implant	Any	N/A	N/A	N/A

It is recommended to include figures with all combos

Appendix L. Combos for this Request

Orange highlighting = parameters used to define combo code output

Green highlighting = parameters used to define combination logic between groups specified in combo codes file

Combo (Figures attached below)

Raw Group	Raw Order	Raw Episode Type	Raw Episode	Raw Record Exclusion
first sinuva stent	1	1: Episodes of this combination item will be created by PATID and RAWGROUP	0 days	0: the combination item is not an exclusion criterion
second sinuva stent	2			
first sinuva stent	1	1: Episodes of this combination item will be created by PATID and RAWGROUP	0 days	0: the combination item is not an exclusion criterion
second sinuva stent	2			
first sinuva stent (NDC)	1	1: Episodes of this combination item will be created by PATID and RAWGROUP	0 days	0: the combination item is not an exclusion criterion
second sinuva stent (PX)	2			
first sinuva stent (RX)	1	1: Episodes of this combination item will be created by PATID and RAWGROUP	0 days	0: the combination item is not an exclusion criterion
no second sinuva stent (PX)	2			1: the combination item is an exclusion criterion
first sinuva stent (PX)	1	1: Episodes of this combination item will be created by PATID and RAWGROUP	0 days	0: the combination item is not an exclusion criterion
second sinuva stent (NDC)	2			
first sinuva stent (PX)	1	1: Episodes of this combination item will be created by PATID and RAWGROUP	0 days	0: the combination item is not an exclusion criterion
no second sinuva stent (RX)	2			1: the combination item is an exclusion criterion
first propel stent (NDC)	1	1: Episodes of this combination item will be created by PATID and RAWGROUP	0 days	0: the combination item is not an exclusion criterion
second propel stent (PX)	2			
first propel stent (RX)	1	1: Episodes of this combination item will be created by PATID and RAWGROUP	0 days	0: the combination item is not an exclusion criterion
no second propel stent (PX)	2			1: the combination item is an exclusion criterion
first propel stent (PX)	1	1: Episodes of this combination item will be created by PATID and RAWGROUP	0 days	0: the combination item is not an exclusion criterion
second propel stent (NDC)	2			
first propel stent (PX)	1	1: Episodes of this combination item will be created by PATID and RAWGROUP	0 days	0: the combination item is not an exclusion criterion
no second propel stent (RX)	2			1: the combination item is an exclusion criterion

Raw Record Window From Start Date	Raw Record Window from End Date	Raw Record Duration	Raw Record Start Date Type	Raw Record End Date Type
-365, -31	-	N/A	ADATEB: the start date of the Base interval	ADATEB: the start date of the Base interval
-730, -31	-	N/A	ADATEB: the start date of the Base interval	ADATEB: the start date of the Base interval
0, 30	-	N/A	ADATEC: the start date of the Combined-to interval	ADATEC: the start date of the Combined-to interval
0, 30	-	N/A	ADATEB: the start date of the Base interval	ADATEB: the start date of the Base interval
0, 30	-	N/A	ADATEB: the start date of the Base interval	ADATEB: the start date of the Base interval
0, 30	-	N/A	ADATEB: the start date of the Base interval	ADATEB: the start date of the Base interval
0, 30	-	N/A	ADATEC: the start date of the Combined-to interval	ADATEC: the start date of the Combined-to interval
0, 30	-	N/A	ADATEB: the start date of the Base interval	ADATEB: the start date of the Base interval
0, 30	-	N/A	ADATEB: the start date of the Base interval	ADATEB: the start date of the Base interval
0, 30	-	N/A	ADATEB: the start date of the Base interval	ADATEB: the start date of the Base interval

****N/A: Not applicable

*The 30 days before the combined-to record are not assessed due to our exposure criteria that Sinuva exposure codes within 30 days of each other refer to the same implant

Combination group: repsinuva_1 and repsinuva_2



Combination group: sinuva_1/propel_1

Raw data



Virtual record



Combination group: sinuva_2/propel_2

Raw data



Virtual record

Combination group: sinuva_3/propel_3

Raw data



Virtual record



Combination group: sinuva_4/propel_4

Raw data



Virtual record



Appendix M. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristics

Covariate Number	Covariate	Care Setting	Principal Diagnosis Position	Code Category	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Covariate Includes Dispensings	Number of Instances the Covariate Should Be Found in Evaluation Period
1	Blepharitis	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
2	Cardiovascular risk factor	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
3	Cardiac and vascular disease	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
4	Cerebrovascular Diseases	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
5	Other cardiovascular disorders	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
6	Corneal abrasion	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
7	Corneal graft	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
8	Diabetes	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
9	Diabetic retinopathy	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
10	Episcleritis	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
11	Fuch's endothelial dystrophy	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
12	Heterochromic cyclitis	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
13	Keratitis	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
14	Macular degeneration	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
15	Inhaled steroids	Any care setting	Any	Drug Code	-183	-1	Evaluation period should search for only evidence of a dispensing date	1
16	Intranasal steroids	Any care setting	Any	Drug Code	-183	-1	Evaluation period should search for only evidence of a dispensing date	1
17	Oral steroids	Any care setting	Any	Drug Code	-183	-1	Evaluation period should search for only evidence of a dispensing date	1
18	Retinitis pigmentosa	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1

Appendix M. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristics								
Covariate Number	Covariate	Care Setting	Principal Diagnosis Position	Code Category	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Covariate Includes Dispensings	Number of Instances the Covariate Should Be Found in Evaluation Period
19	Subconjunctival hemorrhage	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
20	Chronic Kidney Disease	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
21	Uveitis	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
22	Vasculitis	Any care setting	Any	Diagnosis Code	-183	-1	N/A	1
23	Endoscopic Sinus Surgery	Any care setting	Any	Procedure Code	-183	0	N/A	1
24	Combined Comorbidity Score	Any care setting	Any	Diagnosis Code; Procedure Code	-183	-1	N/A	1
25	Nasal Polyps	Any care setting	Any	Diagnosis Code	-183	0	N/A	1

Appendix M. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristics

Covariate Number	Minimum Days Supplied	Minimum Cumulative Dose	Minimum Average Daily Dose	Maximum Average Daily Dose	Forced Supply to Attach to Dispensings	Lab Date Selection Algorithm	Lab Result Values
1	N/A	N/A	N/A	N/A	N/A	N/A	N/A
2	N/A	N/A	N/A	N/A	N/A	N/A	N/A
3	N/A	N/A	N/A	N/A	N/A	N/A	N/A
4	N/A	N/A	N/A	N/A	N/A	N/A	N/A
5	N/A	N/A	N/A	N/A	N/A	N/A	N/A
6	N/A	N/A	N/A	N/A	N/A	N/A	N/A
7	N/A	N/A	N/A	N/A	N/A	N/A	N/A
8	N/A	N/A	N/A	N/A	N/A	N/A	N/A
9	N/A	N/A	N/A	N/A	N/A	N/A	N/A
10	N/A	N/A	N/A	N/A	N/A	N/A	N/A
11	N/A	N/A	N/A	N/A	N/A	N/A	N/A
12	N/A	N/A	N/A	N/A	N/A	N/A	N/A
13	N/A	N/A	N/A	N/A	N/A	N/A	N/A
14	N/A	N/A	N/A	N/A	N/A	N/A	N/A
15	N/A	N/A	N/A	N/A	N/A	N/A	N/A
16	N/A	N/A	N/A	N/A	N/A	N/A	N/A
17	N/A	N/A	N/A	N/A	N/A	N/A	N/A
18	N/A	N/A	N/A	N/A	N/A	N/A	N/A
19	N/A	N/A	N/A	N/A	N/A	N/A	N/A
20	N/A	N/A	N/A	N/A	N/A	N/A	N/A
21	N/A	N/A	N/A	N/A	N/A	N/A	N/A
22	N/A	N/A	N/A	N/A	N/A	N/A	N/A
23	N/A	N/A	N/A	N/A	N/A	N/A	N/A
24	N/A	N/A	N/A	N/A	N/A	N/A	N/A
25	N/A	N/A	N/A	N/A	N/A	N/A	N/A

*****N/A: Not applicable


Exposure: Propel Single Implant
Index date
First valid occurrence of Propel stent implant
Day 0
Study
Most recent data
Enrollment requirement
Required coverage type
Pre-index: [-183, -1]
Allowed coverage gap
45 days
Exclusion criteria*
*[-183, -1]
Inclusion criteria**
**[-183, -1]
Exposure washout
[-183, -1]
Outcome washout*
*[-183, -1]
Censor episode at first occurrence of: Death, Disenrollment, DP end date, Outcome, Sinuva implant (only for non-ITT cohorts)
Glaucoma/Cataract/NSP/DVA/Ocular Hypertension
Assess as point exposure and follow-up until:
• Occurrence of outcome (with and without incorporating lag time)
• Censoring criteria above
Episode length
Covariates***
***[-183, -1]
*Exclusion Criteria
Glaucoma, Cataracts, Diminished visual acuity (DVA), Nasal septal perforation (NSP), Ocular Hypertension, Eye laser surgery, Trabeculoplasty, Cataract surgery
**Inclusion Criteria
At least 18 years of age at index date
***Covariates:
Age, year, sex, endoscopic ethmoid sinus surgery, comorbidity score, health services utilization, use of intranasal, inhaled, or oral steroids, blepharitis, cardiovascular (CV) risk factors, cardiac and vascular diseases, cerebrovascular disease, miscellaneous CV disease, corneal abrasion, corneal graft, diabetes, diabetic retinopathy, Fuchs' endothelial dystrophy, episcleritis, heterochromic cyclitis, keratitis, macular degeneration, retinitis pigmentosa, subconjunctival hemorrhage, chronic kidney disease, uveitis or iritis, and vasculitis


Exposure: Sinuva Single Implant
Index date
First valid occurrence of Sinuva stent implant
Day 0
Study
Most recent data
Enrollment requirement
Required coverage type
Pre-index: [-183, -1]
Allowed coverage gap
45 days
Exclusion criteria*
*[-183, -1]
Inclusion criteria**
**[-183, -1]
Exposure washout
[-183, -1]
Outcome washout*
*[-183, -1]
Episode length
Covariates***
***[-183, -1]
Censor episode at first occurrence of: Death, Disenrollment, DP end date, Outcome, Propel implant (only for non-ITT cohorts)
Glaucoma/Cataract/NSP/DVA/Ocular Hypertension
Assess as point exposure and follow-up until:
• Occurrence of outcome (with and without incorporating lag time)
• Censoring criteria above
*Exclusion Criteria
Glaucoma, Cataracts, Diminished visual acuity (DVA), Nasal septal perforation (NSP), Ocular Hypertension, Eye laser surgery, Trabeculoplasty, Cataract surgery
**Inclusion Criteria
At least 18 years of age at index date
***Covariates:
Age, year, sex, endoscopic ethmoid sinus surgery, comorbidity score, health services utilization, use of intranasal, inhaled, or oral steroids, blepharitis, cardiovascular (CV) risk factors, cardiac and vascular diseases, cerebrovascular disease, miscellaneous CV disease, corneal abrasion, corneal graft, diabetes, diabetic retinopathy, Fuchs' endothelial dystrophy, episcleritis, heterochromic cyclitis, keratitis, macular degeneration, retinitis pigmentosa, subconjunctival hemorrhage, chronic kidney disease, uveitis or iritis, and vasculitis

Sinuva Repeat Implant Cohorts





*Exclusion Criteria	**Inclusion Criteria	***Covariates:
Glaucoma, Cataracts, Diminished visual acuity (DVA), Nasal septal perforation (NSP), Ocular Hypertension, Eye laser surgery, Trabeculoplasty, Cataract surgery	At least 18 years of age at index date Prior Sinuva stent implant (365 or 730 days before)	Age, year, sex, endoscopic ethmoid sinus surgery, comorbidity score, health services utilization, use of intranasal, inhaled, or oral steroids, blepharitis, cardiovascular (CV) risk factors, cardiac and vascular diseases, cerebrovascular disease, miscellaneous CV disease, corneal abrasion, corneal graft, diabetes, diabetic retinopathy, Fuchs' endothelial dystrophy, episcleritis, heterochromic cyclitis, keratitis, macular degeneration, retinitis pigmentosa, subconjunctival hemorrhage, chronic kidney disease, uveitis or iritis, and vasculitis